MXPA00008377A - 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines - Google Patents

Abstract

Compounds of Formula (I) wherein R is selected from the group consisting of R2, R2NH-, or R3R4N-R5-, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof. The invention provides a method of inhibiting cell cycle progression, a method of inhibiting cyclin dependent kinases, particularly cdk-2, a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms, a composition comprising an assayable amount of a compound of Formula (I) in admixture or otherwise in association with an inert carrier, and a pharmaceutical composition comprising an effective inhibitory amount of a compound of Formula (I) in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.

Description

2- [TRANS- (4-AMINOCICLOHEXIL) TO INO] PURINES 6,9- DISSOLVED The present invention relates to 2- [trans- (4-aminociclohexyl) amino] -purines 6,9-disubstituted and methods for using same for antineoplastic agents or for the treatment of degeneration and neuronal damage.

BACKGROUND OF THE INVENTION Cell division, in both normal and neoplastic cells, is a closely controlled event that occurs by defined stages. Inactive cells that do not actively divide are in the G0 phase, such as those terminally differentiated or in a state of temporary arrest. The first phase is the first phase of opening (Gi), during which the cell prepares to synthesize DNA. In the last phase G in what is called a restriction point or point R, the cell enters the S phase during which DNA synthesis occurs. After completing phase S, the cell enters the second phase of opening (G2), during which the cell prepares to divide, which follows after mitosis, or phase M. Initial experiments in the regulation of the cycle revealed the existence of a protein called "Maturation Promoting Factor" (MPF), a heterodimer with kinase activity. Next, the comparison of subsequently identified proteins and their underlying genes revealed a family of yeast genes known as cell division control genes (cdc). Additional experiments showed that some of the cdc genes encode the cmass, and were ultimately called cyclin-dependent kinases (cdks). As a result of this reclassification, some cell cycle proteins have double designations, such as cdkl which is also known as cdc2. The kinase component of MPF is now identified as p34cac2 and the regulatory subunit of MPF is now called cyclin B. Cyclins were first identified as proteins whose levels oscillated during the cell cycle and were specifically degraded in mitosis. To date, animal cyclins A-1 and cdks 1 -8 have been identified. For more complicated nomenclature, the cyclin and cdk subtypes have been identified, such as cyclin B 1 and B2. Subsequent research in cell regulation has shown that the stages of cell division are achieved in part by modulation cyclins and cyclin-dependent kinases (cdks). The cyclins subsequently regulate the cdks and were characterized by a region of amino acid homology 1 00 called the "cyclin box" that is included in attaching a protein kinase pattern. Cdks are closely related in sequence and size (35-40 kDa) and are defined as protein kinases activated by linked cyclin regulatory subunits. The cdks contain a cleaved conserved active site of approximately 300 amino acids that is characteristic of all eukaryotic protein kinases. In this way, both cyclins and cdks appear to be highly conserved protein families. The isolation of individual cyclins and cdks has allowed the additional identification of the roles and interactions of each component in the phase transitions of the cell cycle. Excess levels of cdks persist throughout the cell cycle. Activation of the cdks occurs after cyclin synthesis and by binding to the catalytic cdk subunit, the result of Ip which is the stimulation of the serine / threonine kinase activity of cdk. The complete activation of cdk requires phosphorylation in a conserved threonine residue located in the T cycle by a kinase that activates the cyclin-dependent kinase (CAK), which by itself is a complex of cdk / cyclin composed of cyclin H and cdk7 , and a third protein of approximately 32 kDa. Inactivation of the cdk / cyclin complex can result from the phosphorylation of a threonine and / or tyrosine residue at the ATP binding site of the cdk or the binding of one of a number of endogenous inhibitory proteins. In phase d, D-type cyclins bind to several different cdks, including cdk2, cdk4, cdk5 and cdkβ, but they are more commonly associated with cdk4 and cdkd. Type D cyclins are thought to act as detectors of the growth factor, which link the progress of the cell cycle to external brands. The cyclin E-cdk2 complexes appear in the mammalian cell cycle after the D-cdk type cyclin complexes. Cyclin E synthesis is tightly regulated and occurs in the late G ^ phase and in the early S. The cyclin E-cdk2 complex is essential for the cell to begin DNA replication. The d cyclins, cyclin D and cyclin E, are proteins produced temporarily, with a half-life of 20 minutes. The short half-life is thought to be the result of a sequence of PEST in the C-terminal regions of these proteins, the degradation of which appears to be mediated by the ubiquitination pathway. The G2 cyclins, cyclin A and cyclin B, are stable throughout the interface and are specifically destroyed in mitosis through a ubiquitination pathway. Both cyclin A and cyclin B2 appear to only degrade when complexed with their cdk pattern [cyclin-cdk2 and cyclin A / B-cdk1 (cdc2)]. However, the destruction of cyclin B1 is connected to the integrity of the mitotic apparatus at the end of the metaphase. If the spindle is installed incorrectly, or the chromosomes are aligned incorrectly, then cyclin B1 is avoided. The retinoblastoma protein (Rb), a 105 kDa nuclear phosphoprotein, is a substrate of cyclin-cdk complexes of cdks-2, 4 and 6 in phase G, and functions as one of the main control points in the cycle cellular through dephosphorylation and phosphorylation carefully instrumented. In G0 / G 1, Rb exists in a hypophosphorylated state. As the cell progresses in the last Gi, Rb becomes hyperphosphorylated by the cyclin D complexes, which activates the Rb and leads the cell towards the S phase, resulting in cell cycle progression and cell division. This hyperphosphorylation state of Rb remains in G2. During the last phase M, Rb is dephosphorylated, thus returning to the hypophosphorylated state. The phosphorylation of the Rb protein alters its binding characteristics; in the hypophosphorylated state. The phosphorylation of the Rb protein alters its binding characteristics; in the hypophosphorylated state, Rb binds to and separates the specific transcription factors, such as E2F, the junction of which prevents the exit of the Gi phase. Once the cdks hyperphosphorylate the Rb, the transcription factors are released, which can then activate the transcription of the genes necessary for the progression of the S phase, for example, thymidine kinase, myc, myb, dihydrofolate reductase, and DNA-a polymerase. The location of the cyclin-CDK complexes is also very suggestive about the role that each complex plays in the trajectory. Nuclear cyclins A and E bind to p107 and 91-30, possibly because they are in the nucleus. The mammalian cyclin B1 accumulates in the cytoplasm in the G2 phase and translocates in the nucleus at the beginning of mitosis. Cyclin B is associated with the spindle apparatus, in particular with the spindle layers, and it is thought that the cyclin B-cdc2 kinase can be included in the formation of the spindle through phosphorylating the components of the mitotic apparatus. In addition, cyclin B1 is part of a feedback mechanism that ensures the correct assembly of the metaphase mitotic apparatus. The human cyclin B2 is associated almost exclusively with the membrane compartment, and in particular the Golgi apparatus, cyclin B2-cdc2 is included in the disassembly of the Golgi apparatus when the cells enter into mitosis. The cdc2-cyclin B kinase is a key mitotic factor that seems to be highly conserved and is thought to be included in the cell cycle transitions in all eukaryotic cells. Histone H 1 is a substrate for cdc2-cyclin B; histone H 1 is selectively phosphorylated at specific sites of mitosis, which are thought to be important for chromatin condensation. The cdc2-cyclin B complex also phosphorylates sheet, which is responsible for the disintegration of nuclear sheet. The nuclear lamina is made of a polymer of lamina subunits that are hyperphosphorylated in mitosis, and this phosphorylation is responsible for their disassembly. The sheets are part of the family of intermediate filaments of proteins, and cdc2-cyclin B phosphorylates a subset of the phosphorylated sites in mitosis in the intermediate cytoplasmic filament subunits, vimentin and desmin. In this way, the cdc2-cyclin B complex is included in the reorganization of cellular architecture in mitosis. In addition, cdc2-cyclin B is included in the reorgnanization of microfilaments, through the phosphorylation of non-muscular caldesmon, an 83 kDa protein that binds to actin and calmodulin and inhibits ATPase activity of actomyosin. In mitosis, caldesmon is phosphorylated by cdc2-cyclin B, which weakens its affinity for actin and causes it to be disassociated from microfilaments. Cdc2-cyclin B is involved in the regulation of actomyosin filament, by phosphorylating myosin in the contractile ring, which divides the cell into two (cytokinesis). In metaphase, the light regulatory chain of myosin II (MLC) is phosphorylated at two major sites in the N terminus. Once phosphorylated, myosin is prevented from interacting with actin. In anaphase, these two sites dephosphorylate. Cdc2-cyclin B also plays a role in the reorganization of the membrane compartment in mitosis. For example cdc2-cyclin B phosphorylates rabbi Ap and rab4p. When rab4p is phosphorylated by cdc2-cyclin B, it dissociates from the membrane compartment. In mitosis, most forms of transcription are inhibited. Again, cdc2-cyclin B plays a role in the inhibition of pol lll-mediated transcription by phosphorylating TFIIIB. Since pol I, pol II and pol III mediated transcription share several common factors, such as the TATA binding protein (TBA), it is likely that cdc2-cyclin B is included in the sub-regulation of all forms of transcription in mitosis. Given the importance of cyclin / cdk complexes in activating the cell cycle division, they are under a narrow regulatory mechanism. Since its initial discovery, cyclins and cdks have been shown to interact with other transcription factors and proteins included in a wide range of cell trajectories. Cdk7 has been identified as a component in the IIH transcription factor (TFIIH), which contains the kinase activity of the C-terminal domain (CTD) of RNA polymerase II. More recently, cdkd which is associated with cyclin C, has also been found to phosphorylate the CTD of RNA polymerase II, but appears to possess CAK activity. In this way, it is clear that cdks participate in a wide range of cellular functions in addition to the regulation of the cell cycle. CDK inhibitor proteins (CDIs) are small proteins that bind and inactivate specific cyclin-CDK complexes, or monomeric CDKs. These inhibitors can be grouped into two families based on sequence and functional similarities. The INK4 family includes p1 5INK4B, p16IN K4, p18 and p19 that specifically bind cdk4 and cdk6. p16INK4 and p1 5INK4B, contain four ankyrin repeats and, in addition to sharing significant homology, are encoded by the adjacent genes at the 9p1 2 site. The elevated cellular levels of 916 result in the inactivation of cdk4 because the p16 binds the cyclin complexes D-cdk4 and cyclin D-cdk6. The gene for p16INK4 (MTS 1) is recognized as a potential tumor suppressor gene, since it is reinstalled, deleted or mutated in a large number of tumor cell lines and in some major tumors. In an eetapadio of hereditary melanoma, approximately half of the families had germline mutations in the p16INK4 gene. Rb is a repressor of p1 6INK4. Inactivation of cellular Rb, either by mutation or viral antigens, correlates with increased levels of p16IN K4, p16IN K4, p1 5INK4B and p1 8 inhibit the binding of cyclin D with cdk4 and cdk ?. The second family of CDIs is the Kip / Cip family that includes P21 C'P1 -WAFX P27Kip1 and p57Kip2. p27KIP1 occurs in proliferating cells in a latent or coated form. After stimulation, p27KIP1 is discovered and binds to and inhibits the cyclin-CDK4 / 6 complexes. The proteins of the Kip / Cip family have strong homology e? the term N, the region that binds the cyclin-cdk complexes. Proteins of the Kip / Cip family preferentially bind to and inhibit the cyclin-cdk complexes included in the phase S and S complexes over those included in phase M. P21 (also known as WAF1, Cip1 and Sdi 1) is induced by p53 and forms a ternary complex with the cell proliferating cell antigen (PCNA), a subunit of DNA polymerase d in several cyclin-CDK2 complexes, including cyclin A, D1 and E. The expression of P21 WAF 1 of growth cells , quiescent and senescent is correlated with a role as a negative regulator of the S. mRNA entry of P21 WAF 1 is supraregulated as the cells become senescent or quiescent, and after stimulation of the serum of the quiescent cells, and it is reduced as the cell enters the S phase. p21 inactivates the cyclin E-cdk2, cyclin A-cdk2 and cyclin D1-, D2- and D3-cdk4 complexes. The genetic analysis of numerous human tumors reveals a disproportionate number of altered cell cycle proteins, and it is this aberration that is thought to cause the abnormal cell cycle. For example, cyclin D1 is the bcl-1 / PRAD1 proto-oncogene that is either overexpressed or deregulated in a variety of human tumors. The cyclin D1 / CCND1 gene, located on chromosome 1 1 q1 3, is amplified in a number of cancers, mainly breast and lung carcinomas without small cell. This correlates with the observation that overexpression of cyclin D1 is a common feature in tumors with this specific 1 1 q 13 amplicon. The gene for p16 is reinstalled, deleted or mutated in a large number of tumor cell lines, and in some primary tumors. Mutations in cdk4, specifically in the Arg24Cys mutation, have been identified in two families of unrelated hereditary melanoma. This mutation was found in 1 1/1 of the patients with melanoma, 2/17 uninfected and 0/5 spouses (Zuo, L, ef al, Nature Genetics 12 1996: 97-99). This mutation has a specific effect on the binding domain of p16INK4a of cdk4, because it has no effect on the ability to bind to cyclin D and form a functional kinase. As a result of this mutation, the cyclin D / cdk4 complex is resistant to normal physiological inhibition by p16INK4a. Other eetapadios have shown that approximately half of the familiar melanoma groups show evidence of binding to the 9p21 region of the chromosome that contains the p16INK4a gene. The types of identified p1 6IN K4a mutations include a non-sensitive mutation, marriage donor mutation, and unidentified mutation that prevents the transcription of p16INK4a and 3 non-sensitive mutants that are unable to bind to cdk4 and cdk6. Overexpression of cdk4 as a result of gene amplification has been identified in an eetapadium of 32 glioma cell lines (He. J. et al., Cancer Res. 54: 5804-5807, 1994). This alteration was observed among the ten cases that have intact p16 genes. Genetic analysis of glioma cell lines revealed that 24 out of 32 glioma cell lines had one of two alternative genetic alterations, each of which indicates that increased kdc4 kinase activity is important for glial tumor development. The cdk4 is traced to the long arm of chromosome 12 and is overexpressed in certain tumors due to its amplification as a component of an amplicon that includes other relevant genes, such as SAS and MDM2. All the above conditions lead to the activation of cdk4. Overexpression of cyclins B1 and E in solid and leukemic tumor cell lines, as well as altered patterns of cyclin E expression in breast cancer, has also been reported. Cellular hyperproliferation occurs in a number of disease states. The most common hyperproliferative diseases are neoplasms, which are typically named according to the original source of the hyperproliferative tissue. Neoplasms are defined as new growths of animal or plant tissue that resemble more or less the tissue from which it originates, but have no physiological function, and are benign, potentially malignant or malignant in character. Neoplasms originates as the result of the loss of normal controls, which lead to unregulated growth. The neoplastic cells may lack difference and acquire the ability to invade local tissues and spread by metastasis. Neoplasms can develop in any type of tissue in any organ at any age. The incidence, and mortality rate, of neoplasms generally increases with age, with certain neoplasms having a peak incidence between the ages of 60 and 80 (for example, prostate, stomach, and colon). However, other neoplasms have a peak incidence from birth to 10 years (for example, acute lymphoblastic leukemia). Diets, exposure to carcinogens, particularly tobacco use, and family predispositions also affect the incidence of particular neoplasms. Neoplastic cells differ from normal cells in a number of important aspects, including loss of differentiation, increased invasion and Reduced drug sensitivity Another important difference is the unchecked growth of the cells, which is thought to result from the loss of the normal cellular control mechanisms of these cells whether they are deactivated, diverted or otherwise neglected, leading to cells Neoplastic tumors proliferate without consideration of the normal control mechanisms. The neoplasm is an abnormal mass of tissue, the growth of which exceeds and does not coordinate with that of the normal tissue, and persists in the same excessive way after the cessation of the stimuli that evoke the change.

Neoplasms are classified as either benign or malignant. Benign neoplasms show localized, slow growth that is usually circumscribed due to encapsulation by a capsule of fibrous connective tissue. Although benign neoplasms rarely cause the death of the organism, untreated malignancies have a high probability of killing the organism. Malignant neoplasms are usually not encapsulated, and usually show a faster growth rate. Malignant neoplasms often invade surrounding vessels and tissues and diffuse to distant body sites. Malignant neoplasms are generically described as "cancer" or as "tumors"; the last term denotes swelling. Myeloprofilerative disorders are a group of disorders characterized by abnormal proliferation by one or more hematopoietic cell lines or connective tissue elements. When disorders are usually included as myeloproliferative disorders: you will see polycythemia (primary polycythemia: Vaquez disease), myelofibrosis (agnogenic myeloid metaplasia), chronic myelogenous leukemia and primary thrombocythemia (essence). Acute leukemia, especially erythroleukemia, and paroxysmal nocternal hemoglobinuria are also classified as myeloproliferative disorders. Each of these disorders is identified according to its predominant characteristic or site of proliferation. Although each results from the proliferation of different cells, it has been shown that each is caused by a clonal proliferation that originates at the level of a pluripotent germ cell, which causes variable degrees of abnormal proliferation of erythroid, myeloid and megakaryocytic precursors in the bone marrow All myeloproliferative disorders have a tendency to end in acute leukemia. Leukemias are malignant neoplasm of the tissues that make up the blood. At least two viruses are associated with causing leukemia in humans. The Epstein-Barr virus is associated with Burkitt's lymphoma and the human T-cell lymphotropic virus, also called acute human leukemia / lymphoma virus (HTLV-1), has been linked to some T-cell leukemias and lymphomas. Exposure, especially prolonged exposure to chemical agents, such as benzene and some antineoplastics, or to ionizing radiation, genetic predisposition (eg, Down syndrome) and some familial disorders (eg, Fanconi anemia) result in predispositions to leukemias. The development of leukemia seems to occur through a single cell cycle through two or more stages with subsequent proliferation and clonal expansion. Leukemias are currently classified according to their cell maturity; Acute leukemias are predominantly undifferentiated cell populations and chronic leukemias are more mature cell forms. Acute leukemias are further divided into lymphoblastic types (ALL, also known as acute lymphocytic leukemia) and myeloid (AML, also known as myelocytic, myelogenous, myeloblastic, myelomonoblastic). They can also be classified by morphological appearance and histochemistry according to the French-American-English classification (FAB) or according to the type and degree of differentiation. Chronic leukemias are classified as either lymphocytic (CLL) or myelocytic (CML). CLL is characterized by the appearance of matured lymphocytes in the blood, bone marrow and lymphoid organs. CML is characterized by the predominance of granulocytic cells of all stages of differentiation in the blood, bone marrow, liver, spleen and other organs .. Myelodysplastic Syndrome (MDS) is characterized as a clonal proliferative disorder in which a bone marrow is associated normal or hypercellular bone with anemia and dysmyelopoiesis. MDS is a relatively new designation of the group of disorders known as Preleukemia, Refractory Anemias, Chronic Chronic Myelocytic Leukemia of Chromose Ph, Chronic Myelomonocytic Leukemia and Agnogenic Myeloid Metaplasia. The FAB system provides addition classification of Myelofibrosis. Lymphomas are a heterogeneous group of neoplasms that originate in the lymphatic and reticuloendothelial systems. The main types of lymphomas are Hodgkin's disease and non-Hodgkin's lymphoma, as well as rare Burkitt's lymphoma and mycosis fungoides. Hodgkin's disease is a chronic disease with lymphoreticular proliferation of unknown cause that may be present in a localized or disseminated form, and is also classified according to four histopathological profiles. Non-Hodgkin's lymphomas are a heterogeneous group of diseases that consist of neoplastic proliferation of lymphoid cells that usually spread throughout the body. The above terms, cellular reticulum sarcoma and lymphosarcoma, are now replaced with terms that reflect that cell of origin and the biology of the disease. The Rappaport classification is based on histopathology; in the degree of tumor differentiation; and whether the growth pattern is diffuse or nodular. The classification of Lukes and Collins is based on the cell of origin, specifically if it is T cell or derived B cell, histiocytic (or monocytic) or unclassifiable origin. The Working Form of the International Panel of the National Cancer Institute categorizes non-Hodgkin's lymphomas using the above classifications. Burkitt's lymphoma is a highly undifferentiated B-cell lymphoma that tends to include sites different from the lymph nodes and the reticulendo-gel system. Burkitt lymphoma, unlike other lymphomas, has a specific geographic distribution, which follows an unidentified insect vector and an infectious agent. The evidence points to herpes as the Epstein-Barr virus. Micosis fungoides is an uncommon chronic T-cell lymphoma that mainly affects the skin and occasionally the internal organs. Plasma cell dyscrasias (PCDs), or monoclonal gammopathy, are disorders characterized by the disproportionate proliferation of a clone of cells normally included in Immunoglobulin (Ig) synthesis, and the presence of structurally and electrophoretically homogeneous IG or polypeptide subunit in serum or urine. The disorders can be mainly asymptomatic for non-secret, progressive neoplasms (for example, multiple myeloma). The disorder results from the disproportionate proliferation of a clone that produces a specific Ig: IgG, IgM, IgA, IgD or IgE. Multiple myeloma, also known as plasma cell myeloma or myelomatosis, is a progressive neoplastic disease characterized by cellular tumors of marrow plasma and overproduction of monoclonal Ig (IgG: IgA, IgD or IgE) or Bence Jones protein, which is free of light chains K or? Diffuse osteoporosis or discrete osteolytic lesions originate due to the replacement of expanding plasma cell tumors or a factor that activates the maloclasts secreted by malignant plasma cells. Macroglobulinemia or macroglobulinemia of Waldenstrom or primary is a plasma cell dyscrasia that includes B cells that normally synthesize and secrete IgM. Macrogolulinemia differs from myeloma and other PCDs, and resembles lymphomatous disease. Many patients have symptoms of hyperviscosity, fatigue, weakness, cutaneous and mucosal bleeding and so on. Heavy chain diseases are neoplastic plasma cell dyscrasias characterized by the overproduction of heavy chains of α, μ, a, d Ig. These disorders result in incomplete monoclonal Igs. The clinical picture is more like lymphoma than multiple myeloma. Hypersplenism is a syndrome in which circulating cytopenia is associated with splenomegaly. The treatment of patients with hypersplenism requires therapy for the underlying disease, not splenectomy. Lymphoproliferative and myeloproliferative diseases are some, but not the only, causes of hypersplenism. Myeloproliferative disorders that cause hypersplenism include polycythemia vera, myelofibrosis with myeloid metaplasia, chronic myelogenous leukemia, and essential thrombocythemia. Chronic lymphocytic leukemia and lymphomas (including Hodgkin's disease) are specific lymphoproliferative disorders that can cause hypersplenism. Lung tissue is the site for both benign and malignant primary tumors, as well as the site of metastasis from cancers of many other organs and tissues. Cigarette smoking causes an overwhelming percentage of lung cancers, estimated at ninety percent of cases in men and approximately seventy percent of cases in women. Exposure to occupational agents such as asbestos emissions, radiation, arsenic, chromates, nickel, clomethyl ethers, poisonous gas, and coke oven is also associated with lung cancer. The most common types of lung cancer are squamous cell, large and small cell and adenocarcinoma. Approximately ninety-five percent of stomach cancers are carcinoma; Less common are lymphomas and leiomyosarcomas. Gastric carcinomas are classified according to gross appearance; boss; penetration (the tumor has a well circumscribed, pronounced edge and can be ulcerated) and diffusion or several, which has characteristics of two of the other types. Pancreatic cancers can be exocrine tumors, which are mostly adenocarcinomas that originate from channel cells instead of acinar cells, or endocrine tumors, which include insulinoama. Pancreatic tumors that produce Gastrin that include non-ß-type cells or in the duodenal wall can cause Zollinger-Ellison syndrome, a syndrome marked by hypergastrinemia. Sometimes other polyglandular abnormalities, particularly with the parathyroid, pituitary or adrenal glands, cause a polyglandular disorder known as multiple endocrine neoplasia (MEN). Cellular tumors of the non-β islet can cause a syndrome known as Vipoma Syndrome, which is characterized by massive, prolonged watery diarrhea. Neoplasms of the intestine include tumors of the small intestine, tumors of the large intestine, and cancer of the colon and rectum. Benign tumors of the small intestine may originate from loyal and immature neoplasms, including leiomyomas, lipomas, neurofibromas, and fibroids. Malignant small bowel tumors, such as adenocarcinomas, are not common, and typically originate in the nearby jejunum. Patients with Crohn's disease of the small intestine are more prone to such adenocarcinomas than patients with Crohn's disease of the colon. In patients with Crohn's disease, tumors tend to occur distantly in inflamed or diverted bowel cycles. Carcinoid tumors typically originate in the small intestine, especially ileus, and in about half the cases, there are multiple tumors. Kaposi's sarcoma, which occurs frequently in transplant recipients and patients with AIDS, has gastrointestinal inclusion in approximately half of the cases. Injuries occur anywhere in the Gl tract, but are usually found in the stomach, small intestine, or distal colon. Tumors of the large intestine include colon and rectum polyps. Polyps are a mass of tissue that originates from the intestinal wall and protrudes into the lumen. Polyps are classified on the basis of their histology, such as tubular adenomas, tubulovillous adenomas, villous adenomas, hyperplastic polyps, hamartomas, juvenile polyps, polypoid carcinomas, pseudopolyps, lipomas, leiomyomas and even rare tumors. Malignant tumors can also originate in the anorectal. These are squamous cell carcinoma (squamous cells) of the anorectum that comprise approximately three to five percent of rectal and anal cancers. In Western cities, colon and rectal cancer are after lung cancer to be considered for more cases each year. In the US, approximately 75,000 people died of these cancers in 1989, approximately 70% occurred in the rectum and sigmoid colon and 95% were adenocarcinomas. Neoplasms of the liver include benign neoplasms, which are relatively common but often undetected, and malignant neoplasms. Hepatocellular adenoma is the most important benign liver neoplasm. Small ansitomatic hemangiomas occur in one to five percent of adults. Bile duct adenomas and other mesenchymal neoplasms also occur, but are relatively rare. Malignant neoplasms of the liver are the most common form of liver tumor, and the liver is a frequent site of metastatic spread of blood usually from primary tumors of the lung, breast, colon, pancreas, and stomach. The incidence of hepatocellular carcinoma is linked to the chronic hepatitis B virus in certain parts of Africa and Southeast Asia. In North America, Europe and other areas of low prevalence, the majority of patients have underlying cirrhosis. Fibrolamellar carcinoma is a distant variant of hepatocellular carcinoma with characteristic morphology of malignant hepatocytes entangled in lamellar fibrous tissue. Fibrolamellar carcinoma usually affects relatively young adults, and has no association with pre-existing cirrhosis, hepatitis B virus infection, and other known risk factors. Other primary malignancies of the liver include cholangiocarcinoma (a tumor that originates in the intrahepatic biliary epithelium), hepatoblastoma (which is one of the ~ ^ «* Most common cancers in infants) and angiosarcoma (which is associated with industrial exposure to vinyl chloride). Leukemia and related disorders can include liver tissues, which are thought to be the result of infiltration with abnormal cells. Multiple Endocrine Neoplasm Syndromes (MEN) are a group of genetically distinct familial diseases that include adenomatous hyperplasia and malignant tumor formation in several endocrine glands. These three distinct syndromes have been identified. Type I (MEN-I) is characterized by tumors of the paritoid glands, pancreatic islets and the pituitary gland. Type II (MEN-II) is characterized by medullary carcinoma of the thyroid, pheochromocytoma and hyperpartiroidism. Type III (MEN-III) is characterized by multiple mucosal neuromas, medullary carcinoma of the thyroid, and pheochromocytoma. Carcinoid syndrome is usually caused by metastatic carinoid tumors that secrete excessive amounts of vasoactive substances, including serotonin, bradykinin, histamine, prostaglandins, and polypeptide hormones. Abnormal levels of these substances cause a variety of symptoms, often episodic skin effusion, cyanosis, abdominal pain, diarrhea, and valvular heart disease. Neoplasms of the bone and joints can be benign or malignant. Benign tumors of the bone include osteochondromas (exostoses osteocartilaginosas), which are the most common benign bone tumors in children between 10 to 20, benign chondromas (which are located inside the bone), which occur most commonly in children and young adults between the ages from 1 0 to 30, chondroblastoma (which originates in an epiphysis), which is rare, but more common in children between the ages of 10 to 20, chondromyofibromas, osteoid osteoma, giant cell tumors and fibromatoses. Primary malignant bone tumors include osteogenic sarcoma (osteosarcoma) which is the second most common major bone tumor, fibrosarcomas, malignant fibrous histiocytoma, chondrosarcomas, mesenchymal chondrosarcoma, Ewing's tumor (Ewing's sarcoma), malignant bone lymphoma, multiple myeloma, and malignant giant cell tumor. Primary cancers of other tissues may spread by metastasis to the bone tissue. The most common carcinomas originate in the chest, lung, prostate, kidney and thyroid. The neoplasms of the central nervous system (CNS) are usually classified according to the organ. The primary intracranial neoplasms are subdivided into six classes: tumors of the skeleton (1); (2) the meninges; (3) the cranial nerves; (4) the glia and ependyma; (5) pituitary or pineal gland; and (6) those of congenic origin. Skeletal neoplasms include osteoma, hemangioma, granuloma, xanthoma, and osteosis. Meningitis neoplasms include meningioma, sarcoma and glomatosis. Neoplasms of the cranial nerve include glioma of the optic nerve, and escanoma of the optimal nerves 8 and 5. The neuroglia neoplasms include glioma and ependymomas. Neoplasms of the pineal or pituitary body include pinealoma and pituitary adenoma. Neoplasms of congenital origin include craniopharyngioma, chordoma, germinoma, teratoma, dermoid cyst, agioma, and hemangioblastoma. The neoplasms of the spinal cord, which includes the spinal cord or its roots, originate from the parenchyma of the cord, roots, meninges or vertebrae. Primary spinal cord neoplasms are much less common than intracranial tumors. Metastatic lesions are common and can be caused by carcinomas of the lung, chest, prostate, kidney, thyroid or lymphoma. Genitourinary neoplasms occur at any age and in both sexes; however, they consider 30% of cancer in the male and 4% in the female. Adenocarcinoma of the prostate considers a significant number of malignancies in men over the age of 50. Prostate adenocarcinoma is thought to be the related hormone and its pathology is typically glandular. Kidney carcinoma, adenocarcinoma, is only about one to two percent of adult cancers, but more solid kidney tumors are malignant. Wilms tumors, an embryonal adenomyosarcoma of the kidneys, occur fetally and are often not diagnosed for several years. The neoplasms of the renal pelvis and uterus are histologically similar. Neoplasms of the urinary bladder can be induced by known urinary carcinogens such as aniline dyes, and the most common is transitional cell carcinoma, less common is squamous cell carcinoma. The rarer genitourinary neoplasms include carcinoma of the urethra and penis. The test neoplasms consider the majority of solid malignancies in men below 30. Most malignant testicular tumors originate in the primordial germ cell and are classified according to the type of cell included. Breast cancer is the most common cancer in women. In the US, the cumulative risk for women of all ages to develop breast cancer is about 10%, but that to die from the disease is only about 3.6%. However, the risk increases with age, a family history of breast cancer, exposure to radiation and even diets are implicated in higher risk. Breast cancers are determined by coetapambre for analysis of estrogen and progesterone receptor. Approximately two-thirds of patients have breast tumors (ER +) positive estrogen receptors. Tumors that are positive for progesterone are thought to have a functional estrogen receptor and the presence of both receptors gives a greater likelihood of favorable response to endocrine treatment than the presence of only one receptor. Endocrine therapy, usually tamoxifen, is preferred in estrogen receptor positive tumors. Estrogens and androgens are also effective, but less favorable due to the undesirable side effects induced by higher levels of these hormones than other forms of endocrine treatment. Breast cancer can spread by metastasis to almost any organ in the body, but the most common sites of metastasis are the lung, liver, bone, lymph nodes and skin. Lobular carcinoma in situ (LCIS) or lobular neoplasm is found more frequently in premenopausal women. DCIS occurs in both pre and postmenopausal women. The DCIS forms a palpable mass. LCIS and DCIS consider approximately 90% of all breast cancers. The rarer forms, medullary and tubular lesions, have somehow a better prognosis. The most common gynecological neoplasms are carcinomas, which are classified in four in frequency after breast, colorectal and lung cancers in women. Endometrial carcinomas are characterized by their clinical organization, which varies from in situ in stage 0, to metastasis to distant organs in stage IVB. Endometrial carcinomas typically produce estrogen and the current treatment approaches are progesterone therapy and surgery. Ovarian cancers account for 18% of all gynecological neoplasms. Approximately 80% of malignant ovarian cancers originate in the ovarian epithelium and are classified according to their histology. The tumors can also originate from germ cells or stroma. Vulvar carcinomas account for approximately 3-4 of all gynecological neoplasms. Valvular carcinoma usually occurs after menopause, and approximately 90% are squamous cell carcinomas. Approximately 4% are basal cell carcinomas and the rest include intraepithelial carcinomas, adenocarcinoma of the Bartholin cell, fibrocarcinoma and melanoma. Vaginal carcinoma accounts for approximately 1% of gynecological malignancies, with a peak incidence of approximately 45 to 65 ages. Approximately 95% of vaginal carcinomas are squamous cell carcinoma. Primary carcinoma of the oviduct is rare, and typically diffuses directly or by lymphatics. The trophoblastic disease or neoplasms of trophoblastic origin, may follow after intra- or extrauterine pregnancy. A degenerating pregnancy results in a hydatidiform mole of which approximately 80% are benign. Neoplasms can originate in the ear canal and affect hearing. Ceruminomas are also originated, they are typically malignant although they seem benign histologically and are treated by surgical removal. Basal cell and cell carcinomas frequently develop in the outer ear as the result of regular exposure to the sun, and are also typically treated by surgical removal. The middle ear may be the site of squamous cell carcinomas. Paragangliomas without chromaffin can originate in the temporal bone.

The most common malignant tumor in the nose and paranasal tissue is squamous cell carcinoma; the least common are mucoepidermoid and adenoid cystic carcinomas, mixed malignant tumors, adenocarcinomas, lymphomas, fibrosarcomas, osteosarcomas, chondrosarcomas and melanomas. Squamous cell carcinoma of the nasopharynx is seen most commonly in children and young adults. The most common malignancies of the upper respiratory tract are squamous cell carcinomas of the amygdala and larynx. Both are common in men and are associated with tobacco smoking and ingestion of ethanol; Approximately 85% of patients with cancer of the head or neck have a history of tobacco and ethanol use. In the head and neck, approximately 90% of cancers are squamous cell carcinoma (epidermoid). Melanomas, lymphomas and sarcomas are relatively rare forms of primary head and neck cancers. Cancers of the head and neck are classified according to the size and inclusion site of the primary neoplasm; the number and size of metastases to the cervical lymph nodes; and evidence distant metastases. Ophthalmologic cancers can originate in the skin of the eyelashes and can be benign or malignant. The common benign growths are xanthelasmas, which form flat yellow-white plates of lipid material subcutaneously. Basal cell carcinomas are more common; The treatment is typically surgical removal or radiation therapy. Other less common malignancies are carcinomas of the meibomian or squamous cell gland and other types of melanomas. The most common primary ocular malignancy is malignant melanoma of the choroid. The tumors also originate in the cutaneous tissue, and include benign tumors such as moles, lipomas and the like, as well as malignant tumors. Approximately 40-50% of malignant melanomas originate from melanocytes in moles. Malignant skin cancers are either squamous cell or basal cell carcinomas and often originate in areas of the skin exposed to the sun. They are the most common malignancies, and the incidence is increased. Less common malignancies include malignant melanoma, Paget's disease of Patent nipple or stratum, Kaposi's sarcoma (KS), and cutaneous T-cell lymphoma (mycosis fungoides). The incidence of KS is increased as a result of the increased incidence of AIDS. KS originates in approximately one third of patients with AIDS. Oral cancers account for approximately 5% of cancers in men and 2% of cancers in women. The most common form of oral cancer is squamous cell carcinoma. The incidence increases with age and risk factors, particularly tobacco and alcohol consumption. Surgery is the oldest effective form for the treatment of neoplasms. Success is achieved successfully are the neoplasm is detected in its early stages and has not spread by metastasis. Radiation is also an important therapy, and is the preferred therapy for many neoplasms such as Hodgkin's disease, early stage non-Hodgkin lymphomas, and squamous cell carcinoma of the head and neck. The radiation has proven to be very successful as an adjunct for surgery and antineoplastic drugs. Antineoplastic drugs are also useful in the treatment of neoplasms, and are classified according to their mechanism of action. The numerous combinations, typically of antineoplastic drugs with different mechanism of action, have proven to be particularly effective therapy, which allows lower doses and frequently minimizes negative side effects. Antineoplastic medications frequently target fundamental biological processes necessary for cell growth or replication. Alkylation agents, such as mechlorethamine and cyclophosphamide, alkylate DNA and restricted DNA replication. The antimetabolites, which address the disruption of the necessary cell division trajectories include: Folate antagonists that bind to dehydrofolate reductase and interfere with pyrimidine synthesis. Folate antagonists are specific in S phase. Methotrexate is an antineoplastic folate antagonist very commonly used. Purine antagonists block de novo purine synthesis and are specific in S phase. 6-Mercaptopurine is an example of a purine antagonist. Pyrimidine antagonists interfere with thymidylate tape to reduce thymidine production and are S-phase specific. One frequently used antagonist is 5-fluorouracil. Cytarabine inhibits DNA polymerases and is specific in S phase. Plant alkaloids include vincapervinca and vincristina, and podophyllotoxins, such as etoposido. Plant alkaloids are effective at metaphase and inhibit mitosis by a variety of mechanisms including altering microtubule proteins. Antibiotics include doxorubicin and daunomycin, which are interspersed between strands of DNA to inhibit the unwinding of DNA; bleomycin, which causes incisions in the DNA strands; and mitomycin, which inhibits DNA synthesis by acting as a bifunctional alkylator. Nitroureas include carmustine and lomustine and alkylated DNA or cause amino acids of carbamoylate. Inorganic ions, such as cisplatin, cause inter- and intracalation of DNA strands to inhibit the unwinding of DNA. Biological Response Modifiers, such as interferons, have antiproliferative effects, but their specific role is not known. Interferons include interferon a (leukocyte), interferon beta (fibroblasts) and interferon? (lymphocyte) Enzymes, such as asparaginase, are also used to alter important metabolic pathways in cancer cells. Asparaginase reduces the asparagine cell, on which the leukemic cells depend. Hormones and their analogues, such as tamoxifen, flutamide and progesterone, have non-specific effects but are useful for the treatment of certain neoplasms, which are known to be hormone responsive, especially breast, ovarian and prostate neoplasms. Tamoxifen, often used in the treatment of breast neoplasms, places the cells at rest and binds to the estrogen receptor. Flutamide, frequently used in the treatment of prostate neoplasms, binds to the androgen receptor. Cytokinins are growth regulators of artificial and naturally occurring plants. Natural cytokinins have to be non-specific inhibitors of several protein kinases. The molecular mechanisms by which cytokines regulate cell division and growth are still being determined. The eetapadios have indicated that cytokines can increase the access of DNA annealing, active RNA polymerase, affect the polyadenylation and secondary structure of mRNA and stimulate the formation and activity of polyribosomes. It is thought that cytokines affect cell division by interacting with cell cycle regulatory proteins. Both cytokines and cyclin-dependent kinases (cdks) act as similar and multiple control points of the cell cycle, for example, in the transitions d / S and G2 / M and the S and M phases. Olomoucin, 6- (benzylamino) 2 - [(2-hydroxyethyl) amino] -methylpurine, was first discovered as a herbicide. More recently, Olomoucin has been found to be an artificial cytokine, which specifically inhibits some cdks, including p34 cdc2 / cyclin B kinases, in micromolar concentration, but has no effect on other major protein kinases such as cAMP-dependent kinases and cGMP. , and protein C kinase. Olomoucine has recently shown to have good selectivity for cyclin CDK protein kinases, but has only moderate inhibitory activity with an IC50 of approximately 7 μM. Vesely, J., ef al Eur. J. Biochem. , 1994, 224-771 -786. A 2.1 A crystal structure of olomucin crystallized with cdk2 revealed that the olomoucine purine portion binds in the conserved ATP binding receptacle, while the benzylamino group extends in a region of the active single site to the cdk2 kinases. Roscovitine, 2- (1-ethyl-2-hydroxyethylamino) -6-benzylamino-9-isopropylpurine, is a recently synthesized purine that has been shown to have selectivity towards some cyclin-dependent kinases and is 10 times more active in cdk2 and cdc2 than olomoucine (Meijer, L. et al., Eur. J. Biochem 243: 527-536, 1997 PCT / FR96 / 01 905). Meier et al report that most kinases are not significantly inhibited by roscovitine. However, cdc2-cyclin B, cdk 2-cyclin A, cdk2-cyclin E and cdk 5-p35 are substantially inhibited with IC5o values of 0.65, 0.7, 0.7 and 0.2 μM, respectively. In contrast, roscovitine shows IC50 values greater than 100 μM for cdk 4-cyclin D1 and cdk 6-cyclin D2. Havlicek, L. ef al., J. Med. Chem (1997) 40: 408-412 reports that roscovitine, and related analogs substituted at positions 2,6 and / or 9, inhibit the p34cdc2-cyclin B kinases. None of the analogs had IC50 values. above the enantiomer (R) of Roscovitine, which had an IC50 value of 0.65 μM. these authors conclude that the N6-benzyl substituent of roscovitine had a superior above the isopentenyl or cyclohexylmethyl substituents. The National Cancer Institute (NCI) is a US Government organization aimed at the discovery and development of new therapeutic oncological products. In 1985, the NCI established a new cancer screening strategy that included human tumor cell lines in an in vitro analysis as the primary cancer screening. A total of sixty human tumor cell lines, derived from seventy types of cancer (lung, colon, melanoma, kidney, ovary, brain and leukemia) were selected for inclusion in the NCL panel (Grever, M: R: Seminars in Oncology, 1 9: 1 992: 622-638). The procedures used in the analyzes have also been reported in the literature. The American Type Tissue Collection (ATTC) acts as a depository for these and other tumor cell lines. Useful human tumor cell lines include the following: MCF7: human breast adenocarcinoma; hormone-dependent; MDA-MB-231: adenocarcinoma of the human breast; hormone-independent; HT-29; human colon adenocarcinoma; of grade II moderately well differentiated; HCT-15: human colon adenocarcinoma; A549: human non-small cell lung carcinoma; DMS-1 14: human small cell lung carcinoma; PC-3; human prostate adenocarcinoma, hormone-independent; and DU 145: human prostate carcinoma, hormone-independent; Skehan, P. et al, J: Nati. Cancer Inst. 82: 1 1 07-1 1 12, 1990 establishes useful procedures for using such tumor cell lines to classify antineoplastic drugs. Meijer ef al, supra, reports that roscovitine inhibits the proliferation of in vitro disease-oriented selection.

NCI, that is, 60 lines of the human tumor cell comprising nine types of tumors (leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, melanoma, ovarian cancer, kidney cancer, cancer of prostate, breast cancer) with an average IC50 value of 16 μM. The results of the individual tumor lines are not reported. Two distinct inhibitors of cdk, flavopiridol and olomoucine, suppress the death of neuronal PC12 cells and sympathetic neurons in two neuronal survival model systems (Park ef al, J. Biol .. Chem 271 (14): 8161-8169, nineteen ninety six). The concentration of each required to promote survival related to the amount required to inhibit proliferation. Neuronal apoptosis is an important aspect of both the development of the nervous system and a component of disease and neuronal damage. The PC12 cell line is initially derived from a rat adrenal medullary pheochromocytoma. When it grows in the medium containing the serum, the PC12 cells divide and look like precursors of adrenal chromaffin cells and sympathetic neurons. After the addition of nerve growth factor (NGF), PC12 cells reach the phenotypic properties of sympathetic neurons. After removal of either serum or serum and NGF, both neuronally differentiated and native PC12 cells undergo apoptosis, which is analogous to the response of sympathetic neurons. The role of cell cycle regulation in apoptosis can be demonstrated with the extraction of NGF or serum which results in the uncoordinated cell cycle progression and cell death of native PC-12 cells. The cdk inhibitors do not prevent the death of these proliferating competent PC-12 cells after removal of trophic support. It is hypothesized that sympathetic neurons or post-miotic differences attempt to inappropriately re-enter the cell cycle after NGF extraction, which results in the death of the cell. However, exposure to flavopiridol or olomoucine that inhibit cdks prevent apoptosis in these cells. Changes in the activity of cdks and cyclins are observed during the apoptosis of many different cell types. The apoptosis induced by araC or canftothecin of the HL60 cells is associated with the high cdc2 activity and cyclin E-associated kinase activity. The kappa-induced apoptosis of RKO cells is associated with an increased expression of cyclin D1. Canftothecin causes an apoptotic death of cerebral cortical neurons in the rat. Morris and Geller, J. Cell. Biol. 134: 757-770 (1996). The neuronally differentiated non-proliferating PC1 2 cells treated with canftothecin died within 6 days after treatment, and cultured rat sympathetic neurons died within 5 days after treatment, even in the presence of NGF. Park ef al; J. Neurosci. 17 (4): 1 256-1270 (1 997). However, the administration of either either flavopiridol or olomoucine, or each, in the presence or absence of campythecin resulted in approximately 30% cell death on day 6. Maximum protection of PC12 cells, or rat sympathetic neurons, against death was observed with 1 μM of flavopiridol and 200 μM of olomoucine, which are the minimum concentrations that completely inhibit DNA synthesis by proliferating PC12 cells. The administration of iso-olomoucine, an active analogue of olomoucine, failed to prevent cell death of the neuronal cells treated with canftothecin, Flavopiridol and olomoucine is also shown to protect against cortical neuronal death induced by canftothecin. Park et al, J. Neurosci. 1 7 (4): 1256-1270 (1997). The IC 50 values of flavopyridol and olomoucine were 0.1 μM and 1 00 μM, respectively. The administration of iso-olomoucine failed to prevent cell death of the neuronal cells treated with canftothecin. There are several implications of the previous observations. It is recognized that patients treated with radiation or antineoplastic agents experience undesirable side effects, including the development of new neoplasms and undesirable cellular apoptosis. For example, some patients treated with high-dose araC for refractory leukemia develop a syndrome of cerebellar toxicity, characterized by the loss of Purkinje neurons. Winkelman and Hinges, Ann Neurol. 14: 520-527 (198) and Vogel and Horouipian, Cancer 71: 1 303-1 308 (1 993). Patients treated with cis-platinum have been reported to develop peripheral neuropathies. Wallach ef al J. Fia. Med. Assoc. 79: 821-822 (1992) and Mansfield and Castillo, AJNR Am. J. Neuroradiol. 1 5: 1 1 78-1 180 (1994). In view of these observations, any co-administration or administration alone of the present compound in the treatment of neoplasms would reduce or prevent cellular apoptosis, in particular, neuronal damage caused by treatment with radiation or antineoplastic agents. Cerebrovascular disease is the most common cause of neurological disability in Western countries. The main specific types of cerebrovascular disease are cerebral insufficiency due to transient disturbances of blood flow, infarction, hemorrhage, and intravenous malformation. The attack usually demonstrates ischemic injuries. Undesirable neuronal apoptosis occurs in cerebrovascular disease. Treatment with cdks inhibitors can be an approach to avoid neuronal damage and degeneration in such cases.

SUMMARY OF THE INVENTION The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NH-, or R3R4N-R5- wherein R2 is selected from the group consisting of C_-C? alkyl, R? R6 I (C)? - OM - ((:? 9 <), r > Z R6 R6 wherein each R6 is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl, and phenyl (CH2) m, where m is an integer 0-8, x is an integer 1 -8, n is an integer 0-8, Z is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, and M is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R6 'is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m'-phenyl, wherein m' is an integer 0-8; n 'is an integer 0-8; x 'is an integer 1 -8; Q is hydrogen or C? -C alkyl; and Z 'is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene; and wherein each C9-d or Z alkyl is optionally substituted with 1 to 3 substitutes, which may be the same or different, and which are selected from the group consisting of D, E, - I 6 I - (C) x * -O 'and - (C) rr * - Z "FV R6" wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C-C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocyl, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl and (CH2) m -phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R 6 '"is independently selected from the group consisting of hydrogen, C 3 -C 8 cycloalkyl, C 1 -C 4 alkyl and (CH 2) m" -phenyl, wherein m "' is an integer 0-8; n '"is an integer 0-8; x '"is an integer 1 -8, Q' is hydrogen or C 1 -C 4 alkyl, and Z '" is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z "can be optionally substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and (CH2) m e -phenyl, wherein m "" is an integer 0-8; x "" is an integer 1 -8; Q "is hydrogen or C? -C4 alkyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C4 alkoxy, each E' is independently selected from the group consisting of in Hal, OH, and alkyl C? -C8; R3 and R4 are selected from the group consisting of hydrogen, C-C4 alkyl and (CH2) y-phenyl, wherein y is an integer 0-8, with the proviso that R3 and R4 are not both hydrogen; R5 is C? -C8 alkylene; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof, with the proviso that, when R2 is the group R6 where n is 1 or greater; R1 is isopropyl or cyclopentyl; R6 is hydrogen, C -C4 alkyl or (CH2) m-phenyl; and Z is phenyl, heterocycle or cycloalkyl, that Z is substituted with 1 to 3 substitutes, which may be the same or different, and which are selected from the group consisting of D, - where D, b, R6" , x ", n", M 'and Z' are as previously defined In addition, the present invention provides a method for inhibiting cell cycle progression More specifically, the present invention provides a method for inhibiting cdk-2. present invention also provides a method for preventing apoptosis in neuronal cells. A particularly preferred method of the present invention is to prevent apoptosis of neuronal cells induced by antineoplastic agents or resulting from cerebrovascular disease. Another preferred embodiment of the present invention is the method for preventing apoptosis induced by oxygen depletion. A more preferred invention provides a method for preventing apoptosis induced by cerebrovascular disease. Another preferred invention provides a method for preventing apoptosis induced by attack or infarction. The present invention provides a method for inhibiting the development of neoplasms. The present invention provides a method for treating a patient suffering from a neoplastic disease state comprising administering a compound of the formula provided. It is preferred that the amount administered be a therapeutically effective amount of a compound of the formula. A preferred method of the present invention delivers a unique compound to the formula provided. Alternatively, a preferred method of the present invention delivers an amount of a compound of the formula in conjunction with other antineoplastic agents. In addition, the present invention provides a composition comprising an analyzable amount of a compound of the Formula (I) in admixture or otherwise in association with an inert carrier. The present invention also provides a pharmaceutical composition comprising an effective inhibitory amount of a compound of the Formula (I) in admixture or otherwise in association with one or more pharmaceutically acceptable excipients or carriers.

DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NH-, or R3R4N-R5- wherein R2 is selected from the group consisting of C.-C12 alkyl, wherein each R6 is independently selected from starting from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and phenyl (CH2) m, wherein m is an integer 0-8; x is an integer 1 -8; n is an integer 0-8; Z is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene; and M is selected from the group consisting of hydrogen, C? -C4 alkyl, - wherein each R6 'is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m'-phenyl, wherein m' is an integer 0-8; n 'is an integer 0-8; x 'is an integer 1 -8; Q is hydrogen or C? -C alkyl; and Z 'is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene; and wherein each C9-C? 2 or Z alkyl is optionally substituted with 1 to 3 substitutes, which may be the same or different, and which are selected from the group consisting of D, E, R6"R6" I - (C)? - OM 'and - (O) - * 1 - Z "6" 6"wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and alkoxy C? -C4, each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, b is an integer 0-2, Z? Is selected from the group consisting of phenyl , heterocyl, cycloalkyl and naphthalene; each R6"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m -phenyl, wherein m" is an integer 0-8; n "is an integer 0-8; x" is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C1-C4 alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH.) pv-phenyl, wherein m"' is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can be optionally substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C-C alkyl, and (CH2) m '-phenyl, wherein m "" is an integer 0-8; x "" is an integer 1 -8; Q "is hydrogen or C 1 -C 4 alkyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C alkoxy, each E' is independently selected from the group consisting of in Hal, OH, and C? -C8 alkyl, R3 and R4 are selected from the group consisting of hydrogen, C1-C4 alkyl and (CH2) y-phenyl, wherein y is an integer 0-8, with the condition that R3 and R4 are not both hydrogen, R5 is Ci-C alkylene, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof, with the proviso that, when R2 is the group R6 (< Q) p- R6 where n is 1 or greater; R1 is isopropyl or cyclopentyl; R6 is hydrogen, C? -C4 alkyl or (CH2) m-phenyl; and Z is phenyl, heterocycle or cycloalkyl, that Z is substituted with 1 to 3 substitutes, which may be the same or different, and which are selected from the group consisting of D. - < < px * -S-R6 * -? x * ~ N-Rß "- (Qx-CM y - (Cjn * - Z" Re "-V • R, '* V where D, b, R6", x", n ", M 'and Z' are as previously defined, as used herein the term" heterocycle "means any closed ring residue in which one or more of The ring atoms are a different element to carbon and include, but are not limited to the following: piperidinyl, pyridinyl, isoxazolyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, benzimidazolyl, thiazolyl, thiophene, furanyl, indolyl, 1,3-benzodioxolyl, tetrahydropyranyl, imidazolyl, tetrahydrothiophene, pyranyl, dioxanyl, pyrrolyl, pyrimidinyl, pyrazinyl, triazinyl, oxazolyl, purinyl , quinolinyl and isoquinolinyl. As used herein, the term "C1.C alkyl" refers to a saturated or unsaturated hydrocarbyl radical, directly branched chain, of one to four carbon atoms and includes, but is not limited to the following: methyl, ethyl, propyl, isopropyl, 1-propenyl, 2-propenyl, n-butyl, isobutyl, tertiary butyl, sec-butyl, 1-butenyl, 2-butenyl, 3-butenyl and the like. As used herein, the term "C 1 -C 8 alkyl" refers to a saturated or unsaturated hydrocarbyl radical, directly branched chain, of one to four carbon atoms and includes, but is not limited to the following: methyl, ethyl, propyl, isopropyl, 1-propenyl, 2-propenyl, n-butyl, isobutyl, tertiary butyl, sec-butyl, 1-butenyl, 2-butenyl, 3-butenyl, pentyl, neopentyl, hexyl, heptyl, octyl and the similar. As used herein the term "C9.C12 alkyl" refers to a saturated or unsaturated hydrocarbyl radical, directly branched chain, of nine to twelve carbon atoms and includes, but is not limited to the following: nonyl , decilo, undecilo and dodecilo and the like. As used herein, the term "Ci-C8 alkylene" refers to a saturated or unsaturated hydrocarbylene radical, directly branched chain, of one to eight carbon atoms and includes, but is not limited to the following : methylene, ethylene, propylene, isopropylene, 1-propylene, 2-propenylene, n-butylene, isobutylene, tertiary butylene, sec-butylene, 1-butenylene, 2-butenylene, 3-butenylene, pentylene, neopentylene, hexylene, heptylene, octilene and the like. As used herein, the term "cycloalkyl" refers to a saturated or unsaturated alicyclic residue containing from three to eight carbon atoms and includes, but is not limited to, the following: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl , cycloheptyl, cyclooctyl, and the like. As used herein, the designation (O) b T s refers to a sulfur atom that is oxidized to a sulfoxide (b = 1) or a sulfone (b = 2). As used herein, the term "Hal" refers to a halogen residue and includes fluoro, chloro, bromo and iodo residues. As used herein, the term "optical isomer" or "optical isomers" refers to any of the various isomeric stereo configurations that may exist for given compounds of Formula (I). As used herein, the term "hydrate" or "hydrates" refers to the reaction product of one or more water molecules with a compound of the formula (I) in which the H-OH bond is not divided into includes monohydrates as well as multihydrates. As used herein, the term "pharmaceutically acceptable salts" refers to the reaction product of one or more molecules of any inorganic or organic, non-toxic acid with compounds of Formula (I). Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids. Illustrative organic acids which form suitable salts include mono, di and tricarboxylic acids. Illustrative of such acids are, for example, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, acid hydroxylamino, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, 2-phenoxybenzoic acid and sulphonic acids such as methane sulfonic acid, trifluoromethane sulphonic acid and 2-hydroxyethane sulfonic acid. The compounds of Formula (I) can be prepared by using procedures and techniques well known and appreciated by one skilled in the art. A general synthetic scheme for preparing these compounds is set forth in Scheme A wherein all substituents, unless otherwise indicated, are as previously defined Scheme AI In scheme A, step a, 2,6-dichloropurine (1) is reacted with appropriate alcohol of structure 2 to give the corresponding 9-substituted-2,6-dichloropurine of the compound of structure 3 using techniques and procedures well known to an expert in the field. For example, 2,6-dichloropurine (1) can be reacted with appropriate alcohol of the 2-structure in the presence of triphenylphosphine and diethyl azodicarboxylate in a suitable anhydrous aprotic solvent, such as tetrahydrofuran. The reagents are typically stirred together at room temperature for a period of time ranging from 5 hours to 5 days. The 9-substituted-2,6-dichlopurine resulting from structure 3 can be recovered from the reaction zone by extractive methods as is known in the art or more typically, the 9-substituted-2,6-dichloropurine resulting from structure 3 it is recovered by solvent removal followed by loading directly onto the silica gel column and eluting with a suitable solvent, such as methylene chloride or solvent mixture, such as a mixture of hexane and ethyl acetate. The crude 9-substituted-2,6-dichloropurine of structure 3 can then be purified by chromatography or can be used in the next step without purification. In step b, the 6-chloro functionality of the 9-substituted-2,6-dichloropurine of structure 3 is reacted with an appropriate amine of structure 4 to give the 9-substituted-6-amino-2 compound -chloropurine of structure 5. For example, 9-substituted-2,? -dichloropurine of structure 3 can be reacted with the appropriate amine of structure 4 in a suitable anhydrous polar solvent such as ethanol. The reagents are typically stirred together at reflux temperatures for a period of time ranging from 30 minutes to 3 days. The 9-substituted-6-amino-2-chloropurine resulting from structure 5 is recovered from the reaction zone by extractive methods as are known in the art., or, if the 9-substituted-6-amino-2-chloropurine of structure 5 is precipitated out of the solution, it can be recovered by filtration. In step c, the 2-chloro functionality of the 9-substituted-6-amino-2-chloropurine of structure 5 is reacted with 1,4-cyclohexanediamine (6) to give the corresponding compound of Formula I. for example, the appropriate 9-substituted-6-amino-2-chloropurine of structure 5 can be reacted with a molar excess of 1,4-cyclohexanediamine (6). The reagents are typically placed in a pressure tube, sealed and heated to a temperature of from about 80 ° C to about 150 ° C for a period of time ranging from 30 minutes to 3 days. The resulting compound of Formula I is recovered from the reaction zone by extractive methods as are known in the art and can be purified by chromatography. The starting materials for use in the general synthetic procedures outlined in Scheme A are readily available to one skilled in the art. For example, certain 4-aminopyridines and 3-aminopyridines of structure 4 can be prepared as described in Schemes B and C below. The initial amines of structure 4 for use in Scheme A which are derivatives of 4-amino-1-piperidine and 3-amino-1-pyrrolidone (structure 4.) Can be prepared as shown in Scheme B, where all the substituents, unless otherwise indicated, are as previously defined.

Scheme B t = 0, 1 Sub »optional substitution In Scheme B, step a, the amino-free functionality of an appropriate derivative of appropriate 4-carboxamide-1-piperidine or 3-carboxamide-1-pyrrolidone of structure 7 is reacted with the appropriate alkyl halide of structure 8 to give the corresponding 4-carboxamide-1-alkylated-piperidine or 3-carboxamide-1-alkylated-pyrrolidine of structure 9. For example, 4-carboxamide-1-piperidine or -carboxamide-1-pyrrolidine of structure 7 can be reacted with the appropriate alkyl halide of structure 8 in a suitable organic apoptic solvent, such as 3-pentanone, in the presence of a suitable base, such as cesium carbonate, and a catalytic amount of a suitable alkylation catalyst, such as potassium iodide. The reagents are typically stirred together at a reflux temperature for a period of time ranging from 30 minutes to 1 2 hours. The 4-carboxamide-1-alkylated-piperidine or 3-carboxamide-1 -alkylated-pyrrolidine of structure 9 is recovered from the reaction zone by filtration and evaporation of the solvent. In step b, the carboxamide functionality of appropriate 4-carboxamide-1-alkylated-piperidine or 3-carboxamide-1-alkylated-pyrrolidine of structure 9 is dehydrogenated to give 4-amino-1 -alkylated-piperidine or -amino-1 -alkylated-pyrrolidine of structure 47 For example, the appropriate 4-carboxamide-1-alkylated-piperidine or 3-carboxamide-1-alkylated-pyrrolidine of structure 9 is reacted with a molar excess of bis. (trifluoroacetoxy) -iodobenzene in a suitable aprotic polar solvent such as acetonitrile. The reagents are typically stirred together at a temperature of about 50 ° C to about 95 ° C for a period of time ranging from 30 minutes to 5 hours. The 4-amino-1 -alkylated-piperidine or 3-amino-1 -alkylated-pyrrolidine of the 4-structure is recovered from the reaction zone by extractive methods as are known in the art. Alternatively, the initial amines of structure 4 for use in Scheme A which are 4-amino-1-piperidine or 3-amino-1-pyrrolidine derivatives (structure 4__) can be prepared as shown in Scheme C, where all substituents, unless otherwise indicated, are as previously defined.

Scheme C 12. eleven The optionally Sub Substitution In scheme C, step a, the amino-free functionality of an appropriate 4-piperidone derivative or 3-piperidone derivative of the structure 1_0 is reacted with the appropriate alkyl halide of structure 8 to give the corresponding 1-alkyl-4-piperidone or 1-alkylated-3-pyrrolidone of structure 1_1_. For example, the 4-piperidone or 3-piperidone of structure 1_0 can be reacted with the appropriate alkyl halide of structure 8 in a suitable aprotic organic solvent, such as 3-pentanone, in the presence of a suitable base, such as cesium carbonate, and a catalytic amount of a suitable alkylation catalyst, such as potassium iodide. The reagents are typically stirred together at reflux temperature for a period of time ranging from 30 minutes to 12 hours. The 1 -alkylated 4-piperidone or 1 -alkylated-3-pyrrolidone resulting from structure 1 is recovered from the reaction zone by filtration and evaporation of the solvent. In step b, the ketone functionality of the 1 -alkylated-4-piperidone or 1 -alkylated-3-pyrrolidone of structure 1_i is reacted with hydroxylamine hydrochloride (1_2.) To give the oxime 1 - . 1-alkylated-4-piperidone or corresponding 1-alkylated-3-pyrrolidone of structure 13. For example, 1-alkylated-4-piperidone or 1 -alkylated-3-pyrrolidone of structure 1_1_ is reacted with hydrochloride of hydroxylamine (12) in the presence of a suitable base, such as sodium acetate in a suitable protic solvent, such as aqueous ethanol. The reagents are typically stirred together at reflux temperatures for a period of time ranging from 30 minutes to 5 hours. The 1-alkyl-4-piperidone oxime or 1-alkyl-3-pyrrolidone oxime resulting from structure 1.3 is recovered from the reaction zone by extractive methods as are known in the art. In stage c, the oxime functionality of the appropriate 1-alkyl-4-piperidone or 1-alkylated-3-pyrrolidone oxime of the structure 1__3 is reduced to give the 4-amino-1-pyridine and 3-amino-1-derivatives pyrrolidine (structure 4__). For example, the 1-alkyl-4-piperidone oxime or 1-alkyl-3-pyrrolidone oxime of the structure 1_3. it is reacted with a reducing agent, such as lithium aluminum hydride, in a suitable anhydrous solvent, such as tetrahydrofuran under inert atmosphere. The reagents are typically stirred together at reflux temperatures for a period of time ranging from 30 minutes to 5 hours. The resulting 4-amino-1-pyridine and 3-amino-1-pyrrolidine derivatives (structure 4__) are recovered from the reaction zone by extractive methods as are known in the art. The following examples present typical syntheses as described in Scheme A. These examples are understood to be illustrative only and are not intended to limit the scope of the present invention in any way. As used herein, the following terms have the indicated meanings: "g" refers to grams; "mmol" refers to millimoles; "mL" refers to milliliters; "bp" refers to boiling point; "° C" refers to degrees Celsius; "mm Hg" refers to millimeters of mercury; "μL" refers to microliters; "μg" refers to micrograms; "μM" refers to micromolar; and "APCT" refers to Chemical Ionization by Atmospheric Pressure. The Rf values are determined by a 4x50 AQ column (YMC) with a linear gradient of 100% C to 100% D in four minutes with one minute sustained at 100% D, where C is 5:95 acetonitrile: water with 0.1% of TFA and D is 95: 5 acetonitrile: water with 0.085% TFA. Molecular ion determinations are made using a MAT SSQ-7: 10 mass spectrometer from Finnigan. Example 1 2-.Trans- (4-aminociclohexyl) aminol-6-dihydrochloride. (4- trifluorobenzyl) aminol-9-cyclopentylpurine Scheme A. stage c: 2,6-Dichloro-9-cyclopentylpurine Dissolve cyclopentanol (260 mg, 3.02 mmol), 2,6-dichloropurine (680 mg, 3.60 mmol) and triphenyl phosphine ( 950 mg, 3.60 mmol) in dry THF (20 mL) and cool to 0 ° C. Add nitrogen azodicarboxylate (570 μL, 3.60 mmol) dropwise over a period of 15 minutes under a nitrogen atmosphere. Stir the resulting solution for 60 hours at room temperature. Evaporate the solvent in vacuo, charge directly onto a column of silica gel, and elute with methylene chloride to give the main compound as a crude mixture. Scheme A. stage b: 2-Chloro-6-.4-trifluorobenzyl) amino1-9-cyclopentylpurine Dissolve 2,6-dichloro-9-cyclopentylpurine (3.00 mmol), 4-trifluorobenzylamine (3.00 mmol) and triethylamine (835 μL, 6.00 mmol) in dry ethanol (20 mL). Heat at reflux for 15 hours, cool and filter the solid to give the main compound. Scheme A. stage c; 2-fTrans- (4-aminociclohexyl) aminol-6-dihydrochloride. (4-trifluorobenzyl) amino1-9-cyclopentylpurine Mix 2-chloro-6 - [(4-trifluorobenzyl) amino] -9-cyclopentylpurine (0.287 mmol) and 1,4-cyclohexanediamine (2.00 g, excess) in a tube of pressure, seal and heat at 140 ° C for 18 hours. Cool the reaction mixture, add CH2CI2 (40 mL) and rinse with H2O (2x20 mL). Dry (MgSO4), evaporate the solvent in vacuo, and purify by silica gel chromatography (10: 1: CH2Cl2 / MeOH / NH4OH drops) to give the main compound. Convert the hydrochloride salt. CIMS (NH3) 474 (MH +); Rf (min.) = 0.58. Example 2 2-.Trans- (4-aminociclohexyl) aminol-6- (2-chlorophenylhydrazino) -9-cyclopentylpurine dihydrochloride Scheme A. Stage b: 2-Chloro-6- (2-chlorophenylhydrazino) -9-cyclopentylpurine 2- Chloro-6- (2-chlorophenylhydrazino) 9-cyclopentylpurine is prepared from 2,6-dichloro-6-cyclopentylpurine, 2-chlorophenylhydrazine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2- [Trans- (4-aminociclohexyl) amino.-6- (2-chlorophenylhydrazino) -9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- dihydrochloride ( 2-chlorophenylhydrazin) -9-cyclopentylpurine is prepared from 2-chloro-6- (2-chlorophenylhydrazin) -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 475 (MH +); Rf (min.) = 3.49 Example 3 2-.Trans-, 4-aminocyclohexyl) amino-6- (3,4,5-trimethoxybenzylamino) -9-cyclopentyl I purine dihydrochloride Scheme A, step b : 2-Chloro-6- (3,4,5-trimethoxybenzylamino) -9-cyclopentylpurine 2-Chloro-6- (3,4,5-trimethoxybenzylamino) -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 3,4,5-trimethoxybenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminociclohexyl) aminol-6- (3,4,5-trimethoxybenzylamino) -9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] -6- dihydrochloride ( 3,4,5-trimethoxybenzylamino) -9-cyclopentylpurine is prepared from 2-chloro-6- (3,4,5-trimethoxybenzylamino) -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 496 (MH +); Rf (min.) = 3.42 Example 4 2-.Trans- (4-aminocyclohexyl) amino-6 - (2-dihydrochloride., 6- dimethoxybenzyl) amino1-9-cyclopentylpurine Scheme A. stage b: 2-Chloro-6-f (2,6-dimethoxybenzyl) amino1-9-cyclopentylpurine 2-Chloro-6 - [(2,6-dimethoxy benzyl) ) amino] -9-cyclopenti I purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2,6-dimethoxybenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminociclohexyl) aminol-6-dihydrochloride. (2,6-dimethoxybenzyl) aminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6 - [(2,6-dimethoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride is prepared from 2-chloro- 6 - [(2,6-dimethoxybenzyl) amino] -9-cyclopentiipurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 466 (MH +); Rf (min.) = 2.29 Example 5 2-.Trans- (4-aminocyclohexyl) amino-1-6-, 4-trifluoromethoxy) phenylamino-1-9-cyclopentylpurine dihydrochloride Scheme A, step b : 2-Chloro-6-. (4-trifluoromethoxy) phenylamino.-9-cyclopentylpurine 2-Chloro-6 - [(4-trifluoromethoxy) phenylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine. 4-trifluoromethoxyaniline, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) amino-1-6-f (4-trifluoromethoxy) phenylamino-1-9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] -6 dihydrochloride - [(4-trifluoromethoxy) phenylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [(4-trifluoromethoxy) phenylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 476 (MH +); Rf (min.) = 4.00 Example 6 2-f Trans- (4-aminocloclohexyl) amino1-6-f2- (diethylamino) ethylaminol-9-cyclopentylpurine trihydrochloride Scheme A. stage b: 2-Chloro-6-.2 - (diethylamino) ethylamino-1-9-cyclopentylpurine 2-Chloro-6- [2- (diethylamino) ethylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2-diethylaminoethylamine, and triethylamine essentially as is described above in Example 1, Scheme A, step b. Scheme A. stage c: 2 -.Trans- (4-aminocloclohexyl) aminol-6-.2- (di-methylene) ethylamino-1-9-cyclopentylpurine trihydrochloride 2- [Trans- (4- -aminocyclohexyl) amino] -6- [2- (diethylamino) ethylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [2- (diethylamino) ethylamino] -9-cyclopentylpurine essentially as described in Example 1. Scheme A, stage c. CIMS (NH3) 415 (MH +); Rf (min.) = 3.1 5 Example 7 2-.Trans- (4-aminociclohexyl) aminol-6-dihydrochloride. (1-naphthyl) methylaminol-9-cyclopentylpurine Scheme A, step b: 2-Chloro-6-. (1-naphthyl) methylaminol-9-cyclopentylpurine 2-Chloro-6 - [(1-naphthyl) methylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 1- (aminomethyl) naphthylene, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminocyclohexyl) amnol-6-f (1-naphthyl) methylammonol-9-cyclopentyl-2-dihydrochloride 2- [Trans- (4-aminocyclohexyl) dihydrochloride) amino] -6 - [(1-naphthyl) methylamino] -9-cyclopentylpurine is prepared from 2-chloro-6 - [(1-naphthyl) methylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 456 (MH +); Rf (min.) = 3.43 Example 8 2-.Trans- (4-aminocyclohexyl) amino 1-6- dihydrochloride. (4-methoxybenzyl) amino-9-cyclopentylpurine Scheme A. stage b: 2-Chloro-6-. (4-methoxybenzyl) amnol-9-cyclopentylpurine 2-Chloro-6 - [(4-methoxybenzyl) amino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-methoxybenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2- [Trans- (4-aminocyclohexy) amino1-6- dihydrochloride. (4-methoxybenzyl) aminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6 - [(4-methoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride is prepared from 2-chloro-6 - [( 4-methoxybenzyl) amino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 436 (MH +); Rf (min.) = 2.28 Example 9 2-Trans- (4-aminocyclohexyl) aminol-6-dihydrochloride. (3- (5- methoxyindolyl)) - 2-ethylamino-9-cyclopentylpurine Scheme A. Step b: 2-Chloro-6-f (3- (5-methoxyindolyl)) - 2-ethylamino. -9-cyclopentylpurine 2-Chloro-6 - [(3- (5-methoxy indolyl)) - 2-ethylamino] -9-cyclopentyl I purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 5-methoxytryptamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-fTrans- (4-aminociclohexyl) aminol-6-f (3- (5-methoxyindolyl)) - 2-ethylaminol-9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) -dihydrochloride ) amino] -6 - [(3- (5-methoxyindolyl)) - 2-ethylamino] -9-cyclopentylpurine is prepared from 2-chloro-6 - [(3- (5-methoxyindolyl)) - 2-ethylamino] - 9-Cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 489 (MH +); Rf (min.) = 3.44 Example 10 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (hydroxymethyl) cyclohexanemethylamino-1-9-cyclopentylpurine dihydrochloride Scheme A. stage b_ 2-Chloro-6-f4 - (i) RoximetiPciciohexanometi minol-9-cyclopentyl purine 2-Chloro-6- [4- (hydroxymethyl) cyclohexanemethylamino] -9-cyclopentyl purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4- (aminomethyl) cyclohexanemethanol , and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A, step c: 2-f Trans- (4-aminocyclohexyl) amino-1-6- (4-hydroxymethyl) cyclohexanemethylamino-1 dihydrochloride 9-Cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino) -6- (4- (hydroxymethyl) cyclohexanemethylamino] -9-cyclopentylpurine dihydrochloride is prepared from 2-chloro-6- [4- (hydroxymethyl) cyclohexanemethylamino] -9 -cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 442 (MH +); Rf (min.) 3.34 Example 1 1 2-.Trans- (4-aminociclohexyl) aminol-6-.2-fluorophenylhydrazinol-9-cyclopentylpurine dihydrochloride Scheme A. stage b: 2-Chloro-6-.2-fluorophenylhydrazino1- 9-Cyclopentylpurine 2-Chloro-6- [2-fluorophenylhydrazino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2-fluorophenylhydrazine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) amino. -6-. 2-fluorophenylhydrazol-9-cyclopentylpyrin dihydrochloride 2- [Trans- (4-aminociclohexyl) amino ] -6- [2-fluorophenylhydrazino] -9-cyclopentylpurine is prepared from 2-chloro-6- [2-fluorophenylhydrazino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 425 (MH +); Rf (min.) = 3.41 Example 12 2-.Trans- (4-aminociclohexyl) aminol-6-f (2-methoxybenzyl) amino-9-cyclopentylpurine dihydrochloride Scheme A. stage b: 2-Chloro- 6- (2-methoxybenzyl) aminol-9-cyclopentylpurine 2-Chloro-6 - [(2-methoxybenzyl) amino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2-methoxybenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2-Trans Trans- (4-aminocyclohexyl) amnol-6 dihydrochloride. (2-methoxybenzyl) aminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6 - [(2-methoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride is prepared from 2-chloro-6 - [( 2-methoxybenzyl) amino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 436 (MH +); Rf (min.) = 2.30 Example 1 3 2-.Trans- (4-aminocloclohexyl) amino-6-dihydrochloride. (2,3- dimethoxybenzyl) aminol-9-cyclopentylpurine Scheme A. stage b: 2-Chloro-6-. (2,3-dimethoxybenzyl) aminol-9-cyclopentylpurine 2-Chloro-6 - [(2,3-d-imethoxybenzyl) amino] -9-cyclopentyl-phenyl is prepared from 2,6-dichloro-9-cyclopentylpurine, 2,3 -dimethoxybenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexyl) amino-6-f (2,3-dimethoxy-benzyl) amino-1-9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) -dihydrochloride ) amino] -6 - [(2,3-dimethoxybenzyl) amino] -9-cyclopentylpurine is prepared from 2-chloro-6 - [(2,3-dimethoxybenzyl) amino] -9-cyclopentylpurine essentially as described in the Example 1, Scheme A, stage c. CIMS (NH3) 466 (MH +); Rf (min.) = 2.29 Example 14 2-.Trans- (4-aminociclohexyl) aminol-6-.2- (4-methoxy-3-dihydrochloride in Detila my nol-9-cyclopentyl pneumine Scheme A. stage b: 2- Chloro-6-.2- (4-methoxyphenyl) ethylamino-1-9-cyclopentylpurine 2-Chloro-6- [2- (4-methoxyphenyl) ethylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2- (4-methoxyphenyl) ethylamine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A, step c: d 2-, Trans- (4-aminociclohexyl) amino1-6-.2- (4-methoxyphenyl) ethylaminol-9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] dihydrochloride -6- [2- (4-methoxyphenyl) ethylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [2- (4-methoxyphenyl) ethylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. CIMS (NH3) 450 (MH +); Rf (min.) = 3.53 Example 15 2-.Trans- (4-aminociclohexyl) amino-6-.3- (2-methoxyethoxy) propylminol-9-cyclopentyl purine Dihydrochloride Scheme A. stage b: 2-Chloro-6-.3- (2-methoxyethoxy) propylamino-1-9-cyclopentylpurine 2-Chloro-6- [3- (2-methoxyethoxy) propylamino] -9-cyclopenti I purine is prepared from 2,6-dichloro- 9-cyclopentylpurine, 3- (2-methoxyethoxy) propylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2- [Trans- (4-aminociclohexyl) aminol-6-.3- (2-methoxyethoxy) propylamino-9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] - dihydrochloride 6- [3- (2-methoxyethoxy) propylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [3- (2-methoxyethoxy) propylamino] -9-cyclopenti I purine essentially as described in Example 1, Scheme A, stage c. CIMS (NH3) 432 (MH +); Rf (min.) = 3.31 Example 16 2-.Trans- (4-aminocloclohexyl) aminol-6- (2-methoxyethylamino) -9-cyclopentylpurine dihydrochloride Scheme A. stage b: 2-Chloro-6- (2 -methoxyethylamino) -9-cyclopentylpurine 2-Chloro-6- (2-methoxyethylamino) -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2-methoxyethylamine, and triethylamine essentially as described above in Example 1 , Scheme A, stage b. Scheme A, step c: 2-fTrans- (4-aminocyclohexyl) aminol-6- (2-methoxyethylamino) -9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminocyclohexyl) amino] -6- dihydrochloride ( 2-methoxyethylamino) -9-cyclopentylpurine is prepared from 2-chloro-6- (2-methoxyethylamino) -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 374 (MH +); Rf (min.) = 3.23 Example 1 7 2-.Trans- (4-aminociclohexyl) aminol-6-dihydrochloride. (2,4-dimethoxybenzyl) aminol-9-cyclopentylpurine Scheme A, step b: 2-Chloro-6 - [(214-dimethoxybenzyl) amino-1-9-cyclopentylpurine 2-Chloro-6 - [(2,4 -dimethoxybenzyl) amino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2,4-dimethoxybenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A, step c: 2- [Trans- (4-aminocyclohexyl) amino-6-dihydrochloride. (2,4-dimethoxybenzyl) aminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino) -6 - [(2,4-dimethoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride is prepared from 2-chloro- 6- [(2,4-dimethoxybenzyl) amino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 466 (MH +); Rf (min.) = 2.29 Example 18 2-.Trans- (4-aminociclohexiDamino-6. (3-diethylamino) propylpamino-9-cyclopenti I purine dihydrochloride Scheme A, step b: 2-Chloro-6- (3-diethylamino) propylamino-9-cyclopentylpurine 2-Chloro-6 - [(3-diethylamino) propylamino] -9-cyclopentylpurine is prepared from 2,6-diechloro-9-cyclopentylpurine, 3-diethylaminopropylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step e: 2-.Trans- (4-aminocyclohexyl) amino-1-6- (3-dimethylamino) propylamino- dihydrochloride 9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6 - [(3-diethylamino) propylamino] -9-cyclopentylpurine dihydrochloride is prepared from 2-chloro-6 - [(3-diethylamino) propylamino] - 9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.CIMS (NH3) 429 (MH); Rf (min.) = 3.1 3 Example 1 9 2-.Trans- (4-aminocyclohexylaminole-) dihydrochloride 6-f (3,4-dimethoxybenzyl) amino1-9- (propyl) purine Scheme A. stage a: 2.6-D Icloro-9- (propyl) purine 2,6-Dichloro-9- (2-propyl) purine is prepared from 2,6-diclopurine and isopropanol essentially as described in Example 1, Scheme A, step a, but replacing isopropanol by cyclopentanol. Scheme A. stage b: 2-Chlorine-6-. (3,4-dimethoxybenzyl) amino-9- (2-propy-purine 2-Chloro-6 - [(3,4-dimethoxybenzyl) amino] -9- (2-propyl) purine is prepared from 2,6-dichloro -9- (2-propyl) purine, 3,4-dimethoxybenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b.

Scheme A. stage c: Dihydrochloride dec 2-f Trans- (4-aminociclohexyl) amino1-6-f (3,4-dimethoxybenzyl) amino1-9- (2-propypurine Dihydrochloride 2- [Trans- (4-aminociclohexyl) amino ] -6 - [(3,4-dimethoxybenzyl) amino] -9- (2-propyl) purine is prepared from 2-chloro-6 - [(3,4-dimethoxybenzyl) amino] -9- (2-propyl) purine essentially as described in Example 1, Scheme A, step c.CIMS (NH3) 440 (MH +); Rf (min.) = 3.33 Example 20 2-f Trans- (4-aminociclohexyl) aminol-6-.2,6-dichlorophenylhydrazinol-9-cyclopentylpurine dihydrochloride Scheme A. stage b: 2-Chloro-6-.2,6 -dichlorophenylhydrazol-9-cyclopentylpurine 2-Chloro-6- [2,6-dichlorophenylhydrazino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2,6-dichlorophenylhydrazine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexyl) amino1-6- .2,6-dichlorophenylhydrazinol-9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] -6 dihydrochloride - [2,6-dichlorophenylhydrazino] -9-cyclopentylpurine is prepared from 2-chloro-6- [2,6-dichlorophenylhydrazino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 475 (MH +), Rf (min.) = 3.43 Example 21 2-.Trans- (4-aminociclohexyl) aminol-6- (3-fluorophenylamino) -9-cyclopentylpurine dihydrochloride Scheme A. stage b: 2-Chloro-6- (3-fluorophenylamino) ) -9-Cyclopentylpurine 2-Chloro-6- (3-fluorophenylamino) -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 3-fluoroaniline, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-fTrans- (4-aminociclohexyl) aminol-6- (3-f luorofenylamino) -9-cyclopentyl I Purine Dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] -6 dihydrochloride - (3-fluorophenylamino) -9-cyclopentylpurine is prepared from 2-chloro-6- (3-fluorophenylamino) -9-cyclopentylpurine and essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 448 (MH +); Rf (min.) = 3.44 Example 22 2-.Trans- (4-aminocyclohexyl) amino-1-6-methoxypropylamino) -9-cyclopentylpurine dihydrochloride Scheme A. Step b: 2-Chloro-6- (3-methoxy? Ropylamino @ -9-cyclopentylpurine 2-Chloro-6- (3-methoxypropylamino) -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 3-methoxypropylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-f Trans- (4-aminocloclohexyl) amnol-6- (3-methoxy-ropylamino) -9-cyclopentylpurine Dihydrochloride 2- [ Trans- (4-aminocyclohexyl) amino] -6- (3-methoxypropylamino) -9-cyclopentylpurine is prepared from 2-chloro-6- (3-methoxypropylamino) -9-Cyclopentylpurine essentially as described in Example 1, Scheme A , stage c. CIMS (NH3) 388 (MH +); Rf (min.) = 3.29 Example 23 2-Trans- (4-aminociclohexyl) amnol-6-dihydrochloride. (4- pentyl) phenylaminol-9-cyclopentyl I purine Scheme A. stage b: 2-Chloro-6-. (4-1 pentyl) phenylamino-1-9-cyclopentylpurine 2-Chloro-6 - [(4-pentyl) phenylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-butylphenylamine, and triethylamine essentially as is described above in Example 1, Scheme A, step b. Scheme A. step c: 2-.Trans- (4-aminocyclohexyl) amino-1-6- dihydrochloride. (4-pentyl) phenylamino-1-9-cyclopentyl I purine 2- [Trans- (4-aminocyclohexyl) amino] -6 - [(4-pentyl) phenylamino] -9-cyclopentylpurine dihydrochloride is prepared from 2-chloro-6 - [(4-pentyl) phenylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 462 (MH +); Rf (min.) = 4.15 Example 24 Dihydrochloride of (+/-) - 2-.Trans- (4-aminocyclohexyl) amino-1-6-. (α-Cyclopropyl-4-chlorobenzyl) amino-1-9-cyclopentylpurine Scheme A. Stage b: 2-Chloro-6-. ("-cyclopropyl-4-chlorobenzyl) amino1-9-cyclopentylnurine 2-Chloro-6 - [(α-cyclopropyl-4-chlorobenzyl) amino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, -cyclopropyl-4-chlorobenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexil) aminol-6-. (α-cyclopropyl-4-chlorobenzyl) arrunol-9-cyclopentyl urine Dihydrochloride 2 - [Trans- (4-aminociclohexyl) amino] -6 - [(α-cyclopropyl-4-chlorobenzyl) amino] -9-cyclopentylpurine dihydrochloride prepared from 2-chloro-6 - [(α-cyclopropyl-4-chlorobenzyl) amino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. CIMS (NH3) 480 (MH +); Rf (min.) = 2.35 Example 25 2-Trans- (4-aminociclohexyl) aminol-6-dihydrochloride. (2-trifluorobenzyl) aminol-9-cyclopentylpurine Scheme A, step b: 2-Chloro-6-. (2-trifluorobenzyl) amino1-9-cyclopentylpurine 2-Chloro-6 - [(2-trifluorobenzyl) amino] -9-cyclopentylpurine is prepared from 9,6-dichloro-9-cyclopentylpurine, 2-trifluorobenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminociclohexyl) amino1-6-f (2-trif I uorobenzyl) amino.-9-cyclopentyl pyridin Dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] dihydrochloride -6 - [(2-Tylfluorobenzyl) amino] -9-cyclopentylpurine is prepared from 2-chloro-6 - [(2-trifluorobenzyl) amino] -9-cyclopentylpurine essentially as described in Example 1. Scheme A, stage c. CIMS (NH3) 474 (MH +); Rf (min.) = 2.31 Example 26 2-.Trans- (4-aminociclohexyl) aminol-6- (2-hydroxyethoxyethylamino) -9-cyclopentylpupine dihydrochloride Scheme A. stage b: 2-Chloro-6- (2 -hydroxyethoxyethylamino) -9-cyclopentylpurine 2-Chloro-6- (2-hydroxyethoxyethylamino) -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2- (2-aminoethoxy) ethanol, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6- (2-hydroxyethoxyethylamino) -9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] - 6- (2-hydroxyethoxyethylamino) -9-cyclopentylpurine is prepared from 2-chloro-6- (2-hydroxyethoxyethylamino) -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 404 (MH +); Rf (min.) = 3.16 Example 27 2-.Trans- (4-aminociclohexyl) amino1-6-.2- (3-methoxyphenyl) -ethylamino-9-cyclopentylpurine dihydrochloride Scheme A. stage b: 2-Chloro-6-.2 - (3-methoxyphenyl) etlaminol-9-cyclopentylpurine 2-Chloro-6- [2- (3-methoxyphenyl) ethylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2- (3 -methoxyphenyl) ethylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminocyclohexyl) amynol-6-.2- dihydrochloride (3-methoxyphenyl) ethylamino-9-cyclopentylpurine 2- (Trans- (4-aminocyclohexyl) amino] -6- [2- (3-methoxyphenyl) ethylamino) -9-cyclopentylpurine dihydrochloride is prepared from 2-chloro-6 - [2- (3-methoxyphenyl) ethylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.CIMS (NH3) 450 (MH +); Rf (min.) = 3.54 Example 28 Dihydrochloride 2-.Trans- (4-aminociclohexyl) amnol-6- (3,5-dimethoxybenzyl) amino-9-cyclopentyl urine Scheme A. stage b: 2-Cl Gold-6-f (3,5-dimethoxybenzyl) amino-1-9-cyclopentylpurine 2-Chloro-6 - [(3,5-d-methoxy-be-nyl) -amino] -9-cyclopentyl-phenyl is prepared from , 6-dichloro-9-cyclopentylpurine, 3,5-dimethoxybenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2 -.Trans- (4-aminocloclohexyl) amino-1-6 -! (3,5-dimethoxybenzylDamino-1-9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] -6- dihydrochloride [(3,5-dimethoxybenzyl) amino] -9-cyclopentylpurine is prepared from 2-chloro-6 - [(3,5-dimethoxybenzyl) amino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c) CIMS (NH3) 466 (MH +); Rf (min.) = 2.27 Example 29 Dihydrochloride 2-.Trans- (4-aminociclohexyl) aminol-6- (4-methoxybutylamino) -9-cyclopentylpurine Scheme A. Stage b: 2-Chloro-6- (4-methoxybutylamino) -9-cyclopentylpurine 2-Chloro-6- (4-methoxybutylamino) -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-methoxybutylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminocyclohexyl) amino 1-6- (4-methoxybutylamino) -9-cyclopentylpurine dihydrochloride Dihydrochloride 2- [Trans- (4-aminocyclohexyl) amino] -6- (4-methoxybutylamino) -9-cyclopent Glutin is prepared from 2-chloro-6- (4-methoxybutylamino) -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 388 (MH +); Rf (min.) = 3.29 Example 30 2-Trans- (4-aminociclohexyl) amnol-6-dihydrochloride. (2,3-dimethoxybenzyl) aminol-9- (2-propyl) purine Scheme A, step b: 2-Chloro-6-. (2,3-dimethoxybenzyl) amnol-9- (2-propyl) purine 2-chloro-6 - [(2, 3-dimethoxybenzyl) amino] -9- (2-propyl) purine is prepared from 2,6-dichloro-9- (2-propyl) purine (see Example 19 for preparation), 2,3-dimethoxypenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step P. Scheme A. step c: 2-.Trans- (4-aminocyclohexyl) amino 1-6- dihydrochloride. (2,3-dimethoxybenzyl) amino1-9- (2- propypurine Dihydrochloride 2- [Trans- (4-aminocyclohexyl) amino] -6 - [(2,3-dimethoxybenzyl) amino] -9- (2-propyl) ) purine is prepared from 2-chloro-6 - [(2,3-dimethoxybenzyl) amino] -9- (2-propyl) purine essentially as described in Example 1, Scheme A, step c.CIMS (NH3) 440 Rf (min.) = 3.39 Example 31 5 2-.Trans- (4-aminociclohexyl) aminol-6-.2- (phenylamino) etilamino1-9-cyclopentylpurine trihydrochloride Scheme A. stage b: 2-Chloro-6 -2-phenylamino) ethylaminol-9-cyclopentylpurine 2-Chloro-6- [2- (phenylamino) ethylamino] -9-cyclopentylpurine is prepared from 0,6-dichloro-9-cyclopentylpurine, N-phenylethylenediamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6-.2- (phenylamino) ethylammonol-9-cyclopentyl urine trihydrochloride 5 2- [Trans- (4-aminociclohexyl) amino trihydrochloride ] -6- [2- ^ * ^^^^ ^ -Éj_ -i? Í ___ É__ > E _____________ (phenylamino) ethylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [2- (phenylamino) ethylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 435 (MH +); Rf (min.) = 3.34 Example 32 2-.Trans- (4-aminociclohexyl) amino 1-6- (phenylamino) -9-cyclopentylpurine dihydrochloride Scheme A. stage b: 2-chloro-6- (phenylamino) -9- Cyclopentylpurine 2-Chloro-6- (phenylamino) -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, aniline, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2-fTrans- (4-aminocic-IohexyPam i no1-6- (phenamino) -cyclopentylpurine dihydrochloride 2- [Trans- (4-aminocyclohexyl) amino] -6- (phenylamino) - dihydrochloride 9-Cyclopentylpurine is prepared from 2-chloro-6- (phenylamino) -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. CIMS (NH3) 392 (MH +); Rf (min.) = 3.35 Example 33 2-.Trans- (4-aminociclohexyl) amino] -6- .4- (1-benzyl) piperidinylamino-1-9-cyclopentylpurine trihydrochloride Scheme A. stage b: 2-Chloro-6 -4- (1-benzyl) piperidin-1-amino-9-cyclopentylpurine 2-Chloro-6- [4- (1-benzyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, -amino-1-benzylpiperidine, and _______________ triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminocyclohexyl) amino-6-.4- (1-benzyl) piperidinylaminol-9-cyclopentylpurine trihydrochloride 2- [Trans- (4-aminocyclohexyl) amino trihydrochloride ] -6- [4- (1-benzyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1-benzyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. CIMS (NH3) 489 (MH +); Rf (min.) = 3.29 Example 34 2-.Trans- (4-aminociclohexyl) aminol-6-.3,4-dimethoxy benzyl) amino-9-cyclopentylpurine dihydrochloride Scheme A. stage b: 2- Chloro-6-.3,4-dimethoxybenzyl) amino-1 -9-cyclopentylpurine 2-Chloro-6- [3,4-dimethoxybenzyl) amino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 3,4-dimethoxybenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6-.3,4-dimethoxybenzyl) amino-1-9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] dihydrochloride -6- [3,4-dimethoxybenzyl) amino] -9-cyclopentylpurine is prepared from 2-chloro-6- [3,4-dimethoxybenzyl) amino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. CIMS (NH3) 466 (MH +); Rf (min.) = 2.25 Example 35 2-Trans- (4-aminociclohexyl) amino-6- hydrochloride. (3-voldobenzyl) aminol-9- (2-cyclopentenyl) purine Scheme A. stage: 2,6-Dichloro-9-cyclopentenylpurine 2,6-Dichloro-9-cyclopentenylpurine is prepared from 2,6-dichloropurine and cyclopentenol essentially as described in Example 1, Scheme A, step a, but substituting cyclopentenol for cyclopentanol. Scheme A, step b: 2-Chloro-6-, (3-iodobenzyl) aminol-9-cyclopentenylpurine 2-Chloro-6 - [(3-iodobenzyl) amino] -9-cyclopentenylpurine is prepared from 2,6-dichloro- 9-cyclopentenylpurine, 3-iodobenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2-.Trans- (4-aminociclohexil) amino1-6-. (3-vedobenzyl) aminol-9-cyclopentenylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6 - [(3-iodobenzyl) amino] -9-cyclopentenylpurine hydrochloride is prepared from 2-chloro-6- [(3-iodobenzyl) amino] -9-cyclopentenylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 530 (MH +) Example 36 2-f Trans- (4-aminociclohexyl) amnol-6- (dodecylamino) -9-cyclopentylpurine dihydrochloride Scheme A. Stage b: 2-Chloro-6- (dodecylamino) - 9-Cyclopentylpurine 2-Chloro-6- (dodecylamino) -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, n-dodecylamine, and triethylamine essentially as described above in Example 1, Scheme A, 5 stage b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) amino 1-6- (dodecylamino) -9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminocyclohexyl) amino] -6- (dodecylamino) - dihydrochloride 9-cyclopentylpurine is prepared from 2-chloro-6-10 (dodecylamino) -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 484 (MH +); Rf (min.) = 5.09 Example 37 2-, Trans- (4-aminocyclohexyl) amino 1-6- dihydrochloride. (4-15 methoxybenzyl) amino1-9- (2-propyl) purine Scheme A. stage b: 2-Chloro-6-. (4-methoxybenzyl) aminol-9- (2-propypurine 2-Chloro-6 - [(4-methoxybenzyl) amino] -9- (2-propyl) purine is prepared from 2,6-dichloro-9- (2- propyl) purine (see Example 19 for preparation), 4-20 methoxybenzylamine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A, step c: 2-f Trans- (4-aminocyclohexyamino) dihydrochloride -6- (4-methoxy benzyl) aminol-9- (2-propyl) pu rinate 2- [Trans- (4-aminociclohexyl) amino] -6 - [(4-methoxybenzyl) amino] - dihydrochloride 9- (2-propyl) purine is prepared from 2-chloro-6 - [(4- ______! _______ «________, * ____ __-_-, ^ ________ _ ^ ^ ^ ___« ___ «_____ ^? T ^ M ^^ ¿a ^^^ m ^ ¡¡tm ^ j ^ ^^^^ t ^^^ iß ^^ ^? I? T ^ y ^ methoxybenzyl) amino] -9- (2-propyl) purine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 41 0 (MH +) -, Rf (min.) = 3.37 Example 38 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (4-chlorobenz P) piperidinylaminol-9 -cyclopentyl urine Preparation of 4-Amino-1- (4-chlorobenzyl) piperidine Method 1: Scheme B, step a: 4-Carboxamide-1 - (4-chlorobenzyl) pperidine Dissolve isopenicotamide (39 mmol) in 3-pentanone (25 mL) and heat to reflux, add cesium carbonate (24 mmol) and a catalytic amount of potassium iodide (2 spatula tips, cat) followed by 4-chlorobenzyl chloride (47 mmol) Ag [Tar and reflux for 5 hours filter the hot solution through cel [Ta, rinse the filter cake with hot acetone (4x20mL), combine the filtrate and the rinses, and evaporate the solvent in vacuo and the residue is recrystallized from acetone to give the Main compound: Scheme B. Stage b: 4-Amino-1- (4-chlorobenzyl) piperidine Dissolve bis (trifluoroacetoxy) iodobecene (84 mmol) in acetonitrile (20 mL) and dilute with water (20 mL) Add 4-carboxamide -1 - (4- chlorobenzyl) -piperidine (7 mmol) and heat overnight at 65 ° C. Cool the mixture (cold bath), add water (60 mL), followed by concentrated HCl. Extract with ether (2X). The aqueous layer was concentrated in vacuo, and the residue was dissolved in water in 40 mL of water. Basify with aqueous sodium carbonate, and extract into methylene chloride, the organic layer was dried over Na SO4, and filtered and the solvent was evaporated in vacuo to give the main compound. Method 2: Scheme C. Step a: 1- (4-Chlorobenzyl) -4-piperidone 5 Dissolve 4-piperidone (1.7 mmol) in 3-pentanone (25 mL) and heat to reflux. Add cesium carbonate (19 mmol) and a catalytic amount of potassium iodide, followed by 4-chlorobenzyl chloride (20 mmol). Aggregate and reflux for 4 hours. Filter the hot suspension, rinse the residue with hot acetone (4x20 mL), combine the filtrate and rinses, and evaporate the solvent in vacuo to give the main compound Scheme C. Step b: 1 - (4-Chlorobenzyl) oxime - 4-pperidone Dissolve 1 -4 (chlorobenzyl) -4-piperidone (0.0456 mmol), hydroxylamine hydrochloride (0.0456 mmol) and sodium acetate (0.0455 mmol) in 15 aqueous ethanol (450 mL). Stir approximately 30 minutes to 2 hours while heating. Add methylene chloride (450 mL), separate the organic phase, and extract the aqueous phase with methylene chloride (100 mL). Combine the organic phases and dry (MgSO). Evaporate the solvent in vacuo to give the main compound. 20 Scheme C. Stage c: 4-Amino-1 - (4-chlorobenzyl) piperidine Add 1 - (4-chlorobenzyl) -4- (piperidpene) oxime (1.87 mmol) to a solution of aluminum hydride [Uncle (2.5 mL of 1 M solution in tetrahydrofuran) and place under nitrogen atmosphere. Heat at reflux for 2 hours, cool and pour into dilute aqueous sodium hydroxide. Extract with a mixture of ethyl ether / acetate c_- _ »-__ tf -. -. . , ... -. . . . ... ... .. . , -, «. . c, .-- ¿- **. of ethyl (2x), rinse with aqueous sodium chloride and dry (MgSO4). Evaporate the solvent in vacuo to give the main compound. Scheme A, stage bj 2-Chloro-6-.4- (1 - (4-chlorobenzyl)) pipiperidinylaminol-9-cyclopentyl I purine 2-Chloro-6- [4- (1 - (4-chlorobenzyl)) piperidinylamino ] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-chlorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexyl) amino-6-.4- (1- (4-aminociclohexyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino ] -6- [4- (1 - (4-chlorobenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (4-chlorobenzyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Rf. (min) = 2.29; 94% purity; MS (APCl): 523 M + 1 Example 39 2- [Trans- (4-aminociclohex¡l) amnol-6-í4- (1 - (4-methoxybenzyl)) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1 - (4-methoxybenzylpiperidine) Method 1 Scheme B. stage a: 4-Carboxamide-1 - (4-methoxybenzylpiperidine 4-Carboxamide-1- (4-methoxybenzyl) piperidine can be prepared from isonipecotamide and 4-methoxybenzyl chloride essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1- (4-methoxybenzylpiperidine 4-Amino-1- (4-methoxybenzyl) piperidine is prepared from 4-carboxamide -1- (4-methoxybenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C, step a: 1- (4-Methoxybenzyl-P-4-pperidone 1 - (4-Methoxybenzyl) -4-piperidone is prepared from 4-piperidone and 4-methoxybenzyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b oxime of 1- (4-methoxybenzyl) -4-piperidone oxime of 1- (4-methoxybenzyl) -4-piperidone is prepared from 1- (4-methoxybenzyl) -4-piperidone and hydrochloride of hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1- (4-methoxybenzyl) piperidine 4-Amino-1- (4-methoxybenzyl) piperidine is prepared from 1- (4-methoxybenzyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c Scheme A, step bj 2-Chloro-6-.4- (1- (4-methoxybenzyl)) p.peridinylaminol-9-cyclopentylpurine 2- Chloro-6- [4- (1- (4-methoxybenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-methoxybenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2- [Trans- (4-aminociclohexyl) amino-6-.4- (1- (4-methoxybenzyl)) piperidinylaminol-9-cyclopenti I purine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1- (4-methoxybenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [ 4- (1- (4-methoxybenzyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Rf. (min.) = 2.26; purity 1 00%; MS (APCl) : 5 1 9 M + 1 Example 40 2-.Trans- (4-aminociclohexyl) amino1-6-f4- (1 - (4-methylbenzyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1- (4-methylene-phenylpiperidine) 1 Scheme B. step a: 4-Carboxamide-1 - (4-methylbenzyl) piperidine 4-Carboxamide-1- (4-methylbenzyl) piperidine can be prepared from isonipecotamide and a-chloro-p-xylene essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1- (4-methylbenzyl) piperidine 4-Amino-1- (4-methylbenzyl) piperidine is prepared from 4-carboxamide-1- (4-methylbenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C, step a: 1- (4-Methylbenzyl) -4-piperidone 1- (4-Methylbenzyl) -4-piperidone is prepared from 4-piperidone and a-chloro-p-xylene essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (4-Methylbenzyl) -4-piperidone oxime 1- (4-Methylbenzyl) -4-piperidone oxime is prepared from 1- (4-methylbenzyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (4-methylbenzyl) piperidine 4-Amino-1- (4-methylbenzyl) piperidine is prepared from 1 - (4-methylbenzyl) -4-piperidone oxime essentially as described up in the Example 38, Scheme C, step c. Scheme A, step b: 2-Chloro-6-, 4- (1 - (4-methylbenzyl)) p -peridinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1- (4-methylbenzyl)) piperidinylamino ] -9-cyclopentylpurine is prepared from 2,6-dichloo-9-cyclopentylpurine, 4-amino-1- (4-methylbenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminociclohexyl) amino1-6- (4- (1 -, 4-methylbenzyl)) piperidinylamino-1-9-cyclopentyl I purine 2- [Trans- (4-aminociclohexyl) amino] -6- [4- (1 - (4-methylbenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (4-methylbenzyl)) piperidinylamino] -9-cyclopentylpurine essentially as is described in Example 1, Scheme A, step C. Rf. (min) = 2.26; 100% purity; MS (APCl): 503 M + 1 Example 41 2-, Trans- (4-aminociclohexi0amino. -6- .4- (1 - (3-methoxy benzyl)) piperidin ylamino. -9-cyclopentylpurase Preparation of 4-Amino -1- (3-methoxybenzyl) piperidine Method 1 Scheme B. Stage a: 4-Carboxamide-1 - (3-methoxybenzyl) piperidine 4-Carboxamide-1 - (3-methoxybenzyl) piperidine can be prepared from isonipecotamide and chloride 3- methoxybenzyl essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1- (3-methoxybenzyl) piperidine 4-Amino-1- (3-methoxybenzyl) piperidine is prepared from 4-carboxamide-1- (3-methoxybenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C. Step a: 1- (3-Methoxybenzyl) -4-piperidone 1 - (3-Methoxybenzyl) -4-piperidone is prepared from 4-piperidone and 3-methoxybenzyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C, stage b. 1 - (3-Methoxybenzyl) -4-piperidone oxime 1- (3-Methoxybenzyl) -4-piperidone oxime is prepared from 1- (3-methoxybenzyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Stage c: 4-Amino-1 - (3-methoxybenzyl) pperidine 4-Amino-1- (3-methoxybenzyl) piperidine is prepared from 1 - (3-methoxybenzyl) -4-oxime -piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step b 2-Chloro-6-.4- (1 - (3-methoxybenzyl)) piperidin-1-yl-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3-methoxy benzyl) )) piperidinylamino] -9-cyclopentyl pyrimine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-methoxybenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2- [Trans- (4-aminocyclohexyl) aminol-6-.4- (1- (3-methoxybenzyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] - 6- [4- (1 - (3-methoxybenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (3-methoxybenzyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Rf. (min) = 2.27; 99% purity; MS (APCl): 5 19 M + 1 Example 42 2 -.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (3-chlorobenzyl)) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1 - (3-chlorobenzyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (3-chlorobenzyl) piperidine 4-Carboxamide-1 - (3-chlorobenzyl) piperidine can be prepared from isonipecotamide and 3-chlorobenzyl chloride essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1- (3-chlorobenzyl) piperidine 4-Amino-1- (3-chlorobenzyl) piperidine is prepared from 4-carboxamide-1- (3-chlorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C, step a: 1- (3-Chlorobenzyl) -4-piperidone 1- (3-Chlorobenzyl) -4-piperidone is prepared from 4-piperidone and 3-chlorobenzyl essentially as described above in the Example 38, Scheme C, stage a. Scheme C. stage b: 1 - (3-chlorobenzyl) -4-pperidone oxime 1 - (3-chlorobenzyl) -4-piperidone oxime is prepared from 1- (3-chlorobenzyl) -4-piperidone hydrochloride hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (3-chlorobenzyl) piperidine 4-Amino-1- (3-chlorobenzyl) piperidine is prepared from 1 - (3-chlorobenzyl) -4-piperidone oxime essentially as described up in the Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-.4- (1 - (3-chlorobenzyl)) piperidinyl-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3- chlorobenzyl)) piperidinylamino] -9-cyclopenti I purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-chlorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A, step c: 2-.Trans- (4-aminocyclohexyl) amino1-6-.4- (1- (3-chlorobenzylpiperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6 - [4- (1 - (3-chlorobenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (3-chlorobenzyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c Rf. (min) = 2.25, purity 95%; MS (APCl): 523 M + 1 Example 43 2-.Trans- (4-aminociclohexyl) aminol-6-f4- ( 1- (2-chlorobenzyl)) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1- (2-chlorobenzyl) piperidine Method 1 Scheme B, step a: 4-Carboxamide-1 - (2-chlorobenzyl) piperidine 4 Carboxamide-1 - (2-chlorobenzyl) piperidine can be prepared from isonipecotamide and 2-chlorobenzyl chloride essentially as described above in Example 38, Scheme B, step a.Scheme B. step b: 4-Amino-1 - ( 2-chlorobenzyl) piperidine 4-Amino-1 - (2-chlorobenzyl) piperidine is prepared from 4-carboxamide-1- (2-chlorobenzyl) piperidine essence as described above in Example 38, Scheme B, stage b. Method 2: Scheme C, step a: 1- (2-chlorobenzyl) -4-piperidone 1- (2-chlorobenzyl) -4-piperidone is prepared from 4-piperidone and 2-chlorobenzyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (2-Chlorobenzyl) -4-piperidone oxime 1 - (2-Chlorobenzyl) -4-piperidone oxime is prepared from 1- (2-chlorobenzyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (2-chlorobenzyl) piperidine 4-Amino-1- (2-chlorobenzyl) piperidine is prepared from 1 - (2-chlorobenzyl) -4-piperidone oxime essentially as described up in the Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6- (4- (1 - (2-chlorobenzyl)) piperidinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2-chlorobenzyl)) piperidinylamino] - 9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-chlorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Step c: 2-f Trans- (4-amino) -cyclohexy-Daminol-6-f4- (1- (2-chlorobenzyl)) piperidinylamine-1 -9-cyclopentyl purine 2- [Trans- (4-aminociclohexyl) amino] - 6- [4- (1 - (2-Chlorobenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2-chlorobenzyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Rf. (min) = 2.25, purity 92%, MS (APCl): 523 M + 1 Example 44 2-.Trans- (4-aminocyclohexyl) amino 1-6- .4- (1 - (2-methylbenzyl)) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1- (2-methylbenzyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - ( 2-methylbenzyl) pipe Ridin 4-Carboxamide-1 - (2-methylbenzyl) piperidine can be prepared from isonipecotamide and a-chloro-o-xylene essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1 - (2-methylbenzyl) pperidine 4-Amino-1- (2-methylbenzyl) piperidine is prepared from 4-carboxamide-1 - (2-methylbenzyl) piperidine essentially as described above in the Example 38, Scheme B, step b Method 2: Scheme C. Step a: 1- (2-Methylbenzyl) -4-piperidone 1- (2-Methylbenzyl) -4-piperidone is prepared from 4-piperidone and a-chloro- o-xylene essentially as described above in Example 38, Scheme C, stage a. Scheme C. Stage b: 4-Amino-1- (2-methylbenzyl) pperideone oxime 4-Amino-1- (2-methylbenzyl) piperidone oxime is prepared from 4-amino-1 - (2- methylbenzyl) piperidine and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (2-methylbenzyl) piperidine 4-Amino-1- (2-methylbenzyl) piperidine is prepared from essentially as described above in Example 38, Scheme C, step c Scheme A. stage b: 2-Chloro-6-.4- (1 - (2-methylbenzyl)) piperidinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2-methyl-benzyl) ) piperidinylamino] -9-cyclopentyl purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-methylbenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminociclohexil) aminol-6-f4- (1 - (2-methylbenzyl)) piperidin-laminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino ] -6- [4- (1 - (2-methylbenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2-methylbenzyl)) piperid inylamine] -9- cyclopentyl purine essentially as described in Example 1, Scheme A, step c. Rf. (min) = 2.26; 98% purity; MS (APCl): 503 M + 1 Example 45 2- [Trans- (4-aminociclohexyl) aminol-6-í4- (1 - (2,6-dichlorobenzyl)) piperidinylaminol-9-cyclopentylpurine Preparation of -Amino- 1 - (2,6-dichlorobenzyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (2,6-dichlorobenzyl) piperidine 4-Carboxamide-1 - (2,6-dichlorobenzyl) piperidine can be prepared from isonipecotamide and, 2,6-trichlorotoluene essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (2,6-dichlorobenzyl) piperidine 4-Amino-1- (2,6-dichlorobenzyl) piperidine is prepared from 4-carboxamide-1 - (2,6- dichlorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Stage a: 1- (2,6-Dichlorobenzyl) -4-piperidone 1- (2,6-Dichlorobenzyl) -4-piperidone is prepared from 4-piperidone and V., 2.6 -trichlorotoluene essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: oxime of 1- (2,6-dichlorobenzyl) -4-piperidone oxime of 1- (2,6-dichlorobenzyl) -4-piperidone is prepared from 1- (2,6-dichlorobenzyl) -4- piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C. stage c: 4-Amino-1 - (2,6-dichlorobenzyl) ipiperidine 4-Amino-1- (2,6-dichlorobenzyl) piperidine is prepared from 1 - (2,6-dichlorobenzyl) -4-oxime -piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, stage b_j 2-Chloro-6- [4- (1 - (2,6-dichlorobenzyl)) piperidinylamino-1-9-cyclopentyl I purine 2-Chloro-6- [4- (1 - (2,6-dichlorobenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2,6-dichlorobenzyl) piperidine (made according to Method 1 of Example 45), and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-f Trans- (4-aminocyclohexyl) amnol-6-f4- (1- (2,6-dichlorobenzyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl ) amino] -6- [4- (1 - (2,6-dichlorobenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (2,6-dichlorobenzyl)) piperidinylamino ] -9-cyclopentyl purine essentially as described in Example 1, Scheme A, step c. Rf. (min) = 2.28; 98% purity; MS (APCI): 557M + 1 Example 46 2-ITrans- (4-aminociclohexyl) aminol-6-y4- (1- (4-trifluoromethylbenzyl)) p-phenylamino-9-cyclopentylpurine Preparation of 4-Amino-1 - (4-trifluoromethylbenzyl) piperidine Method 1 Scheme B_ stage at 4-Carboxamide-1 - (4-trifluoromethylbenzylpiperidine 4-Carboxa m ide- 1 - (4-trifluoromethyl I benzyl) piperidine can be prepared from isonipecotamide and a'-chloro-a, a, a-trifluoro-p-xylene essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1- (4-trifluoromethylbenzyl) piperidine 4-Amino-1- (4-trifluoromethylbenzyl) piperidine is prepared from 4-carboxa mida-1- (4-trif-1-uoromethylbenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2 : Scheme C. stage a: 1- (4-trifluoromethylbenzyl) -4-piperidone 1- (4-trifluoromethylbenzyl) -4-piperidone is prepared from 4-piperidone and a'-chloro-a, a-trifluoro-p-xylene essentially as described above in Example 38, Scheme C, stage a) Scheme C. stage b: 1 - (4-trifluoromethylbenzyl) -4-piperidone oxime 1 - (4-Trifluoromethylbenzyl) -4-piperidone oxime is prepared from 1- (4-trifluoromethylbenzyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Step c: 4-Amino-1- (4-trifluoromethylbenzyl) piperidine 4-Amino-1- (4-trifluoromethylbenzyl) piperidine is prepared from 1- (4-trifluoromethylbenzyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (4-trifluoromethylbenzyl)) piperidinyl-amino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4-trifluoromethylbenzyl) ) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-trifluoromethylbenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b . Scheme A, step c: 2-Trans Trans- (4-aminocyclohexyl) amnol-6-.4- (1- (4-trifluoromethylbenzyl)) piperidin-1-ylamol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1- (4-trifluoromethylbenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-trif luorometi I benzyl)) piperidin Has my non] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Rf- (min) = 2.38; 100% purity; MS (APCl): 557 M + 1 Example 47 (+/-) - 2-_Trans- (4-aminociclohexiDaminol-6-.4- (1 - (a-methylbenzyl)) piperidin-laminol-9-cyclopentylpurine Preparation of (RS) -4-Amino-1 - (α-methylbenzyl) piperidine Method 1 Scheme B, step a: 4-Carboxamide-1 - (α-methylbenzyl) p¡peridine 4-Carboxamide-1 - (a -methylbenzyl) piperidine can be prepared from isonipecotamide and an a-methylbenzyl bromide essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: (R, S) -4-Amno-1 - (α-methylbenzyl) piperidine (R, S) -4-Amino-1 - (α-methylbenzyl) p¡peridine is prepared from 4-carboxamide-1 - (α-methylbenzyl) piperidine essentially as described above in Example 38, Scheme B, stage b.

Method 2: Scheme C, step a: 1- (α-Methylbenzyl) -4-pperiodone 1 - (α-Methylbenzyl) -4-piperidone is prepared from 4-piperidone and α-methylbenzyl bromide essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: l - (a-Methylbenzyl) -4-piperidine oxime 1 - (α-Methylbenzyl) -4-piperidone oxime is prepared from 1- (a-methylbenzyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C, step c: (RS) -4-Amino-1 - (α-methylbenzyl) piperidine (R, S) -4-Amino-1 - (α-methylbenzyl) piperidine is prepared from oxime 1 - (a- methylbenzyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6- [4- (1 - (a-methylbenzyl)) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (a-methylbenzyl)) piperidinylamino] - 9-cyclopentyl purine is prepared from 2,6-dichloro-9-cyclopentylpurine, (R, S) -4-amino-1 - (α-methylbenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A , stage b. Scheme A, step c: 2-fTrans- (4-aminocyclohexyl) amnol-6-.4- (1 - (a-methylbenzyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino] -6- [4- (1 - (a-methylbenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (a-methylbenzyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 48 2-.Trans- (4-aminocyclohexy-amino-1-4-.4- (1 - (3-phenoxypropyl)) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1- (3-phenoxypropyl) piperidine Method 1 Scheme B. step a: 4-Carboxamide-1 - (3-phenoxypropyl) pperidine 4-Carboxamide-1 - (3-phenoxypropyl) piperidine can be prepared from isonipecotamide and 1-chloro-3-phenoxypropane essentially as described above in Example 38, Scheme B, step a Scheme B. step b: 4-Amino-1 - (3-phenoxypropyl) pperidine 4-Amino-1- (3-phenoxypropyl) piperidine is prepared of 4-carboxamide-1- (3-phenoxypropyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (3-Phenoxypropyl) -4-piperidone 1- (3-Phenoxypropyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-3-phenoxypropane essentially as described above in the example 38, Scheme C, stage a. Scheme C. Stage b: 1 - (3-Phenoxypropyl) -4-piperidone oxime 1- (3-Phenoxypropyl) -4-piperidone oxime is prepared from 1- (3-phenoxypropyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (3-phenoxypropyl) piperidine 4-Amino-1- (3-phenoxypropyl) piperidine is prepared from 1 - (3-phenoxypropyl) -4-piperidone oxime essentially as described above in Example 38, "Scheme C, step c Scheme A. step b: 2-Chloro-6-f4- (1 - (3-phenoxypropyl)) piperidin-1-amino-9-cyclopentylpurine 2-Chlorine -6- [4- (1 - (3-phenoxypropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-phenoxypropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminocyclohexyl) aminol-6-y4- (1- (3-phenoxypropyl)) piperidinylammonol- 9-Cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-phenoxypropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3-phenoxypropyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 49 2-.Trans- (4-aminociclohexiQaminol- 6-, 4- (1 - (2-phenoxyethyl)) piperidine-lane-nol-9-cyclopentylurea Preparation of 4-amino-1 - (2-phenoxyethyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide -1- (2-phenoxyethyl) piperidine 4-Carboxamide-1- (2-phenoxyethyl) piperidine can be prepared from isonipecotamide and 1-chloro-2-phenoxyethane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1- (2-phenoxyethyl) piperidine 4-Amino-1- (2-phenoxyethyl) piperidine is prepared from 4-carboxamide-1- (2-phenoxyethyl) piperidine essentially as described above at Example 38, Scheme B, step b. Method 2: Scheme C-step a: 1- (2-Phenoxyethyl) -4-piperidone 1- (2-phenoxyethyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-2-phenoxyethane essentially as described above in Example 38, Scheme C, stage a. Scheme C, step b: 1 - (2-phenoxyethyl) -4-piperidone oxime 1- (2-phenoxyethyl) -4-piperidone oxime is prepared from 1- (2-phenoxyethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. stage c: 4-Amino-1- (2-phenoxyethyl) piperidine 4-Amino-1- (2-phenoxyethyl) piperidine is prepared from 1- (2-phenoxyethyl) -4-piperidone oxime essentially as is described above in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-f4- (1 - (2-phenoxyethyl)) piperidyl-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2 -phenoxyethyl)) piperidinylamino] -9-cyclopenti I purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-phenoxyethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1- (2-phenoxyethyl)) p -peridinylamino-1-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino ] -6- [4- (1 - (2-phenoxyethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2-phenoxyethyl)) piperidinylamino] -9-cyclopenti I purine essentially as described in Example 1, Scheme A, step c. Example 50 2-f Trans- (4-aminocyclohexyl) aminol-6-f4- (1 - (2-phenylethyl)) piperidin-1-amino-9-cyclopentylpurine Preparation of 4-Amino-1- (2-phenylethyl) p Peridine Method 1 Scheme B. Stage a: 4-Carboxamide-1 - (2-phenylethyl) piperidine 4-Carboxamide-1 - (2-phenylethyl) piperidine can be prepared from isonipecotamide and (2-chloroethyl) benzene essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1- (2-phenylethyl) piperidine 4-Amino-1- (2-phenylethyl) piperidine is prepared from 4-carboxamide-1- (2-phenylethyl) piperidine essentially as described above at Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (2-Phenylethyl) -4-P -peridone 1- (2-phenylethyl) -4-piperidone is prepared from 4-piperidone and (2-chloroethyl) benzene essentially as described up in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (2-Phenylethyl) -4-piperidone oxime 1 - (2-Phenylethyl) -4-piperidone oxime is prepared from 1- (2-phenylethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Stage c: 4-Amino-1- (2-phenylethyl) piperidine 4-Amino-1- (2-phenylethyl) piperidine is prepared from 1- (2-phenylethyl) -4-piperidone oxime essentially as is described above in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-.4- (1 - (2-phenylethyl)) piperidol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2- phenylethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-phenylethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-f Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (2-phenylethyl)) p -peridinylaminol-9-cyclopentylpurine 2- [Trans- (4- aminocyclohexyl) amino] -6- [4- (1 - (2-phenylethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6-_4- (1- (2-phenylethyl)) piperidine the min] -9-cyclopentyl purine essentially as described in Example 1, Scheme A, step c. Example 51 2-, Trans-, 4-aminociclohexiDamino1-6-.4- (1-propyl) p¡peridinilaminol-9-cyclopentylpurine Preparation of 4-Amino-1-propylpperidine Method 1 Scheme B. stage a: 4- Carboxamide-1-propylpiperidine 4-Carboxamide-1-propylperidine can be prepared from isonipecotamide and 1-chloropropane essentially as described above in Example 38, Scheme B, step a. Scheme B. Step b: 4-Amino-1-propylpiperidine 4-Amino-1-propylpiperidine is prepared from 4-carboxamide-1-propylpiperidine essentially as described above in Example 38, Scheme B, stage b. Method 2: Scheme C, step a: 1-Propyl-4-piperidone 1-Propyl-4-piperidone is prepared from 4-piperidone and 1-chloropropane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1-Propyl-4-piperidone oxime 1-Propyl-4-piperidone oxime is prepared from 1-propyl-4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C , stage b. Scheme C, step c: 4-Amino-1-propylpiperidine 4-Amino-1-propylpiperidine is prepared from 1-propyl-4-piperidone oxime essentially as described above in Example 38, Scheme C, stage c. Scheme A. stage b: 2-Chloro-6-.4- (1-propyl) piperidyl-9-cyclopentylpurine 2-Chloro-6- [4- (1-propyl) piperidinylamino] -9- Cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1-propylpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-f Trans- (4-aminocyclohexyl) aminol-6-f4- (1-propyl) piperidin-9-nolol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino ] -6- [4- (1-propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1-propyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 52 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1-cyclopropylmethyl-piperidinylamino.-9-cyclopentylpurine Preparation of 4-Amino-1-cyclopropylmethylpiperidine Method 1 Scheme B. step a: 4 -Carboxamide-1-cyclopropylmethylpiperidine 4-Carboxamide-1-cyclopropylmethylpiperidine can be prepared from isonipecotamide (chloromethyl) cyclopropane essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1-cycloprop 1-methoxypiperidine 4-Amino-1-cyclopropylmethylpiperidine is prepared from 4-carboxamide-1-cyclopropylmethylpiperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (Cyclopropylmethyl) -4-piperidone 1- (Cyclopropylmethyl) -4-piperidone is prepared from 4-piperidone and (chloromethyl) cyclopropane essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (cyclopropylmethyl) -4-piperidone oxime 1 - (Cyclopropylmethyl) -4-piperidone oxime is prepared from 1- (cyclopropylmethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1-cyclopropylmethylpiperidine 4-Amino-1-cyclopropylmethylpiperidine is prepared from 1 - (cyclopropylmethyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step C. Scheme A. stage b: 2-Chloro-6-.4- (1-cyclopropylmethyl) piperidinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1-cyclopropylmethyl) piperidinylamino] -9-cyclopentylpurine is prepared from , 6-dichloro-9-cyclopentylpurine, 4-amino-1-cyclopropylmethylpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-, Trans- (4-aminociclohexyl) amino1-6-, 4- (1-cyclopropylmethyl) piperidinylaminol-9-cyclopentylpurine * 2- [Trans- (4-aminociclohexyl) amino_-6- _4- (1-cyclopropylmethyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1-cyclopropylmethyl) piperidinylamino] -9-cyclopentyl I purine essentially as described in Example 1, Scheme A, stage c. Rf. (min) = 2.1 9; 100% purity; MS (APCl): 454 M + 1 Example 53 2- [Trans- (4-aminocyclohexyl) aminol-6- [4- (1 - (2-pyridinylmethyl)) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-aminoethoxy 1 - (2-piperidinylmethyl) pperidine Method 1 Scheme B. Step a: 4-Carboxamide-1 - (2-pyridinylmethyl) piperidine 4-Carboxamide-1 - (2-pyridinylmethyl) piperidine can be prepared from isonipecotamide and 2-picolyl chloride hydrochloride essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1- (2-pyridinylmethyl) piperidine 4-amino-1- (2-pyridinylmethyl) piperidine is prepared from 4-carboxamide-1- (2-pyridinylmethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (2-Pyridinylmethyl) -4-piperidone 1- (2-pyridinylmethyl) -4-piperidone is prepared from 4-piperidone and 2-picolyl chloride hydrochloride essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: 1 - (2-pyridinylmethyl) -4-piperidone oxime 1 - (2-pyridinylmethyl) -4-piperidone oxime is prepared from 1- (2-pyridinylmethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1- (2-pridinylmethyl) piperidine 4-Amino-1- (2-pyridinylmethyl) piperidine is prepared from 1- (2-pyridinylmethyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A_, step b_j 2-Chloro-6-.4- (1 - (2-pyridinylmethyl)) piperidinylaminol-9-cyclopentyl purine 2-Chloro-6- [4- (1 - (2-pyridinylmethyl) ) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-pyridinylmethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b . Scheme A. stage c: 2-γ Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (2-pyridinyl methyl)) piperidinylamino-9-cyclopentyl I purine 2- [Trans (4-aminocyclohexyl) amino] -6- [4- (1 - (2-pyridinylmethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (2-pyridinylmethyl)) piperidinylamino ] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 54 2-f Trans- (4-aminocyclohexyl) aminol-6-.4- (1- (3-pyridinylmethyl)) piperidinylamino-9-cyclopentylpurine Preparation of 4-Amino-1 - (3-p) Ridinylmethylpiperidine Method 1 Scheme B. Step a: 4-Carboxamide-1 - (3-pyridinylmethyl) piperidine 4-Carboxamide-1 - (3-pyridinylmethyl) piperidine can be prepared from isonipecotamide and 3-picolyl chloride hydrochloride essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1- (3-pyridinylmetyl) piperidine 4-Amino -1- (3-Pyridinylmethyl) piperidine is prepared from 4-carboxamide-1- (3-pyridinylmethyl) piperidine essentially as described above in Example 38, Scheme B, stage b. Method 2: Scheme C. Step a: 1- (3-Pyridinylmethyl) -4-piperidone 1- (3-pyridinylmethyl) -4-piperidone is prepared from 4-piperidone and 3-picolyl chloride hydrochloride essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: 1 - (3-pyridinylmethyl) -4-piperidone oxime 1 - (3-pyridinylmethyl) -4-piperidone oxime is prepared from 1- (3-pyridinylmethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Step c: 4-Amino-1- (3-pyridinylmethylpiperidine 4-Amino-1- (3-pyridinylmethyl) piperidine is prepared from 1- (3-pyridinylmethyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c Scheme A, step bj 2-Chloro-6-I4- (1- (3-pyridinylmethyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1- (3-pyridinylmethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-pyridinylmethyl) piperidine, and triethylamine as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-f Trans- (4-aminocyclohexyl) amnol-6-.4- (1- (3-pyridinylmethyl)) peprid and nylamino.-9-cyclopentyl pranny 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1- (3-pyridinylmethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (3-pyridinylmethyl)) piperidinylamino ] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 55 2-.Trans- (4-aminocyclohexyl) aminol-6-f4- (1- (4-pyridinylmethyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1- (4-pyridinylmethyl) piperidine Method 1 Scheme B. Step a: 4-Carboxamide-1- (4-pyridinylmethyl) piperidine 4-Carboxamide-1- (4-pyridinylmethyl) piperidine can be prepared from isonipecotamide and 4-picolyl chloride hydrochloride essentially as described above in Example 38, Scheme B, step a. Scheme B. Step b: 4-Amino-1- (4-pyridinylmethyl) piperidine 4-Amino-1- (4-pyridinylmethyl) piperidine is prepared from 4-carboxamide-1- (4-pyridinylmethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (4-pyridinylmethyl) -4-pperidone 1- (4-pyridinylmethyl) -4-piperidone is prepared from 4-piperidone and 4-picolyl chloride hydrochloride essentially as is described above in Example 38, Scheme C, step a. Scheme C. stage b: 1 - (4-pyridinylmethyl) -4-piperidone oxime 1 - (4-pyridinylmethyl) -4-piperidone oxime is prepared from 1- (4-pyridinylmethyl) -4 -piperidone and hydroxylamine hydrochloride essentially as described above in Example 38., Scheme C, step b. Scheme C. Stage c: 4-Amino-1- (4-pyridinylmethyl) pperiodine 4-Amino-1- (4-pyridinylmethyl) piperidine is prepared from 1- (4-pyridinylmethyl) -4-oxime -piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A stage b 2-Chloro-6- [4- (1 - (4-pyridinylmethyl)) piperidin-1-amino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4- pyridinylmethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-pyridinylmethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A step c: 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (4-pyridinyl methyl)) 1 pi I peridin lamino. -9-Cyclopentyl I purine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1- (4-pyridinylmethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- ( 4- (1- (4-pyridinylmethyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 56 2 -.Trans- (4-aminocyclohexyl) aminol-6 .4- (1 - (3- (2,4-Dimeti I isoxazol yl)) methyl) piperidinylaminol-9-cyclopentyl I purine Preparation of 4-Amino-1 - (3- (2,4-dimethylisoxazolyl) methylpiperidine Method 1 Scheme B ^ stage to 4-Carboxamide-1 - (3- (2,4-dimethyl-oxazolyl) methyl) piperidine 4 -Carboxamide-1 - (3- (2,4-dimethylisoxazolyl) methyl) piperidine can be prepared from isonipecotamide and 2,4-dimethyl-3-chloromethyl-isoxazole essentially as described above in Example 38, Scheme B, step a. Scheme B_ stage b_ 4-Amino-1 - (3- (2,4-dimethylisoxazolyl) methi I pipe ridine 4-Amino-1 - (3- (2,4-dimethylisoxazolyl) methylpiperidine is prepared from 4-carboxamide-1 - (3 - (2,4-dimethylisoxazolyl) methyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C. Step a: 1- (3- (2,4-Dimethylisoxazolyl) methyl) -4-piperidine 1- (3- (2,4-Dimethylisoxazolyl) methyl) -4-piperidone is prepared from 4-piperidone and 2,4-dimethyl-3-chloromethyl-isoxazole essentially as described above in Example 38, Scheme C, step a, Scheme C. step b: oxime of 1 - (3- (2,4-dimethylisoxazolyl) methyl) -4-piperide Na 1 - (3- (2,4-Dimethylisoxazolyl) methyl) -4-piperidone oxime is prepared from 1- (3- (2,4-dimethylisoxazololyl) methyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in the Example 38, Scheme C, stage b. Scheme C, step c_ 4-Amino-1 - (3- (2,4-dimethylisoxazole) -methylpiperidine 4-Amino-1- (3- (2,4-dimethylisoxazolyl) methylpiperidine is prepared from 1 - (3- (2, 4-dimethylisoxazolyl) methyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c.

Scheme A, step bj 2-Chloro-6-.4-M - (3- (2,4-dimethylisoxazolyl)) methyl) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3- (2, 4-dimethylisoxazolyl)) methyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3- (2,4-dimethylisoxazolyl) methylpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-Δ Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (3- (2,4-di-methyl) Soxazoll)) methyl) piperidin-1-yl-1-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3- (2,4- dimethylisoxazolyl)) methyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3- (2,4-dimethylisoxazololyl)) methyl) piperid inylamido] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 57 (RS) -2-FTrans- (4-aminociclohexyl) aminol-6- [4- (1-benzyl-3-methyl) piperidinylamino-1-9-cyclopentylpurine Preparation of (RS) -4-Amino-1-benzyl-3-methylpiperidine Method do 1 Scheme B, step a: (RS) -4-Carboxamide-1-benzyl-3-methylpiperidine (R, S) -4-Carboxamide-1-benzyl-3-methylpiperidine can be prepared from (R, S) -4 -carboxamide-3-methylpiperidine and benzyl chloride essentially as described above in Example 38, Scheme B, step a, substituting (R, S) '4-carboxamide-3-methylpiperidine for isonipecotamide. Scheme B, step b: (R, S) -4-Amino-1-benzyl-3-methylpiperlhydrin (R, S) -4-Amino-1-benzyl-3-methylpiperidine is prepared from (R, S) 4-carboxamide-1-benzyl-3-methylpiperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: (RS) -1-Benzyl-3-methyl-4-piperidone (R, S) -1-Benzyl-3-methyl-4-piperidone is prepared from (R, S) - 3-methyl-4-piperidone and benzyl chloride essentially as described above in Example 38, Scheme C, step a, substituting (R, S) -3-methyl-4-piperidone for 4-piperidone. Scheme C. stage b: oxime of (R, S) -1-Benzyl-3-methyl-4-piperidone Oxime of (R, S) -1-Benzyl-3-methyl-4-piperidone is prepared from (R, S) -1-benzyl-3-methyl-4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: (R, S) -4-Amino-1-benzyl-3-methylpiperidine (R, S) -4-Amino-1-benzyl-3-methylpiperidine is prepared from oxime (R, S) -1-benzyl-3-methyl-4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step b: (R, S) -2-Chloro-6-.4- (1-benzyl-3-methyl) piperidinylamino-1-9-cyclopentylpurine (R, S) -2-Chloro-6- [4- (1-benzyl-3-methyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, (R, S) -4-amino-1-benzyl-3-methylpiperidine, and triethylamine essentially as is described above in Example 1, Scheme A, step b. Scheme A. stage c: (RS) -2-fTrans- (4-aminociclohexyl) aminol-6-I4- (1 -benzyl-3-methyl) piperidinylamino-1-9-cyclopentylpurine (R, S) -2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1-benzyl-3-methyl) piperidinylamino] -9-cyclopentylpurine is prepared from (R, S) -2-chloro-6- [4- (1-benzyl -3-methyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 58a (R) -2-, Trans- (4-aminocolclohexyl) aminol-6-.3- (1-benzyl) pyrrolidinylamino. -9-cyclopentylpurine Scheme A. Stage b: (R) -2-Chloro-6-.3- (1-benzyl) pyrrolidinylamino-1-9-cyclopentylpurine (R) -2-Chloro-6- [3- (1-benzyl) pyrrolidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, (R) -4-amino-1-benzyl-pyrrolidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: (R) -2-ÍTrans- (4-aminociclohexyl) aminol-6-.3- (1 -benzyl) pyrrolyninylamino-1-9-cyclopentylpurine (R) -2- [Trans- (4- aminocyclohexyl) amino] -6- [3- (1-benzyl) pyrrolidinylamino] -9-cyclopentylpurine is prepared from (R) -2-chloro-6- [3- (1-benzyl) pyrrolid inylamino] -9- cyclopentyl puss essentially as described in Example 1, Scheme A, step c.

Example 58b (S) -2- [Trans- (4-aminociclohexyl) amino1-6-.3- (1-benzyl) pyrrolidinilaminol-9-cyclopentylpurine Scheme A. stage b: (S) -2-Chlorine -6-.3- (1-benzyl) pyrrolidinylamino. -9-cyclopentylpurine (S) -2-Chloro-6- [3- (1-benzyl) pyrrolidinyl] -9-cyclopentyl I purine is prepared from 2, 6-dichloro-9-cyclopentylpurine, (S) -4-amino-1-benzyl-pyrrolidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: (S) -2-fTrans- (4-aminociclohexyl) amino1-6-I3- (1 -benzyl) pyrrolidinylaminol-9-cyclopentylpurine (S) -2- [Trans- (4- aminocyclohexyl) amino_6- [3- (1-benzyl) pyrrolidinylamino] -9-cyclopentylpurine is prepared from (S) -2-chloro-6- [3- (1-benzyl) pyrrolidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 59 2-. Trans-.4-aminocyclohexyl) aminol-6-.4- (1-butyl) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1-butylpiperidine Method 1 Scheme B. stage a: 4-Carboxamide-1-butylpperide Na 4-Carboxamide-1-butylpiperidine can be prepared from isonipecotamide and 1-chlorobutane essentially as described above in Example 38, Scheme B, stage a.

Scheme B. Step b: 4-Amino-1-butylpiperidine 4-Amino-1-butylpiperidine is prepared from 4-carboxamide-1-butylpiperidine essentially as described above in Example 38, Scheme B, stage b. Method 2: Scheme C, step a: 1-Butyl-4-piperidone 1 -Butyl-4-piperidone is prepared from 4-piperidone and 1-chlorobutane essentially as described above in Example 38, Scheme C, step a. Scheme C. Step b: 1-Butyl-4-1-piperidone oxime 1-Butyl-4-piperidone oxime is prepared from 1-butyl-4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C. step c: 4-Amino-1-butylpiperidine 4-Amino-1-butylpiperidine is prepared from 1-butyl-4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A. Stage b: 2-Chloro-6-.4- (1-butyl) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1-butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1-butylpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-.Trans- (4-aminociclohexil) aminol-6-f4- (1-butiDpiperid i nilaminol-9-cyclopentyl purine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4 - (1-butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1-butyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 60 2-.Trans- (4-aminociclohexyl) aminol-6-f4- (1 - (2-t-methoxyethyl) piperidin-1-yl-1-9-cyclopentylpurine Preparation of 4-Amino-1 - (2-thiomethoxyethyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (2-t-methoxyethyl) piperidine 4-Carboxamide-1 - (2-thiomethoxyethyl) piperidine can be prepared from isonipecotamide and 1-chloro-2-thiomethoxyethane essentially as described above in Example 3 8, Scheme B, step a.

Scheme B. stage b: 4-Amino-1 - (2-thiomethoxyethyl) piperidine 4-Amino-1 - (2-thiomethoxyethyl) piperidine is prepared from 4-carboxamide-1- (2-thiomethoxyethyl) piperidine essentially as described above in Example 38, Scheme B, step b.

Method 2: Scheme C. Step a: 1- (2-Thiomethoxyethyl) -4-piperidone 1- (2-thiomethoxyethyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-2-thiomethoxyethane essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: 1 - (2-thiomethoxyethyl) -4-piperidone oxime 1 - (2-thiomethoxyethyl) -4-piperidone oxime is prepared from 1- (2-thiomethoxyethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (2-thiomethoxyethyl) piperidine 4-Amino-1- (2-thiomethoxyethyl) piperidine is prepared from 1 - (2-thiomethoxyethyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-.4- (1 - (2-thiomethoxyethyl) p-perminylammonol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2 -thiomethoxyethyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-thiomethoxyethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b) Scheme A. step c: 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (2-thiomethoxyethanol) piperidinylamino-9-cyclopentylpurine 2- [ Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-thiomethoxyethyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2-thiomethoxyethyl) piperidinylamino] ] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 61 2 -.Trans- (4-aminociclohexyl) amino 1-6.-4- (1 - (2-f-phenylsulfonyl) etl) p -peridinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1- (2-phenylsulfinylethyl) piperidine Method 1 Scheme B. step a: 4-Carboxamide-1 - (2- phenylsulfonyl) pyridine 4-Carboxamide-1 - (2-phenylsulfinylethyl) piperidine can be prepared from isonipecotamide and 1-chloro-2-phenylsulfinylethane essentially as described above in Example 38, Scheme B, stage a. Scheme B. Stage b: 4-Amino-1 - (2-phenylsulfinylletyl) piperidine 4-Amino-1- (2-phenylsulfinylethyl) piperidine is prepared from 4-carboxamide- 1 - (2- phenylsulfinylethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (2-PhenylsulfinylletiO-4-piperidone 1- (2-Phenylsulfinylethyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-2-phenylsulfinylethane essentially as described up in the Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (2-Phenylsulfinylethyl) -4-piperidone oxime 1 - (2-Phenylsulfinylethyl) -4-piperidone oxime is prepared from 1- (2-phenylsulfinylethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1- (2-phenylsulfinylethyl) piperidine 4-Amino-1- (2-phenylsulfinylethyl) piperidine is prepared from 1- (2-phenylsulfinylethyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A_ stage bj 2-Chloro-6-.4- (1 - (2-phenylsulfinyl) ethyl) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2-f in ylsulfinyl) ethyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-phenylsulfinylethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-fTrans-, 4-aminocyclohexyl) amino1-6-.4- (1- (2-phenylsulphonyl) ethyl piperidinylaminol-9-cyclopentyl I purine 2- [Trans- ( 4-aminocyclohexyl) amino] -6- [4- (1 - (2-phenylsulfinyl) ethyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2-phenylsulfinyl) ethyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 62 2 -.Trans- (4-aminociclohexyl) amino-1-6- (1- (3-hydroxy) propyl) piperidinylamine-9-cyclopentylpurine Preparation of 4-Amino-1 - (3-h idroxy propi Qpiperidine Method 1 Scheme B. stage a: 4-Carboxamide-1- (3-hydroxypropyl) piperidine 4- Carboxamide-1 - (3-hydroxypropyl) piperidine can be prepared from isonipecotamide and 3-chloro-1-propanol essentially as described above in Example 38, Scheme B, step a.Scheme B, step b: 4-Amino-1 - (3-hydroxypropyl) piperidine 4-Amino-1- (3-hydroxypropyl) piperidine is prepared from 4-carboxamide-1- (3-hydroxypropyl) piperidine essentially as is described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (3-Hydroxypropyl) -4-piperidone 1- (3-Hydroxypropyl) -4-piperidone is prepared from 4-piperidone and 3-chloro-1-propanol essentially as described above in Example 38, Scheme C, stage a. Scheme C, step b: 1 - (3-Hydroxypropyl) -4-piperidone oxime 1 - (3-Hydroxypropyl) -4-piperidone oxime is prepared from 1- (3-hydroxypropyl) -4-piperidone and hydrochloride of hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1 -, 3-hvdroxy2propyl) piperidine 4-Amino-1- (3-hydroxypropyl) piperidine is prepared from 1 - (3-hydroxypropyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A_ stage bj 2-Chloro-6-.4- (1 - (3-h id roxi) propyl) piperidine lamino. -9-Cyclopentyl I-purine 2-Chloro-6- [4- (1 - (3-hydroxy) propyl) p -peridin-1,1-amino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9 -cyclopentylpurine, 4-amino-1- (3-hydroxypropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1- (3-hydroxy) propyl) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino] -6- [4- (1 - (3-hydroxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3-hydroxy) propyl) piperid inilam i not ] -9-cyclopenti I purine essentially as described in Example 1, Scheme A, step c. Example 63 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (3-methoxy) propyl) piperidinylamino-9-cyclopentyl I purine Preparation of 4-Amino-1- (3-methoxypropyl) piperidine Method 1: Scheme B. Step a: 4-Carboxamide-1 - (3-methoxypropyl) piperidine 4-Carboxamide-1- (3-methoxypropyl) piperidine can be prepared from isonipecotamide and 1-chloro-3-methoxypropane essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1 - (3-methoxypropyl) piperidine 4-Amino-1- (3-methoxypropyl) piperidine is prepared from 4-carboxamide-1- (3-methoxypropyl) piperidine essentially as described above in Example 38, Scheme B, stage b. Method 2: Scheme G. Step a: 1- (3-Methoxypropyl) -4-piperidone 1- (3-Methoxypropyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-3-methoxypropane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (3-Methoxypropyl) -4-piperidone oxime 1- (3-Methoxypropyl) -4-piperidone oxime is prepared from 1- (3-methoxypropyl) -4-piperidone and hydrochloride of hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (3-methoxypropyl) piperidine 4-Amino-1- (3-methoxypropyl) piperidine is prepared from 1- (3-methoxypropyl) -4-piperidone oxime essentially as is described above in Example 38, Scheme C, step c. Scheme A, stage bj 2-Chloro-6-I4- (1 - (3-methoxy) propyl) piperidin-1-amino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3 -methoxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-methoxypropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A-stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6 ~ .4- (1 - (3-methoxy) propyl) piperidinylamino-9-cyclopentylpurine 2- [Trans - (4-aminocyclohexyl) amino] -6-_4- (1- (3-methoxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3-methoxy) propyl) ) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 64 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (3-ethoxy) propyl) piperidinylaminol-9-cyclopentylpurine Preparation of 4-amino-1 - (3-ethoxypropyl) piperidine Method 1 Scheme B, step a: 4-Carboxamide-1 - (3-ethoxylpropyl) piperidine 4-Carboxamide-1 - (3-ethoxypropyl) piperidine can be prepared from isonipecotamide and 1-chloro-3-ethoxypropane essentially as described above in Example 38, Scheme B, step a.

Scheme B. stage b: 4-Amino-1 -, 3-ethoxypropyl) piperidin 4-Amino-1- (3-ethoxypropyl) piperidine is prepared from 4-carboxamide-1- (3-ethoxypropyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (3-Ethoxypropyl) -4-piperidone 1- (3-Ethoxypropyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-3-ethoxypropane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (3-Ethoxypropyl) -4-piperidone oxime 1 - (3-Ethoxypropyl) -4-piperidone oxime is prepared from 1- (3-ethoxypropyl) -4-piperidone and hydrochloride of hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C. Step c: 4-Amino-1- (3-ethoxypropyl) piperidine 4-Amino-1- (3-ethoxypropyl) piperidine is prepared from 1 - (3-ethoxypropyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A. stage b-. 2-Chloro-6-.4- (1 - (3-ethoxy) propyl) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3-ethoxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-ethoxypropyl) pipepdine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. step c: 2-.Trans- (4-aminocyclohexyl) amino-1-6-. 4 - (1 - (3-ethoxy) propyl) piperidine-lamino. -9-Cyclopentyl purine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-ethoxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [ 4- (1 - (3-ethoxy) propyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 65 2-f Trans- (4-aminocyclohexyl) amino1-6-f4- (1 - (3-propoxy) propyl) piperidinylaminol-9-cyclopentyl I purine Preparation of 4-Amino-1- (3-propoxypropyl) p Peridine Method 1 Scheme B. Step a: 4-Carboxamide-1 - (3-propoxypropyl) piperidine 4-Carboxamide-1 - (3-propoxypropyl) piperidine can be prepared from isonipecotamide and 1-chloro-3-propoxypropane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-.l - (3-propoxypropyl) piperidine 4-Amino-1- (3-propoxypropyl) piperidine is prepared from 4-carboxamide-1- (3-propoxypropyl) piperidine essentially as described up in Example 38, Scheme B, step b. Method 2: Scheme C-step a: 1- (3-Propoxypropyl) -4-piperidone 1- (3-Propoxypropyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-3-propoxypropane essentially as described above at Example 38, Scheme C, step a.

Scheme C step b: 1 - (3-Propoxypropyl) -4-pperidone oxime 1 - (3-Propoxypropyl) -4-piperidone oxime is prepared from 1- (3-propoxypropyl) -4-piperidone and hydrochloride hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (3-propoxypropyl) piperidine 4-Amino-1- (3-propoxypropyl) piperidine is prepared from 1 - (3-propoxypropyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A, stage bj 2-Chloro-6-.4- (1 - (3-propoxy) propyl) piperidin-1-amino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3- propoxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-propoxypropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A , stage b. Scheme A. stage e: 2-.Trans- (4-aminociclohexil) amino1-6-.4- (1 - (3-propoxi) propíl) p¡peridinilamino1-9-cyclopentylpurine 2- [Trans- ( 4-aminocyclohexyl) amino] -6- [4- (1 - (3-propoxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3-propoxy) propyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 66 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (3-butoxy) propyl) piperidinylaminol-9-cyclopentyl pyrimine Preparation of 4-Amino-1 - (3-butoxypropyl) piperidine Method 1 Scheme B. step a: 4-Carboxamda-1 - (3-butoxypropyl) piperidine 4-Carboxamide-1- (3-butoxypropyl) piperidine can be prepared from isonipecotamide and 1-chloro-3-butoxypropane essentially as described above in the Exempio 38, Scheme B, stage a. Scheme B. Stage b: 4-Amino-1 - (3-butoxypropyl) pperidine 4-Amino-1- (3-butoxypropyl) piperidine is prepared from 4-carboxamide-1- (3-butoxypropyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (3-Butoxypropyl) -4-piperidone 1- (3-Butoxypropyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-3-butoxypropane essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (3-Butoxypropyl) -4-piperidone oxime 1 - (3-Butoxypropyl) -4-piperidone oxime is prepared from 1- (3-butoxypropyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (3-butoxypropyl) piperidine 4-Amino-1- (3-butoxypropyl) piperidine is prepared from 1 - (3-butoxypropyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A, step b: 2-Chloro-6-, 4- (1 - (3-butoxy) propyl) piperidinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3-butoxy) propyl) ) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-butoxypropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b . Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6- [4- (1 - (3:: butoxy) propyl) piperidinylammonol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl ) amino] -6- [4- (1 - (3-butoxy) propyl) pipepdinylamino] -9-cyclopentylpupine is prepared from 2-chloro-6- [4- (1 - (3-butoxy) propyl) piperidinylamino ] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 67 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (3-benzyloxy) propyl) piperidinilaminol-9-cyclopenti I purine Preparation of 4-Amino-1 - (3-benzyloxyprop L) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (3-benzyloxypropyl) piperidine 4-Carboxamide-1 - (3-benzyloxypropyl) piperidine can be prepared from isonipecotamide and 1-chloro-3-benzyloxypropane essentially as described above in Example 38, Scheme B, step a. Scheme B. Stage b: 4-Amino-1- (3-benzyloxypropyl) piperidine 4-Amino-1- (3-benzyloxypropyl) piperidine is prepared from 4-carboxamide-1- (3-benzyloxypropyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (3-Benzyloxypropyl) -4-piperidone 1- (3-Benzyloxypropyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-3-benzyloxypropane essentially as described above in Example 38, Scheme C, stage a. Scheme C. Stage b: 1 - (3-Benzyloxypropyl) -4-pperidone oxime 1 - (3-Benzyloxypropyl) -4-piperidone oxime is prepared from 1- (3-benzyloxypropyl) -4-piperidone and hydrochloride of hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C. Stage c: 4-Amino-1 - (3-benzyloxypropyl) piperidine 4-Amino-1- (3-benzyloxypropyl) piperidine is prepared from 1 - (3-benzyloxypropyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A. stage bj 2-Chloro-6-.4- (1 - (3-benzyloxy) propyl) piperid inylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3-benzyloxy) propyl) ) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-benzyloxypropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b . Scheme A. stage c: 2-.Trans-.4-aminociclohexyl) amino1-6-, 4- (1 - (3-benzyloxy) propyl) p -perdynamylamino-9-cyclopentyl I purine 2- [Trans - (4-aminocyclohexyl) amino] -6- [4- (1 - (3-benzyloxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3-benzyloxy) ) propyl) piperidinylamino] -9-cyclopentyl I purine essentially as described in Example 1, Scheme A, step c. Example 68 2-.Trans- (4-aminocyclohexyl) amino1-6-f4- (1 - (3- (2-phenylethyleneoxy) propyl) piperidinylammonol-9-cyclopentylpurine Preparation of 4-Amino- 1- (3- (2-phenylethyloxy) propyl) piperidine Method 1 Scheme B_ stage to 4-Carboxamide-1 - (3- (2-phenylethyloxy) propyl) piperidine 4-Carboxamide-1 - (3- ( 2-phenylethyloxy) propyl) piperidine can be prepared from isonipecotamide and 1-chloro-3- (2-phenylethyloxy) propane essentially as described above in Example 38, Scheme B, step a.Scheme B. step b: 4-Amino- 1 - (3- (2: phenylethenooxyl) propyl) pperiodine 4-Amino-1- (3- (2-phenylethyloxy) propyl) piperidine is prepared from 4-carboxamide-1 - (3- (2-phenylethyloxy) propyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C, step a: 1- (3- (2-Phenylethyleneoxy) -4-piperidone 1- (3- (2-Phenylethyloxy) -4-piperidone is prepared from 4-piperidone and 1-chloro-3- (2-phenylethyloxy) propane essentially as described above in Example 3 8, Scheme C, stage a. Scheme C. Stage b: 1 - (3- (2-Phenylethyleneoxy) -4-piperidone oxime 1 - (3- (2-Phenylethyleneoxy) -4-piperidone oxime is prepared from 1- (3- (2-phenylethyleneoxy) ) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b Scheme C, step c: 4-Amino-1- (3- (2-phenylethyloxy) propyl) piperidine 4- Amino-1 - (3- (2-phenylethyloxy) propyl) piperidine is prepared from 1 - (3- (2-phenylethyloxy) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A, step b 2-Chloro-6-f4- (1 - (3- (2-phenylethyloxy) propyl) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3- (2 phenylethyloxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3- (2-phenylethyloxy) propyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-f Trans- (4-aminocyclohexyl) amino1-6-f4- (1 - (3- (2-phenolyl) lenooxi) propyl) piperidinylamino1-9-cyclopenti I purine 2- [Trans- (4-aminociclohexyl) amino] -6- [4- (1 - (3- (2-phenylethyleneoxy) propyl) piperidinylamino] -9-cyclopentyl I purine is prepared from 2-chloro-6- [4- (1 - (3- (2-phenylethyloxy) propyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 69 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (3- (3-phenylpropyleneoxy) propyl) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1 - (3 - (3-phenylpropyleneoxy) propyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (3- (3-phenylpropyleneoxy) propyl) piperidine 4-Carboxamide-1 - (3- (3- phenylpropyleneoxy) propyl) piperidine can be prepared from isonipecotamide and 1-chloro-3- (3-phenylpropyleneoxy) propane essentially as described above in Example 38, Scheme B, step a, Scheme B, step bj 4-Amino-1 - ( 3- (3-phenylpropyleneoxy) propyl) piperidine 4-Amino-1- (3- (3-phenylpropyleneoxy) propyl) piperidine is prepared from 4-carboxamide-1- (3- (3-phenylpropyleneoxy) propyl) piperidine essentially as described above in Example 38, Scheme B, step b.

Method 2: Scheme C. Stage a: 1 - (3- (3-Phenypropropyloxy) propyl) -4-piperidone 1 - . 1 - . 1- (3- (3-Phenylpropyleneoxy) propyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-3- (3-phenylpropyleneoxy) propane essentially as described above in Example 38, Scheme C, step a . Scheme C. Stage b: 1 - (3- (3-Phenylpropyleneoxy) propyl) -4-piperrodin Oxima of 1- (3- (3-phenylpropyleneoxy) propyl) -4-piperidone is prepared from 1- (3- (3-phenylpropyleneoxy) propyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C, step c 4-Amino-1 - (3- (3-phenylpropyleneoxy) propyl) pperidine 4-Amino-1- (3- (3-phenylpropyleneoxy) propyl) piperidine is prepared from oxime 1 - (3- (3-phenylpropyleneoxy) propyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c.

Scheme A, step bj 2-Chloro-6-.4- (1 - (3- (3-phenylpropyleneoxy) propyl) piperidin-laminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3 - (3-phenylpropyleneoxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3- (3-phenylpropyleneoxy) propyl) piperidine, and triethylamine essentially as described above in Example 1. Scheme A. stage b Scheme A. stage c: 2-, Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (3- (3-phenypropyleneoxy) propyl ) piperidinylamine-1-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -9- [4- (1 - (3- (3-phenylpropyleneoxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3- (3-phenylpropyleneoxy) propyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 70 2-fTrans - (4-aminocyclohexyl) amnol-6-f4- (1 - (3- (4-phenylbutyloxy) propyl) p -peridinylamino-1-9-cyclopentyl purine Preparation 4-Am-no-1 - (3 - (4-phenylbutyloxy) propyl) piperi dina Method 1 Scheme B, step a 4-Carboxamide-1 - (3- (4-phenylbutyloxy) propyl) pi pe ridine 4-Carboxamide-1 - (3- (4-phenylbutyloxy) propyl) piperidine can be prepared from isonipecotamide and 1-chloro-3- (4-phenylbutyloxy) propane essentially as described above in Example 38. Scheme B, step a. Scheme B, step b: 4-Amino-1 -, 3- (4-phenylbutyloxy) propyl) piperidine 4-Amino-1 - (3- (4-phenylbutyloxy) propyl) piperidine is prepared from 4-carboxam ida-1- (3- (4-phenylbutyloxy) propy I) piperidine essentially as described above in Example 38, Scheme B, stage b.

Method 2: Scheme C. Step a: 1- (3- (4-Phenylbutyloxy) propyl) -4-piperidone 1- (3- (4-phenylbutyloxy) propyl) -4-piperidone is prepared from 4-piperidone and 1- chloro-3- (4-phenylbutyloxy) propane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (3- (4-phenylbutyloxy) propyl) -4-piperidone oxime 1 - (3- (4-phenylbutyloxy) propyl) -4-piperidone oxime is prepared from 1 - (3- (4-phenylbutyloxy) propyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in the Example 38, Scheme C, stage b. Scheme C, step c: 4-Amino-1 - (3- (4-phenylbutyloxy) propyl) pperiodine 4-Amino-1 - (3- (4-phenylbutyloxy) propyl) piperidine is prepared from 1 - (3- (4-phenylbutyloxy) propyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, stage c. Scheme A. stage bj 2-Chloro-6-.4- (1 - (3- (4-phen i I butyl nooxy) propyl) piperid y lam i nol-9-cycline pentylpurine 2-Chloro-6- [ 4- (1 - (3- (4-phenylbutylenoxy) propyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - (3- (4-phenylbutyloxy)) propyl) pipepdine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A, step c: 2-.Trans- (4-aminocyclohexyl) amino 1-6-, 4- (1 - (3 - (4-Phenyl-butyloxy) propyl) piperidinylamino-1-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3- (4-phenylbutyloxy) propyl) piperidinylamino] -9 - Cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3- (4-phenylbutyloxy) propyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 71 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (4-hydroxy) butyl) piperidinollamol-9-cyclopentylpurine Preparation of 4-Amino-1 - (4 -hydroxybutyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (4-hydroxybutyl) pperiodine 4-Carboxamide-1 - (4-hydroxybutyl) piperidine can be prepared from isonipecotamide and 4-chloro-1-butanol essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1- (4-hydroxybutyl) piperidine 4-Amino-1- (4-hydroxybutyl) piperidine is prepared from 4-carboxamide-1- (4-hydroxybutyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (4-Hydroxybutyl) -4-pperidone 1- (4-Hydroxybutyl) -4-piperidone is prepared from 4-piperidone and 4-chloro-1-butanol essentially as described above in Example 38, Scheme C, stage a. Scheme C. Stage b: 1 - (4-Hydroxybutyl) -4: piperidone oxime 1- (4-Hydroxybutyl) -4-piperidone oxime is prepared from 1- (4-hydroxybutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Step c: 4-Amino-1- (4-hydroxybutyl) piperidine 4-Amino-1- (4-hydroxybutyl) piperidine is prepared from 1- (4-hydroxybutyl) -4-piperidone oxime essentially as is described above in the Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-y4- (1 - (4-hydroxy) butyl) piperidinylamnol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4-h roxy) butyl) piperidinylamino] -9-cyclopentyl purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-hydroxybutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-f Trans- (4-aminociclohexil) amino1-6- [4- (1 - (4-hydroxy) butyl) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] - 6- [4- (1 - (4-hydroxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-hydroxy) butyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.

Example 72 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1- (4-methoxy) butyl) piperidinylaminol-9-cyclopentyl I purine Preparation of 4-Amino-1- (4-methoxybutyl) ) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1- (4-methoxybutyl) piperidine 4-Carboxamide-1- (4-methoxybutyl) piperidine can be prepared from isonipecotamide and 1-chloro-4-methoxybutane essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1- (4-methoxybutyl) piperidine 4-Amino-1- (4-methoxybutyl) piperidine is prepared from 4-carboxamide-1- (4-methoxybutyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (4-Methoxybutyl) -4-piperidone 1- (4-Methoxybutyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-4-methoxybutane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (4-Methoxybutyl) -4-piperidone oxime 1- (4-Methoxybutyl) -4-piperidone oxime is prepared from 1- (4-methoxybutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1- (4-methoxybutyl) piperidine 4-Amino-1- (4-methoxybutyl) piperidine is prepared from 1 - (4-methoxybutyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-f4- (1 - (4-methoxy) butyl) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4-methoxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-methoxybutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) amnol-6-.4- (1- (4-methoxy) butyl) piperidinylaminol-9-cyclopentylpurine 2- [Trans- ( 4-aminocyclohexyl) amino] -6- [4- (1 - (4-methoxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-methoxy) butyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 73 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (4-ethoxy) butyl) p -peridinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1 - (4- ethoxybutyl) piperidine Method 1 Scheme B. Step a: 4-Carboxamide-1 - (4-ethoxybutyl) piperidine 4-Carboxamide-1- (4-ethoxybutyl) piperidine can be prepared from isonipecotamide and 1-chloro-4-ethoxybutane essentially as described above in Example 38, Scheme B, step a.

Scheme B. stage b: 4-Amino-1- (4-ethoxybutyl) piperidine 4-Amino-1- (4-ethoxybutyl) piperidine is prepared from 4-carboxamide-1- (4-ethoxybutyl) piperidine essentially as described above at Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (4-Ethoxybutyl) -4-piperidone 1- (4-Ethoxybutyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-4-ethoxybutane essentially as described above in Example 38, Scheme C, stage a. Scheme C. Stage b: 1 - (4-Ethoxybutyl) -4-piperidone oxime 1- (4-Ethoxybutyl) -4-piperidone oxime is prepared from 1- (4-ethoxybutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (4-ethoxybutyl) p -peridine 4-Amino-1- (4-ethoxybutyl) piperidine is prepared from 1 - (4-ethoxybutyl) -4-piperidone oxime essentially as is described above in the Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-f4- (1 - (4-ethoxy) butyl) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4-ethoxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-ethoxybutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2-.Trans- (4-aminociclohexyl) amino.-6-.4- (1 - (4-ethoxy) butyl) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] ] -6- [4- (1 - (4-ethoxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-ethoxy) butyl) piperidinylamino] -9- cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 74 2-.Trans- (4-aminoc yclohexyl) aminol-6-.4- (1 - (4-propoxy) butyl) piperid inylammonium-9-cyclopentyl I purine Preparation of 4-Amino-1 - (4-propoxybutyl) pperiodine Method 1 Scheme B. Stage a: 4-Carboxamide-1 - (4-propoxybutyl) piperidine 4-Carboxamide-1- (4-propoxybutyl) piperidine can be prepared from isonipecotamide and 1-chloro -4-propoxybutane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1- (4-propoxybutyl) piperidine 4-Amino-1- (4-propoxybutyl) piperidine is prepared from 4-carboxamide-1- (4-propoxybutyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (4-Propoxybutyl) -4-piperidone 1- (4-Propoxybutyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-4-propoxybutane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (4-Propoxybutyl) -4-piperidone oxime 1 - (4-Propoxybutyl) -4-piperidone oxime is prepared from 1- (4-propoxybutyl) -4-piperidone and hydrochloride of hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C. Stage c: 4-Amino-1- (4-propoxybutyl) piperidine 4-Amino-1- (4-propoxybutyl) piperidine is prepared from 1- (4-propoxybutyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-.4- (1 - (4-propoxy) butyl) p, pperidine-laminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4-propoxy) butyl) piperidinylamino] -9-cyclopenti I purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-propoxybutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-f Trans- (4-aminociclohexyl) amino1-6-14- (1 - (4-propoxy) butyl) pylperidinylaminol-9-cyclopentyl purine 2- [Trans- (4-aminociclohexyl) amino] - 6- [4- (1 - (4-propoxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-propoxy) buti I) piperid inylamino] -9- cyclopentyl puss essentially as described in Example 1, Scheme A, step c. Example 75 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (4-butoxy) butyl) piperidinyl mynol-9-cyclopentyl purine Preparation of 4-Amino-1 - ( 4-butoxybutyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (4-butoxybutyl) piperidine 4-Carboxamide-1- (4-butoxybutyl) piperidine can be prepared from isonipecotamide and 1-chloro 4-butoxybutane essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1- (4-butoxybutyl) piperidine 4-Amino-1- (4-butoxybutyl) piperidine is prepared from 4-carboxamide-1- (4-butoxybutyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C, step a: 1- (4-Butoxybutyl) -4-piperidone 1- (4-Butoxybutyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-4-butoxybutane essentially as described above in Example 38, Scheme C, stage a. Scheme C, step b: 1 - (4-Butoxybutyl) -4-piperidone oxime 1- (4-Butoxybutyl) -4-piperidone oxime is prepared from 1- (4-butoxybutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (4-butoxybutyl) piperidine 4-Amino-1- (4-butoxybutyl) piperidine is prepared from 1 - (4-butoxybutyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-I4- (1- (4-butoxy) butyl) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4-butoxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-butoxybutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1- (4-butoxy) butyl) piperidinylamino-1-9-cyclopentyl I purine 2-_Trans- (4-aminociclohexyl) amino] -6- [4- (1 - (4-butoxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-butoxy) butyl) piperidinylamino] -9 -cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 76 2-.Trans- (4-aminociclohexyl) amino1-6-_4- (1 - (4-benzyloxy) butyl) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1- (4-benzyloxybutyl) piperidine Method 1 Scheme B, step a: 4-Carboxamide-1- (4-benzyloxybutyl) piperidine 4-Carboxamide-1- (4-benzyloxybutyl) piperidine can be prepared from isonipecotamide and 1-chloro-4-benzyloxybutane essentially as described above in Example 38, Scheme B, step a. Scheme B. Stage b.-4-Amino-1- (4-benzyloxybutyl) piperidine 4-Amino-1- (4-benzyloxybutyl) piperidine is prepared from 4-carboxamide-1- (4-benzyloxybutyl) piperidine essentially as described up in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (4-Benzyloxybutyl) -4-pperiodone 1- (4-Benzyloxybutyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-4-benzyloxybutane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (4-Benzyloxybutyl) -4-piperidone oxime 1- (4-Benzyloxybutyl) -4-piperidone oxime is prepared from 1- (4-benzyloxybutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1- (4-benzyloxybutyl) piperidine 4-Amino-1- (4-benzyloxybutyl) piperidine is prepared from 1- (4-benzyloxybutyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A. stage bj 2-Chloro-6-.4- (1 - (4-benzyloxy) butyl) piperidinylamino-1-9-cyclopentyl purine 2-Chloro-6- [4- (1 - (4-benzyloxy) butyl) piperidinylamino ] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-benzyloxybutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1- (4-benzyloxy) butyl) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4- aminocyclohexyl) amino] -6- [4- (1 - (4-benzyloxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-benzyloxy) butyl) piperidinylamino] -9-Cyclopentyl I purine essentially as described in Example 1, Scheme A, step c.

Example 77 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (4- (2-phenylethyloxy) butyl) piperidin-1-ylamol-9-cyclopentylpurine Preparation of 4-Amino-1 - (4- (2-phenylethyloxy) butyl) piperidine 5 Method 1 Scheme B, step a 4-Carboxamide-1 - (4- (2-phenylethyloxy) butyl) piperidine 4-Carboxamide-1 - (4- (2-phenylethyleneoxy) ) butyl) piperidine can be prepared from isonipecotamide and 1-chloro-4- (2-phenylethyloxy) butane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (4- (2-phenylethyloxy) butyl) piperidine 4-Amino-1- (4- (2-phenylethyloxy) butyl) piperidine is prepared from 4-carboxamide-1 - ( 4- (2-phenylethyleneoxy) butyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (4- (2-Phenylethyloxy) butyl) -4-piperidone 1- (4- (2-Phenylethyloxy) butyl) -4-piperidone is prepared from 4-piperidone and 1 - chloro- (2-phenylethyloxy) butane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (4- (2-Phenylethyleneoxy) butyl) -4-piperidone 1 - (4- (2-Phenylethyleneoxy) butyl) -4-piperidone oxime oxime is prepared from 1 - (4 - (2-phenylethyloxy) butyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, - - «-_« - stage b. Scheme C. Stage c: 4-Amino-1 - (4- (2-phenylethyloxy) butyl) piperidine 4-Amino-1- (4- (2-phenylethyloxy) butyl) piperidine is prepared from 1 - (4-) oxime (2-phenylethyloxy) butyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-f4- (1 - (4- (2-phenylethyloxy) butyl) piperidinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4- (2- phenylethyloxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4- (2-phenylethyloxy) butyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (4- (2-phenylethyloxy) butyl) piperidinylamino-1-9-c 2 - [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4- (2-phenylethyleneoxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4 - (1- (4- (2-phenylethyleneoxy) butyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 78 2-.Trans- (4-aminociclohexyl) amino 1-6 -.4- (1 - (4- (3-phenylpropylenoxy) butyl) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1 -, 4- (3-phenylpropyleneoxy) butyl) piperidine Method 1 Scheme B_ Stage 4-Carboxamide-1 - (4- (3-phenylpropyleneoxy) butyl) piperidine 4-Carboxamide-1- (4- (3-phenylpropyleneoxy) butyl) piperidine can be prepared from isonipecotamide and 1-chloro- (4- (3 phenylpropyleneoxy) butane essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1 - (4- (3-phenylpropyleneoxy) butyl) piperidine 4-Amino-1- (4- (3-phenylpropyleneoxy) butyl) piperidine is prepared from 4-carboxamide-1 - ( 4- (3-phenylpropyleneoxy) butyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C, step a: 1- (4- (3-Phenylpropyleneoxy) butyl) -4-piperidone 1- (4- (3-Phenylpropyleneoxy) butyl) -4-piperidone is prepared from 4-piperidone and 1-Chloro- (4- (3-phenylpropyleneoxy) butane essentially as described above in Example 38, Scheme C, step a) Scheme C. Step b: 1 - (4- (3-Phenyl-2-ylpropyleneoxy) butyl) - 4-piperidone oxime 1- (4- (3-Phenylpropyleneoxy) butyl) -4-piperidone oxime is prepared from 1- (4- (3-phenylpropyleneoxy) butyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b Scheme C. step c: 4-Amino-1 -, 4- (3-phenylpropyleneoxy) butyl) piperidine 4-Amino-1- (4- (3-phenylpropyleneoxy) butyl) piperidine is prepared from 1 - (4- (3-phenylpropyleneoxy) butyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-f4- (1 - (4- (3-phenylpropyleneoxy) butyl) piperidin-laminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4- (3-phenylpropyleneoxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4- (3-phenylpropyleneoxy) butyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A, step c: 2-.Trans-, 4-aminocyclohexyl) amino-1-6-f4- (1 - (4- (3-phenylpropyleneoxy) butyl ) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4- (3-phenylpropyleneoxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro- 6- [4- (1 - (4- (3-phenylpropyleneoxy) butyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 79 2-f Trans- (4-aminociclohexyl) aminol-6-I4- (1 - (4- (4-phenylbutyloxy) butyl) piperidine-lactam-9-cyclopentyl-pyrimine Preparation of 4-Amino-1- (4- (4-phenylbutyloxy) butyl) piperidine Method 1 E Scheme B, step a 4-Carboxamide-1 - (4- (4-phenylbutyloxy) butyl) piperidine 4-Carboxamide-1- (4- (4-phenylbutyloxy) butyl) piperidine can be prepared from isonipecotamide and 1-chloro-4- (4-phenylbutyloxy) butane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (4- (4-phenylbutyloxy) butyl) piperidine < ___ ...- 4-Amino-1 - (4- (4-phenylbutyloxy) butyl) piperidine is prepared from 4-carboxamide-1- (4- (4-phenylbutyloxy) butyl) piperidine essentially as described above in the Example 38, Scheme B, stage b. Method 2: Scheme C. Step a: 1- (4- (4-Phenylbutyloxy) butyl) -4-piperidone 1- (4- (4-Phenylbutyloxy) butyl) -4-piperidone is prepared from 4-piperidone and 1-Chloro-4- (4-phenylbutyloxy) butane essentially as described above in Example 38, Scheme C, step a Scheme C. Step b: 1 - (4- (4-Phenylbutylenoxy) butyl) oxime - 4-piperidone 1 - (4- (4-Phenylbutyloxy) butyl) -4-piperidone oxime is prepared from 1- (4- (4-phenylbutyloxy) butyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. stage c: 4-Amino-1 - (4- (4-phenylbutyloxy) butyl) piperidine 4-Amino-1- (4- (4-phenylbutyloxy) butyl) piperidine is prepared from oxime 1 - ( 4- (4-phenylbutyloxy) butyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (4- (4-Phenylbutylenoxy) butyl) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4 - (4-phenylbutyloxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4- (4-phenylbutyloxy) butyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b.

Scheme A, step c: 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (4- (4-phenylbutyloxyl) butyl) piperidinylamino-1-9-cyclopentylpurine 2- [Trans- (4- aminocyclohexyl) amino] -6- [4- (1 - (4- (4-phenylbutyloxy) butyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4- (4- phenylbutyloxy) butyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 80 2-.Trans- (4-aminocyclohexyl) amino-1-6-f4- ( 1- (5- hydroxypentyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1- (5-hydroxypentyl) piperidine Method 1 Scheme B. Step a: 4-Carboxamide-1 - (5-hydroxypentl) p Peridin 4-Carboxarmide-1 - (5-hydroxypentyl) piperidine can be prepared from isonipecotamide and 1-chloro-5-hydroxypentane essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino -1 - (5-hydroxypentyl) piperidine 4-Amino-1 - (5-hydroxypentyl) piperidine is prepared from 4-carboxamide-1 - (5-hjdroxypentyl) piperid ina essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (5-Hydroxypentyl) -4-piperidone 1- (5-Hydroxypentyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-5-hydroxypentane essentially as described above in Example 38, Scheme C, step a.

Scheme C, step b: 1 - (5-Hydroxypentyl) -4-piperidone oxime 1 - (5-Hydroxypentyl) -4-piperidone oxime is prepared from 1- (5-hydroxypentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (5-hydroxypentyl) piperidine 4-Amino-1- (5-hydroxypentyl) piperidine is prepared from 1- (5-hydroxypentyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (5-hydroxypentyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (5-hydroxypentyl)) piperidinylamino] -9 -cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5-hydroxypentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. step c: 2-.Trans- (4-aminociclohexil) amino1-6-.4- (1 - (5-hidroxipentil)) piperidin¡lam¡no1-9-ciclopentilpurina 2- [Trans- (4 -aminocyclohexyl) amino] -6- [4- (1 - (5-hydroxypentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (5-hydroxypentyl)) piperidinylamino] - 9-Cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 81 2-f Trans- (4-aminociclohexyl) aminol-6.4- (1 - (5-methoxy pentyl)) piperid inilam i nol-9-cyclopentyl purine • É ^ I _______________ Preparation of 4-Amino- (5-methoxypentyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (5-methoxypentyl) piperidine 4-Carboxamide-1 - (5-methoxypentyl) piperidine can be prepared of isonipecotamide and 1-chloro-5-methoxypentane essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino- (5-methoxypentyl) piperidine 4-Amino- (5-methoxypentyl) piperidine is prepared from 4-carboxamide-1- (5-methoxypentyl) piperidine essentially as described above in Example 38 , Scheme B, stage b. Method 2: Scheme C. Step a: 1- (5-Methoxy-pentyl) -4-piperidone 1- (5-Methoxy-pentyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-5-methoxypentane essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: 1 - (5-methoxy pentyl) -4-pperidone oxime 1 - (5-methoxy pentyl) -4-piperidone oxime is prepared from 1- (5-methoxypentyl) -4-piperidone and hydrochloride of hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino- (5-methoxypentyl) piperidine 4-Amino- (5-methoxypentyl) piperidine is prepared from 1 - (5-methoxypentyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A. stage bj 2-Chloro-6-.4- (1 - (5-methoxypentyl)) piperidinylamino-1-9-cyclopentyl I purine 2-Chloro-6- [4- (1 - (5-methoxypentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino- (5-methoxypentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-, Trans- (4-aminocyclohexyl) aminol-6-f4- (1- (5-methoxypentyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino] -6- [4- (1 - (5-methoxypentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-10 chloro-6- [4- (1 - (5-methoxypentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. EXAMPLE 82 2-.Trans- (4-aminociclohexyl) amino-6-.4- (1 - (5-ethoxy pentyl)) piperid inylamine-nol-9-cyclopentyl pyrimine Preparation of 4-Amino-1 - ( 5-ethoxy pentyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (5-ethoxy pentyl) piperidine 4-Carboxamide-1 - (5-ethoxy pentyl) piperidine can be prepared from isonipecotamide and 1-chloro-5-ethoxypentane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (5-ethoxy pentyl) piperidine 4-Amino-1 - (5-ethoxy pentyl) pipepdine is prepared from 4-carboxamide-1 - (5-ethoxy pentyl) piperidine essentially as described above at 25 Example 38, Scheme B, step b.

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ Method 2: Scheme C. stage a: 1 - (5-Ethoxy pentyl) -4-piperidone 1 - (5-Ethoxy pentyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-5-ethoxypentane essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: 1 - (5-ethoxy pentyl) -4-piperodine oxime 1 - (5-ethoxy pentyl) -4-piperidone oxime is prepared from 1- (5-ethoxy pentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (5-ethoxy-pentyl) piperidine-4-Amino-1- (5-ethoxy-pentyl) piperidine is prepared from 1- (5-ethoxy-pentyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-.4- (1 - (5-ethoxy-pentyl)) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (5-ethoxy-pentyl)) -piperidinylamino] - 9-Cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5-ethoxy-pentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexyl) amnol-6-.4- (1 - (5-ethoxypentyl)) piperidinylamino-1-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino ] -6- [4- (1 - (5-ethoxy-pentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (5-ethoxypentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. Example 83 2-f Trans- (4-aminocyclohexyl) amnol-6-f4- (1 - (5-propoxy pe nyl)) piperidinyl-i nol-9-cyclopenti I purine Preparation of 4- Amino-1 - (5-propoxypentyl) pperidine Method 1 Scheme B, step a: 4-Carboxamide-1 - (5-propoxypentyl) piperidine 4-Carboxamide-1 - (5-propoxypentyl) piperidine can be prepared from isonipecotamide and 1 -chloro-5-propoxypentane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1- (5-propoxypentyl) piperidine 4-Amino-1- (5-propoxypentyl) piperidine is prepared from 4-carboxamide-1- (5-propoxypentyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C, step a: 1- (5-propoxypentyl) -4-piperidone 1- (5-propoxypentyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-5-propoxypentane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (5-propoxypentyl) -4-piperidone oxime 1 - (5-Propoxypentyl) -4-piperidone oxime is prepared from 1- (5-propoxypentyl) -4-piperidone and hydrochloride of hydroxylamine essentially as described above in Example 38, Scheme C, step b.

Scheme C. stage c: 4-Amino-1 -.5-propoxypentyl) piperidine 4-Amino-1- (5-propoxypentyl) piperidine is prepared from 1- (5-propoxypentyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-f4- (1 - (5-propoxypentyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (5-propoxypentyl)) piperidinylamino] -9- Cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5-propoxypentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexil) aminol-6-! 4- (1 - (S-12ropoxypentl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4 -aminocyclohexyl) amino] -6- [4- (1 - (S-propoxypentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (S-propoxypentyl)) piperidinylamino] - 9-cyclopentylpurine essentially as described in Example 1 1 Scheme A, step c. Example 84 2-.Trans- (4-aminociclohex¡l) aminol-6-.4- (1 - (5-butoxipentil) piperidinilaminol-9-cyclopentilpurine Preparation of 4-Amino-1 - (5-butoxipentil) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (5-butoxypentyl) piperidine 4-Carboxamide-1 - (5-butoxypentyl) piperidine can be prepared from isonipecotamide and 1-chloro-5-butoxypentane essentially as described above in Example 38, Scheme B, step a) Scheme B. step b: 4-Amino-1 - (5-butoxy-pentyl) piperidine 4-Amino-1- (5-butoxy-pentyl) piperidine is prepared from 4-carboxamide-1 - (5-butoxy pentyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C. step a: 1- (5-Butoxy pentyl) -4-piperidone 1 - (5-Butoxyethyl) ) -4-piperidone is prepared from 4-piperidone and 1-chloro-5-butoxypentane essentially as described above in Example 38, Scheme C, stage a. Scheme C, step b: 1 - (5-Butoxy pentyl) -4-piperidone oxime 1 - (5-Butoxy pentyl) -4-piperidone oxime is prepared from 1- (5- butoxy pentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C. Stage c: 4-Amino-1- (5-butoxy-pentyl) piperidine 4-Amino-1- (5-butoxy-pentyl) -piperidine is prepared from 1 - (5-butoxypentyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. 20 Scheme A. stage b: 2-Chloro-6- [4- (1 - (5-butoxy-pentyl) p -peridinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (5-butoxy-pentyl) -piperidinylamino] -9-Cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5-butoxypentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. __________? Scheme A. stage c: 2-.Trans-.4-aminociclohexyl) amino1-6-.4- (1 - (5-butoxypentyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] - 6- [4- (1 - (5-Butoxy-pentyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (5-butoxypentyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 85 2-.Trans- (4-aminociclohexyl) amnol-6-.4- (1 - (5-benzyloxypentiDpiperid i nylaminol-9-cyclopentyl purine Preparation of 4-Amino -1 - (5-benzyloxypentiDpiperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (5-benzylxipentiDpiperidine 4-Carboxamide-1 - (5-benzyloxy pentyl) piperidine can be prepared from isonipecotamide and 1-chloro-5-benzyloxypentane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (5-benzyloxypentyl) pperidine 4-Amino-1- (5-benzyloxypentyl) piperidine is prepared from 4-carboxamide-1- (5-benzyloxypentyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (5-Benzyloxypentyl) -4-piperidone 1- (5-Benzyloxypentyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-5-benzyloxypentane essentially as described above in Example 38, Scheme C, step a.

Scheme C. Stage b: 1 - (5-Benzyloxypentyl) -4-piperidone oxime 1 - (5-Benzyloxypentyl) -4-piperidone oxime is prepared from 1- (5-benzyloxypentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Stage c: 4-Amino-1- (5-benzyloxypentyl) piperidine 4-Amino-1- (5-benzyloxypentyl) piperidine is prepared from 1- (5-benzyloxypentyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A, stage bj 2-Chloro-6-f4- (1 -5-benzyloxypentyl)) piperidinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (5-benzyloxypentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5-benzyloxypentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexil) aminol-6-.4- (1 - (5-benzyloxypentyl) p.peridinimlamino-1-9-cyclopentylpurine 2- [Trans- (4-aminociclohexil) amino] -6- [4- (1 - (5-benzyloxypentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (5-benzyloxypentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 86 2-.Trans- (4-aminocyclohexyl) amnol-6-.4- (1 - (5- (2-phenylethyloxy) pentyl)) piperidinylamino-1-9-cyclopentyl pyrimine Preparation of 4-Amino-1- (5- (2-phenylethyleneoxy) pentyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (5- (2-phenylethylethyleneoxy) pentyl) piperidine 4-Carboxamide-1 - (5- (2-phenylethyloxy) pentyl) piperidine can be prepared from isonipecotamide and 1-chloro-5- (2-phenylethyloxy) pentane essentially as described above in Example 38, Scheme B, Stage a.Scheme B. Stage b: 4-Amino-1 - (5- (2-phenylethyloxy) pentyl) piperidine 4-Amino-1- (5- (2-phenylethyleneoxy) pentyl) piperidi Na is prepared from 4-carboxam ida-1- (5- (2-phenylethyloxy) penti I) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (5- (2-Phenylethyleneoxy) pentyl) -4-pperidone 1- (5- (2-Phenylethyleneoxy) pentyl) -4-piperidone is prepared from 4-piperidone and 1-Chloro-5- (2-phenylethyloxy) pentane essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (5- (2-Phenylethyleneoxy) pentyl) -4-piperidone oxime 1- (5- (2-Phenylethyleneoxy) pentyl) -4-piperidone oxime is prepared from 1- (5- (2-phenylethyloxy) pentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. stage c: 4-Amino-1- (5- (2-phenylethyloxy) ipentyl) piperidine 4-Amino-1- (5- (2-phenylethyloxy) pentyl) piperidine is prepared from oxime _------ > . of 1- (5- (2-phenylethyloxy) pentyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-, 4- (1 - (5- (2-phenylethyleneoxy) pentyl) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (5- (2- phenylethyloxy) pentyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5- (2-phenylethyloxy) pentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (5- (2-phenylethyleneoxy) pentyl) piperidinylamino1-9-cyclopentyl I purine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5- (2-phenylethyleneoxy) penti I)) piperid inylamino] -9-cyclopentyl I purine is prepared from 2-chloro-6- [4- (1 - (5- (2-phenylethyloxy) pentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 87 2-f Trans- (4-aminoc yclohexyl) aminol-6-.4- (1 - (5- (3-phenypropyleneoxy) pentyl)) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1 - ( 5- (3-phenylpropyleneoxy) pentyl) piperidine Method 1 Scheme B_ stage at 4-Carboxamide-1 - (5- (3-phenylpropyleneoxy) pentyl) piperidine 4-Carboxamide-1- (5- (3-phenylpropyleneoxy) pentyl) piperidine can be prepared from isonipecotamide and 1 - chloro-5- (3-phenylpropyleneoxypentane essentially as described above in the Example 38, Scheme B, step a. Scheme B, step bj 4-Amino-1- (5- (3-phenylpropyleneoxy) pentyl) piperidine 4-Amino-1- (5- (3-phenylpropyleneoxy) pentyl) piperidine is prepared from 4-carboxamide-1 - (5- (3-phenylpropyleneoxy) pentyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (5- (3-Phenylpropyleneoxy) pentyl) -4-piperidone 1- (5- (3-Phenylpropyleneoxy) pentyl) -4-piperidone is prepared from 4-piperidone and 1 - chloro-5- (3-phenylpropyleneoxy) pentane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1- (5- (3-Phenylpropyleneoxy) pentyl) -4-piperidone oxime 1- (5- (3-Phenylpropyleneoxy) pentyl) -4-piperidone oxime is prepared from 1 - . 1- (5- (3-phenylpropyleneoxy) pentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C, step CJ 4-Amino-1- (5- (3-phenylpropyleneoxy) pentyl) p -peridine 4-Amino-1- (5- (3-phenylpropyleneoxy) pentyl) piperidine is prepared from 1 - (5-oxime) - (3-phenylpropyleneoxy) pentyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A. stage bj 2-Chloro-6-.4- (1 - (5- (3-phenypropyleneoxy) pentyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - ( 5- (3-phenylpropyleneoxy) pentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5- (3-phenylpropyleneoxy) pentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5- (3-phenylpropyleneoxy) pentyl)) piperidinylamino] -9-cyclopentyl I purine 2- [Trans - (4-aminocyclohexyl) amino] -6- [4- (1 - (5- (3-phenylpropyleneoxy) pentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - ( 5- (3-phenylpropyleneoxy) pentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 88 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (5- (4-phenylbutyloxy) pentyl)) piperidinylamino-9-cyclopentylpurine Preparation of 4-Amino-1 - (5- (4-phenylbutylenoxy) pentiDpiperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (5- (4-phenylbutyloxy) pentyl) piperidine 4-Carboxa mida-1- (5- (4-phenylbutyloxy) pentyl) piperidine can be prepared from isonipecotamide and 1 - chloro-5- (4-phenylbutyloxy) pentane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (5- (4-phenylbutyloxy) pentyl) piperidine _________________ 4-Amino-1 - (5- (4-phenylbutyloxy) pentyl) piperidine is prepared from 4-carboxamide-1- (5- (4-phenylbutyloxy) pentyl) piperidine essentially as described above in Example 38, Scheme B , stage b. Method 2: Scheme C. Step a: 1- (5- (4-Phenylbutyloxy) pentyl) -4-pperiodone 1- (5- (4-phenylbutyloxy) pentyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-5- (4-phenylbutyloxy) pentane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (5- (4-phenyl-bromoyloxy) pentyl) -4-piperidone oxime 1- (5- (4-Phenylbutyloxy) pentyl) -4-piperidone oxime is prepared from 1- (5- (4-phenylbutyloxy) pentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Step c: 4-Amino-1 - (5- (4-phenylbutyloxy) pentyl) pperidine 4-Amino-1- (5- (4-phenylbutyloxy) pentyl) piperidine is prepared from oxime 1- (5- (4-phenylbutyloxy) pentyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, stage bj 2-Chloro-6-.4- (1 - (5-.4-phenylbutylenoxy) pentyl)) piperidinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - ( 5- (4-phenylbutyloxy) pentyl) piperidinylamino] -9-cydopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5- (4-phenylbutyloxy) pentyl) piperidine, and triethylamine essentially as is described above in Example 1, Scheme A, step b. _-------- Scheme A. stage c: 2-.Trans- (4-aminociclohexil) aminol-6-.4- (1 - (5- (4-phen i I butino-lenoxy) pentyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5- (4-phenyl-1-butyloxy) pentyl)) piperid i nor lami] -9-cyclopentyl The braze is prepared from 2-Chloro-6- [4- (1 - (5- (4-phenylbutyleneoxy) pentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 89 2-.Trans- (4-aminociclohexyl) amino1-6-í4- (1 - (6-hydroxy) hexyl) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1- (6-hydroxyhexyl) piperidine Method 1 Scheme B. step a: 4-Carboxamide-1- (6-hydroxyhexyl) piperidine 4-Carboxamide-1- (6-hydroxyhexyl) piperidine can be prepared from isonipecotamide and 6-chloro-1-hexanol essentially as described above in Example 38 , Scheme B, stage a. Scheme B. stage b: 4-Amino-1- (6-hydroxyhexyl) piperidin 4-Amino-1- (6-hydroxyhexyl) piperidine is prepared from 4-carboxamide-1- (6-hydroxyhexyl) piperidine essentially as described above in the Example 38, Scheme B, step b. Method 2: Scheme C, step a: 1- (6-Hydroxyhexyl) -4-piperidone 1- (6-Hydroxyhexyl) -4-piperidone is prepared from 4-piperidone and 6-chloro-1-hexanol essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: oxime of 1- (6-hydroxyhexyl) -4-piperidone oxime of 1- (6-hydroxyhexyl) -4-piperidone is prepared from 1- (6-hydroxyhexyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1- (6-hydroxyhexyl) piperidine 4-Amino-1- (6-hydroxyhexyl) piperidine is prepared from 1- (6-hydroxyhexyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A, step b: 2-Chloro-6-.4- (1 - (6-hydroxy) hexyl) piperidinylamino-1- cyclopentylpurine 2-Chloro-6- [4- (1 - (6-hydroxy) hexyl) piperidinylamino ] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (6-hydroxyhexyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminocloclohexyl) aminol-6-.4- (1- (6-hydroxy) hexyl) piperidinylamino-1-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino ] -6- [4- (1 - (6-hydroxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (6-hydroxy) hexyl) piperidinylamino] -9- cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 90 2-.Trans- (4-aminocyclohexyl) aminol-6-f4- (1- (6-methoxy) hexyl) piperidinylamino-9-cyclopentylpurine Preparation of 4-Amino-1- (6-methoxyhexyl) piperidine Method 1 Scheme B. step a: 4-Carboxamide-1- (6-methoxyhexyi) piperidine 4-Carboxamide-1- (6-methoxyhexyl) piperidine can be prepared from isonipecotamide and 1-chloro-6-methoxyhexane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1- (6-methoxyhexyl) peperidine 4-Amino-1- (6-methoxyhexyl) piperidine is prepared from 4-carboxamide-1- (6-methoxyhexyl) piperidine essentially as described above in the Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (6-Methoxyhexyl) -4-piperidone 1- (6-Methoxyhexyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-6-methoxyhexane essentially as described above in the example 38, Scheme C, step a Scheme C. step b: oxime of 1- (6-methoxyhexyl) -4-piperidone oxime of 1- (6-methoxyhexyl) -4-piperidone is prepared from 1- (6-methoxyhexyl) - 4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1- (6-methoxyhexyl) pperidine 4-Amino-1- (6-methoxyhexyl) piperidine is prepared from 1- (6-methoxyhexyl) -4-piperidone oxime essentially as is described above in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-.4- (1- (6-methoxy) hexylpiperidinylamino-1- cyclopentylpurine 2-Chloro-6- [4- (1- (6-methoxy) hexyl) piperidinylamino] - 9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (6-methoxyhexyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. Step c: 2-.Trans- (4-aminocylclohexyl) aminol-6-.4- (1- (6-methoxy) hexyl) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (6-methoxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (6-methoxy) hexyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 91 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (6-ethoxy) hexyl) piperid inilam i nol-9-cyclopentylpurine Preparation of 4-Amino-1 - (6-hetoxyhexyl) piperidine Method 1 Scheme B, step a: 4-Carboxamide-1 - (6-hetoxyhexyl) piperidine 4-Carboxamide-1- (6-ethoxyhexyl) piperidine p can be prepared from isonipecotamide and 1-chloro-6-ethoxyhexane essentially as described above in Example 38, Scheme B, step a. Scheme B. Step b: 4-Amino-1- (6-ethoxyhexyl) pperidine 4-Amino-1- (6-ethoxyhexyl) piperidine is prepared from 4-carboxamide-1- (6-ethoxyhexyl) piperidine essentially as described above in the Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (6-Ethoxyhexyl) -4-piperidone 1- (6-Ethoxyhexyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-6-ethoxyhexane essentially as described above in Example 38, Scheme C, stage a. Scheme C. Stage b: 1 - (6-Ethoxyhexy) -4-piperidone oxime 1- (6-Ethoxyhexyl) -4-piperidone oxime is prepared from 1- (6-ethoxyhexyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Step c: 4-Amino-1- (6-ethoxyhexyl) piperidine 4-Amino-1- (6-ethoxyhexyl) piperidine will be prepared from 1- (6-ethoxyhexyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A. Stage b: 2-Chloro-6-f4- (1 - (6-ethoxy) hexyl) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (6-ethoxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (6-ethoxyhexyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2-.Trans- (4-aminociclohexyl) amnol-6-f4- (1 - (6-ethoxy) hexyl) piperidinylaminol-9-cyclopentyl purine 2- [Trans- (4-aminociclohexyl) amino] -6- [4- (1 - (6-ethoxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (6-ethoxy) hexyl) piperidinylamino] -9 -cyclopenti I purine essentially as described in Example 1, Scheme A, step c.

Example 92 2-.Trans- (4-aminociclohexyl) amnol-6-.4- (1 - (6-propoxy) hexyl) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1- (6-propoxyhexyl) piper Method 1 Scheme B, -Etapa a: 4-Carboxamide-1 - (6-propoxyhexyl) pperidine 4-Carboxamide-1- (6-propoxyhexyl) piperidine can be prepared from isonipecotamide and 1-chloro-6- propoxyhexane essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1- (6-propoxyhexyl) piperidine 4-Amino-1- (6-propoxyhexyl) piperidine is prepared from 4-carboxamide-1- (6-propoxyhexyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (6-Propoxyhexyl) -4-piperidone 1- (6-Propoxyhexyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-6-propoxyhexane essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (6-Propoxyhexyl) -4-piperidone oxime 1- (6-Propoxyhexyl) -4-piperidone oxime is prepared from 1- (6-propoxyhexyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Step c: 4-Amino-1- (6-propoxyhexyl) piperidine 4-Amino-1- (6-propoxyhexyl) piperidine is prepared from 1- (6-propoxyhexyl) -4-piperidone oxime essentially as described up in Example 38, Scheme C, step c. Scheme A. stage bj 2-Chloro-6-y4- (1 - (6-propoxy) hexyl) piperidinylamino-1-9-cyclopentyl I purine 2-Chloro-6- [4- (1 - (6-propoxy ) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (6-propoxyhexyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-fTrans- (4-aminociciphenylamino-1-6-.4- (1- (6-propoxy) hexyl) piperidinylamino-1-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (6-propoxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (6-propoxy) hexyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 93 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (6-butoxy) hexyl) piperidinylamunol-9-cyclopenti I Purine Preparation of 4-Amino-1- (6-butoxyhexyl) pperidine Method 1 Scheme B. Step a: 4-Carboxamide-1- (6-butoxyhexyl) piperidine 4-Carboxamide-1- (6-butoxyhexyl) piperidine can be prepared from isonipecotamide and 1-chloro-6-butoxyhexane essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1- (6-butoxyhexyl) piperidine 4-Amino- 1- (6-Butoxyhexyl) piperidine is prepared from 4-carboxamide-1- (6-butoxyhexyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C, step a: 1- (6-Butoxyhexyl) -4-piperidone 1- (6-Butoxyhexyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-6-butoxyhexane essentially as described above in the example 38, Scheme C, stage a. Scheme C. Stage b: 1 - (6-Butoxyhexyl) -4-piperidone oxime 1- (6-Butoxyhexyl) -4-piperidone oxime is prepared from 1- (6-butoxyhexyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (6-butoxyhexyl) piperidine 4-Amino-1- (6-butoxyhexyl) piperidine is prepared from 1- (6-butoxyhexyl) -4-piperidone oxime essentially as described up in the Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-r4- (1- (6-butoxy) hexyl) p -peridinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1- (6-butoxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (6-butoxyhexyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-fTrans- (4-aminocyclohexyl) amnol-6-.4- (1 - (6-butoxy) hexi Qpiperidin Mam i nol-9-cyclopenti I purine 2- [Trans - (4-aminocyclohexyl) amino] -6- [4- (1 - (6-butoxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (6-butoxy) hexyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 94 2- [Trans- (4-aminocyclohexyl) aminol-6- [4- (1 - (6-benzyloxphexy I ) piperidin ilaminol-9-cyclopentylpurine Preparation of 4-Amino-1- (6-benzyloxyhexyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1- (6-benzyloxyhexyl) piperidine 4-Carboxamide-1 - (6- Benzyloxyhexyl) piperidine can be prepared from isonipecotamide and 1-chloro-6-benzyloxyhexane essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1- (6-benzyloxyhexyl) piperidine 4 -Amino-1 - (6-benzyloxyhexyl) piperidine is prepared from 4-carboxamide-1- (6-benzyloxyhexyl) piperidine essentially as write above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (6-Benzyloxyhexyl) -4-piperidone 1- (6-Benzyloxyhexyl) -4-piperidone is prepared from 4-piperidone and 1-chloro-6-benzyloxyhexane essentially as described above in Example 38, Scheme C, stage a. Scheme C. Stage b: 1 - (6-Benzyloxyhexyl) -4-piperidone oxime 1- (6-Benzyloxyhexyl) -4-piperidone oxime is prepared from 1- (6-benzyloxyhexyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (6-benzyloxyhexyl) piperidine 4-Amino-1- (6-benzyloxyhexyl) piperidine is prepared from 1- (6-benzyloxyhexyl) -4-piperidone oxime essentially as is described above in Example 38, Scheme C, step c. Scheme A_ stage bj 2-Chloro-6-, 4- (1 - (6-benzyloxy) hexyl) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (6-benzyloxy) hexyl) piperidinylamino] - 9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (6-benzyloxyhexyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-, Trans- (4-aminocyclohexyl) aminol-6-.4- (1- (6-benzyloxy) hexyl) piperidinylamino-1-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (6-benzyloxy) hexyl) piperidinylamino] -9-cyclopentiipurine is prepared from 2-chloro-6- [4- (1 - (6-benzyloxy) hexyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 95 2-f Trans- (4-amino-cyclohexyl) amino-1-6-.4- (1 - (6- (2-phenylethyloxyhexyl) piperidinylamine-9-cyclopentyl I purine 5 Preparation of 4-Amino -1- (6- (2-phenylethyloxy) hexyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1- (6- (2-phenylethyloxy) hexyl) piperidine 4-Carboxamide-1 - (6- (2- phenylethyloxy) hexyl) piperidine can prepare from isonipecotamide and 1-chloro-6- (2-phenylethyloxy) hexane essentially as described above in Example 38, Scheme B, stage a. Scheme B, step b: 4-Amino-1 - (6- (2-phenylethyloxy) hexyl) piperidine 4-Amino-1- (6- (2-phenylethyloxy) hexyl) piperidine is prepared from 4- 15 carboxamide-1 - (6- (2-phenyl Methoxynoxy) hexyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (6- (2-phenylethyloxy) hexyl) -4-piperidone 1- (6- (2-phenylethyloxy) hexyl) -4-piperidone is prepared from 4-piperidone 20 and 1 -chloro-6- (2-phenylethyloxy) hexane essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (6- (2-Phenylethyleneoxy) hexyl) -4-piperidone oxime 1- (6- (2-Phenylethyleneoxy) hexyl) -4-piperidone oxime is prepared from 1 - 25 (6 - (2-phenylethyloxy) hexyl) -4-piperidone and hydrochloride ___________ hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C. stage c: 4-Amino-1 - (6- (2-phenylethyloxy) hexyl) piperidine 4-Amino-1- (6- (2-phenylethyloxy) hexyl) piperidine is prepared from 1 - (6-) oxime (2-phenylethyloxy) hexyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A. stage bj 2-Chloro-6-.4- (1 - (6- (2-phenylethyloxy) hexyl) piperidinylaminol-9-cyclopenti I purine 2-Chloro-6- [4- (1 - (6- ( 2-phenylethyloxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (6- (2-phenylethyloxy) hexyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1- (6- (2-phenylethyloxy) hexyl ) piperidinylaminol-9-cyclopenti I purine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (6- (2-phenylethyloxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2- chloro-6- [4- (1 - (6- (2-phenylethyloxy) hexyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 96 2-fTrans- (4- aminocyclohexyl) aminol-6-f4- (1- (6- (3-phenylpropyleneoxy) hexyl) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1- (6- (3-phenylpropyleneoxy) hexyl) piperidine Method 1 Scheme B_, step a 4-Carboxamide-1- (6- (3-phenylpropyleneoxy) hexyl) piperidine 4-Carboxamide-1 - (6- (3-phenylpropyleneoxy) hexyl) piperidine can be prepared from isonipecotamide and 1-chloro-6- (3-phenylpropyleneoxy) hexane essentially as described above in Example 38, Scheme B, step a. Scheme B, step bj 4-Amino-1 - (6- (3-phenylpropyleneoxy) hexyl) piperidine 4-Amino-1- (6- (3-phenylpropyleneoxy) hexyl) piperidine is prepared from 4-carboxamide-1 - (6 - (3-phenylpropyleneoxy) hexyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (6- (3-Phenylpropyleneoxy) hexyl-4-pperodone 1- (6- (3-phenylpropyleneoxy) hexyl-4-piperidone is prepared from 4-piperidone and 1-chloro-6- (3-phenylpropyleneoxy) hexane essentially as described above in Example 38, Scheme C, step a) Scheme C. step b: 1 - (6- (3-phenylpropyleneoxy) hexyl-4- oxime piperidone 1 - (6- (3-Phenylpropyleneoxy) hexyl-4-piperidone oxime is prepared from 1- (6- (3-phenylpropyleneoxy) hexyl-4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C. stage cj 4-Amino-1 - (6- (3-phenylpropyleneoxy) hexyl) piperidin 4-Amino-1- (6- (3-phenylpropyleneoxy) hexyl) piperidine is prepared from oxime 1 - (6 - (3-phenylpropyleneoxy) hexyl-4-piperidone essentially as described above in Example 38, Scheme C, step c.Scheme A, step bj 2-Chloro-6-r4- (1 -6- (3-phenylpropyleneoxy) ) hexyl) piperidinylaminol-9-cyclopentylpurine 5 2-Chloro-6- [4- (1 - (6- (3-phenylpropyleneoxy) hexyl) piperidinylamino] -9- cyclopentylpurine is prepared from 2,6-dichloro-9- cyclopentylpurine, 4-amino-1- (6- (3-phenylpropyleneoxy) hexyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b.10 Scheme A. step c: 2-yTrans- ( 4-aminociclohexyl) aminol-6-.4- (1- (6- (3-phenylpropyleneoxy) hexyl) piperidinylamino-1-9-cyclopentyl I purine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- ( 1- (6- (3-phenylpropyleneoxy) hexy I) piperid inylamino] -9-cyclopenti I purine is prepared from 2-chloro-6- [4- (1- (6- (3-phenylpropyleneoxy) hexyl) piperidinylamino ] -9- 15 cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 97 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (6- (4-phenylbutyloxyphexyl) piperidinthylaminol-9-cyclopentylpyridine Preparation of 4-Amino-1 - (6- (4-phenylbutyloxy) hexyl) piperidine Method 1 Scheme B, step a_j 4-Carboxamide-1 - (6- (4-phenylbutyloxy) hexyl) piperidine 4-Carboxamide-1- (6- (4-phenylbutyloxy) hexyl) piperidine may prepare isonipecotamide and 1-chloro-6- (4-phenylbutyloxy) hexane ^^^^ t g »* ^ essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (6-, 4-phenylbutyloxy) hexyl) piperidine 4-Amino-1- (6- (4-phenylbutyloxy) hexyl) piperidine is prepared from 4-carboxamide-1- (6- (4-phenylbutyloxy) hexyl) piperidine essentially as described above in Example 38, Scheme B, stage b. Method 2: Scheme C. Step a: 1- (6- (4-Phenylbutyloxy) hexyl) -4-piperidone 1- (6- (4-phenylbutyloxy) hexyl) -4-piperidone is prepared from 4-piperidone and 1- chloro- (4-phenylbutyloxy) hexane essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (6- (4-Phenylbutylene-hexoxy) hexyl) -4-piperidone oxime 1- (6- (4-Phenylbutyloxy) hexyl) -4-piperidone oxime is prepared from 1- (6-) (4-phenylbutyloxy) hexyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C. stage c: 4-Amino-1 - (6- (4-phenylbutyloxy) hexyl) piperidine 4-Amino-1- (6- (4-phenylbutyloxy) hexyl) piperidine is prepared from 1- (6- (4-phenylbutyloxy) hexyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C , stage c. Scheme A., stage bj 2-Chloro-6-.4- (1 - (6-, 4-phenylbutylenoxy) hexyl) piperidinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - ( 6- (4-phenylbutyloxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4- amino-1- (6- (4-phenylbutyloxy) hexyl) piperidine, and triethylamine essentially as is described above in Example 1, Scheme A, step b Scheme A, step c: 2- [Trans-.4-aminocyclohexyl) aminol-6-f4- (1- (6- (4-phenylbutyloxy) hexyl ) piperidinylamine-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1- (6- (4-phenylbutyloxy) hexyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-Chloro-6- [4- (1- (6- (4-phenylbutyloxy) hexyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 98 2-. Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (allyl) piperidinylammonol-9-cyclopentylpurine Preparation of 4-Amino-1- (allyl) pyridine Method 1 Scheme B. stage a : 4-Carboxamide-1 - (allyl) ) piperidine 4-Carboxamide-1 - (allyl) piperidine can be prepared from isonipecotamide and allyl chloride essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1 - (allyl) piperidine 4-Amino-1 - (allyl) piperidine is prepared from 4-carboxamide-1 - (allyl) piperidine essentially as described above in Example 38, Scheme B, stage b. Method 2: Scheme C, step a: 1- (allyl) -4-piperidone 1 - (allyl) -4-piperidone is prepared from 4-piperidone and allyl chloride essentially as described above in Example 38, Scheme C, stage a. Scheme C. Step b: 1 - (allyl) -4-piperidone oxime 1 - (allyl) -4-piperidone oxime is prepared from 1- (allyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (allyl) piperidine 4-Amino-1 - (allyl) piperidine is prepared from 1 - (allyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, stage c. Scheme A. Stage b: 2-Chloro-6-f4- (1 - (allyl) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4-1 - (allyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2, 6-dichloro-9-cyclopentylpurine, 4-amino-1 - (allyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-.Trans- (4-aminociclohexil) amnol-6-.4- (1 - (allyl) piperidin i laminol-9-cyclopentyl purine 2- [Trans- (4-aminociclohexyl) amino ] -6- [4- (1 - (allyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (allyl) piperidinylamino] -9-cyclopentylpurine essentially as described in the Example 1 , Scheme A, stage c. Example 99 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (2- (2-hydroxyethylenoxy) ethyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino- 1 - (2- (2-hydroxyethyloxy) ethyl) piperidine Method 1 Scheme B, Step to 4-Carboxamide-1 - (2- (2-hydroxyethyloxy) ethyl) piperidine 4-Carboxamide-1 - (2- (2-hydroxyethyloxy) ethyl) piperidine can be prepared from isonipecotamide and 2- (2-chloroethoxy) ) ethanol essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1 - (2- (2-hydroxyethyloxy) ethyl) piperidine 4-Amino-1 - (2- (2-hydroxyethyloxy) ethyl) piperidine is prepared from 4-carboxamide-1 - (2- (2-hydroxyethyloxy) ethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (2- (2-Hydroxyethyleneoxy) ethyl) -4-piperidone 1- (2- (2-Hydroxyethyloxy) ethyl) -4-piperidone is prepared from 4-piperidone and - (2-chloroethoxy) ethanol essentially as described above in Example 38, Scheme C, step a. Scheme C. Step b: 1 - (2- (2-Hydroxyethyloxy) ethyl) -4-piperidone oxime 1 - (2- (2-Hydroxyethyloxy) ethyl) -4-piperidone oxime is prepared from 1 - (2- (2-hydroxyethyloxy) ethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (2- (2-hydroxyethyloxy) ethyl) piperidine 4-Amino-1 - (2- (2-hydroxyethyloxy) ethyl) piperidine is prepared from oxime 1 - (2- (2-hydroxyethyloxy) ethyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-f4- (1 - (2- (2-hydroxy-ethyloxy) etl) p -peridinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - ( 2- (2-hydroxyethyloxy) ethyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2- (2-hydroxyethyloxy) ethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans-.4-aminocyclohexyl) amino-1-6-f4- (1 - (2- (2-hydroxyethyleneoxy) ethyl) )) piperidinylamino1-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2- (2-hydroxyethyloxy) ethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2- Chloro-6- [4- (1 - (2- (2-hydroxyethyloxy) ethyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.Example 100 2 -.Trans- ( 4-aminociclohexyl) aminol-6-.4- (1 - (2-N, N-dimethylaminoethylpiperidinylaminol-g-cyclopentylpurine) Preparation of 4-Amino-1 - (2-N. N-dimethylaminoethyl) piperidine Method 1 Scheme a B, step at 4-Carboxamide-1 - (2-N, N-dimethylamine and noetidyl Ridine 4-Carboxamide-1 - (2-N, N-dimethylaminoethyl) piperidine can be prepared from isonipecotamide and 2-N, N-chloruror of dimethylaminoethyl essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1 - (2-N. N-dimethylaminoethyl) piperidine 5 4-Amino-1 - (2-N, N-dimethylaminoethyl) piperidine is prepared from 4-carboxamide-1 - (2 -N, N-dimethylaminoethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (2-N, N-dimethylaminoethyl) -4-piperidone 10 1 - (2-N, N-dimethylaminoethyl) -4-piperidone is prepared from 4-piperidone and 2-piperidone. -N, N-dimethylaminoethyl essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: oxime of 1 - (2-N. N-dimethylaminoethyl) -4-piperidone 1 - (2-N, N-dimethylaminoethyl) -4-piperidone oxime is prepared from 1- (2-N, N-dimethylaminoethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C. stage c: 4-Amino-1 - (2-N, N-dimethylamidoetyl) piperidine 4-Amino-1 - (2-N, N-dimethylaminoethyl) piperidine is prepared from oxime of 20 1 - (2-N, N-dimethylaminoethyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-f4- (1 - (2-N. N-dimethylaminoethyl)) iperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2-N, N- dimethylaminoethyl)) piperidinylamino] -9- 25 cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4- __________ amino-1 - (2-N, N-dimethylaminooethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminociclohexyl) amino1-6-f4- (1 - (2-N. N-dimethylaminoethyl)) piperidinylamino-1-9-cyclopentpipurine 2- [Trans- (4-aminociclohexyl ) amino] -6- [4- (1 - (2-N, N-dimethylaminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2-N, N- dimethylaminoethyl)) piperidimethylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 1 01 2-f Trans- (4-aminociclohexil) aminol-6-I4- (1 - (3-N. N-di metila mi nopropyl)) piperid inilam i nol-9-cyclopentilpurine Preparation of 4-Amino-1 - (3-N, N-dimethylaminopropyl) pyridine Method 1 Scheme B_, step a 4-Carboxamide-1 - (3-N, N-dimethylaminopropyDpiperidine 4-Carboxa mida- 1 - (3-N, N-di methylaminopropyl) piperidine can be prepared from isonipecotamide and 3- N, N-dimethylaminopropyl essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1 - (3-N. N-dimethylaminopropyl) piperidine 4-Amino-1 - (3-N, N-dimethylaminopropyl) piperidine is prepared from 4-carboxamide-1- (3-N, N-dimethylaminopropyl) piperidine essentially as described above in Example 38, Scheme B, stage b. Method 2: Scheme C. Step a: 1 - (3-N, N-dimethylaminopropyl) -4-piperidone 1 - (3-N, N-dimethylaminopropyl) -4-piperidone is prepared from 4-piperidone and 3-piperidone chloride N, N-dimethylaminopropyl essentially as described above in Example 38, Scheme C, step a. Scheme C. Step b: 1 - (3-N, N-dimethylaminopropyl) -4-piperidone oxime 1 - (3-N, N-dimethylaminopropyl) -4-piperidone oxime is prepared from 1- (3-N, N-dimethylaminopropyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in the Example 38, Scheme C, stage b. Scheme C. Stage c: 4-Amino-1 - (3-N-dimethylaminopropyl) piperidine 4-Amino-1 - (3-N, N-dimethylaminopropyl) piperidine is prepared from 1 - (3-N, N-dimethylaminopropyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (3-N, Nd-meth-aminopropyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3-N , N-dimethylaminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-N, N-dimethylaminopropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. step c: 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (3-N. N-dimethylaminopropyl)) piperidin-1-yl-1-9-cyclopentylpurine 2 - [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-dimethylaminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3-N, N-dimethylaminopropyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.

Exampie 102 2-.Trans- (4-aminociclohexyl) amnol-6-.4- (1 - (4-N, N-dimethylaminobutyl)) piperidin-laminole-9-cyclopentyl-pneumine Preparation of 4-Amino- 1 - (4-NN-dimethylaminobutyl) piperidine 10 Method 1 Scheme B, step a 4-Carboxamide-1 -, 4-N, N-dimethylaminobutiDpiperidine 4-Carboxamide-1 - (4-N, N-dimethylaminobutyl) piperidine can be prepared from isonipecotamide and 3-N, N-dimethylaminobutyl chloride essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1 - (4-N. N-dimethylaminobutyl) piperidine 4-Amino-1 - (4-N, N-dimethylaminobutyl) piperidine is prepared from 4-carboxamide-1 - (4- N, N-dimethylaminobutyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1 - (4-N, N-dimethylaminobutyl) -4-piperidone 1- (4-N, N-dimethylaminobutyl) -4-piperidone is prepared from 4-piperidone and 3-N, N-dimethylaminobutyl chloride essentially as described above in Example 38, Scheme C, step a. ______ Scheme C, step b: 1 - (4-N, N-dimethylaminobutyl) -4-piperidone oxime 1 - (4-N, N-dimethylaminobutyl) -4-piperidone oxime is prepared from 1- (4-N) , N-dimethylaminobutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1 - (4-NN-dimethylaminobutyl) pperiodine 4-Amino-1- (4-N, N-dimethylaminobutyl) piperidine is prepared from oxime 1 - (4-N, N-dimethylaminobutyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A. stage bj 2-Chloro-6-.4- (1-4-N, N-methylaminobutyl)) piperidinyl-lane-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4 -N, N-di methylaminobutyl)) piperid inylamido] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-N, N-dimethylaminobutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6-f4- (1 - (4-N, N-dimethylaminobulyl)) p.peridin-1-amino-1- cyclopentylpurine 2- [Trans - (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-dimethylaminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- (4- (1- (4 -N, Nd methylaminobutyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. - * - .._.._- Example 1 03 2- [Trans- (4-aminociclohexyl) aminol-6-f4- (1 - (5-N. N-dimethylaminopentyl)) piperidinylaminol-9-cyclopentyl Glucose Preparation of 4-Amino-1 - (5-N. N-dimethylaminopentyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (5-N. N-dimethylaminopentiDpiperidine 4-Carboxamide-1 - (5-N, N-dimethylaminopentyl) piperidine can be prepared from isonipecotamide and 5-N, N-dimethylaminopentyl chloride essentially as described above in Example 38, Scheme B, step a.Scheme B. step b: 4-Amino- 1- (5-N, N-dimethylaminopentyl) piperidine 4-Amino-1- (5-N, N-dimethylaminopentyl) piperidine is prepared from 4-carboxamide-1- (5-N, N-dimethylaminopentyl) piperidine essentially as described above in Exanple 38, Scheme B, step B. Method 2: Scheme C. stage a: 1 - (5-N, N-dimethylaminopentyP-4-piperidone 1 - (5-N, N-dimethylaminopentyl ) -4-piperidone is prepared from 4-piperidone and 5-N, N-dimethylaminopentyl chloride essentially as described above in the Axis plo 38, Scheme C, stage a. Scheme C. Stage b: 1 - (5-N. N-dimethylaminopentiP-4-piperidone oxime 1 - (5-N, N-dimethylamphenylethyl) -4-piperidone oxime is prepared from 1 - (5-N, N -dimethylaminopentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b Scheme C. step c: 4-Amino-1 - (5-N. N-dimethylaminopentiPpiperidy Na 4-Amino-1 - (5-N, N-dimethylaminopentyl) piperidine is prepared from 1- (5-N, N-dimethylaminopentyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c) Scheme A, step bj 2-Chloro-6-.4- (1 - (5-N, N-dimethylaminopentiP) piperidinylaminol-9-cyclopentyl I purine 2-Chloro-6- [4- (1 - ( 5-N, N-dimethylaminopentyl)) piperid inylamido] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5-N, N-dimethylaminopentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (5-N. N-dimethylaminopent.P) piperidin-1-amino-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-dimethylaminopentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-Chloro-6- [4- (1- (5-N, N-dimethylaminopentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in the Example 1, Scheme A, stage c. Example 104 2-Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (2-N, N-d-ethylaminoetiP) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1- (2-N. N-diethylaminoetiPpiperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (2-N. N-diethylaminoetiPpiperidine 4-Carboxamide-1 - (2-N, N-diethylaminoethyl) peperidine can be prepared from isonipecotamide and 2-N chloride , N-diethylaminoethyl essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1 - (2-N, N-diethylaminoethyl) pyrimidine 4-Amino-1 - (2-N, N-diethylaminoethyl) piperidine is prepared from 4-carboxamide-1- (2-N, N-diethylaminoethyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C. Step a: 1- (2-N, N-diethylaminoethyl) -4-piperidone 1- (2-N, N-diethylaminoethyl) -4-piperidone is prepared from 4-piperidone and 2- (2- N, N-diethylaminoethyl essentially as described above in Example 38, Scheme C, step a) Scheme C. step b: Oxime of 1 - (2-N, N-diethylaminoetiD-4-piperidone 1 - (2-N, N-diethylaminoethyl) -4-piperidone oxime is prepared from 1- (2-N, N-diethylaminoethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Step c: 4-Amino-1 - (2-N, N-diethylaminoethyl) piperidine 4-Amino-1 - (2-N, N-diethylaminoethyl) piperidine is prepared from oxime 1 - (2-N, N-diethylaminoethyl) -4-piperidone essentially as described above in Example 38, Scheme C, step C. Scheme A, step bj 2-Chloro-6-.4- (1 - (2- N. N-diethylaminoetiP) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2-N, N-diethylaminoethyl)) piperidinylamino] -9- cyclopentylpurine is prepared from 2,6- dichloro-9-cyclopentylpurine, 4-amino-1 - (2-N, N-diethylaminoethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-fTrans - (4-aminocyclohexyl) amynol-6-γ4- (1 - (2-N. Nd.ethylaminoetyl)) piperidinylamino-9-cyclopentylpurine 2- [Trans- (4- aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-diethylaminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2-N, N -diethylaminoethyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in E Example 1, Scheme A, stage c. Example 105 2-.Trans- (4-aminocyclohexyPamino1-6-f4- (1 - (3-N, N-diethylammonopropy) piperidin-laminol-9-cyclopentylpurine Preparation of 4-Amino-1 - (3-N, N-diethylaminopropyl) piperidine Method 1 Scheme B_ stage at 4-Carboxamide-1 - (3-N, N-diethylaminopropiPpioridine 4-Carboxamide-1 - (3-N, N-diethylaminopropyl) piperidine can be prepared from isonipecotamide and 3-N, N-diethylaminopropyl chloride essentially as described above in Example 38, Scheme B, step a.Scheme B, step b: 4-Amino-1 - (3-N, N-diethylaminopropii) piperidi Na 4-Amino-1 - (3-N, N-diethylaminopropyl) piperidine is prepared from 4-ca rboxa-mida-1- (3-N, N-diethylamide, nopropyl) piperidine essentially as described above in Example 38 , Scheme B, step b Method 2: _______________ Scheme C. stage a: 1 - (3-N. N-diethylaminopror¡P-4-piptridone 1 - (3-N, N-diethylaminopropyl) -4-piperidone is prepared from 4-piperidone and 3-N chloride , N-diethylaminopropyl essentially as described above in Example 38, Scheme C, step a) Scheme C. Step b: 1 - (3-N, N-diethylaminopropyl) -4-piperidone oxime 1 - ( 3-N, N-diethylaminopropyl) -4-piperidone is prepared from 1- (3-N, N-diethylaminopropyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1 - (3-N. N-diethylaminoproniPpiperidine 4-Amino-1 - (3-N, N-diethylaminopropyl) piperidine is prepared from 1 - (3-N, N-diethylaminopropyl) -4-piperidone essentially as described above in Example 38, Scheme C, step C. Scheme A. stage bj 2-Chloro-6- [4- (1 - (3-N. N-diethylaminoprop) D) piperidinylaminol-9-cyclopentyl I purine 2-Chloro-6- [4- (1 - (3-N, N-diethylaminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-N, N-diethylaminopropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-rTrans- (4-aminociclohexyl) aminol-6-.4- (1 - (3-N. N-diethylaminopropyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino] -6- [4- (1 - (3-N, N-diethylaminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3-N, N-diethylaminopropyl )) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 1 06 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (4-N, N-diethylaminobutyl)) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1 -, 4 -N, N-diethylaminobutiPpiperidine Method 1 Scheme B_ stage at 4-Carboxamide-1 - (4-N, Nd ieti laminobutiPpiperid ina 4-Carboxamide-1 - (4-N, N-diethylaminobutyl) piperidine can be prepared from isonipecotamide and chloride 4-N, N-diethylaminobutyl essentially as described above in Example 38, Scheme B, step a Scheme B, step b: 4-Amino-1- (4-N, N-diethylaminobutyl) piperidine 4-Amino-1 - (4-N, N-diethylaminobutyl) piperidine is prepared from 4-carboxamide-1- (4-N, N-diethylaminobutyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C. step a: 1- (4-N, N-diethylaminobutyl) -4-piperidone 1- (4-N, N-diethylaminobutyl) -4-piperidone is prepared from 4-piperidone and 4-N, N- chloride diaminoethylbutyl essentially as described above in Example 38, Scheme C, step a. , step b: oxime of 1 - (4-N, N-diethylaminobutiP-4-piperidone 1 - (4-N, N-diethylaminobutyl) -4-piperidone oxime is prepared from 1- (4-N, N-diethylaminobutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C, step c: 4-Amino-1 - (4-N, N-diethylaminobutyl) piperidine 4-Amino-1- (4-N, N-diethylaminobutyl) piperidine is prepared from 1 - (4-) oxime N, N-diethylaminobutyl) -4-piperidone essentially as described above in Example 38, Scheme C, step C. Scheme A, step b 2-Chloro-6-y4- (1 - (4-N. N-diethylaminobutyl )) piperidinylaminol-9-cyclopentyl I purine 2-Chloro-6- [4- (1 - (4-N, Nd Ieti lami nobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9- cyclopentylpurine, 4-amino-1- (4-N, N-diethylaminobutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2-.Trans- (4-aminocyclohexyPamino _-6-_4- (1 - (4-N1 N-diethylaminobutiP) piperidinylamino-1-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl ) amino] -6- [4- (1 - (4-N, N-diethylaminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-N, N- diethyl minobutyl)) piperid inylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c Example 1 07 2 -.Trans- (4-aminocyclohex -Paminol-6-.4- (1 - (5-N, Nd-ethylaminopentyl) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1 - (5-N), N-diethylaminophenyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (5-N, N-diethylaminopentiPpiperidine 4-Ca rboxa mide- 1 - (5-N, N- diethylaminopentyl) piperidine can be prepared from isonipecotamide and 5-N, N-diethylaminopentyl chloride essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1 - (5- N. N-diethylaminopentiPpiperidine 4-Amino-1 - (5-N, N-diethylaminopentyl) piperidine is prepared from 4-carboxamide-1- (5-N, N-diethylaminopentyl) piperidine essentially as described above in Example 38, Scheme B, stage b.

Method 2: Scheme C. Stage a: 1 - (5-N, N-diethylaminopentiD-4-piperidone 1 - (5-N, N-diethylaminopentyl) -4-piperidone is prepared from 4-piperidone and 5-piperidone N, N-diethylaminopentyl essentially as described above in Example 38, Scheme C, step a.Step C, step b: 1 - (5-N, N-diethylaminopentyl) -4-piperidone oxime 1 - ( 5-N, N-diethylaminopentyl) -4-piperidone is prepared from 1- (5- N, N-diethylaminopentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C, step c: 4-Amino-1 - (5-N. N-diethylaminopentiPpiperidine 4-Amino-1 - (5-N, N-diethylaminopentyl) piperidine is prepared from 1-oxime (5-N, N- diethylaminopentyl) -4-piperidone essentially as described above in Example 38, Scheme C, step C. Scheme A, step bj 2-Chloro-6-.4- (1 - (5-N, N- ______M___ DiethylaminopentiPpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (5-N, N-diethylaminopentyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino- 1- (5-N, N-diethylaminopentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-f Trans- (4-aminocyclohexyl) ami nol-6-f4- (1 - (5-NN-diethylamide, nopentypiperidinylaminol-9-cyclopentyl purine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N- diethylaminopentyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (5-N, N-diethylaminopentyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, Step C. Example 1 08 2-.Trans- (4-aminocyclohexyl) amino-6-.4- (1 - (2-N, N- dipropylaminoetiP) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino- 1 - (2-N, N-dipropylaminoetiPpiperidine Method 1 Scheme B_ stage a_j 4-Carboxamide-1 - (2-N, N-dipropylaminoetiP piperidine 4-Carboxamide-1 - (2-N, N-dipropylaminoethyl) piperidine can be prepared from isonipecotamide and 2-N, N-dipropylaminoethyl chloride essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1 - (2-N, N-dipropylaminoethyl) piperidine 4-Amino-1 - (2-N, N-dipropylaminoethyl) piperidine is prepared from 4-carboxamide-1 - (2- N, N-dipropylaminoethyl) piperidine essentially as described above in Example 38, Scheme B, step b.

Method 2: Scheme C. Step a: 1- (2-N, N-dipropylaminoethyl) -4-pperidone 1 - (2-N, N-dipropylaminoethyl) -4-piperidone is prepared from 4-piperidone and 2-N, N-dipropylaminoethyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (2-N, N-dipropylaminoetiD-4-piperidone oxime 1 - (2-N, N-dipropylaminoethyl) -4-piperidone oxime is prepared from 1- (2-N, N -dipropylaminoethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b Scheme C, step c: 4-Amino-1 - (2-NN-dipropylamine) Ppiperidine 4-Amino-1 - (2-N, N-dipropylaminoethyl) piperidine is prepared from oxime of 1 - . 1- (2-N, N-dipropylaminoethyl) -4-piperidone essentially as described above in Example 38, Scheme C, step C. Scheme A, step bj 2-Chloro-6-.4- (1 - (2 -N, Nd i propi laminoetiP) piperidinylamino1-9-cyclopentyl puss 2-Chloro-6- [4- (1 - (2-N > N-dipropylaminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6- dichloro-9-cyclopentylpurine, 4-amino-1- (2-N, N-dipropylaminoethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-. Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (2 - N, N-dipropylaminoetiP) piperidinylammonol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-dipropylaminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-Chloro-6- [4- (1 - (2-N, N-dipropylaminoethyl)) piperidinylamino] - 9-Cyclopentylpurine essentially as described in Example 1, Scheme A, step c.

Example 109 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (3-N, N-dipropylaminopropD) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1 - (3 -N, N-dipropylaminopropyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (3-N, N-dipropylaminopropypiperidine 4-Carboxamide-1 - (3-N, N-dipropylaminopropyl) piperidine can be prepared from isonipecotamide and chloride 3-N, N-dipropylaminopropyl essentially as described above in Example 38, Scheme B, step a.Scheme B, step b: 4-Amino-1- (3-N, N-dipropylaminopropyl) piperidine 4-Amino-1 - (3-N, N-dipropylaminopropyl) piperidine is prepared from 4-carboxam ida-1- (3-N, N-dipropylaminopropyl) pi pe ridine essentially as described above in Examplle 38, Scheme B, step b. 2: Scheme C, step a: 1- (3-N, N-dipropylaminopropyl) -4-piperidone 1- (3-N, N-dipropylaminopropyl) -4-piperidone is prepared from 4-piperidone and 3-N chloride , N-dipropylaminopropyl essentially as described above in Example 38, Scheme C, step a Scheme C, step b: 1 - (3-N, N-dipropylaminopropyl) -4-piperidone oxime 1 - (3- N, N-dipropylaminopropyl) -4-piperidone is prepared of 1 - (3-N, N-dipropylaminopropyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (3-N, N-dipropylaminopropyl) piperidine 4-Amino-1 - (3-N, N-dipropylaminopropyl) piperidine is prepared from 1 - (3-N, N-dipropylaminopropyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A_ stage bj 2-Chloro-6-r4- (1 - (3-N, N-dipropylaminopropyl)) piperidinylaminol-9-cyclopentyl urine 2-Chloro-6- [4- (1 - (3-N, N- dipropylaminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-N, N-dipropylaminopropyl) piperidine, and triethylamine essentially as described above in Example 1 , Scheme A, stage b. Scheme A, step c: 2-.Trans- (4-aminociclohexyl) amino-1-6- (4 - (3-N, N-dipropyllampropyl)) pipcridinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-dipropylaminopropyl)) piperidinylamino] -9-cyclopentyl I purine is prepared from 2-chloro-6- [4- ( 1- (3-N, N-dipropylaminopropyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 1 10 2- [Trans-f4-aminocyclohexyl) amino1-6-.4- (1 - (4-N, N- d -propylaminobutyl)) piperidin-1-amino-9-clopentylpurine Preparation of 4-Amino -1- (4-N, N-dipropylaminobutyl) piperidine Method 1 Scheme E stage at 4-Carboxamide-1 - (4-N, N-dipropylaminobutylpiperidine 4-Carboxamide-1 - (4-N, N-dipropylaminobutyl) piperidine may prepared from isonipecotamide and 4-N, N-dipropylaminobutyl chloride essentially as described above in Example 38, Scheme B, step a, Scheme B, step b: 4-Am-no-1-4-N, N- dipropylaminobutyl) piperidine 4-Amino-1 - (4-N, N-dipropylaminobutyl) piperidine is prepared from 4-caboxbox m ida-1 - (4-N, N-dipropylaminobutyl) piperidine, essentially as described above in Example 38, Scheme B, stage b.

Method 2: Scheme C, step a: 1- (4-N, N-dipropylaminobutyl) -4-piperidone 1- (4-N, N-dipropylaminobutyl) -4-piperidone is prepared from 4-piperidone and 4-piperidone N, N-dipropylaminobutyl essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (4-N, N-dipropylaminobutyl) -4-piperidone oxime 1 - (4-N, N-dipropylaminobutyl) -4-piperidone oxime is prepared from 1- (4-N, N-dipropylaminobutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (4-N, N-dipropylaminobutyl) piperidine 4-Amino-1- (4-N, N-dipropylaminobutyl) piperidine is prepared from 1 - (4-) oxime N, N-dipropylaminobutyl) -4-piperidone essentially as described above in Example 38, Scheme c, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (4-N. N-dipropylaminobutyl)) piperidol-9-cyclopentylpurine 2-Chloro-6- [4 - (1 - (4-N, N-dipropylaminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-N, N-dipropylaminobutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (4-N, N-dipropylaminobutyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-dipropylaminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4- N, N-dipropylaminobutyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 1 1 1 2-fTrans- (4-aminocolclohexyl) aminol-6-, 4- (1 - (5-N, N-dipropyminopentyl)) piperidinyl ammonium-9-cyclopentylpump Preparation of 4- Amino-1 - (5-N, N-dipropylaminopentyl) piperidine Method 1 Scheme B, step aj 4-Carboxamide-1 - (5-N, N-dipropy lami nopentyl) piperidine 4-Carboxamide-1 - (5-N) , N-dipropylaminopentyl) piperidine can be prepared from isonipecotamide and 5-N, N-dipropylaminopentyl chloride essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-Amino-1 - (5-N, N-dipropylaminopentyl) piperidine 4-Amino-1 - (5-N, N-dipropylaminopentyl) piperidine is prepared from 4-carboxamide-1 - (5-N, Nd-propylaminopentyl) piperidine essentially as described above in Example 38, Scheme B, stage b. Method 2: Scheme C, step a: 1- (5-N, N-dipropylaminopentyl) -4-piperidone 1- (5-N, N-dipropylaminopentyl) -4-piperidone is prepared from 4-piperidone and 5- N, N-dipropylaminopentyl essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (5-N, N-dipropylaminopentyl) -4-piperidone oxime 1 - (5-N, N-dipropylaminopentyl) -4-piperidone oxime is prepared from 1- (5-N, N-dipropylaminopentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C. stage c: 4-Amino-1 - (5-N, N-dipropylaminopentyl) piperidine 4-Amino-1 - (5-N, N-dipropylaminopentyl) piperidine is prepared from 1 - (5-N, N-dipropylaminopentyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A_, sten bj 2-Chloro-6-f4- (1 - (5-N. N-dipropylaminopentyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (5-N), N-dipropylaminopentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5-N, N-dipropylaminopentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2-f Trans- (4-aminocyclohexyl) amnol-6-r4- (1- (5-N, N-dipropylaminopentyl)) piperidinylamino-1-9-cyclopentylpurine 2- [Trans (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-dipropylaminopentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (5- N, N-dipropylaminopentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 1 12 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-dibutylaminoethyl)) piperidinylamino] -9-cyclopentylpurine Preparation of 4-Amino-1 - (2 -N, N-dibutylaminoethyl) piperidine Method 1 Scheme B_ stage to 4-Carboxamide 1 - (2-N, N-dibutylaminoetiQpiperidine 4-Ca rboxa mide- 1 - (2-N, N-dibuty myoethyl) pipe ridine it can be prepared from isonipecotamide and 2-N, N-dibutylaminoethyl chloride essentially as described above in Example 38, Scheme B, step a.

Scheme B, step b: 4-Amino-1- (2-N, N-dibutylaminoethyl) piperidine 4-Amino-1- (2-N, N-dibutylaminoethyl) piperidine is prepared from 4-carboxamide-1- ( 2-N, N-dibutylaminoethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C, step a: 1- (2-N, N-dibutylaminoethyl) -4-piperidone 1- (2-N, N-dibutylaminoethyl) -4-piperidone is prepared from 4-piperidone and 2- chloride N, N-dibutylaminoethyl essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1- (2-N, N-dibutylaminoethyl) -4-piperidone oxime 1- (2-N, N-dibutylaminoethyl) -4-piperidone oxime is prepared from 1- (2-N, N-dibutylaminoethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1- (2-NN-d-butylaminoethyl) piperidine 4-Amino-1- (2-N, N-dibutylaminoethyl) piperidine is prepared from 1 - (2-N, N-dibutylaminoethyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, stage bj 2-Chloro-6-.4- (1- (2-NN-di buti the minoethyl)) piperid ini lam i nol-9-cyclopentylpurine 2-Chloro-6- [4- (1- (2-N, N-dibutylaminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-N, N-dibutylaminoethyl) piperidine, and triethylamine essentially as is described above in Example 1, Scheme A, step b.

Scheme A. stage c: 2-rTrans- (4-aminociclohexyl) amino1-6-f4- (1 - (2-N, Nd-butylaminoethyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl ) amino] -6- [4- (1 - (2-N, N-dibutylaminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2-N, N- dibutylaminoethyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 1 1 3 2-.Trans- (4-aminociclohexyl) amino1-6-, 4- (1 - (3-N, N-dibutylaminopropyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1 - (3- Nl Nd.butylaminopropyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (3-N, N-dibutylaminopropypiperidine 4-Carboxamide-1 - (3-N, N-dibutylaminopropyl) piperidine can be prepared from isonipecotamide and sodium chloride. 3-N, N-dibutylaminopropyl essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1- (3-N, N-dibutylaminopropyl) piperidine 4-Amino-1 - (3-N, N-dibutylaminopropyl) piperidine is prepared from 4-carboxamide-1- (3-N, N-dibutylaminopropyl) piperidine essentially as described above in Example 38, Scheme B, step b.

Method 2: Scheme C, step a: 1 - (3-N, N-dibutylaminopropyl) -4-pperidone 1 - (3-N, N-dibutylaminopropyl) -4-piperidone is prepared from 4-piperidone and 3-N, N-dibutylaminopropyl essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (3-N, N-dibutyllamidopropyl) -4-piperidone oxime 1 - (3-N, N-dibutylaminopropyl) -4-piperidone oxime is prepared from 1 - ( 3-N, N-dibutylaminopropyl) -4-piperidone and hydroxychloride hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (3-N, N-dibutylaminopropyl) piperidine 4-Amino-1 - (3-N, N-dibutylaminopropyl) piperidine is prepared from oxime 1 - ( 3-N, N-dibutylaminopropyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-f4- (1 - (3-N, N-dibutylaminopropyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3- N, N-dibutylaminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-N, N-dibutylaminopropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. step c: 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (3-N, N-dibutylaminopropyl)) piperidinylamide-1 -9-cyclopentylpurine 2 - [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-dibutylaminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 9-chloro-6- [4- (1 - (3-N, N-dibutylaminopropyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 1 14 2-rTrans- (4-aminocyclohexyl) aminol-6-.4- (1 - (4-N, N-dibutylaminobutyl) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1 - .4-N, N-dibutylaminobutyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (4-N, N-dibutylaminobutypiperidine 4-Carboxamide-1 - (4-N, N-dibutylaminobutyl) piperidine can be prepared from isonipecotamide and 4-N, N-dibutylaminobutyl chloride essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1- (4-NN-dibutylaminobutyl) piperidine 4-Amino-1 - (4-N, N-dibutylaminobutyl) piperidine is prepared from 4-carboxam ida-1- (4-N, N-dibutylaminobutyl) pi pe ridine essentially as described above in Example 38, Scheme B , stage b.

Method 2: Scheme C, step a: 1 - (4-N, N-dibutylaminobutyl) -4-piperidone 1 - (4-N, N-dibutylaminobutyl) -4-piperidone is prepared from 4-piperidone and 4- chloride N, N-dibutylaminobutyl essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (4-N, N-dibutylaminobutyl) -4-piperidone oxime 1 - (4-N, N-dibutylaminobutyl) -4-piperidone oxime is prepared from 1- (4- N, N-dibutylaminobutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (4-N, N-dibutylaminobutyl) piperidine 4-Amino-1- (4-N, N-dibutylaminobutyl) piperidine is prepared from 1 - (4-) oxime N, N-dibutylaminobutyl) -4-piperidone essentially as described above in Example 38, Scheme C, step C. Scheme A, step bj 2-Chloro-6-.4- (1 - (4-N, N- dibutylaminobutiDpiperidi nor the minol-9-cyclopentyl purine 2-Chloro-6-_4- (1 - (4-N, N-dibutylaminobutyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-N, N-dibutylaminobutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A, step c: 2-.Trans- (4-aminociclohexyl) ) amnol-6-.4- (1 - (4-N, N-dibutylaminobutyl) piperidinylamino1-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-dibutylaminobutyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (4-N, N-dibutylaminobutyl) piperidinylamino] -9-cyclopentylpurine essentially as described in n Example 1, Scheme A, step c. Exemplol 15 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (5-N, N-dibutylaminopentyl)) p -peridinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1 - (5- N, N-dibutylaminopentyl) piperidine Method 1 Scheme B, step a 4-Ca rboxa m da-1 - (5-N, N-dibutylaminopentiQpiperidine 4-Carboxamide-1 - (5-N, N-dibutylaminopentyl) piperidine can be prepared of isonipecotamide and 5-N, N-dibutylaminopentyl chloride essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1 - (5-N, N-dibutylaminopentyl) piperidine 4-Amino-1 - (5-N, N-dibutylaminopentyl) piperidine is prepared from 4-carboxamide-1- (5-N, N-dibutylaminopentyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C, step a: 1- (5-N, Nd-butylaminopentyl) -4-piperidone 1- (5-N, N-dibutylaminopentyl) -4-piperidone is prepared from 4-piperidone and 5-piperidone. -N, N-dibutylaminopentyl essentially as described above in Example 38, Scheme C , stage a. Scheme C, step b: 1 - (5-N, N-dibutylaminopentyl) -4-piperidone oxime 1 - (5-N, N-dibutylaminopentyl) -4-piperidone oxime is prepared from 1- (5-N, N-dibutylaminopentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (5-N, N-dibutylaminopentyl) pperiodine 4-Amino-1 - (5-N, N-dibutylaminopentyl) piperidine is prepared from oxime 1 - (5-N, N-dibutylaminopentyl) -4-piperidone essentially as described above in Example 38, Scheme C, step C. Scheme A, stage bj 2-Chloro-6-.4- (1 - (5-N, N-dibutylaminopentyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1- (5-N, N-dibutylaminopentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5-N, N-dibutylaminopentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2-.Trans- (4-aminociclohexi0aminol-6-f4- (1 - (5-N, N-dibutilaminopentyl)) piperidin-laminol-9-cyclopentylpurine 2- [Trans- (4- aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-dibutylaminopentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (5-N, Nd ibuti la mi nope nti I)) piperid inilam i no] -9-cycline pentyl purine essentially as described in Example 1, Scheme A, step c.Example 1 16 2-, Trans- (4-aminocyclohexyl) amino -6-.4- (1 - (2-N, N-dibenzylammethyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1- (2-N, N-dibenzylaminoethyl) pperiodine Method 1 Scheme B, step a 4-Carboxamide-1 - (2-N, N-dibenzylaminoetiDpiperidine 4-Carboxamide-1 - (2-N, N-dibenzylaminoethyl) piperidine can be prepared from isonipecotamide and 2-N, N- chloride dibenzylaminoethyl essentially as described above in Example 38, Scheme B, step a) Scheme B. step b: 4-Amino-1-2-N, N-dibenzylaminoethyl) piperidine 4-Amino-1 - (2-N, N-dibenci laminoethyl) piperidine is prepared from 4-carboxamide-1- (2-N, N-dibenzylaminoethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1 - (2-N, N-dibenzylaminoethyl) -4-piperidone 1- (2-N, N-dibenzylaminoethyl) -4-piperidone is prepared from 4-piperidone and 2- chloride N, N-dibenzylaminoethyl essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (2-N, N-dibenzylamidenoetyl) -4-piperidone oxime 1 - (2-N, N-dibenzylaminoethyl) -4-piperidone oxime is prepared from - (2-N, N-dibenzylaminoethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Step c: 4-Amino-1 - (2-N, N-dibenzylaminoethyl) piperidine 4-Amino-1 - (2-N, N-dibenzylaminoethyl) piperidine is prepared from 1 - (2-N, N-dibenzylaminoethyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (2-N, N-dibenzylaminoethyl)) piperidin-laminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2-N) , N-dibenzylaminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-N, N-dibenzylaminoethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b.

Scheme A, step c: 2-f Trans- (4-aminocyclohexyl) aminol-6- [4- (1 - (2-NN-dibenzylaminoethyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-dibenzylaminoethyl)) piperidinylaminoj-9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2-N, N-dibenzylaminoethyl)) piperidinylamino ] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 1 17 2-rTrans- (4-aminociclohexil) amnol-6-r4- (1 - (3-N, N-dibencilamnopropyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1 - (3 -N, N-dibenzylaminopropyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (3-N, Nd-benzylminopropyl) piperidine 4-Carboxamide 1 - (3-N, N-dibenzylaminopropyl) pperidine can be prepared from isonipecotamide and chloride of 3-N, N-dibenzylaminopropyl essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (3-NN-dibenzylaminopropyl) piperidine 4-Amino-1 - (3-N, N-dibenzylaminopropyl) piperidine is prepared from 4-carboxamide-1 - (3-N, N-dibenzylaminopropyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (3-N, N-dibenzylamnopropyl) -4-piperidone 1- (3-N, N-dibenzylaminopropyl) -4-piperidone is prepared from 4-piperidone and 3-N, N-dibenzylaminopropyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (3-N, N-dibenzylaminopropyl) -4-piperidone oxime 1 - (3-N, N-dibenzylaminopropyl) -4-piperidone oxime is prepared from 1- (3-N, N-dibenzylaminopropyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (3-N, N-dibenzylaminopropyl) piperidine 4-Amino-1- (3-N, N-dibenzylaminopropyl) piperidine is prepared from oxime 1 - (3- N, N-dibenzylaminopropyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (3-N, Nd-benzylaminopropyl)) piperidin-laminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3 -N, N-di benz laminopropyl)) piperid ini lami no] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-N, N-dibenzylaminopropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A, step c: 2-.Trans-.4-aminociclohexyl) aminol-6-, 4- (1 - (3-N, N-dibenzlaminopropyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-dibenzylaminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3- N, N-dibenzylaminopropyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 1 1 8 2-f Trans- (4-aminocyclohexyl) aminol-6- [4- (1 - (4-N, N-dibenzylaminobutyl)) piperidinylaminol-9-cyclopenti I purine Preparation-of 4-Amino-1 - ( 4-N, N-dibenzylaminobutyl) pperiodine Method 1 Scheme B, step a 4-Carboxamide-1 - (4-N, N-dibenzylaminobutiDpiperidine 4-Ca rboxamide-1 - (4-N, N-di-benzyl lam-nobutyl) piperidine can be prepared from isonipecotamide and chloride 4-N, N-dibenzylaminobutyl essentially as described above in Example 38, Scheme B, step a.Scheme B, step b: 4-Amino-1- (4-N, N-dibenzylaminobutyl) piperidine 4-Amino-1 - (4-N, N-dibenzylaminobutyl) piperidine is prepared from 4-carboxamide-1- (4-N, Nd-benzylaminobutyl) piperidine essentially as described above in Example 38, Scheme B, stage b.

Method 2: Scheme C-step a: 1- (4-NN-dibenzyl-lane-butyl-4-piperidone 1- (4-N, N-dibenzylaminobutyl) -4-piperidone is prepared from 4-piperidone and 4-piperidone) -N, N-dibenzylaminobutyl essentially as described above in Example 38, Scheme C, step a, Scheme C, step b: 1 -, 4-N, N-dibenzylaminobutyl) -4-piperidone oxime 1 - ( 4-N, N-dibenzylaminobutyl) -4-piperidone is prepared from 1- (4-N, N-dibenzylaminobutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C, step c: 4-Amino-1 - (4-N, N-dibenzylaminobutyl) piperidine 4-Amino-1- (4-N, N-dibenzylaminobutyl) piperidine is prepared from 1 - (4-N, N-dibenzylaminobutyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-I4- (1 - (4-N, N-dibenzylaminobutyl)) piperidinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4-N, N-dibenzylaminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-N, N-dibenzylaminobutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A, step c: 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (4-N, N-dibenzylaminobutyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) ) amino] -6- [4- (1 - (4-N, N-dibenzylaminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-N, N- dibenzylaminobutyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 1 19 2-.Trans- (4-aminoc yclohexyl) aminol-6-f4- (1 - (5-N, N-dibenzylaminopentyl)) piperidinylaminol-9-cyclopentyl purine Preparation of 4-Amino-1 - (5-N, N-dibenzylaminopentyl) piperidine Method 1 ^^^^^ ___ ^ __ ^^ gj ^^^^^^^ Scheme B, step a 4-Carboxamide-1 - (5-N, N-dibenzylaminopentiQpiperidine 4-Carboxamide-1 - (5-N, N- dibenzylaminopentyl) piperidine can be prepared from isonipecotamide and 5-N, N-dibenzylaminopentyl chloride essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino-1 - (5-NN- dibenzylaminopentyl) piperidine 4-Amino-1 - (5-N, N-dibenzylaminopentyl) piperidine is prepared from 4-carboxamide-1- (5-N, N-dibenzylaminopentyl) piperidine essentially as described above in Example 38, Scheme B Step b: Method 2: Scheme C. Step a: 1- (5-N, N-dibenzylaminopentyl) -4-piperidone 1- (5-N, N-dibenzylaminopentyl) -4-piperidone is prepared from 4-piperidone and 5-N, N-dibenzylaminopentyl chloride essentially as described above in Example 38, Scheme C, step a) Scheme C. Step b: 1 - (5-N, N-dibenzylaminopentyl) -4-piperidone oxime 1- (5-N, N-dibenzylaminopentyl) -4-piperidone is prepared from 1 - . 1- (5-N, N-dibenzylaminopentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Stage c: 4-Amino-1 - (5-N. N-dibenzylaminopentyl) piperidine 4-Amino-1 - (5-N, N-dibenzylaminopentyl) piperidine is prepared from 1 - (5-N, N-dibenzylaminopentyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c.

Escape A, stage bj 2-Chloro-6-f4- (1 - (5-N, N-dibenzylamine-pentyl)) p, per-n-1-ylam-1-9-cyclopentylpurine, 2-Chloro-6 - [4- (1 - (5-N, N-dibenzylaminopentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (5-N, N-dibenzylaminopentyl) ) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-, Trans- (4-aminociclohexil) aminol-6-r4- (1 - (5-N. Nd¡bencylaminopentyl)) piperidin-1-amino-9-cyclopentylpurine 2- [Trans- ( 4-aminociclohexyl) amino] -6- [4- (1 - (5-N, N-dibenzylaminopentyl)) piperidylamino] -9-cyclopentyl purine is prepared from 2-chloro-6- [4- (1 - ( 5-N, N-dibenzylaminopentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 120 2-f Trans- (4-aminocyclohexyl) amnol-6-f4- (1 - (2-N, N-di- (2-phenylethylene) aminoethyl)) p -peridinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1 - (2-N, Nd- (2-phenylethylene) aminoethyl) pyridine Method 1 Scheme B. step aj 4-Carboxamide-1 - (2-N, Nd) - (2-phenylethylene) aminoethyl) piperidine 4-Carboxamide-1 - (2-N, N-di- (2-phenylethylene) aminoethyl) piperidine can be prepared from isonipecotamide and 2-N, N-di- (2- phenylethyleneamino) ethyl essentially as described above in Example 38, Scheme B, step a. Scheme B, step bj 4-Amino-1 - (2-N, Ndl- (2-phenylethylene) aminoethyl) p -peridine 4-Amino-1 - (2-N, N-di- (2-phenylethylene) aminoethyl ) piperidine is prepared from 4-carboxamide-1 - (2-N, N-di- (2-phenylethylene) aminoethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C, step a: 1 - (2-N. N-di- (2-phenylethylene) aminoethyl) -4-piperidone 1- (2-N, N-di- (2-phenylethylene) aminoethyl) - 4-piperidone is prepared from 4-piperidone and 2-N, N-di- (2-phenylethyleneamino) ethyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: 1 - (2-N, N-di- (2-phenylethylene) aminoethyl) -4-piperidone oxime 1 - (2-N, N-di- (2-phenylethylene) aminoethyl ester) oxime) -4-piperidone is prepared from 1- (2-N, N-di- (2-phenylethylene) aminoethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme (Y stage CJ 4-Amino-1 - (2-NN-di- (2-phenylethylene) aminoethyl) pi pe ridine 4-Amino-1 - (2-N, N-di- (2-phenylethylene) aminoethyl) piperidine is prepared from 1 - (2-N, N-di- (2-phenylethylene) aminoethyl) -4-piperidone essentially oxime as described above in Example 38, Scheme C, step c.Scheme A, step b: 2-Chloro-6-r4-1 - (2-N, N-di- (2-phenylethylene) aminoethyl)) pyperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2-N), N-di- (2-phenylethylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - (2-N, N-di- (2- phenylethylene) aminoethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6-, 4- (1 - (2-N, N-di- (2-phenyletylene) aminoethyl)) piperidinylam Nol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-di- (2-phenylethylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1- (2-N, N-di- (2-phenylethylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 121 2-f Trans- (4-aminocyclohexyl) amino1-6- [4- (1 - (3-N. N-di- (2-phenylethylene) aminopropyl)) piperidinylaminol-9-cyclopenti I purine Preparation of 4-Amino -1- (3-N, N-di- (2-phenylethylene) aminopropyl) piperidine Method 1 Scheme B, step a 4-Ca rboxa mida- 1 - (3-N. Nd i- (2-phenylethylene) ami nopropyl) piperidine 4-Carboxamide-1 - (3-N, N-di- (2-phenylethylene) aminopropyl) piperidine can be prepared from isonipecotamide and 3-N, N-di- (2-phenylethyleneamino) propyl chloride essentially as described above in the Example 38, Scheme B, step a. Scheme B, step bj 4-Amino-1 - (3-N. Nd¡- (2-phenylethylene) aminoproipyl) piperidine 4-Amino-1 - (3-N, N-di- (2-phenylethylene) ) aminopropyl) piperidine is prepared from 4-carboxamide-1 - (3-N, N-di- (2-phenylethylene) aminopropyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1 - (3-N, N-di- (2-phenylethylene) aminopropyl) -4-piperidone 1 - (3-N, N-di- (2-phenylethylene) aminopropyl ) -4-piperidone is prepared from 4-piperidone and 3-N, N-di- (2-phenylethyleneamino) propyl chloride essentially as described above in Example 38, Scheme C, siep a. Scheme C. stage b: 1 - (3-N, N-di- (2-phenylethylene) aminopropyl) -4-pyrperidone oxime 1 - (3-N, N-di- (2-phenylethylene)) oxime aminopropyl) -4-piperidone is prepared from 1- (3-N, N-di- (2-phenylethylene) aminopropyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b . Scheme C. Stage CJ 4-Amino-1 - (3-N, N-di- (2-phenylethylene) aminopropyl) piperidine 4-Amino-1 - (3-N, N-di- (2-phenylethylene) aminopropyl) piperidine is prepared from 1 - (3-N, N-di- (2-phenylethylene) aminopropyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-.4- (1 - (3-N, N-di- (2-phenylethylene) aminopropyl)) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4 - (1 - (3-N, N-di- (2-phenylethylene) aminopropyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - (3-N, N-di- (2-phenylethylene) aminopropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A, step c: 2-.Trans-.4-aminociclohexyl) aminol-6 -f4- (1 - (3-N, N-di- (2-phenylethylene) aminopropyl)) piperidinylamino-1-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-di- (2-phenylethylene) aminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-Chloro-6- [4- (1 - (3-N, N-di- (2 phenylethylene) aminopropyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 122 2-.Trans- (4-ammocyclohexyl) amino.-6-.4- (1 - (4-NN-di- (2-phenylethylene) aminobutyl)) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino -1- (4-N, N-di- (2-phenylethylene) aminobutyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (4-N. N-di- (2- __________ phenylethylene) aminobutyl) piperidine 4-Carboxamide-1 - (4-N, N-di- (2-phenylethylene) aminobutyl) piperidine can be prepared from isonipecotamide and 4-N, N-di- (2-phenylethyleneamino) butyl chloride essentially as described above in Example 38, Scheme B, step a. Scheme B_ stage bj 4-Amino-1 - (4-N. N-di- (2-phenylethylene) aminobutyl) piperidine 4-Amino-1 - (4-N, N-di- (2-phenylethylene) aminobutyl) piperidine is prepared from 4-carboxamide-1- (4-N, N-di- (2-phenylethylene) aminobutyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. stage a: 1- (4-N-di- (2-phenylethylene) aminobutyl) -piperidone 1 - . 1- (4-N, N-di- (2-phenylethylene) aminobutyl) -4-piperidone is prepared from 4-piperidone and 4-N, N-di- (2-phenylethyleneamino) butyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: oxime of 1 - (4-N. N-di- (2-phenylethylene) aminobutyl) -4-piperidone oxime of 1 - (4-N, N-di- (2-phenylethylene) aminobutyl) -4-piperidone is prepared from 1- (4-N, N-di- (2-phenylethylene) aminobutyl) -4-piperidone hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step CJ 4-Amino-1 - (4-N, Nd¡- (2-phenylethylene) aminobutyl) piperidine 4-Amino-1 - (4-N, N-di- (2-phenylethylene) aminobutyl) piperidine is prepared from 1 - (4-N, N-di- (2-phenylethylene) aminobutyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. 5 Scheme A. stage b: 2-Chloro-6-.4- (1 - (4-N, N-di- (2-phenylethylene) aminobutyl)) piperidimethylamino-9-cyclopentylpuphine 2-Chloro-6 - [4- (1 - (4-N, N-di- (2-phenylethylene) aminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - (4-N, N-di- (2- phenylethylene) aminobutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (4- N- Nd- (2-phenylethylene) aminobutyl)) pyridinyl-nolonol- 9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-di- (2-phenylethylene) aminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-N, N-di- (2-phenylethylene) aminobutyl)) piperid inylamino] -9-cycline pentylpurine essentially as described in Example 1 , Scheme A, stage c. 20 Example 123 2-f Trans- (4-aminocyclohexyl) aminol-6-f4- (1 - (5-N. Nd- (2-phenylethylene) aminopentyl)) piperidinylamino-9-cyclopentylpurine Preparation of 4- Amino-1 - (5-N, N-di- (2-phenylethylene) aminopentyl) pyridine 25 Method 1 ____________! -kÉi _________? Scheme B, step a_j 4-carboxamide-1 - (5-N, N-di- (2- Phenylethylene) aminopentyl) piperidine 4-carboxamide-1 - (5-N, N-di- (2-phenylethylene) aminopentyl) piperidine can be prepared from isonipecotamide and 5-N, N-di- (2-phenylethyleneamino) pentyl chloride essentially as described above in Example 38, Scheme B, step a. Scheme B_ step bj 4-Amino-1 - (5-NN-di- (2-phenylethylene) aminopentyl) piperidine 4-Amino-1 - (5-N, N-di- (2-phenylethylene) aminopentyl) piperidine of 4-carboxamide-1 - (5-N, N-di- (2-phenylethylene) aminopentyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. step a: 1 - (5-N. N-di- (2-phenylethylene) aminopentyl) -4-piperidone 1 - (5-N, N-di- (2-phenylethylene) aminopentyl) - 4-piperidone is prepared from 4-piperidone and 5-N, N-di- (2-phenylethyleneamino) pentyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: oxime 1 - (5-N, N-di- (2-phenylethylene) aminopentyl) -4-piperidone oxime 1 - (5-N, N-di- (2-phenylethylene) aminopentyl) -4-piperidone is prepared from 1- (5-N, N-di- (2-phenylethylene) aminopentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b.

Scheme C, step 4-Amino-cj 1 - (. 5-N N-di- (2-phenylethylene) aminopentyl) piperidine 4-Amino-1 - (5-N, N-di- (2-phenylethylene) aminopentyl) piperidine is prepared from 1 - (5-N, N-di- (2-phenylethylene) aminopentyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A. stage b: 2-Chloro-6-, 4- (1 - (5-N. N-di- (2-phenylethylene) aminopentyl)) piperidin-1-amino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (5-N, N-di- (2-phenylethylene) aminopentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - (5 -N, N-di- (2-phenylethylene) aminopentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2- [Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (5-N. N-di- (2-phenylethylene) aminopentyl)) - piperidin-laminol-9- cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-di- (2-phenylethylene) aminopentyl)) - piperidinylamino] -9-cyclopentylpurine 2 Chloro-6- [4- (1 - (5-N, N-di- (2-phenylethylene) aminopentyl)) - piperidinylamine] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 1 24 2-f Trans- (4-aminociclohexil) amnol-6-í4- (1 - (2-N. N-di- (3-f-enyl-propylene) -aminoethyl)) piperidin -lamino. -9-cyclopentylpurase Preparation of 4-Amino-1 - (2-N, N-di- (3-phenypropylene) aminoethyl) pipe ridine Method 1 Scheme B, step a: 4-Carboxamide-1 - (2-N) , Nd¡- (3-phenylpropylene) aminoethyl) piperidine 4-carboxamide-1 - (2-N, N-di- (3-phenylpropylene) aminoethyl) piperidine may be prepared from isonipecotamide and 2-N chloride, N-di- (3-phenylpropyleneamino) ethyl essentially as described above in Example 38, Scheme B, step a. Scheme B_, step bj 4-Amino-1 - (2-N. N-di- (3-phenylpropylene) aminoethyl) piperidine 4-Amino-1 - (2-N, N-di- (3-phenylpropylene) aminoethyl) piperidine is prepared from 4-carboxamide-1 - (2-N, N-di- (3-phenylpropylene) aminooethyl) pi pe ridine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. step a: 1 - (2-N. N-di- (3-phenylpropylene) aminoethyl) -4-piperidone 1 - (2-N, N-di- (3-phenylpropylene) aminoethyl) - 4-piperidone is prepared from 4-piperidone and 2-N, N-di- (3-phenylpropyleneamino) ethyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: 1 - (2-N. Ndl- (3-phenylpropylene) aminoethyl) -4-pperiodone oxime of 1 - (2-N, N-di- (3-phenylpropylene) ) aminoethyl) -4-piperidone is prepared from 1- (2-N, N-di- (3-phenylpropylene) aminoethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C_ stage c__. 4-Amino-1 - (2-N. N-di- (3-phenylpropylene) aminoethyl) pyrifin 4-Amino-1 - (2-N), N-di- (3-phenylpropylene) aminoethyl) piperidine is prepared from 1 - (2-N, N-di- (3-phenylpropylene) aminoethyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, stage c. Scheme A, step b: 2-Chloro-6-.4- (1 - (2-NN-di- (3-phenylpropylene) aminoethyl)) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- ( 1 - (2-N, N-di- (3-phenylpropylene) anminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - (2-N, N -di- (3-phenylpropylene) aminoethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. step c: 2-.Trans- (4-aminociclohexyl) aminol-6-f4- (1 - (2 - N, N-di- (3-phenylpropylene) aminoethyl)) piperidinylammonol-9-cyclopentylpurine 2 - [Trans- (4-aminocyclohexyl) amino_-6- [4- (1 - (2-N, N-di- (3-phenylpropylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6 - [4- (1 - (2-N, N-di- (3-phenylpropylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.

Example 125 2-.Trans-.4-aminocyclohexyl) aminol-6, 4-.1 - (3-N, N-di- (3-phenylpropylene) aminopropyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1 - (3-N. N-di- (3-phenylpropylene) aminopropyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (3-N. N-di- (3- phenylpropylene) aminopropyl) pperidine 4-Carboxamide-1 - (3-N, N-di- (3-phenylpropylene) aminopropyl) piperidine can be prepared from isonipecotamide and 3-N, N-di- (3-) chloride phenylpropyleneamino) propyl essentially as described above in Example 38, Scheme B, step a. Scheme B, step bj 4-Amino-1 - (3-N N-di- (3-phenylpropylene) aminopropyl) piperidine 4-Amino-1 - (3-N, N-di- (3-phenylpropylene) aminopropyl) piperidine is prepared from 4-carboxamide-1 - (3-N, Ndl- (3-phenylpropylene) aminopropyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. step a: 1 - (3-N, N-di- (3-phenylpropylene) aminopropyl) -4-piperidone 1 - (3-N, N-di- (3-phenylpropylene) aminopropyl) - 4-piperidone is prepared from 4-piperidone and 3-N, N-di- (3-phenylpropyleneamino) propyl chloride essentially as described above in Example 38, Scheme C, step a.

Scheme C. Stage b: 1 - (3-N. Ndl- (3-phenylpropylene) aminopropyl) -4-piperidone oxime 1 - (3-N, N-di- (3-phenylpropylene) aminopropyl) oxime - 4-piperidone is prepared from 1- (3-N, N-di- (3-phenylpropylene) aminopropyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme O, step c 4-Amino-1 - (3-N. N-di- (3-phenylpropylene) aminopropyl) piperidine 4-Amino-1 - (3-N, N-di- (3-phenylpropylene) aminopropyl) piperidine is prepared from 1 - (3-N, N-di- (3-phenylpropylene) aminopropyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, stage c. Scheme A. stage b: 2-Chloro-6-.4- (1 - (3-N. N-di- (3-phenylpropylene) aminopropyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4 - (1 - (3-N, N-di- (3-phenylpropylene) aminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - (3-N) , N-di- (3-phenylpropylene) aminopropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-, Trans- (4-aminociclohexyl) amino1-6-, 4- (1 - (3-N-di- (3-phenypropylene) aminopropyl) p -peridinylaminol -9-Cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) aminoj-6- [4- (1 - (3-N, Nd] - (3-phenylpropylene) aminopropyl)) piperidinylamino] -9-cyclopentylpurine is prepared from -Cloro-6- [4- (1 - (3-N, N-di- (3-phenylpropylene) aminopropyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 126 5 2-f Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (4-N, N-di- (3-phenylpropylene) aminobutyl) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino -1- (4-N, N-di- (3-phenylpropyne) aminobutyl) piperidine Method 1 10 Scheme B. stage to 4-Carboxamide-1 - (4-N. N-di- (3-phenolpropyl Leno) aminobutyl) piperidine 4-Carboxamide-1 - (4-N, N-di- (3-phenylpropylene) aminobutyl) piperidine can be prepared from isonipecotamide and 4-N, N-di- (3-phenylpropyleneamino) chloride butyl essentially as described above in Example 38, Scheme B, step a Scheme B, step bj 4-Amino-1-4-N, Nd 1 - (3-phenyl-1-propylene) aminobutyl) phenyl Ridin 4-Amino-1 - (4-N, N-di- (3-phenylpropylene) aminobutyl) piperidine is prepared from 4-carboxamide-1 - (4-N, N-di- (3-phenylpropylene) aminobutyl) piperidine 20 essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. step a: 1- (4-N, N-di- (3-phenylpropylene) aminobutyl) -4-piperidone 25 1 - (4-N, N-di- (3-phenylpropylene) aminobutyl) -4-piperidone is prepared from __________ 4-piperidone and 4-N, N-chloruron of di- (3-phenylpropylene nomine) butyl essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: 1 - (4-N, N-di- (3-phenylpropylene) aminobutyl) -4-pperidone oxime 1 - (4-N, N-di- (3-phenylpropylene) oxime) aminobutyl) -4-piperidone is prepared from 1 - (4-N, N-di- (3-phenylpropylene) aminobutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step cj 4-Amino-1 - (4-N. N-di- (3-phenyl-ropylene) amino-butyl) -piperidine 4-Amino-1 - (4-N, N-di- (3-phenylpropylene) ) aminobutyl) piperidine is prepared from 1 - (4-N, N-di- (3-phenylpropylene) aminobutyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (4-N, N-di- (3-phenylpropylene) aminobutyl)) piperidinylamino-1-9-cyclopentylpurine 2-Chloro-6 - [4- (1 - (4-N, N-di- (3-phenylpropylene) aminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - ( 4-N, N-di- (3-phenylpropylene) aminobutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexyl) amino1-6-r4- (1 - (4-N, N-di- (3-phenylpropylene) aminobutyl)) piperidinylaminol-9-cyclopentylpurine 2- [ Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-di- (3-phenylpropylene) aminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4-N, N-di- (3-phenylpropylene) aminobutyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 127 2-.Trans- (4-aminocyclohexyl) aminol-6- (4- (1 - (5-N, N-di- (3-phenypropylene) aminopentyl)) pyrimethylammonol -9-Cyclopentylpurine Preparation of 4-Amino-1 - (5-N, N-di- (3-phenylpropylene) aminopentyl) piperidine Method 1 Scheme B, step a 4-Ca rboxa mide - 1 - (5-N Nd - (3-phenypropylene) aminopentyl) pilperidine 4-Carboxamide-1 - (5-N, N-di- (3-phenylpropylene) aminopentyl) piperidine can be prepared from isonipecotamide and 5-N, N-dihydrochloride. (3-phenylpropyleneamino) pentyl essentially as described above in Example 38, Scheme B, step a.Scheme B_ stage bj 4-Amino-1 - (5-N. Nd- (3-phenylpropylene) aminopentyl) pyridine 4-Amino-1 - (5-N, N-di- (3-phenylpropylene) aminopentyl) piperidine is prepared from 4-carboxamide-1 - (5-N, N-di- (3-phenylpropylene) aminopentyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C, step a: 1 - (5-N, N-di- (3-phenylpropylene) aminopentyl) -4-piperidone 1- (5-N, N-di- (3-phenylpropylene) aminopentyl) -4 -piperidone is prepared from 4-piperidone and 5-N, N-di- (3-phenylpropyleneamino) pentyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (5-N, N-di- (3-phenypropylene) aminopentyl) -4-piperidone oxime 1 - (5-N, N-di- (3-phenylpropylene) aminopentyl) oxime) -4-piperidone is prepared from 1- (5-N, N-di- (3-phenylpropylene) aminopentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme O, stage CJ 4-Amino-1 - (5-N, N-di- (3-phenylpropylene) aminopentyl) pyridine 4-Amino-1 - (5-N, N-di- (3- phenylpropylene) aminopentyl) piperidine is prepared from 1 - (5-N, N-di- (3-phenylpropylene) aminopentyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, stage c. Scheme A, step bj 2-Chloro-6-.4- (1 - (5-N. N-di- (3-phenylpropylene) aminopentyl)) p -peridinylaminol-9-cyclopentyl I purine 2-Chloro-6- [ 4- (1 - (5-N, N-di- (3-phenylpropylene) aminopentyl)) piperidinylamino] -9-cyclopentyl I purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - ( 5-N, N-di- (3-phenylpropylene) aminopentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b.

Scheme A. step c: 2-.Trans- (4-aminocyclohexyl) aminol-6-F4- (1 - (5- N, N-di- (3-phenylpropylene) aminopentyl)) 9-cyclopentylpurine piperidinilaminol-2- [ Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-di- (3-f in yl propylene) aminopent i I)) piperid inylamino] -9-cyclopentyl purine is prepared from 2-Chloro-6- [4- (1 - (5-N, N-di- (3-phenylpropylene) aminopentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Eiemplo 128 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (2-N, N-di- (4- phenylbutylene) aminoethyl)) piperidinilamino1-9-cyclopentylpurine Preparation of 4-Amino- 1 - (2-N, N-di- (4-phenylbutylene) aminoethyl) piperidine Method 1 Scheme B. step a 4-Carboxamide-1 - (2-N, N-di- (4-phenylbutylene) aminoethyl) piperidine 4 -Carboxamide-1 - (2-N, N-di- (4-phenylbutylene) aminoethyl) piperidine can be prepared from isonipecotamide and 2-N, N-di- (4-phenylbutyleneamino) ethyl chloride essentially as described above in Example 38, Scheme B, step a. Scheme B, step bj 4-Amino-1 - (2-N, N-di- (4-phenylbutylene) aminoethyl) piperidine 4-Amino-1 - (2-N, N-di- (4-phenylbutylene) aminoethyl) piperidine is prepared from 4-carboxamide-1 - (2-N, N-di- (4-phenylbutyleneaminoethyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C. step a: 1 - (2-N, N-di- (4-Phenylbutylene) amynoethyl) -4-piperidone 1- (2-N, N-di- (4-phenylbutylene) aminoethyl) -4-piperidone is prepared of 4-piperidone and 2-N, N-di- (4-phenylbutyleneamino) ethyl chloride essentially as described above in Example 38, Scheme C, step a.Scheme C. Step b: 1 - (2- N. N-di- (4-phenylbutylene) aminoethyl) -4-piperidone 1 - (2-N, N-di- (4-phenylbutylene) aminoethyl) -4-piperidone is prepared from 1- (2-N) , N-di- (4-phenylbutylene) aminoethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b Scheme C, step CJ 4-Amino-1 - (2- N, Nd- (4-phenylbutylene) aminoethyl) piperid ina 4-Amino-1 - (2-N, N-di- (4-phenylbutylene) aminoethyl) piperidine is prepared from 1 - (2-N, N-di- (4-phenylbutylene) aminoethyl) -4- oxime piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-f4- (1 - (2-N. N-di- (4-phenylbutylene) aminoethyl) (piperidinyl-i-nol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2-N, N-di- (4-phenylbutylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - (2-N, N-di- (4-phenylbutylene) aminoethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminociclohexyl) aminol-6 -4- (1 - (2-N. N-di- (4-phenylbutylene) aminoethyl)) piperidinylammonol-9-cyclopentylpurine. 2- [Trans- (4-aminocyclohexyl) Amino] -6- [4- (1 - (2-N, N-di- (4-phenylbutylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-Chloro -6- [4- (1 - (2-N, N-di- (4-phenylbutylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 129 2-.Trans- (4-aminociclohexyl) amino1-6-.4- (1 - (3-N, Nd¡- (4-phenylbutylene) aminopropyl)) piperidinylaminol-9-cyclopentylpurine Preparation-of 4- Amino-1 - (3-N, N-di- (4-phenylbutylene) aminopropy I) piperidine Method 1 Scheme B, step a 4-Ca rboxa mide- 1 - (3-N. Nd i- (4-phenylbutylene ) aminopropyl) piperidine 4-Carboxamide-1 - (3-N, N-di- (4-phenylbutylene) aminopropyl) piperidine can be prepared from isonipecotamide and 3-N, N-di- (4-phenylbutyleneamino) propyl chloride essentially as is described above in the Example 38, Scheme B, step a. Scheme B_ stage bj 4-Amino-1 - (3-N. N-di- (4-phenylbutylene) aminopropyl) piperidine 4-Amino-1 - (3-N, N-di- (4-phenylbutylene) aminopropyl) piperidine is prepared from 4-carboxamide-1 - (3-N, N-di- (4-phenylbutylene) aminopropyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. step a: 1 - (3-N, N-di- (4-phenylbutylene) aminoropyl) -4-piperidone 1 - (3-N, N-di- (4-phenylbutylene) aminopropyl) - 4-piperidone is prepared from 4-piperidone and 3-N, N-di- (4-phenylbutyleneamino) propyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C. stage b: 1 - (3-N, N-di- (4-phenylbutylene) aminopropyl) -4-piperidone oxime 1 - (3-N, N-di- (4-phenylbutylene) oxime) aminopropyl) -4-piperidone is prepared from 1- (3-N, N-di- (4-phenylbutylene) aminopropyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b . Scheme C, step CJ 4-Amino-1 - (3-N, Ndl- (4-phenylbutylene) aminopropyl) piperidine 4-Amino-1 - (3-N, N-di- (4-phenylbutylene) aminopropyl ) piperidine is prepared from 1 - (3-N, N-di- (4-phenylbutylene) aminopropyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A, stage bj 2-Chloro-6-f4- (1 - (3-N. N-di- (4-phenylbutylene) aminopropyl) piperidinylaminol-9-cyclopentyl I purine 2-Chloro-6- [4- ( 1 - (3-N, N-di- (4-phenylbutylene) aminopropyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - (3-N, N- di- (4-phenylbutylene) aminopropyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminociclohexyl) aminol-6 f4- (1 - (3- N- di- (4-phenylbutylene) aminopropyl) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- ( 1 - (3-N, N-di- (4-10 phenylbutyl) aminopropyl)) piperidi nor the mi no] -9-cyclopentyl puss is prepared from 2-chloro-6- [4- (1 - (3 -N, N-di- (4-phenylbutylene) amypropyl)) piperidinyl-amino] -9-cyclopentyl-I purine essentially as described in Example 1, Scheme A, step c.Emple 130 2-.Transforming (4-aminociclohexil) aminol-6- [4- (1 - (4-N, N-di- (4-phenyl-ilbuti-leñóla mi nobutil) ) piperid inilam i nol-9-cyclopenti 11 purine Preparation of 4-Amino-1 - (4-N, Ndl- (4-phenylbutylene) aminobutyl) piperidine 20 Method 1 Scheme B, step a 4-Carboxamide-1 - ( 4-N. Nd 1 - (4-phenylbutylene) aminobutyl) pyridine 4-Carboxamide-1 - (4-N, N-di- (4-phenylbutylene) aminobutyl) piperidine can be prepared from isonipecotamide and 4-N, N-chloride -di- (4-25 phenylbutyleneamino) butyl essentially as described above in • ÉdÜMb ^ Ú Example 38, Scheme B, step a. Scheme B_ stage bj 4-Amino-1 -, 4-N, N-di- (4-phenylbutylene) aminobutyl) piperidine 4-Amino-1 - (4-N, N-di- (4-phenylbutylene) aminobutyl) piperidine is prepared from 4-carboxamide-1 - (4-N, N-di- (4-phenylbutylene) aminobutyl) piperidine essentially as described above in Example, 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (4- (Di- (4-phenylbutylene) aminobutyl) -4-piperidone 1- (4- (Di- (4-phenylbutylene) aminobutyl) -4-piperidone is prepared from 4-piperidone and 4-N, N-di- (4-phenylbutyleneamino) butyl chloride essentially as described above in Example 38, Scheme C, step a) Scheme C. step b: oxime of 1 - (4- ( Di- (4-phenylbutylene) aminoethyl) -4-piperidone 1 - (4- (Di- (4-phenylbutylene) aminobutyl) -4-piperidone is prepared from 1- (4- (di- (4-phenylbutylene)) aminobutyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme C, step c 4-Amino-1 - (4-N. N-di- (4-phenylbutylene) aminobutyl) pyridine 4-Amino-1 - (4-N, N-di- (4- phenylbutylene) aminobutyl) piperidine is prepared from 1 - (4- (di- (4-phenylbutylene) aminobutyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c.

Scheme A. stage b: 2-Chloro-6-.4-.1 -.4-N. N-di- (4-phenylbutylene) aminobutyl)) piperidinyl-amino-1-9-cyclopentylpurine 2-chloro-6- [4- (1 - (4-N, N-di- (4-phenylbutylene) aminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-N, N-di- (4-phenylbutylene) aminobutyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans-, 4-aminociclohexyl) aminol-6-.4- (1 - (4-N, N-di-, 4-phenyltbutylene) aminobutyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-di- (4-phenylbutylene) aminobutyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro -6- [4- (1 - (4-N, N-di- (4-phenylbutylene) aminobutyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 1 31 2-.Trans-.4-aminocyclohexyl) amino-1-6-.4- (1 - (5-N, N-di- (4-phenylethylene) aminopentyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4 -Amino-1 - (5-N, N-di- (4-phenylbutylene) aminopentyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (5-N, N-di- (4-phenylbutylene) aminopentyl ) piperidine 4-Carboxamide-1 - (5-N, N-di- (4-phenylbutylene) aminopentyl) piperidine can be prepared from isonipecotamide and 5-N, N-di- (4-phenylbutyleneamino) pentyl chloride essentially as described up in the Example 38, Scheme B, step a. Scheme B_ stage bj 4-Amino-1 - (5-N, N-di- (4-phenylbutylene) aminopentyl) piperidine 4-Amino-1 - (5-N, Nd] - (4-phenylbutylene) aminopentyl) piperidine is prepared from 4-carboxamide-1 - (5-N, N-di- (4-phenylbutylene) aminopentyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. step a: 1 - (5-N, N-di- (4-phenylbutylene) aminopentyl) -4-piperidone 1 - (5-N, N-di- (4-phenylbutylene) aminopentyl) - 4-piperidone is prepared from 4-piperidone and 5-N, N-di- (4-phenylbutyleneamino) pentyl chloride essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (5-N, Ndl- (4-phenylbutylene) aminopentyl) -4-piperidone oxime 1 - (5-N, N-di- (4-phenylbutylene) aminopentyl) - 4-piperidone is prepared from 1- (5-N, N-di- (4-phenylbutylene) aminopentyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Stage CJ 4-Amino-1 - (5-N. Nd¡- (4-phenylbutylene) aminopentyl) piperidine 4-Amino-1 - (5-N, N-di- (4-phenylbutylene) aminopentyl) piperidine is prepared from 1 - (5-N, N-di- (4-phenylbutylene) aminopentyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A. stage bj 2-Chloro-6-f4- (1 - (5-N. N-di- (4-phenylbutylene) aminopentyl)) piperidinyllamnol-9-cyclopentylpurine 5 2-Chloro-6 - [4- (1 - (5-N, N-di- (4-phenylbutylene) aminopentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - ( 5-N, N-di- (4-phenylbutylene) aminopentyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. 10 Scheme A. stage c: 2-, Trans- (4-aminociclohexyl) aminol-6-f4- (1 - (5- N-di- (4-f-enyl butyl) aminopentyl)) piperid inilam i nol -9- Cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-di- (4-phenylbutylene) aminopentyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (5-N, N-di- (4-phenylbutylene) aminopentyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 1 32 20 2-f Trans- (4-aminocyclohexyl) aminol-6-f4- (1 - (3-tetrahydrofuranyl) methyl) p -peridin-laminol-9-cyclopentylpurine Preparation of 4-Amino-1 - (3 -tetrahydrofuranylmethyl) piperidine Method 1 25 Scheme B, step a: 4-Carboxamide-1 - (3-tetrahydrofuranylmethyl) __M_i________ piperidine 4-Carboxamide-1 - (3-tetrahydrofuranylmethyl) piperidine can be prepared from isonipecotamide and tetrahydrofurfuryl chloride essentially as described above in Example 38, Scheme B, step a. Scheme B. Stage b: 4-Amino-1- (3-tetrahydrofuranylmethyl) piperidine 4-Amino-1- (3-tetrahydrofuranylmethyl) piperidine is prepared from 4-carboxamide-1- (3-tetrahydrofuranylmethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (3-tetrahydrofuranylmethyl) -4-piperidone 1- (3-Tetrahydrofuranylmethyl) -4-piperidone is prepared from 4-piperidone and tetrahydrofurfuryl chloride essentially as described above in Example 38 , Scheme C, stage a. Scheme C. Stage b: 1 - (3-Tetrahydrofuranylmethyl) -4-piperidone oxime 1 - (3-Tetrahydrofuranylmethyl) -4-piperidone oxime is prepared from 1- (3-tetrahydrofuranylmethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. stage c: 4-Amino-1 - (3-tetrahydrofuranylmethyl) piperidine 4-Amino-1 - (3-tetrahydrofuranylmethyl) piperidine is prepared from 1 - (3-tetrahydrofuranylmethyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A, stage bj 2-Chloro-6-.4- (1 - (3-Tetrahydrofu ranyl) methyl) piperidinylamine-9-cyclopentyl-pug 2-Chloro-6- [4- (1 - ( 3-tetrahydrofuranyl) methyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-tetrahydrofuranylmethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2-fTrans- (4-aminociclohexyl) amnol-6-f4- (1 - (3-tetrahydrofuranyl) methyl) pyridinylammonol-9-cyclopentylpurine 2- [Trans - (4-aminocyclohexyl) amino] -6-_4- (1- (3-tetrahydrofuranyl) methyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3-tetrahydrofuranyl) methyl] ) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 1 33 2- [Trans- (4-aminocyclohexyl) aminol-6-f4- (1 - (2- (1-pyrrolidinyl) ethyl) piperidinylamino] -9- cyclopentylpurine Preparation of 4-Amino-1 - (2- ( 1-pyrrolidinyl) ethyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (2- (1-pyrrolidinol) etl) piperidine 4-Carboxamide-1 - (2- (1-pyrrolidinyl) ethyl) piperidine can be prepared from isonipecotamide and 1- (2-chloroethyl) pyrrolidine essentially as described above in Example 38, Scheme B, step a.Scheme B, step b: 4-Amino- 1- (2- (1-pyrrolidinyl) ethyl) piperidine 4-Amino-1- (2- (1-pyrrolidinyl) ethyl) piperidine is prepared from 4-carboxamide-1 - (2- (1-pyrrolidinyl) ethyl) ) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C. Step a: 1- (2- (1-Pyrrolidinyl) ethyl) -4-piperidone 1 - (2- (1 -Pyrrolidinyl) ethyl) -4-piperidone is prepared from 4-piperidone and 1- (2-chloroethyl) pyrrolidine essentially as described above in Example 38, Scheme C, step a Scheme C. step b: or 1 - (2- (1-Pyrrolidinyl) ethyl) -4-piperidone oxime 1 - (2- (1-Pyrrolidinyl) ethyl) -4-piperidone is prepared from 1- (2- (1-pyrrolidinyl) ethyl ) -4-piperidone and hidoxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1 - (2- (1-pyrrolidinyl) ethyl) piperidine 4-Amino-1- (2- (1-pyrrolidinyl) ethyl) piperidine is prepared from 1 - (2- (1-pyrrolidinyl) ethyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (2- (1-pyridyldinyl) ethyl)) piperidin-laminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - ( 2- (1-pyrrolidinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2- (1-pyrrolidinyl) ethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (2- (1-pyrrolidinyl) ethyl)) piperidn-lam inol-9-cyclopentyl I purine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2- (1-pyrrolidinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4 - (1 - (2- (1-pyrrolidinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 134 2-f Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (2- (1-Piperidinyl) ethyl)) piperidyl-9-cyclopentylpurine Preparation of 4-Amino -1 - (2- (1-Piperidinyl) ethyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (2- (1-piperidinyl) ethyl) piperidine 4-Carboxamide-1 - (2- (1-piperidinyl) ethyl) piperidine can be prepared from isonipecotamide and 1- (2-chloroethyl) piperidine essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (2- (1-piperidinyl) ethyl) piperidine 4-Amino-1 - (2- (1-piperidinyl) ethyl) piperidine is prepared from 4-carboxamide -1 - (2- (1-piperidinyl) ethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (2- (1-Pperidinyl) ethyl) -4-piperidone 1- (2- (1-Pperidinyl) ethyl) -4-piperidone is prepared from 4-piperidone and 1- (2-Chloroethyl) piperidine essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (2- (1-Piperidinyl) ethyl) -4-piperidone oxime 1 - (2- (1-Piperidinyl) ethyl) -4-piperidone oxime is prepared from 1- (2- (1-piperidinyl) ethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38 , Scheme C, stage b. Scheme C. step c: 4-Amino-1 - (2- (1-piperidinyl) etl) piperidine 4-Amino-1 - (2- (1-piperidinyl) ethyl) piperidine is prepared from oxime 1 - (2- (1-piperidinyl) ethyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (2-piperidinyl) ethyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2- (1 - piperidinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2- (1-piperidinyl) ethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminocyclohexyl) aminol-6-f4- (1 - (2- (1-piperidinyl) etl)) p -peridinylaminol-9-cyclopentylpurine 2- [Trans- ( 4-aminocyclohexyl) amino] -6- [4- (1 - (2- (1-piperidinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2- (1-piperidinyl) ethyl)) piperidinylamino] -9-cyclopentyl pyrimine essentially as described in Example 1, Scheme A, step c. Example 135 2-f Trans- (4-aminocyclohexyl) aminol-6-f4- (1 - (2- (4-morpholinyl) ethyl)) pperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1 - (2- (4- morpholinyl) ethyl) piperidine Method 1 Scheme B. stage a: 4-Carboxamide-1 - (2- (4-morpholinyl) ethyl) pperidine 4-Carboxamide-1 - (2- (4-morpholinyl) ethyl) piperidine may prepare isonipecotamide and 1- (2-chloroethyl) morpholine essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (2- (4-morpholinyl) ethyl) piperidine 4-Amino-1 - (2- (4-morpholinyl) ethyl) piperidine is prepared from 4-carboxamide-1 - ( 2- (4-morpholinyl) ethyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (2- (4-Morpholinyl) ethyl) -4-piperidone 1- (2- (4-Morpholinyl) ethyl) -4-piperidone is prepared from 4-piperidone and 1- (2-Chloroethyl) morpholine essentially as described above in Example 38, Scheme C, step a. Scheme C. - Step b: 1 - (2- (4-Morpholinyl) ethyl) -4-piperidone oxime 1- (2- (4-Morpholinyl) ethyl) -4-piperidone oxime is prepared from 1 - (2 - (4-morpholinyl) ethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1 - (2- (4-morpholinyl) ethyl) piperidine 4-Amino-1 - (2- (4-morpholinyl) ethyl) piperidine is prepared from 1 - (2- (4-morpholinyl) ethyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step b 2-Chloro-6-.4- (1 - (2- (4-morpholinyl) ethyl)) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2- (4-morpholinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-Amino-1- (2- (4-morpholinyl) ethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. step c: 2- [Trans- (4-aminociclohex¡l) aminol-6-f4- (1 - (2- (4-morpholinyl) ethyl)) piperidinyllamnol-9-cyclopentylpurine 2 - [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2- (4-morpholinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- ( 1- (2- (4-merfolinyl) ethyl) plperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 1 36 2-.Trans- (4-aminocyclohexyl) aminol-6-f4- (1 - (3- (1-piperidinyl) propyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1 - (3- (1-piperidinyl) propyl) piperidine Method 1 Scheme B, step a 4-Ca rboxa mide- 1 - (3- (1-piperidyl) propyl) piperidine 4-Carboxamide-1 - (3 - (1-piperidinyl) propyl) piperidine can be prepared from isonipecotamide and 1- (3-chloropropyl) piperidine essentially as described above in Example 38, Scheme B, step a. Scheme B. Stage b: 4-Amino-1 - (3- (1-piperidinyl) propyl) piperidine 4-Amino-1 - (3- (1-piperidinyl) propyl) piperidine is prepared from 4-carboxamide-1 - ( 3- (1-piperidinyl) propyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1 - (3- (1-Piperidinyl) propyl) -4-piperidone 1- (3- (1-Piperidinyl) propyl) -4-piperidone is prepared from 4-piperidone and 1- (3- chloropropyl) piperidine essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (3- (1-Piperidinyl) propyl) -4-piperidone oxime 1 - (3- (1-Piperidinyl) propyl) -4-piperidone oxime is prepared from - (3- (1-piperidinyl) propyl) -4-piperidone and hidoxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. Stage c: 4-Amino-1 - (3- (1-piperidinyl) propyl) piperidine 4-Amino-1 - (3- (1-piperidinyl) propyl) piperidine is prepared from oxime 1 - (3- (1-piperidinyl) propyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step bj 2-Chloro-6-.4- (1 - (3- (1-p -peridinyl) prop.p) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3 - (1-piperidinyl) propyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3- (1-piperidinyl) propyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-f Trans- (4-aminociclohexyl) aminol-6-r4- (1 - (3- (1-piperidinyl) propyl) )) piperidinylammonol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3- (1-piperidinyl) propyl)) piperidinylamino] - 9-Cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (3- (1-piperidinyl) propyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c Example 1 37 (RS) -2-f Trans- (4-aminocyclohexyl) aminol-6-f4- (1 - (3- (1-methyl) p -peridinyl) methyl)) piperidinylaminol-9-cyclopentylpurine Preparation of (R) , S) -4-Amino-1 - (3- (1-methylpiperidinyl) methyl) piperidine Method 1 Scheme B, step a (RS) -4-Carboxamide-1 - (3- (1-methylpiperidinyl) methyl) piperidine (R, S) -4-Carboxamide-1 - (3- (1 - methylpiperidinyl) methyl) piperidine can be prepared from isonipecotamide and (R, S) -3-chloromethyl-1-methylpiperidine essentially as described above in Example 38, Scheme B,. stage a. Scheme B, step b (R, S) -4-Amino-1 - (3- (1-methylpiperidinyl) methyl) piperidine (R, S) -4-Amino-1 - (3- (1-methylpiperidinyl) methyl) piperidine is prepared from (R, S) -4-carboxamide-1 - (3- (1-methylpiperidinyl) methyl) piperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Stage a: (R, S) -1 - (3- (1-Methylpiperidinyl) methyl) -4-piperidone (R, S) -1 - (3- (1-Methylpiperidinyl) methyl) -4-piperidone is prepared from 4-piperidone and (R, S) -3-Chloromethyl-1-methylpiperidine essentially as described above in Example 38 , Scheme C, stage a. Scheme C, step b: oximede (R, S) -1 - (3- (1-methyl-piperidinyl) methyl) -4-piperidone oxime (R, S) -1 - (3- (1-methyl-piperidinyl) methyl) - 4-piperidone is prepared from (R, S) -1 - (3- (1-methylpiperidinyl) methyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c_j (R, S) -4-Amino-1 - (3- (1-rnethylpiperidinyl) methyl) piperidine (R, S) -4-Amino-1 - (3- (1-methylpiperidinyl) methyl) piperidine is prepared from (R, S) -1 - (3- (1-methylpiperidinyl) methyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A_ stage bj (R, S) -2-Chloro-6-.4- (1 - (3- (1-methyl) piperidinyl) methyl) piperidinilaininol-9-cyclopentylpurine (R, S) -2-Chloro-6 - [4- (1 - (3- (1-methyl) piperidinyl) methyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, (R, S) -4-amino- 1- (3- (1-methyl piperidinyl) methyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: (R, S) -2- [Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (3- (1-methyl) piperidinyl) methyl) piperidine! laminol-9-cyclopentylpurine (R, S) -2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3- (1-methyl) piperidinyl) methyl) piperidinylamino] -9-cyclopentylpurine is prepared from (R, S) -2-chloro-6- [4- (1 - (3- (1-methyl) piperidinyl) methyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A , stage c.

Example 1 38 (R, S) -2-rTrans- (4-aminocyclohexyl) amnol-6-f4- (1 - (2- (3- (1-metippyrrolidinyl) ethyl)) piperidinylaminol-9-cyclopentylpurine Preparation of (RS) -4-Amino-1 - (2- (3- (1-methylpyrrolidinyl)) ethyl) pperidine Method 1 Scheme B. stage a: (R, S) -4-Carboxamide-1 - ( 2- (3- (1-ethylpyrrolidinyl) ethyl piperidine (R, S) -4-Carboxamide-1 - (2- (3- (1-methylpyrrolidinyl) ethyl) piperidine can be prepared from isonipecotamide and (R, S) - 3- (2-chloroethyl) -1-methylpyrrolidine essentially as described above in Example 38, Scheme B, step a Scheme B_ step bj (R, S) -4-Amino-1 - (2- (3- ( 1-methylpyrrolidinyl)) ethyl) piperidine (R, S) -4-Amino-1 - (2- (3- (1-methylpyrrolidinyl) ethyl) piperidine is prepared from (R, S) -4-carboxy-mida-1- (2- (3- (1-methylpyrrolidinyl) ethyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C. Step a: (R, S) -1 - (2- (3- (1-methylpyrrolidinyl) ethyl) -4-piperidone (R, S) -1 - (2- (3- (1-methylpyrrolidinyl) ethyl) - 4-piperidone is prepared from 4-piperidone and (R, S) -3- (2-chloroethyl) -1-methylpyrrolidine essentially as described above in Example 38, Scheme C, step a.Scheme C. stage b: oxime of (R, S) -1 - (2- (3- (1-methyl-pyrrolidinyl) ethyl) -4-piperidone oxime (R, S) -1 - (2- (3- (1-methylpyrrolidinyl) ethyl) -4-piperidone is prepared from (R, S) -1 - (2- (3- (1-methylpyrrolidinyl) ethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b, Scheme C, step CJ (RS) -4-Amino-1 - (2- (3- (1-methylpyrrolidinyl)) ethyl) p-peridine (R, S) -4-Amino-1 - ( 2- (3- (1-methylpyrrolidinyl)) ethyl) piperidine is prepared from (R, S) -1 - (2- (3- (1-methylpyrrolidinyl) ethyl) -4-piperidone oxime that essentially as described above in Example 38, Scheme C, step c. Scheme A, step b: (RS) -2-Chloro-6-f4- (1 - (2- (3- (1-methyl) prrollidinyl) ethyl)) piperidinylammonol-9-cyclopentylpurine (R, S) -2-Chloro-6- [4- (1 - (2- (3- (1-methyl) pyrrolidinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9 -cyclopentylpurine, (R, S) -4-amino-1 - (2- (3- (1-methyl pyrrolidinyl)) ethyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b . Scheme A. stage c: (R, S) -2-.Trans-.4-aminociclohexyl) amino1-6-.4- (1 - (2- (3- (1-methyl) pyrrolidinyl) ethyl)) piperidinylaminol-9-cyclopentylpurine (R, S) -2- [Trans- (4-aminociclohexyl) amino] -6- [4- (1 - (2- (3- (1-methyl) pi rrol idi nil) ethyl)) piperidinylamino] -9-cyclopentyl I purine is prepared from (R, S) -2-Chloro-6- [4- (1 - (2- (3- (1-methyl) pyrrolidinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 1 39 2-.Trans- (4-aminociclohexyl) aminol-6-.4- (1 - (2- (1 - (4-methyl) piperazinyl) ethyl)) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino- 1 - (2- (1 - (4-methylpiperazinyl)) ethyl) piperidine Method 1 Scheme B, step a 4-Ca rboxa mide-1 - (2- (1 - (4-methylpiperazinyl)) ethyl) piperidine 4-Carboxamide-1 - (2- (1 - (4-methylpiperazinyl)) ethyl) piperidine can be prepared from isonipecotamide and 1- (2-chloroethyl) -4-methylpiperazine essentially as described above in Example 38, Scheme B, step a. Scheme B_ stage bj 4-Amino-1 - (2- (1 - (4-methylpiperazinyl)) etl) pperiodine 4-Amino-1 - (2- (1- (4-methylpiperazinyl)) ethyl ) piperidine is prepared from 4-carboxamide-1 - (2- (1- (4-methyl-piperazinyl)) ethyl) piperidine essentially as described above in Example 38, Scheme B, step b.

Method 2: Scheme C. Step a: 1 - (2- (1- (4-Met.lpiperazinyl)) ethyl) -4-piperidone 1- (2- (1- (4-Methylpiperazinyl)) ethyl) -4- piperidone is prepared from 4-piperidone and 1- (2-chloroethyl) -4-methylpiperazine essentially as described above in Example 38, Scheme C, step a. Scheme C, step b: 1 - (2- (1 - (4-Methylpiperazinyl)) etl) -4-piperidone oxime of 1 - (2- (1- (4-Methylpiperazinyl)) ethyl) -4 -piperidone is prepared from 1- (2- (1- (4-methylpiperazinyl)) ethyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, stage b. Scheme (Y step c 4-Amino-1 - (2- (1 - (4-methylpiperazinyl)) etl) pyridine 4-Amino-1 - (2- (1- (4-methylpiperazinyl)) ethyl) piperidine is prepared from 1 - (2- (1- (4-methylpiperazinyl)) ethyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c Scheme A. stage bj 2-Chlorine -6-í4- (1 - (2- (1 - (4-methyl) piperazinyl) ethyl)) piperidinylamino-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2- (1 - (4-methyl) piperazinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino- 1 - (2- (1- (4-methylpiperazine il)) ethyl) pi pe ridine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminociclohexyl) amino1-6-f4- (1 - ( 2- (1 - (4-methyl) piperazinyl) ethyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2- (1 - (4- methyl) piperazinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2- (1 - (4-methyl) piperazinyl) ethyl) ) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 140 (R, S) -2-.Trans-.4-aminocyclohexyl-aminol-6-.4-, 1- (2-phenyl-2-hydroxyethyl)) pylperidinylaminol-9-cyclopentylpurine Preparation of IR .SV -4-Amino-1 - (2-phenyl-2-hydroxyethyl .Diperidine Method 1 Scheme B, step a: (R, S) -4-Ca rboxa mide -1 - (2-phenyl-2-hydroxyethiDpiperidine (R, S) -4-Carboxamide-1 - (2-pheny) - 2-hydroxyethyl) piperidine can be prepared from isonipecotamide and (R, S) -1-hydroxy-2-chloroethylbenzene essentially as described above in Example 38, Scheme B, step a.Scheme B. step b: (R, S) -4-Amino-1 - (2-phenyl-2-hydroxyethyl) piperidine (R, S) -4-Amino-1- (2-phenyl-2-hydroxyethyl) piperidine is prepared from (R, S) - 4-carboxamide-1 - (2-phenyl-2-hydroxyethyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C. step a: (R, S) -1 - ( 2-Phenyl-2-hydroxyethyl) -4-piperidone (R, S) -1 - (2-Phenyl-2-hydroxyethyl) -4-piperidone is prepared from 4-piperidone and (R, S) - 1-Hydroxy-2-chloroethylbenzene essentially as described above in Example 38, Scheme C, step a) Scheme C. Step b: Oximetry of (RS) -1 - (2-Phenyl-2-hydroxyethyl) -4-piperidone Oxime of (R, S) -1 - (2-Phenyl-2-hydroxyethyl) -4-piperidone is prepared from (R, S) -1 - (2-Phenyl-2-hydroxyethyl) -4-piperidone hydroxylamine hydrochloride essentially as described above in the Example 38, Scheme C, stage b. Scheme C. stage c: (RS) -4-Amino-1 - (2-phenyl-2-hydroxyethyl) piperidine (R, S) -4-Amino-1 - (2-phenyl-2-hydroxyethyl) piperidine is prepared from (R, S) -1 - (2-phenyl-2-hydroxyethyl) -4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A. stage b: (RS) -2-Chloro-6-I4- (1 - (2-phenyl-2-hydroxyethyl)) piperidinylaminol-9-cyclopentylpurine (R, S) -2- Chloro-6- [4- (1 - (2-Phenyl-2-hydroxyethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, (R, S) -4-amino-1 - (2-phenyl-2-hydroxyethyl) piperidine, and triethylanine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: (R, S) -2- [Trans-, 4-amynocyclohexyl) aminol-6-f4- (1- (2-phenyl-2-hydroxyethyl)) piperidin-laminol-9-cyclopent Glutin (R, S) -2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-phenyl-2-hydroxyethyl)) piperidinylamino] -9-cyclopentylpurine is prepared from (R , S) -2-Chloro-6- [4- (1 - (2-phenyl-2-hydroxyethyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 141 2-.Trans- (4-aminocyclohexyl) amino-1-6- [4- (1 - (3,4-methylenedioxybenzyl)) p.perdynamylamino-9-cyclopentylpurine Preparation of 4-Amino- (3, 4-Methylenedioxybenzyl) pyridine Method 1 Scheme B__ stage to 4-Carboxamide-1 - (3,4-methylenedioxybenzydipperidine 4-Ca rboxamide-1 - (3,4-methylenedioxy benzyl) piperidine can be prepared from isonipecotamide and 5-chloromemethyl -1, 3-benzodioxole essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-Amino- (3,4-methylenedioxybenzyl) piperidine 4-Amino- (3,4-methylenedioxybenzyl) ) piperidine is prepared from 4-carboxamide-1- (3,4-methylenedioxybenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Method 2: Scheme C-step a: 1 - (3.4 Methylenedioxy) benzyl-4-piperidone 1- (3,4-Methylenedioxy) benzyl-4-piperidone is prepared from 4-piperidone and 5-chloromemethyl-1,3-benzodioxole essentially as described above in Example 38, Scheme C, stage A. Scheme C. etap ab: 1 - (3,4-Methylenedioxy) benzyl-4-piperidone oxime 1 - (3,4-Methylenedioxy) benzyl-4-piperidone oxime is prepared from 1- (3,4-methylenedioxy) benzyl-4-piperidone hydrochloride of hydroxylamine essentially as described above in Example 38, Scheme C, step b. Scheme C. Stage c: 4-Amino- (3,4-methylenedioxybenzyl) pperiodine 4-Amino- (3,4-methylenedioxybenzyl) piperidine is prepared from 1 - (3,4-methylenedioxy) benzyl-4- oxime piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A. stage bj 2-Chloro-6-, 4- (1 - (3,4-methylenedioxybenzyl)) piperidinylammonol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (3 , 4-methylenedioxybenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino- (3,4-methylenedioxybenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: 2- [Trans- (4-aminocyclohexylamino1-6-.4- (1- (3,4-methylenedioxybenzyl)) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3,4-methylenedioxybenzyl)) piperidinylamino] -9-cyclopentylpurine is prepared from 2-Chloro-6- [4- (1- (3,4-methylenedioxybenzyl)) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. Example 142 2-f Trans- (4-aminocyclohexyl) amnol-6-f4- (1- (2-benzimidazolinyl) methyl) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1 - (2-benzimidazolini) methylpiperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (2-benzimidazoliniDmethylpi eridine 4-Ca rboxa mide- 1 - (2-benzimidazolinyl) meti I pipe Ridin can be prepared from isonipecotamide and 2- (chloromethyl) benzimidazole essentially as described above in Example 38, Scheme B, step A. Scheme B. Step b: 4-Amino-1- (2-benzimidazole) 4-Amino-1 - (2-benzimidazolinyl) methylpiperidine is prepared from 4-caboxboxamide-1 - (2-benzimidazolinyl) methyl piperidine essentially as described above in Example 38, Scheme B Step b: Method 2: Scheme C. Step a: 1- (2-Benzimidazolyl) methyl-4-piperidone 1- (2-Benzimidazolyl) methyl-4-piperidone is prepared from 4-piperidone and 2- (chloromethyl) ) benzimidazole essentially as described above in Example 38, Scheme C, step a) Scheme C. Step b: 1 - (2-Benzimidazolyl) methyl-4-piperidone oxime 1 - (2-Benzimidazolyl) methyl-4 oxime -piperidone is prepared from 1- (2-benzimidazolyl) methyl-4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C. step c: 4-Amino-1- (2-benzimidazolinyl) methylpiperidine 4-Amino-1- (2-benzimidazolinyl) methylpiperidine is prepared from 1- (2-benzimidazolyl) methyl-4-piperidone oxime essentially as described above in Example 38, Scheme C, step c. Scheme A, step b 2-Chloro-6-.4- (1 - (2-benzimidazolinyl) methyl) piper- dynamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2-benzimidazolinyl) methyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-benzimidazolinyl) methylpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c. 2-.Trans- (4-aminocyclohexyl) aminol-6-.4- (1 - (2-benzimidazolinyl) methyl) piperidine minol-9-cyclopentyl urin 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-benzimidazolinyl) methyl) piperid inylamide] -9-cycline pentylpurine is prepared from 2-chloro-6- [4- (1 - (2-benzimidazolinyl) methyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c.

Example 143 2-rTrans- (4-aminocyclohexyl) aminol-6-.4- (1 - (4- (2-methyl) thiazolinyl) methyl) piperidinylamino-1-9-cyclopentylpurine Preparation of 4-Amino-1 - (4- (2-methylthiazolinyl) methyl) piperidine Method 1 Scheme B, step a 4-Carboxamide-1 - (4- (2-methylthiazolinyl)) methylpiperidine 4-Carboxamide-1 - (4- (2-methylthiazolinyl)) methylpiperidine can be prepared from isonipecotamide and 2-methyl-5- (chloromethyl) thiazole essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (4- (2-methylthiazolinyl) methyl) piperidine 4-Amino-1 - (4- (2-methylthiazolinyl) methyl) piperidine is prepared from 4-carboxamide-1- (4- (2-methylthiazolinyl)) methylpiperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. - Step a: 1- (4- (2-Methylthiazolinyl) methy1) -4-piperidone 1- (4- (9-Methylthiazolinyl) methyl) -4-piperidone is prepared from 4-piperidone and 2-methyl-5- (chloromethyl) thiazole essentially as described above in Example 38, Scheme C, step a. Scheme C. Stage b: 1 - (4- (2-Methylacetazolnol) methyl) -4-piperidone oxime 1- (4- (2-Methylthiazolinyl) methyl) -4-piperidone oxime is prepared of 1- (4- (2-methylthiazolinyl) methyl) -4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C, step c: 4-Amino-1- (4- (2-methylthiazolinyl) methyl) piperidine 4-Amino-1- (4- (2-methylthiazolinyl) methyl) piperidine is prepared from 1 - (4-) oxime (2-methylthiazolinyl) methyl) -4-piperidone essentially as described above in Example 38, Scheme C, step c. Scheme A, step b 2-Chloro-6-.4- (1 - (4- (2-methyl) thiazolinyl) methyl) piperidinylamine-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (4 - (2-methyl) thiazolinyl) methyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2, 6-dichloro-9-cyclopentylpurine, 4-amino-1- (4- (2-methylthiazolinyl) methyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexil) aminol-6-í4- (1 - (4- (2-methyl) táazolinil) methyl) piperidinilaminol-9-cyclopentylpurine 2- [Trans- ( 4-aminocyclohexyl) amino] -6- [4- (1 - (4- (2-methyl) thiazolinyl) methyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (4 - (2-methyl) thiazolinyl) methyl) piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 144 2-.Trans- (4-aminociclohexyl) amino1-6-r4- (1 - (2-thiophenoyl) methyl) piperidinylaminol-9-cyclopentylpurine Preparation of 4-Amino-1- (2-thiophenoyl) methylpiper Method 1 Scheme B, step a: 4-Carboxamide-1- (2-thiophenoyl) methylpiperidine 4-Carboxamide-1- (2-thiophenoyl) methylpiperidine can be prepared from isonipecotamide and 2- (chloromethyl) thiophene essentially as is described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1- (2-thiophenoyl) methylpiperidine 4-Amino-1- (2-thiophenoyl) methylpiperidine is prepared from 4-carboxamide-1- (2-thiophenoyl) methylpiperidine essentially as described above in Example 38, Scheme B, step b. Method 2: Scheme C. Step a: 1- (2-Thiophenoyl) methyl-4-piperidone 1- (2-thiophenoyl) methyl-4-piperidone is prepared from 4-piperidone and 2- (chloromethyl) thiophene essentially as described up in the Example 38, Scheme C, step a. Scheme C, step b: 1 - (2-thiophenoyl) methyl-4-piperidone oxime 1 - (2-Thiophenoyl) methyl-4-piperidone oxime is prepared from 1- (2-thiophenoyl) methyl-4-piperidone and hydroxylamine hydrochloride essentially as described above in Example 38, Scheme C, step b. Scheme C.-step c: 4-Amino-1- (2-thiophenoyl) methylpiperidine 4-Amino-1- (2-thiophenoyl) methylpiperidine is prepared from oxime of 1- (2-thiophenoyl) methyl-4-piperidone essentially as is described above in Example 38, Scheme C, step c. Scheme A, stage bj 2-Chloro-6-.4- (1 - (2-thiophenoyl) methyl) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1 - (2-thiophenoyl) methyl) piperidinylamino] -9-cyclopenti I purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1 - (2-thiophenoyl) methylpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminocolclohexyl) aminol-6-.4- (1 - (2-thiophenoyl) methyl) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino ] -6- [4- (1 - (2-thiophenoyl) methyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1 - (2-thiophenoyl) methyl) piperidinylamino] -9- cyclopentylpurine essentially as described in Example 1, Scheme A, step c. Example 145a Trans-2-Trans- (4-aminocyclohexyl) aminol-6-f (4-hydrox) cyclohexylamino-1-9-cyclopentypurine dihydrochloride Scheme A. stage b: Trans-2-chloro-6-f (4 -hydroxy) cyclohexylamino-9-cyclopentylpurine Trans-2-Chloro-6 - [(4-hydroxy) -cyclohexylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, Trans-4- (amino) cyclohexanol, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: Trans-2- [Trans- (4-aminocyclohexyl) amino1-6-y (4-hydroxy) cyclohexylamino-9-cyclopentylpurine dihydrochloride Trans-2- [Trans- (4-aminocyclohexyl) amino] dihydrochloride ] -6 - [(4-hydroxy) cyclohexylamino] -9-cyclopentylpurine is prepared from Trans-2-Chloro-6 - [(4-hydroxy) cyclohexylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A , stage c.

CIMS (NH3) 414 (MH +) Rf (min.) = 3.25 Example 145b Cis-2-f Trans- (4-aminocyclohexyl) aminol-6-dihydrochloride. (4-hydroxy) cyclohexylamino-9-cyclopentylpurine Scheme A, step b: Cis-2-chloro-6-. (4-hydroxy) cyclohexylamino-9-cyclopentylpurine Cis-2-Chloro-6 - [(4-hydroxy) -cyclohexylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, cis-4- (amino) cyclohexanol, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: Cis-2-f Trans- (4-aminociclohexyl) aminol-6-f (4-hydroxy) cyclohexyllamino-1-9-cyclopentylpurine dihydrochloride Cis-2- [Trans- (4-aminociclohexyl) dihydrochloride] amino] -6 - [(4-hydroxy) cyclohexylamino] -9-cyclopentylpurine is prepared from cis-2-chloro-6 - [(4-hydroxy) cyclohexylamino] -9-cyclopentylpurine hydrochloride essentially as described in Example 1 , Scheme A, stage c. CIMS (NH3) 414 (MH +) Rf (min.) = 3.25 Example 146 (R, S) -2-. Trans- (4-aminociclohexyl) aminol-6-f (1-hydroxymethyl) cyclopentylamino-9-cyclopentylpurine dihydrochloride Scheme A, stage bj (R, S) -2-Chlorine-6-. (1-hydroxymethyl id) cyclopentylamino-9-cyclopentylpurine (R, S) -2-Chloro-6 - [(1-hydroxymethyl) cyclopentylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, (R, S) -2-hydroxymethyl-1-aminocyclopentane, and triethylamine essentially as described above in Example A., Scheme A, step b. Scheme A. stage c: Dihydrochloride of (R, S) -2-.Trans- (4-aminociclohexyl) aminol-6-f (1-hydroxmethyl) cyclopentylamino-9-cyclopentylpurine Dihydrochloride of (R, S) -2- [ Trans- (4-aminocyclohexyl) amino] -6 - [(1-hydroxymethyl) cyclopentylamino] -9-cyclopentylpurine is prepared from (R, S) -2-Chloro-6 - [(1-hydroxymethyl) cyclopentylamino ] -9-cyclopenti I purine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 414 (MH +) Rf (niln.) = 3.27 Example 147 2-.Trans- (4-aminociclohexyl) aminol-6- (2-dihydrochloride, 4-dichlorophenylhydrazino) -9-cyclopentylpurine Scheme A. Stage b: 2-Chloro-6- (2,4-dichlorophenylhydrazino) -9-cyclopentylpurine 2-Chloro-6- (2,4-dichlorophenylhydrazino) -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 2,4-dichlorophenylhydrazine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminocyclohexyl) aminol-6- (2,4-dichlorophenylhydrazino) -9-cyclopentylpurine dihydrochloride 2- [Trans- (4-aminociclohexyl) amino] -6- (2, 4-dichlorophenylhydrazino) -9-cyclopentylpurine is prepared from 2-chloro-6- (2,4-dichlorophenylhydrazino) -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. CIMS (NH3) 475 (MH +) Rf (min.) = 3.49 Example147-a 2-.Trans- (4-aminociclohexyl) amino] -6-y4- trihydrochloride. 1- (1-naphthyl) methyl-piperidinylaminol-9-cyclorentilpurine Scheme B. stage a: 4-Carboxamide-1 - (1-naphthyl) methylpiperidine 4-Carboxamide 1- (1-naphthyl) methylpiperidine can be prepared from isonipecotamide and 1- (chloromethyl) naphthalene (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-amino-1- (1 -naphthyl) methylpiperidine 4-Amino-1- (1 -naphthyl) methylpiperidine is prepared from 4-carboxamide-1- (1 -naphthyl) methylpiperidine essentially as described above in Example 38, Scheme B, step b. Scheme A. stage b: 2-Chloro-6-f4-1 - (1 -naphthyl) methyl-piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4-1 - (1 -naphthyl) methyl] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (1 -naphthyl) methylpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b.Scheme A. stage c: 2- [Trans- (4-aminociclohexyl) amino1-6- [4-p - (1-naphthyl) metillpiperid ini lam inol-9-cyclopentylpurine trihydrochloride 2- [Trans- (4-- aminocyclohexyl) amino] -6- [4- [1 - (1 -naphthyl) methyl] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4-1 - (1 -naphthyl) methyl] piperidinylamino] - 9-Cyclopentylpurine essentially as described in Example 1, Scheme A, step c. APCl: 539 (M + 1) Rf (min.) = 2.33 Example 147-b 2-.Trans- (4-aminociclohexyl) aminol-6-f4-.1 - (2-trifluoromethyl benzylpyrifinylaminol- trihydrochloride 9-cyclopentyl pyrimine Scheme B, step a 4-Carboxamide-1 - (2-trifluoromethyl be nyl) piperidine 4-Carboxamide-1- (2-trifluoromethylbenzyl) pperidine can be prepared from isonipecotamide and 2- (trifluoromethyl) bromide ) benzyl (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a.Scheme B, step b: 4-amino-1- (2-trifluoromethylbenzyl) piperidine 4-Amino-1 - (2-trifluoromethylbenzyl) piperidine is prepared from 4-carboxamide-1- (2-trifluoromethylbenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Scheme A, step bj 2-Chloro-6 -4-M - (2-trifluoromethyl benzyl piperidin-ilaminol-9-cyclopentyl purine 2-Chloro-6- [4- [1 - (2-trifluoromethyl-benzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2.6 -dichloro-9-cyclopentylpurine, 4- amino-1 - (2-trifluoromethylbenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminociclohexyl) amino1-6- [4-f 1 - (2-trifluoromethylbenzyl piperidine i laminol-9-cyclopentylputran trihydrochloride Trihydrochloride 2- [Trans- (4- aminocyclohexyl) amino] -6- [4- [1- (2-trifluoromethyl-benzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (2-trifluoromethyl-benzyl) -lpiperidinylamino] -9- cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 557 (M + 1) Rf (min.) = 2.29 Example 147-c 2-.Trans- (4-aminociclohexyl) ammonol trihydrochloride 6-.4-.1 - (3,5-dimethoxy benzyl) l pi pe ridinilaminol-9-cyclopentyl pranny Scheme B, step a: 4-Carboxamide-1 - (3,5-dimethoxybenzyl) piperidine 4-Carboxamide-1 - (3,5-dimethoxybenzyl) piperidine can be prepared from isonipecotamide and 3,5-dimethoxybenzyl chloride (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (3,5-dimethoxybenzyl) piperidine 4-Amino-1- (3,5-dimethoxybenzyl) piperidine is prepared from 4-Carboxamide-1 - ( 3,5-dimethoxybenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A, step b: 2-Chloro-6-f4-ri - (3,5-dimethoxybenzyl) 1-piperidinyl-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (3,5-dimethoxybenzyl)] piperidinylamino ] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3,5-dimethoxybenzyl) -piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminocyclohexyPamino1-6-.4-. 1 - (3,5-dimethoxybenzyl) lpiperidinylaminol-9-cyclopentylpipurine Trihydrochloride 2- [Trans- (4-aminociclohexyl) ) amino] -6- [4- [1 - (3,5-dimethoxybenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1 - (3,5-dimethoxybenzyl)] piperidinylamino ] -9-Cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 549 (M + 1) Rf (min.) = 2.27 Example 147-d 2-, Trans- (4-aminocyclohexyl) Trihydrochloride aminol-6-.4-. 1 -.3,5- bis (trifluoromethyl) benzyl-piperidinylamino-1-9-cyclopentylpurine Scheme B, step a 4-Ca rboxa mid a-1 - (3, 5-bis-trif luorometi IbenciPpiperid ina 4-Ca rboxam ida- 1 - (3, 5-bis-trif luorometi I benci l) pi perid i na can be prepared from isonipecotanil and bis (3,5-trifluoromethyl) benzyl bromide (available from the Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, stage a. Scheme B. stage b: 4-amino-1- (3,5-bis-trifluoromethylbenzyl) piperidine 4-Amino-1- (3,5-bis-trifluoromethylbenzyl) piperidine is prepared from 4-carboxamide-1 - (3, 5- bis-trif luoromethylbenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A, stage bj 2-Chloro-6- [4- [1 - (3, 5-bis-trif luorometi Ibenci DI piperidin ilaminol-9-cyclopenti I purine 2-Chloro-6- [4- [1 - (3 , 5-bis-trifluoro methylbenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro, -9-cyclopentylpurine, 4-amino-1 - (3, 5-bis-trif luorometi I benci Dpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2- [Trans- (4-aminocyclohexyl) amino1-6-.4-H- (3, 5-bis- (trifluoromethylbenzDlpiperidinylaminol-9-cyclopentylpurine) 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- [1 - [3,5-bis (trifluoromethyl) benzyl]] - piperidinylamino] -9-hydrochloride - Cyclopentylpurine is prepared from 2-Chloro-6- [4- [1-bis (3,5-trifluoromethyl) benzyl)] piperid-n-nylamino] -9-cyclopentyl-pyrimine essentially as described in Example 1, Scheme A, step C. APCl: 625 (M + 1) Rf (min.) = 2.37 Example 147-e 2- [Trans- (4-aminociclohexyl) amino1-6-.4-. 1 - (2,3-difluorobenzyl) pip trihydrochloride erid i nilaminol-9-cyclopentyl I purine Scheme B. stage a: 4-Carboxamide-1 - (2,3-difluorobenzyl) pperiodine 4-Carboxamide-1 - (2,3-difluorobenzyl) piperidine can be prepared from isonipecotamide and 2,3-difluorobenzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B, step b: 4-amino-1 - (2,3-difluorobenzyl) piperidin 4-amino-1- (2,3-difluorobenzyl) piperidine is prepared from 4-carboxamide-1 - (2, 3-difluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A, stage bj 2-Chloro-6-.4-, 1 - (2,3-difluorobenzPlpiperidinilaminol-9-cyclopentyl purine 2-Chloro-6- [4- [1 - (2,3-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2,3-difluorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) amynol-6- [4-f 1 - (2,3-difluorobenzyl) -1piperidinylaminol-9-cyclopentylpurine Trihydrochloride 2- [Trans] Trihydrochloride - (4-Aminocyclohexyl) amino] -6- [4- [1 - (2,3-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1 - (2,3 -difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 525 (M + 1) Rf (min.) = 2.26 Example 147-f Tri-2-Hydrochloride. (4-aminociclohexil) aminol-6- [4-. 1 - (2,5-difluorobenc¡Dlpiperidinilaminol-9-cyclopentylpurine Scheme B. stage a: 4-Carboxamide-1 - (2.5 -difluorobenzyl) peiperidine 4-Carboxamide-1 - (2,5-difluorobenzyl) piperidine can be prepared from isonipecotamide and 2,5-difluorobenzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B. Stage b: 4-amino-1 - (2,5-d-fluorobenzyl) piperidine 4-Amino-1- (2,5-difluorobenzyl) piperidine is prepared from 4-carboxamide-1 - (2,5- difluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A, step bj 2-Chloro-6-f4-M - (2,5-difluorobenzDlpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (2,5-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2,5-difluorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c : 2-.Trans- (4-aminocyclohexyPaminol-6-.4-. 1 - (2,5-difluorobenzyl) lpiperidinylaminol-9-cyclopentylpurine trihydrochloride 2- [Trans- (4-aminocyclohexyl) amino] - trihydrochloride 6- [4- [1 - (2,5-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1 - (2, 5-dif I uorobenzyl)] piperidinylamino] - 9-Pentyl Purine Cycle essentially as described in Example 1, Scheme A, step C. APCl: 525 (M + 1) Rf (min.) = 2.26 Example 147-q 2-.Trans- (4-aminocyclohexyPaminol Trihydrochloride -6-.4-.1 - (3,5-difluorobenzPlpiperidinilaminol-9-cyclopenti I purine Scheme B. stage a: 4-Carboxamide-1 - (3.5-d) ifluorobenzyl) piperidine 4-Carboxamide-1 - (3,5-difluorobenzyl) piperidine can be prepared from isonipecotamide and 3,5-difluorobenzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-amino-1- (3,5-difluorobenzyl) piperidine 4-Amino-1- (3,5-difluorobenzyl) piperidine is prepared from 4-carboxamide-1- (3,5-difluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A. stage bj 2-Chloro-6-f4-f 1 - (3,5-difluorobenzPlpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1- (3,5-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3,5-difluorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. Step c: 2-f Trans- (4-aminocyclohexyl) aminol-6- [4-f 1 - (3,5-difluorobenzyl) -1piperidin-9-nolol-9-cyclopentylpurine Trihydrochloride 2- [Trans- (4 -aminocyclohexyl) amino] -6- [4- [1 - (3,5-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1 - (3,5-difluorobenzyl) ] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 525 (M + 1) Rf (min.) = 2.25 Example 147-h 2-.Trans- (4-) Trihydrochloride aminociclohexiDamino1-6-.4-. 1 - (2,4- difluorobenciPlpiperidinilaminol-9-cyclopentilpurine Scheme B. stage a: 4-Carboxamide-1 - (2,4-di) fluorobenzyl) piperidine 4-Carboxamide-1- (2,4-difluorobenzyl) piperidine can be prepared from isonipecotamide and 2,4-difluorobenzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a . Scheme B. Stage b: 4-Amino-1 - (2,4-difluorobenzyl) pperidine 4-Amino-1- (2,4-difluorobenzyl) piperidine is prepared from 4-carboxamide-1 - (2,4-difluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A. stage bj 2-Chloro-6-.4-.1 - (2,4-difluorobenzDlpiperidinilaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (2,4-difluorobenzyl)] piperidinylamino] - 9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2,4-difluorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. A. stage c: 2-.Trans- (4-aminocloclohexyDamino-6-.4-. 1 - (2,4-difluorobenzDlp.peri-dinaminol-9-cyclopentylpurine Trihydrochloride Trihydrochloride 2- [Trans - (4-aminocyclohexyl) amino] -6- [4- [1 - (2, 4-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-Chloro-6- [4- [1- (2,4-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. APCl: 525 (M + 1) Rf (min.) = 2.25 Example 147-i 2-.Trans- (4-amylocyclohexyl) -Dayne-6-.4-f 1 - (3-methyl-benzyl) trihydrochloride DI piperid inilaminol-9-cyclopentylpurine Scheme B. stage a: 4-Carboxamide-1 - (3-methylbenzyl) piperidine 4-Carboxamide-1 - (3-methylbenzyl) piperidine can prepared from isonipecotamide and 3-methylbenzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-amino-1 - (3-methylbenzyl) piperidine 4-Amino-1 - (3 -methylbenzyl) piperidine is prepared from 4-carboxamide-1- (3-methylbenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Scheme A, ster >; b: 2-Chloro-6-f4-f 1 - (3-methylbennyl) lpe-ridinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (3-methylbenzyl)] piperidinylamineO] -9-cyclopentylpurine is prepare froin 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-methylbenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2- [Trans- (4-aminocloclohexyPaminol-6-y4-f 1 - (3-methylbenzyl) l-piperidinylaminol-9-cyclopentylpurine Trihydrochloride 2- [Trans- (4-aminociclohexyl ) amino] -6- [4- [1 - (3-methylbenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (3-methylbenzyl)] piperid inylamino] - 9-Cyclopentyl purine essentially as described in Example 1, Scheme A, step C. APCl: 503 (M + 1) Rf (min.) = 2.24 Example 147-2-f Trans- (4-aminocyclohex) -Paymino1- Trihydrochloride 6-f4-f 1 - (3-fluorebenzPlpiperidinylaminol-9-cyclopentylpurine Scheme B, step a: 4-Carboxamide-1 - (3-fluorobenzylpiperidine 4-Carboxamide-1 - (3-fluorobenzyl) piperidine can be prepared from isonipecotamide and bromide 3-Fluorobenzyl (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-amino-1- (3-fluorobenzyl) piperidine 4-Amino- 1- (3-fluorobenzyl) piperidine is prepared from 4-carboxam da-1 - (3-fluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. SchemeA. stage b: 2-Chloro-6-.4-. 1- (3-fluorobenzyl) lpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (3-f luorobenzyl)] piperidyl] nylamino] -9-cyclopentyl-phenyl is prepared from 2,6-dichloro-9 -cyclopentylpurine, 4-amino-1- (3-fluorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2- [Trans- (4-aminocyclohexyPamino1-6-.4-. 1 - (3-fluorobenzDlpiperdynamylamino-9-cyclopentyrapine 2- [Trans- (4-aminociclohexyl) trihydrochloride] amino] -6- [4- [1 - (3-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (3-fluorobenzyl)] - piperidinylamino] -9- cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 507 (M + 1) Rf (min.) = 2.25 Example 147-k 2-f Trans- (4-aminocyclohexylPamino) Trihydrochloride -6- [4-H - (2-fluorobenzyl) lpiperidinylamino-1-9-cyclopentylpurine Scheme B. stage a: 4-Carboxamide-1 - (2-fluorobenzyl) piperidine 4-Carboxamide-1 - (2-fluorobenzyl) piperidine can be prepared from isonipecotamide and 2-fluorobenzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a.Scheme B. step b: 4-amino-1 - (2- fluorobenzyl) piperidine 4-Amino-1 - (2-fluorobenzyl) piperidine is prepared from 4-carboxa mida-1 - (2-fluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A. stage b: 2-Chloro-6-.4-.1 - (2-fluorobenzDlpiperidinylaminol-9-cyclopentylpurine 2-Chlore-6- [4- [1 - (2-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-fluorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-.Trans- (4-aminociclohexiPaminol-6-.4-H - (2-fluorobenciPlpiperidinilaminol-9-cyclopentylpurine Trihydrochloride Trihydrochloride 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- [1 - ( 2-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (2-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 507 (M + 1) Rf (min.) = 2.22 Example 147-1 2- [Trans- (4-aminociclohex¡Paminol-6-í4-f 1 - (4-fluorobenciPlpiperidinilaminol-9-cyclopenti) Trihydrochloride I purine Scheme B. stage a: 4-Carboxamide-1 - (4-fluorobenzyl) piperidine 4-Carboxamide-1 - (4-fluorobenzyl) piperidine can be prepared from isonipecotamide and 4-fluorobenzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B. step b: 4-amino-1- (4-fluorobenzDpiperidine 4-Amino-1- (4-fluorobenzyl) piperidine is prepared from 4-carboxamide-1- (4-fluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Scheme A. step b: 2-Chloro-6-y4-.l - (4-fluorobenzyl-piperidinylammonol-9-cyclopentylpurine 2-Chloro-6- [4- [ 1- (4-fl uorobenzyl)] piperidinylamino] -9-cyclopentyl purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (4-fluorobenzyl) piperidine, and triethylamine substantially as described above in Example 1, Scheme A, step b Scheme A. step c: 2- [Trans- (4-aminocyclohexyl) aminol-6-f4-.1 - (4-fluorobenzyl-piperidinyl) -aminol trihydrochloride -9-cyclopentylpurine 2-.Trans- (4-aminociclohexyl) amino] -6- [4- [1- (4-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride is prepared from 2-chloro-6- [4 - [1- (4-Fluorobenzyl)] - piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. APCl: 07 (M + 1) Rf (min.) = 2.23 Example 147-m 2-.Trans- (4-aminociclohexyl) aminol-6-f4-.1 - (3-trifluoromethylbenzylpiperidinyl ammonium-9-cyclopentyl I purine trihydrochloride Scheme B, step a 4-Ca rboxa m da-1 - (3-trifluoromethylbenzylpiperidine 4-Carboxamide-1 - (3-trifluoromethylbenzyl) piperidine can be prepared from isonipecotamide and 3- (t-trifluoromethyl) benzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, stage a. Scheme B. Step b: 4-amino-1- (3-trifluoromethylbenzylpiperidine 4-Amino-1- (3-trifluoromethylbenzyl) piperidine is prepared from 4-carboxamide-1 - (3-trifluoromethylbencippiperidine essentially as described above. Example 38, Scheme B, step b Scheme A, step bj 2-Chloro-6- [4-ri - (3-trifluoromethylbenzyl) lpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (3-trifluoromethylbenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-trifluoromethylbenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-f Trans- (4-aminocloclohexyDaminol-6-.4-M - (3-trifluoromethylbenzylpiperidinylaminol-9-cyclopentylpurine Trihydrochloride 2- [Trans- ( 4-aminocyclohexyl) amino] -6- [4- [1- (3-trifluoromethylbenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (3-trifluoromethylbenzyl)] piperidinylamino] -9- Essential cyclopentylpurine as described in Example 1, Scheme A, step c. APCl: 557 (M + 1) Rf (min.) = 2.31 Example 147-n 2-f Trans- (4-aminociclohexyl) aminol-6-f4-f 1 - (2-Chloro-6-fluorobenzyl) lpiperidyl trihydrochloride n-laminol-9-cyclopentylpurine Scheme B, step a 4-Carboxamide-1 - (2-Chloro-6-fluorobenzylpiperidine 4-Carboxa mida-1- (2-chloro-6-fluorobenzyl) piperidine can be prepared from isonipecotamide and chloride of 2-chloro-6-fluorobenzyl (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-amino-1- (2-Chloro-6-) fluorobenzyl) p -peridine 4-Amino-1- (2-chloro-6-fluorobenzyl) piperidine is prepared from 4-carboxamide-1- (2-chloro-6-fluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Scheme A, step bj 2-Chloro-6-.4-M - (2-Chloro-6-fluorobenzylpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (2 -chloro-6-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-Amino-1 - (2-chloro-6 -fluorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b.

Scheme A. stage c: 2-.Trans- (4-aminociclohexiPaminol-6-f4- [1 - (2-chloro-6-fluorobenciPlpiperidinilaminol-9-ciclopenti I purine trihydrochloride] 2- [Trans- (4-aminociclohexyl) trihydrochloride ) amino] -6- [4- [1 - (2-Chloro-6-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2- Chloro-6- [4- [1 - (2-Chloro-6- fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. APCl: 541 (M + 1) Rf (min.) = 2.22 Example 147-0 2-.Trans- (4-aminociclohexyl) amnol-6- [4-.1 - (3,4- d- chlorobenzyl DI trihydrochloride piperidin i laminol-9-cyclopentyl puss Scheme B. stage a: 4-Carboxamide-1 - (3,4-dichlorobenzylpiperidine 4-Carboxamide-1 - (3,4-dichlorobenzyl) piperidine can be prepared from isonipecotamide and chloride 3,4 -dichlorobenzyl (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-Amino-1 - (3,4-dichlorobenzyl) pperidine 4-Amino-1- (3,4-dichlorobenzyl) piperidine is prepared from 4-carboxamide- 1 - (3,4- dichlorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. SchemeA. Stage bj 2-Chloro-6-f4-f 1 - (3,4-dichlorobenzyl) lp -peridin-laminol-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (3,4-diechlorobenzyl)] piperidinylamino ] -9- cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3,4-dichlorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b . Scheme A. stage c: 2-f Trans- (4-aminociclohex¡Paminol-6-, 4-. 1 - (3,4-d¡clorobencíl) lpiperidinilaminol-9-cyclopentilpurine trihydrochloride Trihydrochloride of 2- [Trans- (4-aminocyclohexyl) amino] -6-_4- [1- (3,4-dichlorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (3,4-dichlorobenzyl) )] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 557 (M + 1) Rf (min.) = 2.33 Example 147-p 2-, Trans- (4) trihydrochloride -aminocyclohexyPaminol-6-.4-.l - (2-naphthiPmethylpiperidinylaminol-9-cydopentylpurine Scheme B. stage a: 4-Carboxamide-1 - (2-naphthyl) methylpiperidine 4-Carboxamide-1 - (2- naphthyl) methylpiperidine can be prepared from isonipecotamide and 2- (chloromethyl) naphthalene (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a.Scheme B. step b: 4-amino-1 - ( 2-naphthyl) methylpiperidine 4-Amino-1 - (2-naphthyl) methylpiperidine is prepared from 4-carboxamide -1- (2-naphthyl) methylpiperidine essentially as described above in Example 38, Scheme B, step b.

Scheme A. stage b: 2-Chloro-6- [4-1 - (2-naphthiPmetinpiperidinyl-9-cyclopentylpurine 2-Chloro-6- [4-1 - (2-naphthyl) methyl] piperidinylamino ] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-naphthyl) methylpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. A. stage c: 2-.Trans- (4-aminociclohexyl) aminol-6-f4-f 1 - (2-naphthyl) methyl-piperidinylaminol-9-cyclopentylpurine trihydrochloride 2- [Trans- (4-aminociclohexyl) amino] trihydrochloride -6- [4- [1 - (2-Naphthyl) methyl] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4-1 - (2-naphthyl) methyl] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 539 (M + 1) Rf (min.) = 2.30 Example 147 q 2-.Trans- (4-aminocloclohexyl) aminol-6-trihydrochloride. 4-f 1 - (2-methoxybenzyl) 1-piperidinyl-9-cyclopentylpurine Scheme B. stage a: 4-Carboxamide-1 - (2-methoxybenzydipperidine 4-Carboxamide -1- (2-methoxybenzyl) piperidine can be prepared from isonipecotamide and 2-methoxybenzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B. Step b: 4-amino-1- (2-methoxybenzydiperpiperidin 4-Amino-1- (2-methoxybenzyl) piperidine is prepared from 4-carboxamide-1- (2-methoxybenzyl) piperidine essentially as described above in Example 38, Scheme B, stage b. Scheme A. stage bj 2-Chloro-6-r4-M - (2-methoxy-benzylpiperidin-lam-nol-9-cyclopentyl-phenyl) 2-Chloro-6- [4- [1- (2-methoxy-benzyl)] -piperidinylamino] - 9-cyclopentyl purine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-methoxybenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. , step c Trihydrochloride 2-f Trans- (4-aminocyclohexyl) amino-6-.4-. 1 - (2-methoxybenzyl) lp -peridinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) trihydrochloride ) amino] -6- [4- [1 - (2-methoxybenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (2-methoxybenzyl)] piperidinylamino] -9- cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 5 1 9 (M + 1) Rf (min.) = 2.19 Example 147-r 2-.Trans- (4-aminocyclohexyPaminol-6-Trihydrochloride f4-.1 - (2,5-dichlorobenzyl) 1piperidinylamine-9-cyclopentylpurine Scheme B. stage a: 4-Carboxamide-1 - (2,5-dichlorobenzyl) pep eridin 4-Carboxamide-1 - (2,5-dichlorobenzyl) piperidine can be prepared from isonipecotamide and 2,5-dichlorobenzyl chloride (available from Lancaster) essentially as described above in Example 38, Scheme B, stage a. Scheme B. stage b: 4-amino-1 - (2,5-dichlorobenzyl) piperidine 4-Amino-1 - (2,5-dichlorobenzyl) piperidine is prepared from 4-carboxamide- 1 - (2,5- dichlorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A., stage bj 2-Chloro-6-.4-M - (2,5-dichlorobenzDlpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (2,5-dichlorobenzyl)] piperidinylamino] - 9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2,5-dichlorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. A. stage c: 2- [Trans- (4-aminocyclohexyl) aminol-6-.4-. 1 - (2,5-d-chlorobenzyl) Dl-piperidin-ylaminol-9-cyclopentylpurine 2- [Trans- (4-methyl-4-aminocyclohexyl) trihydrochloride] -amin-occyclohexyl) amino] -6- [4- [1 - (2,5-dichlorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1 - (2, 5- dichlorobenzyl)] piperid in i lam i no) -9-cyclopentyl pyrimine essentially as described in Example 1, Scheme A, step c APCl: 557 (M + 1) Rf (min.) = 2.22 Example 147-s Trihydrochloride 2-fTrans-, 4-aminocloclohexyDaminnol-6-.4- (1-cyclohexylmethylpiperidinylaminol-9-cyclopentylpurine Scheme B. stage a: 4-Carboxamide-1-cycloh Exylmethylpiperidine 4-Carboxamide-1-cyclohexylmethylpiperidine can be prepared from isonipecotamide and cyclohexylmethyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B. Stage b: 4-amino-1-cyclohexylmethylpiperidine 4-Amino-1-cyclohexylmethylpiperidine is prepared from 4-carboxamide-1-cyclohexylmethylpiperidine essentially as described above in Example 38, Scheme B, step b. Scheme A. stage b: 2-Chloro-6- [4- (1-cyclohexylmethyl) piperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- (1-cyclohexy-I-methyl) piperidin-ylamino] -9-cyclopentyl-puss prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1-cyclohexylmethylpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminociclohexyl) amino-6-f4- (1-cyclohexylmethyl) piperidyl-9-cyclopentylpurine Trihydrochloride 2- [Trans- (4-aminociclohexyl) ) amino] -6- [4- (1-cyclohexylmethyl) piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- (1-cyclohexylmethyl) piperidinylamino] -9-cyclopentylpurine-essentially as described in Example 1, Scheme A, step c.

APCI: 495 (M + 1) Rf (min.) = 2.25 Example 147-t 2-.Trans- (4-aminocyclohexyPamino] -6-.4-M - (2-chloro-4-fluorobenzylpiperidinylaminol-9-cyclopentylpurine trihydrochloride Scheme B_, step a 4-Carboxamide-1 - (2-chloro-4-fluorobenz I) pipe ridin 4-Carboxamide-1 - (2-Chloro-4-fluorobenzyl) piperidine can be prepared from isonipecotamide and 2-chlorochloride 4-fluorobenzyl (available from Lancaster or Acros) essentially as described above in the Example 38, Scheme B, step a. Scheme B. stage b: 4-amino-1 - (2-chloro-4-fluorobenzDpiperidine 4-Amino-1 - (2-Chloro-4-fluorobenzyl) piperidine is prepared from 4-carboxamide-1 - (2-chloro- 4-fluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Scheme A_ step bj 2-Chloro-6-.4-H - (2-chloro-4-fluorobenzyl) lpiperidinylaminol-9 -cyclopentyl purine 2-Chloro-6- [4- [1 - (2-chloro-4-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino- 1- (2-Chloro-4-fluorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: 2-f Trans- (4-aminociclohex) Daminol- trihydrochloride 6- [4-M - (2-Chloro-4-fluorobenzyl) lpiperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) amino] -6- [4- [1 - (2-Chloro)] Trihydrochloride -4-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (2-chloro-4-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine essence as described in Example 1, Scheme A, step c. APCl: 541 (M + 1) Rf (min.) = 2.28 Example 147-u 2-.Trans- (4-Aminocyclohexyl) amino-1-6-.4- Trihydrochloride. 1- (3,4-difluorobenzyl) piperidinylaminol-9-cyclopentylpurine Scheme B. stage a: 4-Carboxamide-1 - (3,4-difluorobenzyl) piperidine 4-Carboxamide-1 - (3,4-difluorobenzyl) piperidine can be prepared from isonipecotamide and 3,4-difluorobenzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-amino-1 - (3,4-difluorobenzyl) piperidine 4-amino-1- (3,4-difluorobenzyl) piperidine is prepared from 4-carboxamide-1 - (3,4-difluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A, stage bj 2-Chloro-6-.4-M - (3,4-difluorobenzyl) lpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1- (3,4-difluorobenzyl)] piperidinylamino] The sky-blue sky is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3,4-difluorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c Trihydrochloride of: 2-fTrans- (4-aminocyclohexyl) amnol-6-.4-. 1- (3,4-difluorobenzyl) piperidinylaminol-9-cyclopentylpurine 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- [1- (3,4-difluorobenzyl)] piperidinylamino] -hydrochloride] -9 -cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (3,4-difluorobenzyl)] piperidinylamine] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. APCl: 525 (M + 1) Rf (min.) = 2.29 Example 147-v 2-.Trans- (4-Aminocyclohexyl) aminol-6-.4- Trihydrochloride. 1- (2,6-difluorobenzyl) lpiperidinylamino] -9- cyclopentylpurine Scheme B. Step a: 4-Carboxamide-1- (2,6-difluorobenzyl) piperidine 4-Carboxamide-1- (2,6-difluorobenzyl) piperidine may prepared from isonipecotamide and 2,6-difluorobenzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a. Scheme B. stage b: 4-amino-1- (2,6-difluorobenzyl) piperidine 4-Amino-1- (2,6-difluorobenzyl) piperidine is prepared from 4-carboxamide-1- (2,6-difluorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A, stage bj 2-Chloro-6-.4-M - (2,6-difluorobenzPlpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1- (2,6-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (2,6-difluorobenzyl) piperidine, and triethylanilin essentially as described above in Example 1, Scheme A, step b Scheme A. Step c: 2- [Trans- (4-aminocyclohexyPaminol-6-, 4-. 1 - (2,6-difluorobenzylPl-piperidinylamino-9-cyclopenylpurine Trihydrochloride 2- [Trans- (4-aminociclohexyl) amino]] -6- [4- [1 - (2,6-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (2,6-difluorobenzyl)] piperidinylamino] -9 -cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 525 (M + 1) Rf (min.) = 2.26 Example 147-w 2-.Trans- (4-aminocyclohexyl) amino-2-hydroxychloride -6-.4-f 1 - (3,5- d-chloro benzylpiperidinylamine-9-cyclopentyl I purine Scheme B. stage a: 4-Carboxamide-1 - (3 .5-dichlorobenzyl) piperidine 4-Carboxamide-1- (3,5-dichlorobenzyl) piperidine can be prepared from isonipecotamide and 3,5-dichlorobenzyl chloride (available from Trans World Chemicals or Fluorochem Ltd.) essentially as described above in US Pat. Example 38, Scheme B, step a. Scheme B. stage b: 4-amino-1- (3,5-dichlorobenzyl) piperidine 4-Amino-1- (3,5-dichlorobenzyl) piperidine is prepared from 4-Carboxamide- 1- (3,5-dichlorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A, stage bj 2-Chloro-6-.4-M - (3,5-dichlorobenzyl) lpiperidin-1-amino-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (3,5-dichlorobenzyl )] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3,5-dichlorobenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A , stage b. - Scheme A. stage c: 2-f Trans- (4-aminocyclohexyDaminol-6- [4- [1 - (3, 5-d-chlorobenzyl-1-piperidinylaminol-9-cyclopentylpurine Trihydrochloride 2- [Trans- (4-- aminocyclohexyl) amino] -6- [4- [1 - (3, 5-dichlorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (3,5-dichlorobenzyl)] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, stage c. APCl: 557 (M + 1) Rf (min.) = 2.3 1 Example 147-x 2-.Trans- (4-aminocyclohexyl) amino-1-6-f4- (2,4-dichlorobenzylpiperidinylamine) trihydrochloride -9-cyclopenti I purine Scheme B. stage a: 4-Carboxamide-1 - (2,4-dichlorobenxyl) piperidine 4-Carboxamide-1 - (2,4-dichlorobenzyl) piperidine can be prepared from isonipecotamide and 2,4-dichlorobenzyl chloride (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-amino-1- (2,4-dichlorobenzydiperidine 4-Amino-1 - (2, 4-dichlorobenzyl) piperidine is prepared from 4-carboxamide-1- (2,4-dichlorobenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Scheme A, step bj 2-Chloro-6-. 4-M - (2,4-dichlorobenzyl piperid i nor the minol-9-cyclopentyl purine 2-Chloro-6- [4- [1- (2,4-dichlorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from , 6-dichloro-9-cyclopentylpurine, 4-amino-1- (2,4-dichlorobenzyl) piperidine, and triethylamine As described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-.Trans- (4-aminocyclohexyl) amnol-6- [4-f 1 - (2,4-dichlorobenzyl) -1-piperidinylamine-1-9-cyclopentylpurine trihydrochloride Trihydrochloride 2- [Trans- (4-aminocyclohexyl) amino] -6- [4- [1- (2,4-dichlorobenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1 - (2 , 4-dichlorobenzyl)] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. APCl: 557 (M + 1) Rf (min.) = 2.31 Example 147-v 2-.Trans- (4-aminocyclohexyPamino1-6-f4-.1 - (3-chloro-4-methylbenzyl) lpiperidinylamide trihydrochloride no1-9-cyclopentylpurine Scheme B, step a: 4-Carboxamide-1 - (3-chloro-4-methylbenzyl) piperidine 4-Carboxamide-1 - (3-chloro-4-methylbenzyl) piperidine can be prepared from isonipecotamide and chloride 3-Chloro-4-methylbenzyl (available from Pfaltz-Bauer) essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-amino-1- (3-Chloro-4-methylbenzyl) ) piperidin 4-Amino-1 - (3-chloro-4-methylbenzyl) piperidine is prepared from 4-carboxamide-1- (3-chloro) -4-methylbenzyl) piperidine essentially as described above in Example 38, Scheme B, stage b. Scheme A, stage b 2-Chloro-6-f4-p - (3-Chloro-4-methylbenzyl) piperidinyl-minol-9-cyclopentyl-puss 2-Chloro-6- [4- [1 - (3-Chloro-4 -methylbenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-chloro-4-methylbenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A, step CJ trihydrochloride 2-f Trans- (4-aminociclohexiPaminol-6-.4-. 1 - (3-chloro-4-methylbenzyl) lpiperidinylaminol-9-cyclopenti I purine Trihydrochloride of 2 - [Trans- (4-aminocyclohexyl) amino] -6- [4- [1- (3-chloro-4-methylbenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6-_4- [ 1- (3-Chloro-4-methylbenzyl)] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 537 (M + 1) Rf- (min.) = 2.25 Example 147-z 2-f Trans- (4-aminociclohexyl) aminol-6-f4-f1 - (4-trifluoromethoxybenzylPlpiperidinylaminol-9-cyclopentylpurine trihydrochloride Scheme B. step aj 4-Carboxamide-1 - (4-trifluoromethoxybenzylpiperidine 4-Carboxamide-1- (4-trifluoromethoxybenzyl) piperidine can be prepared from isonipecotamide and 4- (trifluoromethoxy) benzyl bromide (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a.Scheme B. step b: 4-amino-1- (4-trifluoromethoxybenzyl) piperidine 4-Amino-1- (4-trifluoromethoxybenzyl) piperidine is prepared from -carboxa mida- 1 - (4-trif-1-uoromethoxybenzyl) piperidine essentially as described above in Example 38, Scheme B, step b Scheme A, step bj 2-Chloro-6-.4-M - (4- trifluorometboxi be nciPlpiperid inilam i nol-9-cyclopentyl puss 2-Chloro-6- [4- [1 - (4-trifluoromethoxybenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2,6-dichloro-9-cyclopentylpurine, 4 -amino-1- (4-trifluoromethoxybenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b Scheme A. step c: Trihydrochloride 2- [Trans- (4-ami notion) hexi Daminol-6-.4-i1 - (4-trifluoromethoxy benzyl Pi piperidinthylaminol-9-cyclopenti I purine Trihydrochloride 2- [Trans- (4-aminocyclohexyl) amino] -6- [ 4- [1- (4-trifluoromethoxybenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (4-trifluoromethoxybenzyl)] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step c. APCl: 573 (M + 1) Rf (min.) 2.23 Example 147-aa Trans-2-f Trihydrochloride (4-a mycyclohexylDamino1-6-.4-.1 - (2,4-bis-trif luorometi I benzyPlpiperidinylaminol-9-cyclopenti I purine Scheme B, step a 4-Carboxamide-1 - (2,4-bis-trifluoromethylbenzylpiperidine 4-Ca rboxamide-1 - (2,4-bis-trif Ioromethylbencippiperidine can be prepared from isonipecotamide and bis bromide) (2,4-trifluoromethyl) benzyl (available from Aldrich Chemical Company) essentially as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-amino-1- (2,4-bis-trifluoromethylbenzyl) piperidine 4-Amino-1- (2,4-bis-trifluoromethylbenzyl) piperidine is prepared from 4-carboxamide-1- (2,4-bis-trif-1-uoromethylbenzyl) piperidine essentially as described above in Example 38 , Scheme B, step b Scheme A, step bj 2-Chloro-6-r4-M - (2,4-bis-trif luoromethylbenzyl) lpiperidinylammonol-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (2, 4-bis-trif luorometi I benci I)] piperidinylamino] -9-cyclopentylpurine and prepared from 2,6-dichloro-9-cyclopentylpurine, 4-a-my-1 - (2,4-bis-trifluoromethylbenzyl)] piperidine, and triethylamine essentially as described above in Example 1, Scheme A, stage b. Scheme A. stage c: Trihydrochloride 2- [Trans- (4-aminociclohexiPa mi nol-6-f4-f 1 - (2,4-bis-trif) loromethyl-benzylpiperid-nilaminol-9-cyclopentylpurine 2- [Trans- (4-aminociclohexyl) trihydrochloride ) amino] -6- [4-_1 - (2,4-bis-trifluoromethylbenzyl)] - piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1 - (2, 4-bis -trif luoromethylbenzyl)] piperid ini the mino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 625 (M + 1) Rf (min.) = 1.44 Example 147-ab Trihydrochloride of 2-.Trans- (4-aminociclohex¡l) amino1-6-.4-M - (2-trifluoromethoxy benzyl) 1 piperidinthylaminol-9-cyclopentylpraine Scheme B, step a 4-Carboxamide-1 - ( 2-trifluoromethoxybenzylpiperidine 4-Ca rboxa m ida-1 - (2-trifluoromethoxybenzyl) piperidine can be prepared from isonipecotamide and 2- (trifluoromethoxy) benzyl bromide (available from Fluorochem Ltd.) essentially as described above in Example 38 , Scheme B, stage a.Scheme B. stage b: 4-amino-1 - (2- trifluoromethoxybenzylpiperidine 4-Amino-1- (2-trifluoromethoxybenzyl) piperidine is prepared from 4-ca rboxa m-1 - (2-trifluoromethoxybenzyl) piperidine essentially as described above in Example 38, Scheme B, step b. Scheme A, step bj 2-Chloro-6-.4-M - (2-trifluoromethoxybenzylDlpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1- (2-trylfuoromethoxybenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared of 2, 6-dichloro-9-cyclopentylpurine, 4-amino-1- (2-trifluoromethoxybenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminocyclohexyl) amino1-6-f4-f1 - (2-trifluoromethoxybenzylDlpiperidinylaminol-9-cyclopenanti Trihydrochloride I purine 2- [Trans- (4-aminocyclohexyl) amino] - Trihydrochloride 6- [4- [1 - (2-trifluoromethoxybenzyl)] - piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (2-trifluoromethoxybenzyl)] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 573 (M + 1) Rf (min.) = 2.26 Example 147-ac 2-.Trans-.4-aminocyclohexyDaminol-6-.4- Trihydrochloride ( 1-benzyl) piperidinylmethalaminol-9-cyclopentylpurine N-Benzyl-4- (aminomethyl) piperidine N-Benzyl-4-aminomethylpiperidine is prepared from 4- (aminomethyl) piperidine (available from Aldrich Chemical Company) as described by LG Humber [J. Med. Chem., 9, 441-443 (1 966)] Scheme A, step b: 2-Chloro-6-.4- (1-benzyl) piperidinylmethylamino-1-9-cyclopentylpurine 2-Chloro-6- [4- (1-benzyl) piperidinylmethylamino] -9-cyclopentylpurine is prepared from 2, 6-dichloro-9-cyclopentylpurine, N-benzyl-4-aminomethylpiperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. Scheme A. stage c: 2-f Trans- (4-aminociclohexiPaminol-6-.4- (1-bencíl) piperidinilimethylaminol-9-cyclopentylpurine trihydrochloride 2- [Trans- (4-aminociclohexyl) amino] -6 trihydrochloride - [4- (1-Benzyl) piperidinylmethylamino] -9-cyclopentylpurine is prepared from 2-chloro-6-_4- (1-benzyl) piperidinylmethylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 503 (M + 1) Rf (min.) = 2.24 Example 147-ad 2-.Trans- (4-aminociclohex¡Damino1-6-.4-.1 - (3-Phenoxybenzyl) lpiperidinylamide Trihydrochloride. No1-9- cyclopentylpurine Scheme B. stage a: 4-Carboxamide-1 - (3-phenoxybenzylpiperidine 4-Carboxamide-1- (3-phenoxybenzyl) piperidine can be prepared from isonipecotamide and 3-phenoxybenzyl chloride (available from Lancaster) as described above in Example 38, Scheme B, step a.Scheme B. Step b: 4-amino-1- (3-phenoxybenzylpiperidine 4-Amino-1- (3-phenoxybenzyl) piperidine is prepared from 4-carboxamide- 1- (4-phenoxybenzyl) piperid ina essentially as described above in Example 38, Scheme B, step b. Scheme A. stage b: 2-Chloro-6-.4-f 1 - (3-phenoxybenzyl) Dlpiperidinylaminol-9-cyclopentylpurine 2-Chloro-6- [4- [1 - (3-f-enoxy-benzyl)] piperidinylamino] - 9-cyclopentyl puss is prepared from 2,6-dichloro-9-cyclopentylpurine, 4-amino-1- (3-phenoxybenzyl) piperidine, and triethylamine essentially as described above in Example 1, Scheme A, step b. step c: 2-.Trans- (4-aminocyclohexy-Paminol-6-.4- [1- (3-phenoxybenzyl-piperidinylamino-9-cyclopentylpurine trihydrochloride 2- [Trans- (4-aminociclohexyl) amino] -hydrochloride] 6- [4- [1 - (3-phenoxybenzyl)] piperidinylamino] -9-cyclopentylpurine is prepared from 2-chloro-6- [4- [1- (3-phenoxybenzyl)] piperidinylamino] -9-cyclopentylpurine essentially as described in Example 1, Scheme A, step C. APCl: 581 (M + 1) Rf (min.) = 2.35 The term "neoplastic disease state" as used herein refers to an abnormal condition or condition characterized by uncontrolled proliferation. Oplastics include leukemias, carcinomas and adenocarcinomas, sarcomas, melanomas, and mixed types of neoplasms. Leukemias include, but are not limited to, acute lymphoblastic, chronic lymphocytic, acute myeloblastic, and chronic myelocytic leukemias. Carcinomas and adenocarcinomas include, but are not limited to, those of the cervix, chest, prostate, esophagus, stomach, small intestines, colon, ovaries, and lungs. Sarcomas include, but are not limited to, osteromas, osteosarcoma, lipoma, lipsarcoma, hemangiomas, and hemangiosarcoma. Melanomas include, but are not limited to, amelanotic and melanotic melanomas. Mixed types of neoplasms include, but are not limited to, carcinosarcoma, type of lymphoid tissue, follicular reticulum, cell sarcoma and Hodgkins Disease. The term "therapeutically effective amount" of a compound of a formula (I) refers to an amount that is effective, by the administration of single dose or multiple doses to the patient, to control growth of the neoplasm or metastasis of the neoplasm or to prevent apoptosis. A therapeutically effective amount of a compound of the formula will vary according to the age, weight, type of neoplasm to be treated, the combination of other antineoplastic substances, and other criteria well known to those skilled in the art using a clinical standard and tests. of laboratory and procedures. A therapeutically effective amount of a compound of the formula will vary according to the type of cell susceptible to apoptosis, the site of infarction, as well as age, weight and other criteria well known to those skilled in the art. The term "controlling the growth" of the neoplasm refers to decrease, interrupt, limit, stop the growth of the neoplasm or metastasis of the neoplasm. The term "controlling the growth" of the neoplasm also refers to killing the neoplasm or metastasis of the neoplasm. An effective amount of a compound of the formula is that amount which is effective, for the administration of a multiple or single dose to the patient to provide an antineoplastic effect or to prevent apoptosis. An "antineoplastic effect" refers to the decrease, interruption, prevention, or destruction of the additional growth of neoplastic cells. An effective antineoplastic amount of a compound of the formula can be readily determined by a skilled diagnostician, as one skilled in the art, by the use of known techniques and by observing the results obtained under analogous circumstances. To determine the effective amount, a number of factors are considered by the expert in making diagnoses, including but not limited to, mammalian species; its size, age and general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound of the formula administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose of the selected regimen; the use of concomitant medication; and other relevant circumstances.

A further embodiment of the present invention includes a method for the prophylactic treatment of a patient at risk of developing a neoplastic disease state comprising administering a prophylactically effective antineoplastic amount of a compound of the formula. The term "a patient at risk of developing a neoplastic disease state" refers to the patient, who, due to a genetic predisposition identified to neoplasms, had or currently has neoplasms, exposure of carcinogenic substances, diet, age or other factors of risk associated with the development of the neoplastic disease state. Preferred patients at risk of developing a neoplastic disease state include patients who are positive for oncogenic viruses are in remittance of a previous treatment of neoplasm (s), use of tobacco products or have previously been exposed to carcinogens such as asbestos, or They are positive for various neoplastic genetic references. Oncogenic viruses are those associated with cancer. For example, chicken Rous sarcoma, rabbit Shope papilloma, murine leukemia virus are animal viruses recognized to have a role in the development of various cancers. The human papillomavirus is associated with genital cancer. Molluscum contagiosum virus is associated with contagious molluscum tumors. The JC virus, a human papovirus, is associated with disorders of the reticulendothelial system such as leukemia and lymphoma. Human retroviruses such as T-cell lymphotropic viruses (HTLV) types 1 and 2 are associated with some human leukemias and lymphomas. Human immunodeficiency virus (HIV) types 1 and 2 are the cause of AIDS. The Epstein-Barr virus has been associated with several malignancies, including nasopharyngeal carnicoma, African Burkitt's lymphoma and lymphomas in immunosuppressed organ transplant recipients. Genetic references such as mutations, rearrangements and the like in BRCA 1, bcl-1 / PRAD1, cyclin D1 / CCND1, p16, cdk4, especially an Arg24Cys mutation, p16INK4a. Genetic references are associated with predispositions to several neoplasms. For example, alterations in the BRCA 1 gene are associated with a high risk for breast and ovarian cancer. Other genetic references include alterations in the MMSC1 gene, which interacts with the gene for prostate cancer and brain MMCAI, in the CtlP gene, which is linked to the BRACA1 gene in breast and ovarian cancer, binds to the BRCA1 gene and binds to the oncogenic access path E1 A, and in the MKK3 gene, which is a cell cycle control gene that acts as a suppressor tumor in lung cancer by the activation of apoptosis. Patients at risk of developing a neoplastic disease state include patients who overexpress several cell-cycle proteins, including cdk4, B1 and E. cilclins. Patients at risk of developing a neoplastic disease state include those with high levels of tumor references . Known tumor references include prostate-specific antigen (PSA) and factor-1 growth factor-1 (IGF-1) as plasma insulin, both of which are references for prostate cancer. Nuclear matrix proteins (NMPs) are associated with the presence of cancer, particularly gallbladder and colon cancer. It is expected that an effective amount of a compound of the formula ranged from about 25 nonograms per kilograms of body weight per day (ng / kg / day) to about 500 mg / kg / day. Preferred effective amounts of a compound of the formula are from about 1 μg / kg / day to about 500 μg / kg / day. A more preferred amount of a compound of the formula is from about 1 μg / kg / day to about 50 μg / kg / day. A compound of the formula can be administered in any form or mode that makes the compound viable in effective amounts. The compounds of the formula can be administered orally or parentally. The compounds of the formula can be administered orally, subcutaneous, intramuscular, intravenous, transdermal, intranasal, rectal, ocularly and as desired. Oral administration is preferred. An expert in the field of the preparation of pharmaceutical formulas can easily determine appropriate forms of a compound of the formula by determining the particular characteristics of the compound, the disease to be treated, the progression of the disease, the response to other patients and other circumstances. Relevant A compound of the formula can be combined with carriers, excipients and other compounds to prepare compositions of a compound of the formula. A composition of the formula comprises a compound of the formula in admixture or otherwise in association with one more inert carriers. The compositions of the formula are useful, for example, as convenient for making volume loading, or for preservation, of a compound of the formula. An inert carrier is a material that does not degrade or otherwise react covalently with a compound of the formula. An inert vehicle can be solid, semi-solid or liquid material. Preferred vehicles are water, aqueous regulators, organic solvents and pharmaceutically acceptable excipients or vehicles. Preferred aqueous regulators provide a range of regulation in which a compound of the formula is not degraded. The preferred regulation ranges are from about pH4 to about pH9. The preferred organic solvents are acetonitrile, ethyl acetate, hexane. A pharmaceutical composition of a compound of the formula comprises a compound of the formula in admixture or otherwise in association with one or more pharmaceutically acceptable excipient (s) or carrier (s). A pharmaceutically acceptable excipient or carrier can be a solid, semi-solid or liquid material that can serve as a vehicle or medium for the compound of the formula. Suitable pharmaceutically acceptable excipients or vehicles are better known to those skilled in the art.

A pharmaceutical composition of a compound of the formula can be adapted for the route of administration. A pharmaceutically preferred composition of a compound of the formula is a tablet, lozenge, capsule, elixir, syrup, wafer, chewing gum, suppository, solution or suspension if the route of administration is oral, parental or typical. An oral, preferred pharmaceutical composition of a compound of the formula comprises a compound of the formula with an inert diluent or with an edible carrier. Preferred forms for oral pharmaceutical compositions of a compound of the formula are tablets, lozenges, capsules, elixirs, syrups, wafers, chewing gum, solutions or suspensions. Preferred pharmaceutical compositions of a compound of the formula contain about 4% a approximately - 80% of the compound. Preferred pharmaceutical compositions contain an amount of the compound of the formula from about 50 μg to about 500 μg; the most preferred pharmaceutical composition contains an amount of the compound of the formula from about 1 μg to about 200 μg. A compound of the formula can be administered alone or in the form of a pharmaceutical composition in combination with pharmaceutically acceptable excipients or vehicles. The following abbreviations are used in this: mg, milligram; μg, microgram; ? g, nanogram; TEA, triethyl amine; mmol, millimole: mL, milliliter; C, Celsius; hr, hour; TLC, thin layer chromotography; CH2CL2, methylene chloride; MeOH, methanol; EtOH, ethanol; N, Normal; HCl, hydrogen chloride; TFA, trifluoroacetic acid, DIEA, disopropylethylamine; RT PCR, polymerase chain reaction of opposite transcription; HEPES, 4-2 (-hidoxyethyl-1-pentaperazine, ethanesulfonic acid); MgCl 2, magnesium chloride; EGTA, ethylene glycol bis (β-aminoethylether) -N, N, N ', N'-tetraacetic acid; EDTA, ethylenediaminetetraacetic acid; DTT, dithiothreitol; MOI, multiplicity of infection; NaF, Sodium Fluoride; BSA, bovine serum albumin; p.o. , oral (mind) iv. , intravenous (mind); s.c. , subcutaneous (mind). EXAMPLE 148 Analysis of cyclin-dependent kinase 4 The IC5_ values for the inhibition of cdk-4 were by the following method: Substrate: Glutathione S-transferase- retinoblastoma fusion protein (GST-Rb) (Kaelin, WG, Jr., et. al .., CeM 64: 521-532, 1 991) was obtained from Dr. William Kaelin. GST-Rb was prepared by the transformation of E. coli with the plasmid pGEX-Rb (379-928). The transformed bacteria grew overnight at saturation, then diluted in YT broth and incubated at 37 ° C for 2 h. The protein was induced by incubation with 0.1 mM isopropyl thioglicoside for 3 h. After sedimentation by centrifugation, the cells were dissolved by sonication in STE buffer (0.1 mM NaCl, 10 mM Tris, pH 8.0, 1 Mm EDTA) containing 1 0% sarcosil. The particulate matter was moved by centrifugation and the lysate was incubated with clutationa-sepharose at 4 ° C. The beads were washed with kinase regulator and then the quantification of the Coomassie blue colored proteins separated by SDS-PAGE was changed by the use of a standard protein of known concentration. Expression of CDK4 / Cyclin D1 in insect cells: Human cyclin-dependent kinase 4 (cdk4) was cloned by RT PCR using degenerate primaries based on the published amino acid sequence (Matsushime, H, et al., Cell, 71: 323-334, 1992). The cDNA for human cyclin D1 was cloned by RT PCR using genomic DNA from MCF-7 cells. The sequence was consistent with the published sequence (Xiong, Y., et al., Cell 65: 691, 699, 1991). Both, the cDk-4 and cyclin D1 cDNAs were cloned into pFastBac (Life Technologies) and recombinant Bacmid DNA containing cDNAs was produced by site-specific transposition using the Bac-a-Bac Baculovirus expression system acquired from Life Technologies ( catalog # 10359-016). The Bacmidoo DNA was used to transfer Sf9 insect cells to produce recombinant virus. After the plaque purification of the virus, viral preparations were expanded until high concentrations of grafts were reached. The optimal co-expression of the recombinant proteins was determined to be achieved with an MOI of 0.1 for both, cdk4 and cyclin D1 in 72h after infection.

The lysates are prepared by lysis of Sf9 cells coinfected with cdk4 and cyclin D1 in 50 mH HEPES, pH 7.5, 1 mM MgCl2, 1 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride, 5 μg / ml aprotinin, and 5 μg / ml leupeptin using a PARR pump under nitrogen pressure 500 ps i for 5 min. at 4 ° C. The insoluble material is sedimented at 10,000 x g for 20 min at 4 ° C. The glycerol was added to the supernatant at 10% and stored at -80 ° C in aliquots. Kinase Analysis: Pre-wetted Miltipore Multiscreen 96-well filter plates (0.65 μm Durapore Filters) with 200 μl kinase buffer (50 mH HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA). GST-Rb (0.5 μg) bound to glutathione-Sepharose beads is added in 50 μg per well and the solution is eliminated by the application of vacuum. The analysis contains 50 mH HEPES, pH 7.5, 10 mM MgCl2, 1 mM EDTA, 1 mM DTT, 1 mM EGTA, 1 0 mM ß-glycerophosphate, 0.1 mM sodium orthovanadate, 0.1 mM NaF, 0.25% BSA, 10 μM ATP and 0.25 μCi of [? 33P] -ATP. 0.1 μg cdk4 / cyclin D1 (insect cell lysate) is added to start the analysis. Incubate 30 min at 37 ° C. The reaction is terminated by filtration in Millipore Vacumm Manifold. Wash four times with TNEN (20 mM Tris, pH 8.0, 1 00 mM NaCl, 1 mM EDTA, 0.5% nonideto P-40). After the plates were dried at room temperature, the filter plates were placed on adapter plates (Packard) and 40 μl of Microscint-O® (Packard) was added to each well. A Superior Seal A film was used to cover the plates before being counted in a Superior Counter Scintillation Counter. The results are given in Table 1. EXAMPLE 149 cdk-2 Inhibition Studies The IC5o values for inhibition of CDK-2 were determined by the following method: Cyclin-dependent Kinase-2 Assay Substrate: GST-Rb as described above for cdk4 / cyclin D1 Expression of CDK2 / Cyclin E in Insect cells: Recombinant baculoviruses for human cdk2 and cyclin E were obtained from Dr. David Morgan at UC, Berkeley (Desai, D. et al., Molec., Bio. Cell, 3: 571-582, 1992). Optimum coexpression in insect cells was obtained in MOI's of 0.1 and 1.0 for cdk2 and cyclin E, respectively, in 72 h after infection. Kinase Analysis: The analysis conditions for cdk2 / cyclin E were identical to those for cdk4 / cyclin D1 including the substrate. The concentration of recombinant cdk2 / cyclin E in the analysis was 0.1 μg per 1 00 μl of analysis. Incubation was for 30 min at 30 ° C. The results are given in Table 1. Example 1 Analysis Method Cdk7 / Cyclin H Substrate: Peptide Substrate H. N-RRR (YSPTSPS) ¿-COOH based on the CTD sequence of RNA polymerase II. Expression of CDK7 / Cyclin H in insect cells: The human cdk7 was cloned by the reverse transcription PCR. The sequence was consistent with that reported by Tassan, J. P., ef al. , J. Cell Biol. 127: 467-478, 1 994 and Darbon, J. M. ef al. Oncogene, 9: 3127-3138, 1994. The cDNA for cyclin H was also cloned by reverse transcription PCR and the sequence was consistent with that reported by Fisher & Morgan, Cell, 78: 71 3-724, 1 994. Recombinant Bacmido DNA and viral groups were prepared as described above for cdk4 and cyclin D1. Optimum coexpression was achieved in MOI's of 1 and 2 for cdk7 and cyclin H, respectively 48 h after infection. Kinase Analysis: The assay measures the phosphorylation of a peptide substrate (based on the C-terminus domain of RNA polymerase II) by cyclin-dependent kinase 7, which was activated by cyclin H. [? 33P] -phosphate transmitted from [? 33P] -ATP to the peptide substrate by the enzyme. The analysis is run on 96-well V-bottom plates, after completion the reaction was transferred to 96-well phosphocellulose filter plates of Miltipore Multiscreen. The peptide was retained on the phosphocellulose membrane after being washed with a phosphoric acid solution. Method: The analysis of the enzyme is carried out in 96-well V-bottom plates with a total volume of 100 μl. The analysis contains 15 μM ATP, 0.5 μCi [? 33P] -ATP, 50 mH Hepes, pH 7.5, 10 mM MgCl2, 1 Mm EDTA, 1 mM DTT, 1 0 mM ß-glycerophosphate, 0.1 mM sodium orthovanadate, 0.1 mM NaF, 1 0 μM substrate of peptide. To start the analysis, 0.125 ng of cdk7 and cyclin H (lysate of the insect cell) are added. The incubation is for 5 min at 24 ° C. The reaction is terminated by the addition of cold 40 μl of 300 mM phosphoric acid to each sample. The contents of the V-bottom cavities were then transferred to 96-well Millipore phosphocellulose filter plates. After stirring for 15 min at room temperature, the vacuum was applied to the filter plate and the wells were washed 4 x with cold 100 μl of 75 mM phosphoric acid. After the removal of the subdired installation, the filters are completely dried, placed in Multiscreen microplate adapters, and 40 μl of Micro-Scint O was added to each cavity. The plates were covered with Superior Seal A film and counted for 1.5 minutes using a Packard Superior Count Scintillator Counter. The results are given in Table 1. Example 1 51 Analysis Procedure CDK1 / Cyclin Bf33Pl Substrate: The analysis is used as a biotinylated peptide substrate (biotin-PKTPKKAKKL) derived from the phosphorylation side p34c c2 in vitro of histone H 1. Expression of CDK1 / Cyclin H in insect cells: The human cdkl was cloned by reverse transcription PCR. The sequence was consistent with that reported by Lee, M. G.

And Nurse, P, Natural, 327: 31-33, 1987. Cyclin H cDNA was also cloned by RT PCR and the sequence was consistent with that reported by Pines, J. And Hunter, T., Cell, 58: 833-846, 1989. Recombinant Bacmido DNA and viral bases were prepared as described above for cdk4 and cyclin D1. Optimal co-expression was achieved at an MOI of 0.1 for both cdkl and cyclin B1, 48 h after infection. Kinase Analysis: the kinase enzyme analysis kit p34c c2 SPA [33P] was purchased from Amersham Life Science (catalog # RPNQ01 70) and the procedure was run as a 96-cavity format analysis as suggested by the manufacturer . Each assay contains 50 mM Tris HCl, pH 8.0, 1.0 mM MgCl2, 0.1 mM Na3VO4 (sodium orthovanadate), 0.5 uM ATP, 0.2 μCi33P-ATP, 2 μM DTT and 0.75 uM biotinylated peptide and 3 μg cdkl / cyclin B lysate of insect cell in a total assay volume of 100 μl. The incubation was for 30 min at 30 ° C. The reaction was terminated by the addition of 200 uL of stop buffer (50 uM ATP, 5 mM EDTA, 0.1% v / v) Triton X-1 00 in phosphate buffered saline) , / streptavidin-coated SPA beads (2.5 mg / ml). The plate was left at room temperature overnight then covered with a Superior Packard Seal and counted in a Superior Packard Counter. The IC50 value was determined by fitting the data in a sigmodial curve using GraphPad Prism software. Example 1 In Vitro In Vitro Inhibition In Vitro Proliferation Analysis: The proliferation of tumor cells was measured using an analysis of sulforhodamine B as described in Skehan, P., et al. , J. Natl. Cancer Inst. 82: 1 107-1 1 12, 1990. Tumor cells are harvested with trypsin-EDTA, cells that excluded blue typing were counted, added to 96-well plates and incubated overnight at 37 ° C. The medicine was added to the cavities after dilution in the culture medium. Three days later, the medium was removed and supplied with the medium containing fresh medicine and incubated for 4 more days. The cells were then fixed with 0.1 ml 1 0% trichloroacetic acid for 60 min at 4o C. Plates were rinsed five times with tap water, air dried and stained for 30 min with 0.4% sulforhodamine B in 1% acid. acetic and air-dried. A bound dye was solubilized with 0.1 ml 10 mM Tris (pH 1 0.5) for 5 min and the absorbance was measured at 490 nm using a Titertek Multiscan MCC / 340 plate reader .. Alternatively, the analysis of CyQUANT cell proliferation it was used to quantify the proliferation of the cell. Proliferation Analysis of the CyQUANT Cell: Alternatively, the CyQUANT cell proliferation assay was used to quantify the proliferation of tumor cells. The tumor cells were harvested with trypsin-EDTA, the cells that excluded trypan blue were counted, added to 96-well plates and incubated overnight at 37 ° C. The medicine was added to the cavities after dilution in the culture medium.

Three days later the medium was removed and the plates were frozen at -80 ° C for at least 30 minutes. After thawing the plates, 200 μL of CyQUANT-GR in Cell Lysis Regulator (Molecular Probes # C-7026) was added to each well and incubated for 3-5 minutes at room temperature. The Fluorescence of CyQUANT-GR was measured in a microwell reader of Fluorescence Fmax Molecular mechanisms (excitation 458 nm, emission 530 nm). Cell Lines: MCF7: human breast adenocarcinoma; hormone-dependent; MDA-MB-231: adenocarcinoma of the human breast; hormone-independent; HT-29; human colon adenocarcinoma; of grade II moderately well differentiated; HCT-1 5: human colon adenocarcinoma; A549: human non-small cell lung carcinoma; DMS-1 14: human small cell lung carcinoma; PC-3; human prostate adenocarcinoma, hormone-independent; and DU 145: human prostate carcinoma, hormone-independent; All cell lines were obtained from the American Type Tissue Collection, with the access number ATCC in parentheses. The MCF-7, MDA-MB-435 and MDA-MB-231 cells grew in an improvised minimal essential medium (Biofluids) without phenol red, they were supplemented with 5% fecal bovine serum, 0.01 mg / ml gentamicin and 3 mM L-glutamine. All other cell lines grown in RPMI 1640 medium (Life Techologies) were supplemented with 5% faecal bovine serum 0.01 mg / ml gentamicin and 3 mM L-glutamine. The results are given in Table 1.

© O © O - • - * - * "• 341 _ ______________

Claims (10)

1. CLAIMS 1. A compound of the formula wherein R is selected from the group consisting of R2, R2NH-, or R3R4N-R5- wherein R2 is selected from the group consisting of C9-C12 alkyl, wherein each R6 is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C?-C4 alkyl and phenyl (CH2) m, wherein m is an integer 0-8; x is an integer 1 -8; n is an integer 0-8; Z is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene; and M is selected from the group consisting of hydrogen, C? -C alkyl) wherein each R6 'is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m'-phenyl, wherein m' is an integer 0-8; n 'is an integer 0-8; x ' -_______________! ____. is an integer 1 -8; Q is hydrogen or C? -C alkyl; and Z 'is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene; and wherein each C9-C? _ or Z alkyl is optionally substituted with 1 to 3 substitutes, which may be the same or different, and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocyl, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m - phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C1-C4 alkyl, * t wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C alkyl and (CH2) m -phenyl, wherein m'" is an integer 0- 8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C1-C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m "-phenyl, wherein m" "is an integer 0-8; x "" is an integer 1 -8; Q "is hydrogen or C? -C alkyl; each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E 'is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; R3 and R4 are selected from the group consisting of hydrogen, C? -C4 alkyl and (CH2) y-phenyl, wherein y is an integer 0-8, with the proviso that R3 and R4 are not both hydrogen; R5 is C? -C8 alkylene; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl and the pharmaceutically acceptable salts, optical isomers and hydrates thereof, with the proviso that, when R2 is the group P6 P) n- R6 where n is 1 or greater; R1 is isopropyl or cyclopentyl; R6 is hydrogen, C? -C alkyl or (CH2) m-phenyl; and Z is phenyl, heterocycle or cycloalkyl, that Z is substituted with 1 to 3 substitutes, which may be the same or different, and which are selected from the group consisting of D, - ((W- S- R6 * - (C)? - N-rV wherein D, b, R6", x", n ", M 'and Z' are as previously defined 2. A compound according to claim 1 characterized in that it is wherein R is R 2, wherein R 2 is C 1 -C 6 alkyl, which may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E , (O) b B "R" e "T l ß I - < C) x- -SR. * (C)? - N-R6" Re "R_" wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C?-C alkoxy; each E is independently selected from the group consisting of Hal, OH and C? -C8 alkyl; b is an integer 0-2; each R6"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m-phenyl, wherein m" is an integer 0-8; x "is an integer 1 -8; n" is an integer 0-8; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, - (C)? - OQ 'and - (vQn'-i- Z "' Re" "V where each R6 '" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C-alkyl ? -C and (CH2) m-phenyl, where m '"is an integer 0-8, n'" is an integer 0-8, x '"is an integer 1 -8, Q' is hydrogen or alkyl C C4; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can be optionally substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and (CH2) m -phenyl, wherein m "" is an integer 0-8; x "" is an integer 1 -8; Q "is hydrogen or alkyl each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy, each E' is independently selected from the group consisting of Hal, OH and Ci-C8 alkyl: R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof 3. A compound according to claim 2, characterized in that R2 is Cn alkyl -C? 2. A compound according to claim 3, characterized in that R2 is C? 2 alkyl 5. A compound according to claim 4, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -dihydrochloride. 6- (dodecylamino) -9-cyclopentylpurine 6. A compound according to claim 1, characterized in that it is wherein R is R2, wherein R2 is wherein each R6 is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl and (CH2) m-phenyl, wherein m is an integer 0-8; x is an integer 1 -8; and M is selected from the group consisting of hydrogen, Ci-C4 alkyl, wherein each R6 'is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl and (CH2) m-phenyl, wherein m' is an integer 0-8; n 'is an integer 0-8; x 'is an integer 1 -8; Q is hydrogen or C1-C4 alkyl; and Z 'is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 7. A compound according to claim 6, characterized in that M is hydrogen. 8. A compound according to claim 6, characterized in that M is C1-C alkyl. 9. A compound according to claim 8, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- (2-methoxyethylamino) -9-cyclopentyl I purine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- (3-methoxypropylamino) -9-cyclopentylpurine dihydrochloride; or 2- [trans- (4-aminocyclohexyl) amino] -6- (4-methoxybutylamino) -9-cyclopentylpurine dihydrochloride. 10. A compound according to claim 6, characterized in that M is the group wherein R6 ', x' and Q are as defined in claim 6. 1 1. A compound according to claim 10, characterized in that Q is hydrogen. 12. A compound according to claim 1, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- (2-hydroxyethoxyethylamino) -9-cyclopentylpurine dihydrochloride. 3. A compound according to claim 10, characterized in that Q is C 1 -C 4 alkyl. 14. A compound according to claim 1, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [3- (2-methoxyethoxy) propylamino] -9-cyclopentylpurine dihydrochloride. 15. A compound according to claim 6, characterized in that M is the group I - (C) n: Z '"V wherein R6', n 'and Z' are as defined in claim 6. 16. A compound according to claim 1, characterized in that R is R2, wherein R2 is wherein each R6 is independently selected from the group consisting of hydrogen, C-C8 cycloalkyl, C? -C alkyl and (CH2) m-phenyl, wherein m is an integer 0-8; n is an integer 0-8; and Z is naphthalene, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C -CS alkyl; b is an integer 0-2; each R6"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m -phenyl, wherein m" is an integer 0-8; x "is an integer 1 -8; n" is an integer 0-8; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, and M 'is selected from the group consisting of hydrogen, C1-C alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C alkyl and (CH2) m-phenyl, wherein m"' is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m? - phenyl, where m "" is an integer 0-8; x "" is an integer 1 -8; Q "is hydrogen or C? -C alkyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C alkoxy, each E' is independently selected from the group consisting of in Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 7. A compound according to claim 16, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6 - [(1-naphthyl) methylamino] -9-cyclopentylpurine dihydrochloride 18. A compound according to claim 1, characterized in that R is R2, wherein R2 is Z, wherein Z is phenyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is selected independently from the group which consists of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; each R6"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C?-C4 alkyl and (CH2) m-phenyl, wherein m" is an integer 0-8; x "is an integer 1 -8; n" is an integer 0-8; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, and M 'is selected from the group consisting of hydrogen, C? -C alkyl, - (C) xu, ~ OQ, and - < Q) n- Z "'F and v wherein each R6'" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m -phenyl, wherein '"is an integer 0-8; n'" is an integer 0-8; x '"is an integer 1 -8, Q' is hydrogen or C 1 -C alkyl, and Z '" is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z "can optionally be replaced with groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl, and (CH2) m- phenyl, where m "" is an integer 0-8; x "" is an integer 1 -8; Q "is hydrogen or C? -C alkyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C alkoxy, each E' is independently selected from the group consisting of in Hal, OH, and C? -C? alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 9. A compound according to claim 1 8, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- (phenylamino) -9-cyclopentyl I purine dihydrochloride 20. A compound according to claim 18, characterized in that Z is substituted with the group D. A compound according to claim 20, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6 - [(4-trifluoromethoxy) phenylamino] -9-cyclopentylpurine dihydrochloride 22. A compound according to claim 18, characterized in that Z is replaced with the group or E. 23. A compound according to claim 22, characterized in that E is Hal. 24. A compound according to claim 23, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- (3-fluorophenylamino) -9-cyclopentylpurine dihydrochloride. 25. A compound according to claim 22, characterized in that E is C? -C8 alkyl. 26. A compound according to claim 25, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6 - [(4-pentyl) phenylamino] -9-cyclopentylpurine dihydrochloride. 27. A compound according to claim 1, characterized in that R is R2, R2 is R6 wherein each R6 is independently hydrogen or Cs-Cs cycloalkyl, with the proviso that at least one of R6 is C3-C8 cycloalkyl; n is an integer 1 -8; and Z is phenyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, D "R" I 6 i 6 - (C) x * - OM 'and - (C) n3 - Z "R6 ° Rβ" wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 4 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; each R6"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C?-C4 alkyl and (CH2) m-phenyl, wherein m" is an integer 0-8; x "is an integer 1 -8; n" is an integer 0-8; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m-phenyl, wherein m"' is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R 6"" is independently selected from the group consisting of hydrogen, C 3 -C 8 cycloalkyl, C 1 -C 4 alkyl 10 and (CH2) m -femlo, where m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C 1 -C 4 alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy, each E' is independently selected from the group consisting of Hal, OH, and CT-C alkyl.; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 28. A compound according to claim 27, characterized in that it is (+/-) - 2- [trans- (4-aminocyclohexyl) amino] -6 - [(α-cyclopropyl-4-chlorobenzyl) amino] -9- dihydrochloride. - cyclopentylpurine. 29. A compound according to claim 1, characterized in that R is R2, R2 is 25 ! ______. R6 (C) n2 R6 wherein each R6 is independently selected from the group consisting of hydrogen, C? -C4 alkyl, and (CH2) m-phenyl, wherein m is an integer 0-8; n is an integer 1 -8; and Z is phenyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, - wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C?-C alkoxy; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m - phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C? -C alkyl, wherein each R6"'is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m-phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, alkyl, and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C alkoxy, each E' is independently selected from the group which consists of Hal, OH, and alkyl and R1 is selected from the group consisting of cyclopentyl and isopropyl and the pharmaceutically acceptable salts, optical isomers and hydrates thereof 30. A compound according to claim 29, characterized in that Z is replaces with the group D. 31. A compound according to claim 30, characterized in that D is trifluoromethyl. 32. A compound according to claim 31, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6 - [(4-trifluorobenzyl) amino] -9-cyclopentylpurine dihydrochloride or 2- [trans- (4-) dihydrochloride] aminocyclohexyl) amino] -6 - [(2-trifluorobenzyl) amino] -9-cyclopentyl purine. 33. A compound according to claim 30, characterized in that D is C? -C alkoxy. 34. A compound according to claim 33, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- (3,4,5-trimethoxybenzylamino) -9-cyclopentylpurine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6 - [(2,6-dimethoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6 - [(4-methoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6 - [(2-methoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6 - [(2,3-dimethoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [2- (4-methoxyphenyl) ethylamino] -9-cyclopentylpurine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6 - [(2,4-dimethoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6 - [(3,4-dimethoxybenzyl) amino] -9- (2-propyl) purine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [2- (3-methoxyphenyl) ethylamino] -9-cyclopentylpurine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6 - [(3,5-dimethoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6 - [(2,3-dimethoxybenzyl) amino] -9- (2-propyl) purine dihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [3,4-dimethoxybenzyl) amino] -9-cyclopentylpurine dihydrochloride; or 2- [trans- (4-aminocyclohexyl) amino] -6- (4-methoxybenzyl) amino] -9- (2-propyl) purine dihydrochloride. 35. A compound according to claim 1, characterized in that R is R2, R2 is R6 (C) rv R6 wherein each R6 is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) n-phenyl; n is an integer 0-8; and Z is phenyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C1-C alkoxy; each E is independently selected from the group consisting of Hal, OH and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C1-C alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C-C4 alkyl and (CH2) m-phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"it 10 selects from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M 'and Z "can optionally be substituted with the groups D', E 'or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-20 8; Q "is hydrogen or C1-C alkyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C?-C4 alkoxy, each E' is independently selected from the group consisting of Hal, OH, and alkyl dCS, and R1 is cyclopentyl and pharmaceutically acceptable salts, 25 optical isomers and hydrates thereof. Müll _______? 36. A compound according to claim 35, characterized in that Z is replaced with the group E. 37. A compound according to claim 36, characterized in that E is Hal. 38. A compound according to claim 37, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6 - [(3-iodobenzyl) amino] -9- (2-cyclopentenyl) purine hydrochloride. 39. A compound according to claim 1, characterized in that R is R2, wherein R2 is Z, wherein Z is heterocycle, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are they select from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R6"'is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C-C alkyl and (CH2) m" -phenyl, wherein m "' is an integer 0-8; n '"is an integer 0-8; x '"is an integer 1 -8, Q' is hydrogen or C 1 -C 4 alkyl, and Z '" is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z "can optionally be replaced with groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C4 alkyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C4 alkoxy, each E' being independently selected from the group consists of Hal, OH, and CrC8 alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 40. A compound according to claim 39, characterized because Z is piperidine 41. A compound according to claim 40, characterized in that Z is replaced with group D. 42. A compound according to claim 40, characterized in that Z is substituted with the group E. 43. A compound according to the claim 42, characterized in that E is C?-C8 alkyl, 44. A compound according to claim 43, characterized in that it is 2- [trans- (4-aminociclohexyl) amino] -6- [4- (1-propyl) piperidinylamino) - 9-Cyclopentylpurine; 2- [t rans- (4-aminocyclohexyl) amino] -6- [4- (1-butyl) piperidinylamino) -9-cyclopentylpurine; or 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1-allyl) piperidinylamino) -9-cyclopentylpurine. 45. A compound according to claim 40, characterized in that Z is replaced with the group wherein R6", x" and b are as defined in claim 39. 46. A compound according to claim 45, characterized in that B is 0. 47. A compound according to claim 46, characterized in that it is 2- [trans- ( 4-aminocyclohexyl) amino] -6- [4- (1 - (2-thiomethoxyethy I) piperidinthylamino] -9-cyclopentyl pyrimine 48. A compound according to claim 45, characterized in that b is 1. 49. A compound according to Claim 48, Characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-phenylsulfinyl) ethyl) piperidinylamino] -9-cyclopentyl I purine. 50. A compound according to claim 40, characterized in that Z is replaced with the group wherein R6"and x" are as defined in claim 39. 51. A compound according to claim 50, Characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-dimethylaminoethyl)) piperidinylamino] -9-cyclopentyl I purine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-dimethylaminopropyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-25 aminociclohexyl) amino] -6- [4- (1 - (4-N, N- ________________ dimethylaminobutyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-dimethylaminopentyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-diethylaminoethyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-diethylaminopropyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-diethylaminobutyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-diethylaminopentyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-dipropylaminoethyl)) piperidinylamino] -9-cyclopentyl I purine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-dipropylaminopropyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-dipropylaminobutyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-dipropylaminopentyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-dibutylaminoethyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-dibutylaminopropyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-dibutylaminobutyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-dibutylaminopentyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-dibenzyl-amine)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-dibenzylaminopropyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-dibenzylaminobutyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-dibenzylaminopentyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-di- (2-phenylethylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-di- (2-phenylethylene) aminopropyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-di- (2-phenylethylene) aminobutyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-di- (2-phenylethylene) aminopentyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-di- (3-phenylpropylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-di- (3-phenylpropylene) aminopropyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-di- (3-phenylpropylene) to minobutyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-di- (3-phenylpropylene) aminopentyl)) piperidinylamino] -9-cycline pentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-N, N-di- (4-phenylbutylene) aminoethyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-N, N-di- (4-phenylbutylene) aminopropyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-N, N-di- (4-phenylbutylene) aminobutyl)) piperidinylamino] -9-cyclopentylpurine; or 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-N, N-di- (4-phenylbutylene) aminopentyl)) piperidinylamino] -9-cyclopentylpurine. 52. A compound according to claim 40, characterized in that Z is replaced with the group wherein R6", x" and M 'are as defined in claim 39. 53. A compound according to claim 52, characterized in that M 'is hydrogen. 54. A compound according to claim 53, characterized in that x "is 2. 55. A compound according to claim 54, Characterized in that it is (R, S) -2- [trans- (4-aminocyclohexyl) amino] -6- ^ - ~ - "» * - "-. ..... . -. - .. , _... ....... [4- (1 - (2-phenyl-2-hydroxyethyl)) piperidinylamino] -9-cyclopentylpurine. 56. A compound according to claim 53, characterized in that x "is 3. 57. A compound according to claim 56, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - ( 3-hydroxy) propyl) piperidinylamino] -9-cyclopentylpurine 58. A compound according to claim 53, characterized in that x "is 4. 59. A compound according to claim 58, characterized in that it is 2- [trans- (4-aminociclohexyl ) amino] -6- [4- (1 - (4-hydroxy) butyl) piperidinylamino] -9-cyclopentylpurine. 60. A compound according to claim 53, characterized in that x "is 5. 61. A compound according to claim 60, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - ( 62. A compound according to claim 53, characterized in that x "is 6. 63. A compound according to claim 62, characterized in that it is 2- [trans- (4-hydroxypentyl) piperidinyl amine] -9-cyclopentyl pyrimine. -aminocyclohexyl) amino] -6- [4- (1- (6-hydroxy) hexyl) piperidinylamino] -9-cyclopentylpurine 64. A compound according to claim 52, characterized in that M 'is C -C4 alkyl. compound according to claim 64, characterized in that x "is 1. 67. A compound according to claim 64, characterized in that x "is 2. 68. A compound according to claim 65, characterized in that x" is 3. 69. A compound according to claim 68, characterized in that it is 2- [trans- (4- aminocyclohexyl) amino] -6- [4- (1 - (3-methoxy) propyl) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-ethoxy) propyl) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-propoxy) propyl) piperidylamine] -9-cyclopentyl-phenyl; or 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-butoxy) propyl) piperidinylamino] -9-cyclopentylpurine. 70. A compound according to claim 65, characterized in that x "is 4. 71. A compound according to claim 70, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - ( 4-methoxy) butyl) piperidinylamino] -9-cyclopentyl purine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-ethoxy) butyl) piperidinylamino] -9-cyclopentylpurine; - [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-propoxy) butyl) piperidinylamino] -9-cyclopentylpurine; or 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-butoxy) butyl) piperidinylamino] -9-cyclopentylpurine 72. A compound according to claim 65, characterized in that x "is 5. 73. A compound according to claim 72, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-methoxypentyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-ethoxy-pentyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-propoxypentyl)) piperidinylamino] -9-cyclopentylpurine; or 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5-butoxypentyl)) piperidinylamino] -9-cyclopentylpurine. 74. A compound according to claim 65, characterized in that x "is 6.75. A compound according to claim 74, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - ( 6-methoxy) hexyl) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (6-ethoxy) hexyl) piperidinylamino] -9-cyclopentylpurine; [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (6-propoxy) hexyl) piperid inylamino] -9-cyclopentyl-phenyl or 2- [trans- (4-aminociclohexyl) amino] -6- [4- (1 - (6-butoxy) hexyl) piperidinylamino] -9-cyclopentylpurine 76. A compound according to claim 52, characterized in that M 'is a group of the formula wherein R6 '", x'" and Q 'are as defined in claim 39. 77. A compound according to claim 76, characterized in that Q 'is hydrogen. 78. A compound according to claim 77, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2- (2-hydroxyethyleneoxy) ethyl) piperidinylamino] -9-cyclopentylpurine. 79. A compound according to claim 76, characterized in that Q 'is C 1 -C 4 alkyl 80. A compound according to claim 52, characterized in that M' is a group of the formula wherein R6 '", n'" and Z '"are as defined in claim 39. A compound according to claim 80, characterized in that Z'" is phenyl. 82. A compound according to claim 81, characterized in that x "is 2. 83. A compound according to claim 82, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - ( 2-phenoxyethyl)) piperidinylamino] -9-cyclopentylpurine 84. A compound according to claim 81, characterized in that x "is 3. 85. A compound according to claim 84, characterized in that it is 2- [trans- (4-aminociclohexyl) amino] -6- [4- (1 - (3-phenoxypropyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-benzyloxy) propyl) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3- (2-phenylethyleneoxy) propyl) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3- (3-phenylpropyleneoxy) propyl) piperidinylamino] -9-cyclopentyl I purine, or 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3- (4-phenylbutyleneoxy) propyl) piperidinylamino] -9-cyclopentylpurine 86. A compound according to claim 81, characterized in that x "is 4. 87. A compound according to claim 86, characterized in that it is 2- [trans] (4-aminocyclohexyl) amino] -6- [4- (1 - (4-benzyloxy) butyl) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-benzyloxy) propyl) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4- (2-phenylethyleneoxy) butyl) piperidinylamino] -9 -cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4- (3-phenylpropyleneoxy) butyl) piperidinylamino] -9-cyclopentylpurine; or 2- [trans- (4- aminocyclohexyl) amino] -6- [4- (1 - (4- (4-phenylbutyleneoxy) butyl) piperidi nilamino] -9-cyclopentylpurine. 88. A compound according to claim 81, characterized in that x "is 5. 89. A compound according to claim 88, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - ( 5- benzyloxypentyl)) pipepdylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5- (2-phenylethyleneoxy) pentyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (5- (3-phenylpropyleneoxy) pentyl)) piperidinylamino] -9-cyclopentylpurine; or 2- [trans- (4-aminociclohexyl ) amino] -6- [4- (1 - (5- (4-phenylbutyleneoxy) pentyl)) piperidinylamino] -9-cyclopentylpurine 90. A compound according to claim 81, characterized in that x "is 6. 91. A compound according to claim 90, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1- (6-benzyloxy) hexyl) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (6- (2-phenylethyleneoxy) hexyl) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (6- (3-phenylpropyleneoxy) hexyl) piperidinylamino] -9-cyclopentylpurine; or 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (6 - (4-phenylbutyleneoxy) hexyl) piperidinylamino] -9-cyclopentylpurine 92. A compound according to claim 40, characterized in that Z is substituted with the group wherein R6", n" and Z "are as defined in claim 39. 93. A compound according to claim 92, characterized in that Z" is phenyl. 94. A compound according to claim 93, characterized in that n "= 1. 95. A compound according to claim 94, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1-trihydrochloride. -benzyl) piperidinylamino] -9-cyclopentylpurine; (R, S) -2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1-benzyl-3-methyl) piperidinylamino] -9-cyclopentylpurine or (+/-) - 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (a-methylbenzyl)) piperidinylamino] -9-cyclopentylpurine 96. A compound according to claim 93, characterized in that n "= 2. 97. A compound according to claim 96, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1- (2-phenylethyl)) piperidinylamino trihydrochloride. ] -9-cyclopentylpurine 98. A compound according to claim 63, characterized in that Z "is substituted with the group D \ 99. A compound according to claim 98, characterized in that D 'is C1-C alkoxy. 100. A compound according to claim 99, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1- (4-methoxybenzyl)) piperidinylamino] -9-cyclopentyl I purine or 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-methoxybenzyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3,5-dimethoxybenzyl)) piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-methoxybenzyl)) piperidinylamino] -9-cyclopentylpurine trihydrochloride. 1 01. A compound according to claim 98, characterized in that D 'is trifluoromethyl. 1 02. A compound according to claim 1, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1- (4-trifluoromethylbenzyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-trifluoromethylbenzyl)) piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3,5-bis (trifluoromethyl) benzyl)) piperidinylamino] -9-cyclopentyl I purine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (3-trifluoromethyl-benzyl)] piperidinthylamino] -9-cyclopentyl-pyridine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (2,4-bis-trifluoromethyl-benzyl)] piperidinyl-myo] -9-cyclopentyl-pyridine trihydrochloride. 1 03. A compound according to claim 93, characterized in that Z "is substituted with the group E \ 104. A compound according to claim 1, characterized in that E 'is C? -C8 alkyl, 105. A compound according to claim 1 04, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4-methylbenzyl)) piperid inylamide] -9-cyclopentyl I purine, or 2- [trans] (4-aminocyclohexyl) amino] -6- [4- (1 - (2-methylbenzyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [trihydrochloride] 1- (3-methylbenzyl)] piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1- (3-chloro-4-methylbenzyl)] piperidylamine trihydrochloride ] -9-cyclopentylpute 106. A compound according to claim 1, characterized in that E 'is Hal. 107. A compound according to claim 106, characterized in that it is 2- [trans- (4-aminociclohexyl) amino] -6. - [4- (1 - (4-chlorobenzyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminoci) clohexyl) amino] -6- [4- (1 - (3-chlorobenzyl)) piperidimethylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-chlorobenzyl)) piperidinylamino] -9-cyclopentylpurine; or 2- [trans- (4-aminocyclohexyl) to my no] -6- [4- (1 - (2,6-d-chlorobenzyl)) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (2,3-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (2, 5-difluorobenzyl)] piperidinthylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (3,5-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (2,4-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (3-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (2-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1- (4-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1- (4-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1- (3,4-dichlorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (2,5-d-chlorobenzyl)] piperidin-ylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (2-chloro-4-fluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (3,4-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (3,4-difluorobenzyl)] piperidinylamino] -9-cyclopentylpurine trihydrochloride; trihydrochloride 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (3,4-difluorobenzyl)] piperid i or the mino] -9-cyclopentyl I purine; trihydrochloride 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (3,4-difluorobenzyl)] piperidinyl-amino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1 - (3-chloro-4-methyl-benzyl)] piperidinthylamino] -9-cyclopentyl-pyridine trihydrochloride. 108. A compound according to claim 92, characterized in that Z "is heterocycle 1 09. A compound according to claim 1 08, characterized in that Z" is 1,3-benzodioxolyl. 10. A compound according to claim 109, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3,4-methylenedioxybenzyl)) piperidinylamino] -9-cyclopentylpurine. 1 1 1 A compound according to claim 1, characterized in that Z "is pyridinyl 12. A compound according to claim 11, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-pyridin-1-methyl) -piperidin-amylamino] -9-cyclopentyl-pyrimine; 2- [trans- (4-aminociclohexyl) amino] -6- [4- (1 - (3-pyridinylmethyl)) piperidinylamino] - 9- cyclopentylpurine, or 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1- (4-pyridinylmethyl)) piperidinylamino] -9-cyclopentylpurine. 1 3. A compound according to claim 108, characterized in that Z "is isoxazolyl. A compound according to claim 1, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3- (2,4-dimethylisoxazolyl)) methyl) piperidinylamino] -9-cyclopentylpurine. 1 1 5. A compound according to claim 108, "_. characterized in that Z "is tetrahydrofuranyl 16. A compound according to claim 1, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3-tetrahydrofuranyl) methyl) piperidinylamino] -9-cyclopentylpurine 17. A compound according to claim 108, characterized in that Z "is pyrrolidinyl. 1 1 8. A compound according to claim 1 1 7, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2- (1-pyrrolidinyl) ethyl) piperidinylamino] - 9-Cyclopentylpurine or (R, S) -2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2- (3- (1-methyl) pyrrolidinyl) ethyl) piperidinylamino] -9 -cyclopentylpurine 19. A compound according to claim 108, characterized in that Z "is piperidinyl, 120. A compound according to claim 1, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [ 4- (1 - (2- (1-piperidinyl) ethyl)) piperidinyl lamyl] -9-cyclopentyl-phenyl; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3- (1-piperidinyl) propyl)) piperidinylamino] -9-cyclopentylpurine; or (R, S) -2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (3- ( 1-methyl) piperidinyl) methyl) piperidinylamino] -9-cyclopentylpurine A compound according to claim 1 08, characterized in that Z "is morpholinyl, 122. A compound according to claim 121, characterized in that it is 2- [trans - (4-aminocyclohexyl) amino] -6- [4- (1 - (2- (4-morpholinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine. 123. A compound according to claim 108, characterized in that Z "is piperazinyl 124. A compound according to claim 123, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - ( 2- (1- (4-methyl) piperazinyl) ethyl)) piperidinylamino] -9-cyclopentylpurine 125. A compound according to claim 108, characterized in that Z "is benzimidazolinyl. 126. A compound according to claim 1, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-benzimidazolinyl) methyl) piperidinylamino] -9-cyclopentylpurine. 127. A compound according to claim 1, characterized in that Z "is thiazolinyl, 128. A compound according to claim 127, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (4- (2-methyl) thiazolinyl) methyl) piperidinylamino] -9-cyclopentylpurine 129. A compound according to claim 108, characterized in that Z "is thiophenyl. 1 30. A compound according to claim 129, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1 - (2-thiophenyl) methyl) piperidinylamino] -9-cyclopentylpurine. 131 A compound according to claim 92, characterized in that Z "is cycloalkyl 132. A compound according to claim 1 31, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1-cyclopropylmethyl) piperidinylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (1-cyclohexylmethyl) piperidinylamino] -9-cyclopentylpurine trihydrochloride. 1 33. A compound according to claim 39, characterized in that Z is pyrrolidine. 134. A compound according to claim 133, characterized in that Z is replaced with the group wherein R6", n" and Z "are as defined in claim 39. 135. A compound according to claim 1, characterized in that Z" is phenyl. 1 36. A compound according to claim 1, characterized in that it is (R) -2- [trans- (4-aminocyclohexyl) amino] -6- [3- (1-benzyl) pyrrolidinylamino] -9-cyclopentylpurine or (S) ) -2- [trans- (4-aminocyclohexyl) amino] -6- [3- (1-benzyl) pyrrolidinylamino] -9-cyclopentylpurine. 137. A compound according to claim 1, characterized in that R is R2, R2 is R6 (C) rv R6 wherein each R6 is independently selected from the group consisting of hydrogen or C3-C8 cycloalkyl, with the proviso that at least one of R6 is C3-C8 cycloalkyl; n is an integer 1 -8; and Z is heterocycle; wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C?-C alkoxy; each E is independently selected from the group consisting of Hal, OH and alkyl b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C?-C4 alkyl and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. claim 1, characterized in that R is R2, R2 is R6 I (C) n 2 R6 wherein each R6 is independently selected from the group consisting of hydrogen, C? -C4 alkyl and (CH2) n -phenyl where n 'is an integer 1 -8, and Z is a heterocycle, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C1-C alkoxy; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; x" is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C1-C alkyl, wherein each R6' "is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and ( CH2) m -phenyl, wherein m "'is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C4 alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. claim 138, characterized in that Z is replaced with group D. 140. A compound according to claim 139, characterized in that D is C1-C4 alkoxy.141 A compound according to claim 140, characterized in that it is 2- [trans] dihydrochloride - (4-aminocyclohexyl) amino] -6- [3- (5-methoxyindolyl)) - 2-ethylamino] -9-cyclopentylpurine 142. A compound according to claim 1, characterized in that it is R2, R2 is R6 C) n - R6 where each R6 is independently selected by pair from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl and (CH2) n-phenyl; n is an integer 0-8; and Z is heterocycle; wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and Ci-C4 alkoxy, each E being independently selected from the group consisting of Hal, OH, and CrC8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; x" is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C? -C alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m-phenyl, wherein m"' is an integer 0-8; n '"is an integer 0-8; x '"is an integer 1 -8, Q' is hydrogen or C 1 -C alkyl, and Z '" is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z "can optionally be replaced with groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m -phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C4 alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is cyclopentenyl and the pharmaceutically acceptable salts, optical isomers and hydrates thereof 143. A compound according to claim 1, characterized in that R is R2, R2 is Z , wherein Z is cycloalkyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and Ci-C alkoxy, each E being independently selected from the group consisting of Hal, OH, and C?-C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m - phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C? -C alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and (CH2) m -phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C 1 -C 4 alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and Ci-C alkoxy, each E' is independently selected from the group consists of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. claim 143, characterized in that Z is replaced with group E. 145. A compound according to claim 144, characterized in that E is OH 146. A compound according to claim 145, characterized in that it is 2- [trans- (4-) dihydrochloride. aminocyclohexyl) amino] -6 - [(4-hydroxy) cyclohexylamino] -9-cyclopentylpurine or cis-2- [trans- (4-aminociclohexyl) amino] -6 - [(4-hydroxy) cyclohexylamino] -9- dihydrochloride Cyclopentylpurine 147. A compound according to claim 143, characterized by or because Z is replaced with the group wherein R6", x" and M 'are as defined in claim 143. 148. A compound according to claim 147, characterized in that M' is hydrogen. 149. A compound according to claim 148, characterized in that it is (R, S) -2- [trans- (4-aminocyclohexyl) amino] -6 - [(1-hydroxymethyl) cyclopentylamino] -9-cyclopentylpurine dihydrochloride. 1 50. A compound according to claim 1, characterized in that R is R2, RS is R6 wherein each R6 is independently selected from the group consisting of hydrogen or C3-C8 cycloalkyl, n is an integer 1 - . 1-8; and Z is cycloalkyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and Ci-C4 alkoxy, each E being independently selected from the group consisting of Hal, OH, and C?-C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C alkyl and (CH2) m - phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8;; and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, ft "ft" - (C) x * "~ OQ 'and - (Qri- 2" ft "ft" where each R6' "is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m-phenyl, wherein m '"is an integer 0-8; n'" is an integer 0-8; x '"is an integer 1 -8, Q' is hydrogen or C 1 -C alkyl, and Z '" is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z "can optionally be replaced with groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C alkoxy?; each E 'is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 151 A compound according to claim 1, characterized in that R is R2, R2 is R6 C) n -R6 wherein each R6 is independently selected from the group consisting of hydrogen, C? -C alkyl, and (CH2) n -phenyl, where n 'is an integer 0-8; n is an integer 1 -8; and Z is cycloalkyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C1-C alkoxy; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m - phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C? -C alkyl, wherein each R 6 '"is independently selected from the group consisting of hydrogen, C 3 -C 8 cycloalkyl, C 1 -C 4 alkyl and (CH 2) mephenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and (CH2) m- -phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C4 alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. claim 1 51, characterized in that Z is replaced with the group wherein R6", x" and M 'are as defined in claim 146. 153. A compound according to claim 1, characterized in that M' is hydrogen. 154. A compound according to claim 1, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- [4- (hydroxymethyl) cyclohexanemethylamino] -9-cyclopentylpurine dihydrochloride. 155. A compound according to claim 1, characterized in that R is R2, R2 is R6 (C) rv R6 wherein each R6 is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? C4, and (CH2) n-phenyl; n is an integer 0-8; and Z is cycloalkyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C1-C alkoxy; each E 'is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, Ci-C alkyl and (CH2) m - phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m-phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and (CH2) m-phenyl, wherein m "" is an integer 1 -8; x "" is an integer 0-8; Q "is hydrogen or C 1 -C 4 alkyl or phenyl, each D 'is selected from independent milarian from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E 'is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; and R1 is cyclopentenyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 156. A compound according to claim 1, characterized in that R is R2-NH, wherein R2 is C9-C12 alkyl which may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from of the group consisting of D, E, R «(°) b Rfi" Rß "i6 t r I - < C) x * -S-R6"- (C)? - N-R6" R6"• Re" wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m -phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C1-C4 alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m "" is an integer 1 -8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C alkoxy, each E' is independently selected from the group consisting of in Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. claim 1, characterized in that R is R2NH-, wherein R2 is wherein each R6 is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C alkyl, and (CH.) m-phenyl; where m is an integer 0-8; x is an integer 1 -8; and M 10 is selected from the group consisting of hydrogen, Ci- C4 alkyl, ft 'ft' - (C) x «- OQ and - (0) n '- Z 15 R ft' wherein each R6 'is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, alkyl C ^ -C and (CH2) m-phenyl, where m 'is an integer 0-8; n 'is an integer 0-8; x 'is an integer 1 -8; Q is hydrogen or C 1 -C 4 alkyl; and Z 'is selected to 20 from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 158. A compound according to claim 1, Characterized in that R is R2NH-, where R2 is - ^. á ^ tá -------. R 6 I (C) n z R 6 wherein each R6 is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl; where m is an integer 0-8; n is an integer 0-8; and Z is naphthalene, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, F VL6e "(A ° > b R I e 6" R I 66"- (C)? - -S-R. - (C) x« -N-RÉ R, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C?-C alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m -phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C? -C alkyl, ft "ft" - (C)? - OQ 'and - (C) n * - = - 2"ft" ft "where each R6'" is independently selected from the group consisting of hydrogen, C3 cycloalkyl -C8, C?-C alkyl and (CH 2) m-phenyl, wherein m "'is an integer 0-8; n'" is an integer 0-8; x '"is an integer 1 -8, Q' is hydrogen or C 1 -C 4 alkyl, and Z '" is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene; wherein the groups M 'and Z "can optionally be substituted with the groups D', E 'or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and pharmaceutically acceptable salts, optical isomers and hydrates thereof. according to claim 1, characterized in that R is R2NH-, wherein R2 is Z, wherein Z is phenyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from of the group consisting of D, E, Rf wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C?-C4 alkyl, - (C) - -OQ * and - &Qt; n'- 2"' ft "ft" wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and (CH2) m-phenyl, wherein m"' is an integer 0 -8; n '"is an integer 0-8; x"' is an integer 1 -8; Q 'is hydrogen or C1-C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups' and Z' can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C?-C4 alkyl and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or CrC 4 alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C alkoxy, each E' is independently selected from the group consisting of Hal, OH, and alkyl and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof 160. A compound according to claim 159, characterized in that Z is replaces with group E. 161. A compound according to claim 160, characterized in that E is Hal 162. A compound according to claim 161, characterized in that it is 2- [trans- (4-aminocyclohexyl) amino] -6- dihydrochloride. [2,6-dichlorophenylhydrazino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [2-chlorophenylhydrazino] -9-cyclopentylpurine dihydrochloride; 2- [trans- (4-aminociclohexyl) dihydrochloride] amino] -6 - [- 2-fluorophenylhydrazi) no] -9-cyclopentylpurine; or 2- [trans- (4-aminocyclohexyl) amino] -6- [2,4-dichlorophenylhydrazino] -9-cyclopentylpurine dihydrochloride. 163. A compound according to claim 1, characterized in that R is R2NH-, wherein R2 is R 6 I (C) n z R 6 wherein each R6 is independently hydrogen or Cs-Cs cycloalkyl, with the proviso that at least one of R6 is C3-C8 cycloalkyl; n is an integer 1 -8; and Z is phenyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from from the group consisting of trifluoromethyl, trifluoromethoxy and C?-C alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R6"'is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m-phenyl, wherein m"' is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C?-C4 alkyl and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C 1 -C 4 alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. Claim 1, characterized in that R is R2NH-, wherein R2 is R 6 I (C) n Z R 6 wherein each R6 is independently selected from the group consisting of hydrogen, C? -C4 alkyl and (CH2) m-phenyl, wherein m is an integer 0-8; n is an integer 1 -8; and Z is phenyl, wherein Z is substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; Each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl and (CH2) m-phenyl, wherein m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C1-C alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m-phenyl, wherein m"' is an integer 0-8; n '"is an integer 0-8; 25 x'" is an integer 1 -8; Q 'is hydrogen or C? -C alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, _________ cycloalkyl and naphthalene; wherein the groups M 'and Z "can optionally be substituted with the groups D', E 'or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0- 10 8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C4 alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof 165. A compound according to claim 1, characterized in that R is R2NH-, wherein R2 is R 6 20 I (C) n z R 6 wherein each R6 is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and 25 (CH2) m-phenyl, wherein m is an integer 0-8; n is an integer 01 -8; and Z is phenyl, wherein Z may be optionally substituted with 1 to 3 --'- * * - - - '--- ""' "'- -" - -' - * - s * - ^^ t substitutes, which may be the same or different and which are selected from the group consisting of D, E, p .. (O) b R. R - V6 i I 6 I 6 - (C) x «S-R. - ((C)? - -R. ft " wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m -phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or Wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl and (CH2) m- phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C1-C alkyl or phenyl, each D 'is independently selected from the group consisting of 15 trifluoromethyl, trifluoromethoxy and C 1 -C alkoxy; each E 'is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; and R1 is cyclopentenyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 166. A compound according to claim 1, Characterized in that R is R2NH-, wherein R2 is Z, wherein Z is heterocycle, optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E , 25 | ÉB ^ ^ jaaa? _ab_ (O) b ft "ft" T - (C)? - -S-R. * (C)? - N-R (R. "RB" wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C ^ Cs alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C1-C4 alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C-C4 alkyl and (CH2) m-phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M" and Z "can optionally be substituted with the groups D', E 'or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C4 alkyl or phenyl; each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C alkoxy; each E 'is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 167. A compound according to claim 1, characterized in that R is R2NH-, wherein R2 is wherein each R6 is independently hydrogen or C3-C8 cycloalkyl, with the proviso that at least one of R6 is C3-C8 cycloalkyl; n is an integer 1 -8; and Z is heterocycle, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m-phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C4 alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. Claim 1, characterized in that R is R2NH-, wherein R2 is wherein each R6 is independently hydrogen, C? -C alkyl, and (CH2) m-phenyl, wherein m is an integer 0-8; n is an integer 1 -8; and Z is heterocycle, wherein Z is substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, dC alkyl and (CH2) m-phenyl , where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m-phenyl, wherein m"' is an integer 0-8; n '"is an integer 0-8; x '"is an integer 1 -8, Q' is hydrogen or C1-C4 alkyl, and Z '" is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene; wherein the groups M 'and Z "can optionally be substituted with the groups D', E 'or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and (CH2) m- phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C 1 -C 4 alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof 169. A compound according to claim 1, characterized in that R is R2NH-, where R2 is wherein each R6 is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C4 alkyl, and (CH2) m-phenyl, wherein m is an integer 0-8; n is an integer 0-8; and Z is heterocycle, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, (O) b R. FL- e "y '" ft? ß - < C)? - S-R "- < C) x * -N-R £ Re "'ft" wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C? -C alkyl, wherein each R 6"'is independently selected from the group consisting of hydrogen, C 3 -C 8 cycloalkyl, C 1 -C 4 alkyl, and (CH 2) m -phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C-C4 alkyl and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C4 alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is cyclopentenyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof 170. A compound according to claim 1, characterized in that R is R2NH-, where R2 is Z, wherein Z is cycloalkyl, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -Calkoxy, each E is independently selected from the group consisting of Hal, OH, and d-C? alkyl; b is an integer 0-2; Z "is selected from the group which consists of phenyl, heterocycle, cycloalkyl and naphthalene; each R6"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m" is an integer 0-8; n "is an integer 0-8; x" is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C1-C4 alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m-phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x"' is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl. 10 and (CH2) m-- phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C 1 -C 4 alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy, each E' is independently selected from the group consisting of Hal, OH, and Alkyl CrC8; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. 171. A compound according to claim 1, characterized in that R is R2NH-, where R2 is 20 R 6 I (C) n z R 6 wherein each R6 is independently hydrogen or C3-25 C8 cycloalkyl, with the proviso that at least one R6 is C3-C8 cycloalkyl; n is an integer 1 -8; and Z is cycloalkyl, wherein Z can be substituted _______ * _ i_ optionally with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C 1 -C 4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C1-C alkyl and (CH2) m - phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C? -C alkyl, wherein each R6 '"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m -phenyl, wherein m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C4 alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl, and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or d-C4 alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C alkoxy, each E' is independently selected from the group consists of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof. Claim 1, characterized in that R is R2NH-, wherein R2 is R 6 I (C) n z I R 6 wherein each R 6 is independently selected from the group consisting of hydrogen, C 1 -C alkyl and (CH 2) m-phenyl, wherein m is an integer 0-8; n is an integer 1 -8; and Z is cycloalkyl, wherein Z is substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C?-C alkoxy; each E is independently selected from the group consisting of Hal, OH, and d-C8 alkyl; b is an integer 0-2; Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, each R6" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C alkyl and (CH2) m- phenyl, where m "is an integer 0-8; n" is an integer 0-8; x "is an integer 1 -8; and M 'is selected from the group consisting of hydrogen, C? -C4 alkyl, wherein each R 6 '"is independently selected from the group consisting of hydrogen, C 3 -C 8 cycloalkyl, C 1 -C 4 alkyl and (CH 2) m - phenyl, where m'" is an integer 0-8; n '"is an integer 0-8; x'" is an integer 1 -8; Q 'is hydrogen or C? -C alkyl; and Z '"is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene, wherein the groups M' and Z" can optionally be substituted with the groups D ', E' or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C? -C4 alkyl and (CH2) m -phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C alkoxy, each E' is independently selected from the group consisting of Hal, OH, and C? -C8 alkyl, and R1 is selected from the group consisting of cyclopentyl and isopropyl, and pharmaceutically acceptable salts, optical isomers and hydrates thereof. claim 1, characterized in that R is R2NH-, wherein R2 is R 6 I (C) n z R 6 wherein each R6 is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, d-C4 alkyl and (CH2) m-phenyl, wherein m is an integer 0-8; n is an integer 0-8; and Z is cycloalkyl, optionally substituted with 1 to 3 substitutes, independently selected from the group consisting of D, E, wherein Z may be optionally substituted with 1 to 3 substitutes, which may be the same or different and which are selected from the group consisting of D, E, R "R" Ye | ß - (C) x * - OM 'and - (C-Jrt * Z "Re" ft "where each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C?-C alkoxy; E is independently selected from the group consisting of Hal, OH, and C?-C8 alkyl, b is an integer 0-2, Z "is selected from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene each R6"is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C-C4 alkyl and (CH2) m-phenyl, wherein m" is an integer 0-8; n "is an integer 0-8, x "is an integer 1 -8, and M 'is selected from the group consisting of hydrogen, C? -C alkyl, wherein each R6'" is independently selected from the group which consists of hydrogen, C3-C8 cycloalkyl, C?-C4 alkyl and (CH2) m-phenyl, where m '"is an integer 0-8; n'" is an integer 0-8; x '"is a integer 1 -8; Q 'is hydrogen or C? -C alkyl; and Z' "is selected a from the group consisting of phenyl, heterocycle, cycloalkyl and naphthalene; wherein the groups M 'and Z "can optionally be substituted with the groups D', E 'or wherein each R6"" is independently selected from the group consisting of hydrogen, C3-C8 cycloalkyl, C?-C4 alkyl and (CH2) m-phenyl, wherein m "" is an integer 0-8; x "" is an integer 0-8; Q "is hydrogen or C? -C alkyl or phenyl, each D 'is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy and C? -C alkoxy, each E' is independently selected from the group which consists of Hal, OH, and C? -C8 alkyl, and R1 is cyclopentenyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof 174. A compound according to claim 1, characterized in that R is R3R4N-R5- , wherein R3 and R4 are selected from the group consisting of hydrogen, d-C4 alkyl and (CH2) n-phenyl, wherein n is an integer 0-8, with the proviso that R3 and R4 are not both hydrogen, R 5 is C 1 -C 8 alkylene, and R 1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers and hydrates thereof 175. A compound according to claim 174, characterized in that it is 2- [trans- (4-aminociclohe trihydrochloride xyl) amino] -6- [2-N, N-diethylamino) ethylamino] -9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [3-N, N-diethylamino) propylamino] -9-cyclopentylpurine trihydrochloride; or 2- [trans- (4-aminocyclohexyl) amino] -6- [2- (phenylamino) ethylamino] -9-cyclopentylpurine trihydrochloride. 176. A method for treating a hyperproliferative disorder in a patient, by administering a compound according to claim 1. 177. The method according to claim 176, characterized in that the hyperproliferative disorder is a neoplastic disease state. 178. The method according to claim 177, characterized in that the neoplastic disease state is selected from leukemia, carcinoma, adenocarcinoma, sarcoma, melanoma or a mixed type of neoplasm. 179. The method according to claim 178, characterized in that the leukemia is selected from acute lymphoblastic leukemia, chronic leukemia, acute myeloblastic leukemia and chronic myocytic leukemia. 180. The method according to claim 178, characterized in that the carcinoma is selected from those of cervis, breast, prostate, esophagus, stomach, small intestine, colon, ovary and lungs. 181 The method according to claim 1, characterized in that the adenocarcinoma is selected from those of cervis, breast, prostate, esophagus, stomach, small intestine, colon, ovary and lungs. 1 82. The method according to claim 178, characterized in that the sarcoma is selected from an esteroma, osteosarcoma, lipoma, lipsarcoma, hemangiomas and hemangiosarcoma. 183. The method according to claim 1 78, characterized in that the melanoma is selected from amelanotic melanoma and melanotic melanoma. 184. The method according to claim 1, characterized in that the mixed type of neoplasm is selected from carcinosarcoma, lymphoid tissue type, follicular reticulum, cellular sarcoma and Hodgkins disease. 185. The method according to claim 1 76, characterized in that the hyperproliferative disorder is a neoplastic disease state. 1 86. A method to prevent apoptosis in neuronal cells. The method according to claim 186, characterized in that the apoptosis is induced by antineoplastic agents. 188. The method according to claim 186, characterized in that apoptosis is induced by cerebrovascular disease. 189. The method according to claim 1 86, characterized in that the apoptosis is induced by blow or infraction. 90. A method for protecting the neural cell protection method of apoptosis, characterized in that it comprises the administration of a compound according to claim 1. 1 91. A method for protecting neuronal cells from damage induced by antineoplastic agents, characterized in that it comprises the administration of a compound according to claim 1. 192. A composition characterized in that it comprises an experimental amount of a compound according to claim 1, in admixture or otherwise in association with an inert carrier. 193. A pharmaceutical composition characterized in that it comprises an effective inhibitory amount of cdk-2 of a compound according to claim 1, in admixture or otherwise association with one or more pharmaceutically acceptable carriers or excipients. 1 94. The compound according to claim 1, characterized in that Z is a heterocycle substituted with Cn- (Rß ") 2-Z'7. 195. The compound according to claim 1 94, characterized in that Z "is naphthalene 1 96. The compound according to claim 1 95, characterized in that n" is 1. 197. The compound according to claim 1 94, characterized in that the compound is 2- [trans- (4-aminociclohexyl) amino] -6- [4- [1 - (2-naphthyl) meti I] piperidinthylamino] - trihydrochloride. 9-cyclopentylpurine; 2- [trans- (4-aminocyclohexyl) amino] -6- [4- [1- (1-naphthyl) methyl] piperidinylamino] -9-cyclopentylpurine trihydrochloride.